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Small molecule libraries have become essential for the development of drug 
discovery campaigns and chemical genetics. The studies towards the synthesis of a 
small molecule library, based upon the cis-ring fused phenanthridine core I, will be 
described. 
 
The first section of this thesis examines the development and application of a novel 
intramolecular Heck cyclisation to the synthesis of core phenanthridine structure II, 
via precursor III (Chapter 2). 
 
 
The second section (Chapter 3) describes the extension of this methodology towards 
the development of a library of phenanthridines IV. This includes methodology 
designed to incorporate the key principles of diversity-oriented synthesis, namely 
appendage, stereochemical and skeletal diversity. 
 
 
The final part of this thesis (Chapter 4) describes the merging of these various 
methodologies to generate a small library of novel phenanthridine analogues. 
Preliminary biological evaluation of the phenanthridine library using whole organism 
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1.1 Chemical libraries 
Modern drug discovery relies upon small molecule libraries to generate potential 
leads through the process of high-throughput screening.1 These libraries are screened 
against a pre-validated biological target and any suitably active compounds (known 







    
 
 
Figure 1.1 The process of modern drug discovery. 
 
More recently, compound libraries have been required to further the field of chemical 
genetics, an area that seeks to emulate the success of classical genetics by using 
small molecules to probe the function of proteins. This can be performed in a 
forward or reverse manner as depicted in Figure 1.2.2,3 Forward chemical genetics 
involves identification of a phenotype in an organism or cell that is caused by a small 
molecule, in the example shown the mitotic spindle is in disarray. The protein target 
that has been modulated can then be identified, hence providing its function and a 
small molecule modulator from one process. Reverse chemical genetics involves the 
selection of a protein target (here a Lux-R type protein), against which small 
molecules are screened for candidates that affect the protein’s activity (here pigment 







































function of a protein can be determined. This is akin to classical drug discovery, but 




Figure 1.2 A Forward chemical genetics. B Reverse chemical genetics.3  
A) A small molecule binds to the Eg5 motor protein causing disarray of the mitotic spindle (tubulin 
green, DNA blue). B) An agonist binds to a Lux-R type protein activating pigment production. 
  
The ultimate goal of chemical genetics is to identify small molecules that perturb the 
function of every gene product, this is known as chemical genomics. Approximately 
10% of the human genome (25,000 genes) is thought to encode proteins that will 
bind drug-like compounds, and of these only 1000 have a known small molecule 
chemical modulator.3 In addition, for all the approved therapeutic drugs, only 324 
biological targets have been identified, therefore the potential for research in this area 
is huge.  
 
Both chemical genetics and modern drug discovery processes put demands on the 
need for small molecule libraries. Library sources can be found in the form of in-
house compound collections,3 commercially acquired libraries from combinatorial 
chemistry campaigns,2 or even virtual libraries.4 However, many such libraries suffer 
from a lack of diversity as a result of their origin. For example, pharmaceutical in-
house compound collections can be biased as a result of the previous projects 
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undertaken in the company and by specific guidelines such as Lipinski’s rules.γ 
Therefore recently there has been renewed interest in compound libraries derived 
from natural products,5 and in libraries synthesised with the aim of maximising 
structural and skeletal diversity such as diversity-oriented synthesis (DOS) libraries,3 
and biologically-oriented synthesis (BIOS) libraries.6 Approaches towards these 
different types of library synthesis will be addressed in this chapter. 
 
1.2 Advances in combinatorial chemistry 
Combinatorial chemistry enables the rapid assembly of collections of small 
molecules, usually using a solid support.7 Compared to target-oriented synthesis, 
combinatorial chemistry allows multiple reactions to be performed in parallel using 
different building blocks to access a diverse range of products (Figure 1.3). In 
combination with solid-phase split-pool chemistry, the rapid assembly of small 
molecule collections in high yield is possible. 
                  
A      B 
 
C   
Figure 1.3 Single molecule (A), combinatorial (B) and (C) split-pool synthesis.7 
                                                 
γ Lipinski’s analysis of the world drug index led to the ‘rule-of-five’, which identifies key properties 
considered appropriate for small molecules intended for oral administration. These properties are: 
molecular mass <500 Da, number of H-bond donors <5; number of H-bond acceptors <10; octanol-
water partition coefficient <5.8 
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These small molecules can then be screened as mixtures following cleavage from the 
solid-support, and any active hits can be deconvoluted and resynthesised individually 
using the existing route. More recently a wealth of technology has been developed to 
facilitate faster, cleaner and more robust synthesis, for example the use of automated 
microwave reactors to perform many reactions in sequence.9 Other areas include 
automated weighing devices, LCMS and NMR systems for automated sample 
analysis, and radio-frequency tagging or optical coding to track each specific 
compound throughout the synthesis process.10 Similarly, computer systems have 
been developed to manage the library and keep track of every compound synthesised, 
along with its purity and location, removing the need for human intervention to a 
large extent.9  
At its outset, combinatorial chemistry promised the synthesis of libraries comprising 
millions of compounds, which would rapidly accelerate the drug discovery hit to lead 
optimisation stage. However, more recently, questions have been raised as to 
whether this approach really fulfilled its promise, since some of the libraries 
produced few or no hits.11 Although the libraries created by combinatorial chemistry 
campaigns were large and structurally diverse from each other, compound members 
within a library were less so, as a result of the similar building blocks and reaction 
sequences used to construct them. As a result of this, the focus of library synthesis 
has shifted toward approaches that enable the introduction of greater structural 
diversity and wider population of chemical space.12 
 
1.3 Chemical space  
Chemical space refers to the infinite number of chemical substances that in principle 
can be synthesised. Calculations have estimated this to represent approximately 1060 
drug-like compounds, an unachievable number when considered there are only 1051 
atoms on earth.13 Chemical space can be represented in 3D using different molecular 
descriptors as the three axis, where descriptors are characteristics of compounds such 
as molecular weight.14 The chemical space explored by three different approaches to 







Figure 1.4 Exploration of chemical space by Target-oriented synthesis (A), Focused 
library synthesis (B) and DOS (C).14 
 
Within chemical space there are voids where there are no molecules of biological 
interest, but likewise there are areas that correlate to excellent bioactivity.3 Several 
different approaches have been developed to try and identify the regions of chemical 
space for which the likelihood of obtaining biologically active compounds is given, 
or at least enhanced.  
A recent principal component analysis, based on several molecular descriptors 
(number of chiral centers, rotatable bonds, C-N bonds, C-S bonds. C-O bonds, C-X 
bonds, degree of ring fusion, ratio of aromatic rings to ring atoms) showed that 
natural products and drug compounds occupied far greater areas of chemical space 
than combinatorial libraries (Figure 1.5).15 This suggests that the best chance of 
identifying bioactive molecules lies with a library that depends not on size, but on the 
quality and diversity of its components. The majority of approaches currently being 
investigated in the literature make use of natural products to varying degrees, as 
inspiration for the synthesis of high quality and diverse libraries. 
 
Figure 1.5 Principle component analysis of a) a random selection of combinatorial 




1.4 Natural product based library synthesis 
Despite the intrinsic bioactivity of natural products, their use in drug discovery 
libraries has been neglected over recent years.5 Much of this can be attributed to their 
structural complexity, which rendered them incompatible with high-throughput 
synthesis for many years, and difficult to modify into analogues. Natural products are 
also notoriously difficult to obtain and purify, and so are often screened as mixtures 
that are difficult and time-consuming to deconvolute. Additionally, despite natural 
products being used clinically to great success, they do not tend to lie within the 
parameters dictated by Lipinski’s rules,8 making them less favoured as potential drug 
leads. 
However, despite these drawbacks, natural products still possess a higher hit-rate in 
drug discovery than any unspecific library. For example, between 1981 and 2002, 
61% of the 877 new chemical entities approved by the FDA were natural product-
based.16 Nature designed these molecules for a specific biological purpose and 
function, and given the close relationship shared by the genomes of all organisms, 
evolution selected natural products to bind to proteins similar to human proteins.11 
Despite the recent lack of interest from mainstream pharmaceutical companies, 
natural product synthesis has formed the basis of much of the organic synthetic 
literature.17 As a result, many new pieces of methodology for manipulation and 
generation of these complex architectures have been reported, along with several 
reports of solid phase total synthesis.11 Additionally, advances in microbial 
genomics,5 and separation/purification technology have made the prediction, 
identification and isolation of natural products less challenging.18,19  
Natural products are unmatched in terms of their inherent bioactivity and their ability 
to probe chemical space.5 Therefore they offer excellent, biologically validated 
starting points upon which to base chemical library design. The three main ways in 




1.4.1 Libraries based on the core scaffolds of individual natural products 
Libraries based on the core scaffolds of individual natural products are a useful way 
of optimising the activity of a parent compound, and establishing structure-activity 
relationships.20 Fortunately, the combinatorial methods that caused the initial decline 
of natural product screening are now proving highly useful for this type of library 
synthesis. Typically, complex natural product skeletons (usually derived from total 
synthesis or semi-synthesis efforts) are immobilised on solid support, thus enabling 
relatively simple derivatisation.5,21 This method was used to prepare a library of 
analogues closely based on the anti-tubulin natural products sarcodictyin A and B 
(Scheme 1.1).22 In this example, immobilisation of  advanced intermediate 5 on a 
solid support enabled the introduction of diversity at three points (R’, R’’ and R’’’) 
on the core structure. A small library of 30 analogues was prepared, with several 
showing equal or better activity than the parent structures, including against taxol-
resistant cancer strains. 
 




An alternative approach to libraries of this type can be realised by making use of a 
synthetic route developed during the original natural product synthesis. If this pre-
established chemistry is compatible with solid support, multi-component building 
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blocks can be used to rapidly build a focused library of analogues.21 This approach 
was successfully used for the generation of a 44-member library based on the natural 
products epothilone A and B (Scheme 1.2).23 The epothilones share their unusual 
anti-mitotic mode of action with paclitaxel, however they possess a more accessible 
core structure and have the advantage of being several-thousand times more active 
against paclitaxel resistant cell lines.24 The epothilone library was derived using 
radiofrequency tagged Merrifield resin that enabled sorting and tracking of 
intermediates throughout the split-pool synthesis. The key step involved 
simultaneous formation and release of the lactone macrocycle 11 by a ruthenium 
carbene-catalysed ring-closing metathesis reaction. Nine of the synthesised 
analogues showed cytotoxic activity against breast and ovarian cancer cells.  
 
Scheme 1.2 Solid phase-SMART microreactor synthesis of a 44-member epothilone 
library.
23 
a) i) NaHMDS (3 eq), THF:DMSO 1:1, 25 oC, 12 h; ii) A (2 eq), THF, 0 oC, 3 h; b) 0.2 M HCl in 
THF, 25 oC, 12 h; c) (COCl)2 (4 eq), DMSO (8 eq), Et3N (12.5 eq), -78 → 25 
oC; d) i) B (2 eq), LDA 
(2.2 eq), THF, -78 → - 40 oC; ii) ZnCl2 (2 eq), -78 → -40 
oC, 2 h; e) C (5 eq), DCC (5 eq), DMAP (5 
eq), 25 oC, 15 h; f) Grubbs I (0.2 eq), CH2Cl2, 25 




Individual natural products have also been the inspiration for libraries used to 
address a variety of biological targets.20 This approach works on the proposal that 
libraries based on a natural product that is known to bind one particular protein 
domain should be a rich source of compounds that bind selectively to other targets 
sharing the same protein fold.11 This is known as biologically oriented synthesis 
(BIOS) and is discussed in a separate section below (see section 1.6). 
 
1.4.2 Libraries based on specific substructures from classes of natural products 
Specific substructures of natural products can also be considered biologically 
validated, and libraries based on these foundations are becoming increasingly 
popular.  The concept of a ‘scaffold tree’ was recently reported as a method for 
categorising natural product substructures.6 Stepwise deconstruction of complex 
structures into smaller parent structures was achieved using a set of rules derived 
from organic and medicinal chemistry. This maps the underlying scaffolds of natural 
products in a hierarchical manner based upon their cyclic frameworks and linkers 
(Figure 1.6). Within the scaffold tree, three scaffold classes are distinguished: 
carbocycles, N-heterocycles and O-heterocycles, with the most common scaffolds 








The significance of this approach lies in its ability to enable correlation between 
different classes of scaffold, which is performed during BIOS (See section 1.6).6 It 
also enables the identification of biologically relevant core scaffolds for the design 
and synthesis of focused library collections. Such libraries are enhanced by their 
natural product origins, but also have the added benefit of increased structural 
diversity so that a wider range of biological targets might be addressed. 
One of the earliest examples of this type of substructure-based focused library 
synthesis incorporated the 2,2-dimethylbenzopyran unit 12 (Scheme 1.3).21,25,26 This 
structural motif lies at the heart of many natural products including the flavenoids, 
stillbenoids, coumarins, rotenoids and the chromene glycosides, several of which 
have important medicinal applications. Initial efforts were concentrated on the 
combinatorial split-pool synthesis of six focused libraries, based around 2,2-
dimethylbenzopyran targets of recent biological interest. This resulted in the 
development of novel solid-phase selenium-based cycloloading methodology for the 
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construction and elaboration of structures containing this template (Scheme 1.3).21 
The selenyl bromide resin encompassed the essential features of both a solid-phase 
reagent and a traceless linker, eliminating the presence of any residual functionality 
in the product structure upon oxidative cleavage from the resin. 
 





This novel methodology was then applied in conjunction with the IRORI NanoKan 
optical encoding system, to synthesise a 10,000 member library containing 
approximately 1-2 mg of each small molecule.25 The library was then subjected to 
comprehensive biological screening, followed by parallel solution-phase 
optimisation to increase the number and diversity of library members, and aid 
identification of key structure activity relationships.26 As a result, several 
cyanostilbenes were identified which had low micromolar activity against MRSA, 
including compound 17 (Figure 1.7) which exhibited a 5 µM MIC (minimum 
inhibitory concentration) against six different MRSA strains. Another screen 
identified novel anti-steroidal agonists of the farnesoid X reporter gene, including 
compound 18, fexachloramide, which displayed an EC50 value of 188 nM. While the 
active compounds are not potent enough to represent drug candidates, they do offer 




Figure 1.7 Bioactive compounds discovered from the synthesis of a 10,000-member 
library based on a 2,2-dimethylbenzopyran core.
21,25,26 
 
1.4.3 Libraries based on the general characteristics of natural products 
Libraries can also be synthesised using the general structural characteristics of 
natural products, rather than their specific structures or substructures. Natural 
products show bioactivity because their rigid structures are able to present functional 
groups in a favourable arrangement. Therefore mimicking the complex structures of 
natural products by the incorporation of dense stereochemical and functional 
diversity around a rigid molecular skeleton may lead to the identification of novel 
pharmacophores.20 Although this approach forgoes any direct connection to specific 
natural product structures, it does offer a unique opportunity for the synthesis of 
novel small molecules that may be able to address targets currently considered 
undruggable. 
This type of library synthesis was applied to the 1,3-dioxane structure illustrated in 
Figure 1.8.27 The 1,3-dioxane was chosen due to its structural rigidity and its 
reproducible stereoselective synthesis in the presence of diverse ancillary groups. 
Initial efforts focused on the synthesis of a 1890-member pilot library using solid-




Figure 1.8 1,3-dioxane library overview.27 
 
From this library several bioactive compounds were identified including uretupamine 
B 19, a novel inhibitor of the yeast nutrient responsive signaling proteins Ure2p 
(Figure 1.9). Two selective inhibitors of the histone deacetylase (HDAC) family 
were also discovered, tubacin 20 and histacin 21. This led to the identification of a 
new potential antimetastatic and antiangiogenic therapeutic target, HDAC6.27 
 
 




More recently, this 1,3-dioxane library was expanded to 18,000 members through the 
incorporation of additional building blocks and stereochemical diversity. Principal 
component analysis assessed that the 18,000-member library explored an equivalent 
volume of chemical space to a known library of 2000 bioactive compounds (Figure 
1.10 A).28 From the biological screening results, compound 22 (Figure 1.10, B) was 
shown to have a detrimental effect on cardiovascular development in embryonic 
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zebrafish, whereas its enantiomer, synthesised in the earlier library, did not. This 




          B  
Figure 1.10 Stereochemical enrichment of a 1,3-dioxane library.28 
A: 1,3-dioxanes (red) and a known bioactive library (various colors) plotted in molecular diversity 
space. B: Compound 22 induces cardiac malfunction in zebrafish while its enantiomer does not. 
 
Libraries constructed in this manner are termed by some to be diversity-oriented 
synthesis (DOS) around a privileged structure. Likewise, libraries synthesised around 
a natural product substructure could also technically earn this name. There is a fine 
line between these different approaches that tend to be described in different ways by 
different authors. However, for the purposes of this overview, DOS will refer to 
library synthesis governed by the specific rules and thought processes described in 
the next section (1.5). 
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1.5 Diversity-oriented synthesis (DOS) 
It is clear from the natural product-based examples reported above (section 1.4) that 
the more complex and diverse a library is, the greater its chances are of producing a 
novel bioactive small molecule. The field of diversity-oriented synthesis was 
developed with the aim of creating structurally diverse libraries of architectures that 
mimic the overall complexity of natural products.14 The goals of DOS include the 
development of pathways that lead to the synthesis of collections of small molecules 
in three-to-five steps. These pathways must allow the incorporation of skeletal and 
stereochemical diversity by the use of complexity-generating reactions, and ideally 
lead to molecules with defined coordinates in chemical space. DOS methodology 
should also allow the incorporation of different building-blocks from the outset, and 
additionally create sites for the potential appendage of further building-blocks post-
screening, so that active hits might be optimised. 
 
1.5.1 Forward-thinking synthetic analysis 
In contrast to target-oriented synthesis that employs retrosynthetic analysis, DOS 
makes use of forward synthetic planning to move in the direction of simple and 
similar structures to complex and diverse structures (Figure 1.11).14 
 
Figure 1.11 Retrosynthetic analysis versus forward-synthetic analysis.14 
 
The key subunits of retrosynthesis are the ‘retrons’ that must be identified before the 
application of a transformation. In contrast, the key subunit of forward-synthetic 
analysis is the transformation itself, which enables the conversion of a group of 
substrates into a group of products.14 The key element for the implementation of 
forward-synthetic analysis is the identification of reactive subunits common to a 
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group of compounds, which enables them all to be potential substrates for the same 
reaction. DOS makes use of both complexity-generating reactions, and diversity-
generating processes in its quest to populate chemical space, both methods can be 
considered independently, and will be discussed below. 
 
1.5.2 Complexity generating reactions (simple → complex) 
DOS requires reactions, or transformations, that promote its quest for the conversion 
of simple starting materials into complex products. Many multicomponent reactions 
are suitable for this purpose, including the asymmetric [3+2] azomethane ylide 
cycloaddition,29 and the Cu(II)-pybox catalysed Passerini reaction,30 both illustrated 
in Scheme 1.4. Both reactions proceed in excellent yield and in a highly 
stereoselective manner, generating complex products in just one step from relatively 
simple starting materials. 
 
Scheme 1.4 Highly stereoselective complexity-generating reactions.29,30 
A: Asymmetric [3+2] azomethine ylide cycloaddition. B: Three-component Passerini reaction. 
 
Further complexity can be introduced by the identification of pairwise-relationships, 
where the product of one reaction is the substrate for another. These offer enormous 
potential for the generation of increasingly complex skeletons.14 This was shown in 
an Ugi/Diels-Alder/ring-rearrangement metathesis sequence to the synthesis of 




Scheme 1.5 Three-step synthesis of a complex polycyclic 7-5-5-7 ring system.31 
a) MeOH, THF, 48 h, 67%; b) KHMDS, allyl bromide, r.t., 18 h, 69%; c) Grubbs II, CH2Cl2, 40 
oC, 
36 h, 69%. 
 
Careful choice and combination of transformations can therefore be a very powerful 
method for developing complex products in very few steps. Numerous examples of 
these types of reactions, and others, have been reported in the synthesis of DOS 
libraries.32-34 
 
1.5.3 Diversity-generating processes (similar → diverse) 
In order to populate large areas of chemical space efficiently, DOS aims to move in 
the direction of similar structures to diverse structures. In order to do this, a series of 
products-equals-substrates relationships must be planned, where the products of one 
diversity-generating reaction share some common reactive functionality suitable for 
another reaction.14 Three different types of diversity can be identified in realising the 




1.5.3.1 Appendage diversity 
Combinatorial chemistry uses coupling reactions in conjunction with split-pool 
chemistry, to attach different building blocks to a molecular skeleton.7 In forward-
synthetic analysis these are referred to as appending processes and tend to be 
performed using more sophisticated organic transformations than standard 
combinatorial synthesis. Multiple appending processes can be used on a common 
molecular skeleton to huge success, resulting in libraries of hundreds, thousands or 
even millions of members.35 One such example is illustrated in Scheme 1.6, where 
acyclic precursor 40 undergoes oxidative cyclisation to rigid skeleton 41, followed 
by four separate appending processes.36  
 
Scheme 1.6 Appending processes for the elaboration of a molecular skeleton.36 
a) i) PhI(OAc)2, (CF3)2CHOH, CH2Cl2, 23 
oC; ii) Pd(PPh3)4, morpholine-THF, 23 °C; b) R
1OH, PPh3, 
DIAD, THF, 0 °C; c) i) R2SH, 2,6-lutidine; ii) nBuLi, THF 0 → 40 °C; d) R3CHO, AcOH, MeOH-
THF, then NaBH3CN in MeOH, 23 °C or R
3COCl, 2,6-lutidine, CH2Cl2, 23 °C or R
3NCO, CH2Cl2, 23 




These processes encompass a Mitsunobu reaction to couple R1; conjugate addition of 
thiols (R2) to the cyclic enone; condensation or alkylation of the nucleophilic 
secondary amine to couple R3; and finally reaction of the electrophilic ketone with 
hydroxylamines or hydrazines to couple R4. As a result a library of 2527 molecules 
was submitted for biological screening, resulting in the identification of a novel 
compound that blocks protein transport from the Golgi apparatus to the cell 
membrane.36 
 
1.5.3.2 Stereochemical diversity 
The incorporation of stereochemical diversity is essential to DOS-library synthesis in 
order that the orientations of macromolecule-interacting elements are maximised. 
This requires the use of enantio- or diastereoselective reactions that are also general, 
since they must be amenable to a collection of substrates.14 One such example is the 
diastereoselective intermolecular Diels-Alder transformation of chiral 
dialkenylboronic acid 46 into cycloadduct 47, with the selective formation of three 
stereocentres (Scheme 1.7).37 In this example, steric interactions with the TIPS-
protected hydroxymethyl group direct cycloaddition to the less hindered face of the 
diene, giving rise to only one stereoisomer. 
 
Scheme 1.7 Stereoselective Diels-Alder reaction of a chiral dialkenylboronic acid.37 
 
Although highly stereoselective reactions may increase the overall yields of DOS 
processes, they do have a disadvantage in that they limit the potential synthesis of the 
other possible stereoisomer products. In a situation where maximum diversity is 
required, the potential to tune particular reaction conditions in order to obtain any 





For example, chiral catalyst 48 can be used in a hetero-Diels-Alder reaction to 
overcome the stereochemical bias of a chiral substrate 49 and generate 
diastereomeric products with high selectivity. (Scheme 1.8)14,38 The (1S,2R) catalyst 
shown leads to the formation of product 50, however selective use of the enantiomer 
of catalyst 48 leads to the formation of the diastereomeric product 51. The discovery 
of powerful reagents that are able to override stereochemical bias are essential to the 
further development of stereochemical diversity in DOS. 
 




1.5.3.3 Skeletal diversity 
The introduction of skeletal diversity to a small molecule library can be achieved 
using either a reagent–based approach (Figure 1.12, A), or a substrate-based 
approach (Figure 1.12, B).3 Reagent-based approaches encompass the use of a 
pluripotent functionality, where the same part of the molecule is subjected to 
different transformations induced by different reagents; or, the use of a multiple-
group pairing strategy where different parts of the same densely functionalised 
molecule, are transformed by different reagents. Alternatively, a substrate-based 
approach called a folding process can be used, where different structurally encoding 






Figure 1.12 Generalised methods for achieving skeletal diversity.3 
 
An example of achieving skeletal diversity through the use of pluripotent 
functionality is illustrated in Scheme 1.9, using polyfluorocarbon tagged diazoacetate 
52.39 The fluorous tag enables the use of various purification technologies, making 
the methodology compatible with high-throughput solution-phase combinatorial 
chemistry. The diazoacetate was utilised in various divergent reactions to give a wide 
variety of molecular skeletons including 54, 56 and 58. A small molecule collection 
of 223 compounds was synthesized in total, and found to occupy a greater area of 
chemical space than a focused library, or small pharmacological library, when 
assessed using molecular descriptors and PCA. 
 
Scheme 1.9 Pluripotent functional group strategy using a fluorous-tagged 
diazoacetate.
39 
a) C6H6, Rh2(O2CCF3)4, 70%; b) RC≡CH, Rh2(OAc)4, [BuC≡CH, 57%]; c) RNH2, NaOH then 




Multiple-group pairing strategies make use of densely functionalised molecules with 
pendant functionality. Different pairings of pendant functionalities give rise to 
multiple scaffolds using different reagents.3 For example, pairing the nitro and ester 
functionality of substrate 59 gives rise to lactam 60 under reductive cyclisation 
conditions (Scheme 1.10).40 Alternatively the nitro functionality of 59 could be 
activated towards reaction with the alkyne through intramolecular 1,3-cycloaddition 
of the derived nitrile-oxide, to afford bicyclic isoxazole 61. Finally, the alkyne could 
be subjected to microwave-promoted enyne metathesis conditions to afford diene 62, 
suitable for further elaboration under Diels-Alder conditions. 
 
Scheme 1.10 Multiple-group pairing approach to skeletal diversity.40 
a) i) Zn, AcOH/THF; ii) Na2CO3 (aq), 92%; b) PhNCO, Et3N, PhMe, r.t., 74%; c) Grubbs I, ethylene, 
µwave (150 W), 60 oC, CH2Cl2; d) N-phenylmaleamide, µwave (300 W), 160 
oC, PhMe, 98%, 2 steps. 
 
The folding process approach to DOS library synthesis makes use of substrates 
containing pre-encoded skeletal information (σ elements) that can be transformed 
into distinct molecular skeletons using common reaction conditions.14 Folding 
processes present a useful way to introduce new skeletons towards the end of a 
synthesis, whilst also enabling the generation of skeletons that might otherwise be 
difficult to access. Folding processes are also highly amenable to split-pool solid 
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phase synthesis, as a result of the structural similarity and therefore common 
reactivity, that is present until a later stage in the synthesis.  
To plan such folding processes, a relatively unreactive core structure must first be 
identified, that can be transformed into a more reactive intermediate upon treatment 
with mild reagents.14 Various pre-encoded appendages (σ elements) having 
complementary reactivity to the reactive intermediate can then be attached to the 
common core. Finally, mild conditions are used to liberate the reactive intermediate, 
trigger reaction with the σ elements, and generate the different skeletons.  
One such example of a relatively unreactive core is the aromatic furan ring that, upon 
treatment with a mild oxidant, can liberate a highly reactive cis-enedione 
intermediate (Scheme 1.11).14,41 By the appendage of three distinct two-carbon 
chains containing zero, one, or two hydroxyl groups to the furan core, it was possible 
to transform three similar substrates into three skeletally diverse products, using 
oxidative (NBS) then acidic (PPTS) conditions. Product 65 was formed via an 
oxidative ring opening followed by olefin isomerisation.42 Bicyclic ketal 67 was 
formed via NBS-mediated oxidative ring expansion followed by subsequent 
ketalisation.43 Finally, following oxidative ring expansion, substrate 68 underwent 
acid-catalysed dehydration to afford pyran-3-one 69.  
 
Scheme 1.11 A skeletal diversity-generating folding process.14 
M = macrobead. 
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1.5.4 Summary of DOS 
Although the logic of DOS is still evolving, the information described above 
illustrates the clear guidelines and principles that are in place to promote its further 
development. The libraries that have been created so far using these principles of 
appendage, stereochemical, and skeletal diversity have shown great promise in both 
biological screens and PCA analysis, providing validation for the approach as a 
method for bioactive small molecule discovery.  
An alternative approach to small molecule library synthesis is known as biologically 
oriented synthesis (BIOS).6 While DOS centres on libraries that are structurally 
diverse and complex, BIOS centres on libraries based around scaffolds of proven 
biological relevance. Although these approaches are conceptually different, they are 
not mutually exclusive since DOS libraries can be based around biologically 
privileged structures and BIOS libraries can be derived from hits generated in DOS 
campaigns. BIOS also significantly overlaps with the principles behind natural 
product libraries, however there are important differences that will be discussed 
below. 
 
1.6 Biologically oriented synthesis (BIOS) 
BIOS relies on principles derived from matching the complementary properties of 
bioactive small molecules, with their protein targets. If nature only explored a tiny 
amount of chemical space during evolution then it makes sense that there are huge 
untapped areas where great bioactivity may be discovered (this has been discussed 
previously, see section 1.3). The same is true for protein structures, nature only made 
use of a tiny fraction of all the possible amino acid combinations during evolution.6 
Additionally, the three-dimensional folds of protein structures are highly conserved 
in structure, since similar fold structures can be formed by different amino acid 
sequences.  
As a result of this, BIOS forges both natural products and proteins in its approach to 
library synthesis. Only scaffolds of proven biological relevance are chosen as starting 
points for library design, and the libraries generated are small, focused and limited in 
diversity. BIOS uses two concepts to aid its development, the scaffold tree (discussed 
previously, section 1.4.2) and protein structure similarity clustering (PSSC).6  
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1.6.1 Protein structure similarity clustering (PSSC) 
Proteins are built up from one or more domains that can be classified by their fold 
types (the spatial arrangement of secondary structure elements such as α-helices and 
β-sheets). It is estimated that the majority of proteins are built up from only 1000 
fold types, although between 1000 and 10,000 different folds should exist in nature.6 
As a consequence of this, and the limited number of natural product scaffolds, the 
prediction of small molecule scaffolds that might target whole groups of structurally 




Figure 1.13 The principles of BIOS.6 
Complementary binding between small molecules and proteins may lead to the identification of a 
similar complementary interaction between protein folds and small molecule core scaffolds. 
 
 
PSSC uses computational algorithms to identify proteins in which the fold structure 
around the small molecule ligand-sensing core is similar. These structures are then 
assigned to the same protein similarity structure cluster. If a small molecule ligand is 
known for one member of the cluster, then it is rational to use the scaffold as the 





1.6.2 PSSC and Structural classification of natural products (SCONP) 
The scaffold tree (Figure 1.6) is a method for the structural simplification of 
complex architectures that also enables links between scaffold types to be realised. 
The inner segment of the scaffold tree depicts less complex scaffolds, therefore 
moving inward along branches of the tree leads to the structural simplification of 
complex scaffolds.6 This can be used to identify suitable scaffolds for the basis of a 
library, following the identification of a small molecule during PSSC. This method 
was used to study the Cdc25A phosphatase protein cluster (Figure 1.14),44 which 
consists of Cdc25A phosphatase, AChE and 11β-hydroxysteroid dehydrogenase 
(11βHBD). Glycyrrhetinic acid 70 is known to be a ligand of 11βHBD, so its 
pentacyclic core was deconstructed using the scaffold tree to give several simpler 
scaffolds. One of these scaffolds, the dehydrodecaline 71 also formed the core 
structure of dysidiolide 72, whose natural receptor Cdc25A was also part of the 
cluster. This core structure was therefore considered to be a double-validated starting 
point for synthesis of a library of 11βHBD inhibitors, and indeed the resulting 500-
member library produced 30 inhibitors with IC50 values below 10 µM. This success 














1.7 Conclusions  
Chemical genetics and drug discovery require small molecule libraries to further 
their development, and over the last decade or so, many approaches have been 
reported in the literature towards realising these demands. Many of these approaches 
are reliant upon solid-phase synthesis, and developments in this area have been 
fundamental to the advancement of library synthesis. Underpinning the majority of 
approaches is the use of natural products as a basis for library design. This can be in 
a very general sense (e.g. DOS), or more specifically (e.g. TOS, focused libraries, 
BIOS libraries). However, regardless of the approach that is used, the biological 
results clearly speak for themselves, fully justifying these methods for the successful 
discovery of novel bioactive small molecule ligands. 
 
1.8 Proposed work 
This thesis documents the work performed towards the synthesis of a small library of 
compounds based on the phenanthridine core 73 (Figure 1.15). The phenanthridine 
core forms an excellent basis for library design as it lies at the heart of numerous 
bioactive natural products including the antitumor antibiotic pancratistatin 74;45 
antiviral lycorine 75;45,46 and the tubulin polymerization inhibitor chelidonine 76 
(Figure 1.15).47,48  
 







We decided to focus our library around the cis-ring fused phenanthridine core  
(Figure 1.16) as the corresponding trans-analogues had already received significant 
attention in the literature.45,46 In realising our library, we developed novel Heck 
methodology for the synthesis of cis-ring fused phenanthridine core structures, which 
is described in Chapter 2.49 Additionally, methodology for the further elaboration of 
the phenanthridine core was developed, using the principles of DOS library synthesis 
(skeletal, stereochemical and appendage diversity) and natural product library design 
(Figure 1.16). This work is described in Chapter 3. 
 
Figure 1.16 Phenanthridine library synthesis using the principles of DOS. 
 
The methodology developed in Chapters 2 and 3 was then applied to the synthesis 
of a small library of phenanthridine analogues in Chapter 4. The biological 
assessment of the library was carried out using whole organism phenotype screening 
in zebrafish,50 which allows the simultaneous evaluation of all possible targets 
resulting from the protein domain similarities highlighted by PSSC.6 
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A survey of conditions for the palladium catalysed intramolecular Heck cyclisation 
of protected benzylamines 77 to afford cis-ring fused phenanthridines 78 was 
conducted to determine the optimal conditions to carry out this transformation. This 
survey involved a catalyst screen, application of the optimal conditions to a range of 
protected benzylamines and a mechanistic study to probe the double bond isomers 
obtained as a result of the Heck cyclisation. 
 
 
Scheme 2.1 Heck cyclisation studied in Chapter 2.
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2.1 The Heck reaction 
The Pd(0) catalysed vinylation of an aryl halide was reported over 30 years ago in 
independent studies by Mizoroki51 and Heck.52 The transformation is now generally 
referred to as the Heck reaction and is defined as the Pd(0) catalysed coupling of an 




Scheme 2.2 The Heck reaction. 
R = H, alkyl, aryl, CN, CO2R, OR, OAc, NHAc. R’ = aryl, vinyl. X = I, Br, Cl, OTf. 
 
The reaction proceeds via a catalytic cycle (Scheme 2.3) and involves oxidative 
addition of the Pd(0) to the C-X bond, migratory insertion of the Pd(II) into the 
alkene bond, β-hydride elimination to give the coupled alkene product, followed by 




Scheme 2.3 Traditional mechanism of the Heck reaction. 
R, R’ and X as above. Ligands omitted for simplicity. 
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Since its discovery, the Heck reaction has been studied intensively, furthering the 
development of conditions to allow a huge range of couplings to take place 
efficiently. The first intramolecular Heck reaction was reported in 1977, by Mori and 
Ban54 and this was further developed into the asymmetric intramolecular Heck 
reaction, first reported independently by Shibasaki55 and Overman in 1989.56  
 
 
Scheme 2.4 First examples of an asymmetric Heck reaction.55,56 
a) Pd(OAc)2, (R)-BINAP, Ag2CO3, NMP, 60 
oC; b) Pd(OAc)2, (R,R)-DIOP, Et3N, benzene, r.t. 
 
Shibasaki’s work illustrated for the first time that an intramolecular Heck reaction 
could be used for the creation of a tertiary stereocentre. Overman illustrated that the 
intramolecular Heck reaction could be used to establish a quaternary stereocentre. 
Despite the modest enantioselectivities achieved with these initial examples, both 
studies illustrated the enormous potential of the asymmetric Heck cyclisation, and it 
has subsequently become the focus of many research groups worldwide and found 
successful application in many total syntheses.57-59 
 
Another area of Heck chemistry that has received a lot of attention is the 
development and study of new catalyst systems for more efficient Heck couplings. 
Traditionally, catalysts employed in the Heck reaction have a turnover number 
(TON) somewhere in the region of 102 – 103 (loadings 1 – 5 mol%). While this is 
more than acceptable for application in pharmaceutical and fine chemical synthesis, 
it is less so for plant scale synthesis where a TON of >103 (0.1 mol% loading) is 
desirable. To this end, extensive research has given rise to numerous catalytic 
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systems able to deliver such TONs, including palladacycles, coordinatively 
unsaturated Pd catalysts featuring bulky phosphanes [e.g (tBu3P)2Pd], carbene 
ligands and even ligandless palladium.60 Catalysts like (
tBu3P)2Pd have also proved 
to be particularly effective for the cross coupling of aryl chlorides and for room 
temperature cross-couplings.61,62 
 
Like most organometallic cross-coupling reactions, the Heck reaction has been 
successfully carried out under microwave conditions.63 This rapid method of heating 
allows the elevated temperatures required for reaction to be reached in seconds, and 
in conjunction with the pressurised, sealed reaction vessels permits successful 
coupling in a matter of minutes. Generally microwave mediated cross-coupling 
reactions are found give less side products than conventional heating methods as the 
whole volume of the reaction solution can be heated simultaneously and uniformly. 
They are seen as a greener alternative to standard heating methods with regard to the 
amount of electricity employed, and the volume of water that is not wasted on 
condenser cooling.64 
 
One final area of Heck chemistry that has received much attention recently is the 
reaction mechanism.65,66 The sheer wealth of catalysts, ligands and results that have 
been generated in this area have led to some debate as to what the exact mechanism 
of the Heck reaction actually is. Recent reports have made claims for Pd(II)/(IV) 
catalytic cycles, and indeed some Pd(IV) species have been isolated.67,68 However 
generally, the standard neutral Pd(0)/Pd(II) cycle (Scheme 2.3) is accepted as the 
most accurate mechanism, although this can be diverted into the cationic manifold 
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2.2 Proposed work 
We were attracted to an intramolecular Heck cyclisation-based approach to the 
phenanthridine framework (Scheme 2.5) as there is good precedent for cis-
stereocontrol in the formation of the 6,6-ring junction in related phenanthridone 
systems.  
 
Scheme 2.5 Phenanthridine retrosynthesis. 
P = protecting group. 
 
For example, Grigg et al.70,71 reported the successful cyclisation of aryl iodide 86 to 
afford predominantly the cis-ring fused ∆1,2 phenanthridone 87, along with some of 
the ring junction ∆10b,1 double bond isomer 88, and Szmuzkovicz72 reported the 
formation of ∆1,2 and ∆2,3 cis-ring junction phenanthridones 90 and 91 from aryl 
iodide 89 (Scheme 2.6). The addition of Tl2CO3 permitted the reaction of 86 to be 
diverted into a cationic manifold and thus deliver solely cis ∆1,2 isomer 87. 
 
 
Scheme 2.6 Literature precedent for cis 6,6-ring junction.70-72 
a) Pd(OAc)2 (0.1 eq), PPh3 (0.2 eq), K2CO3 (2 eq), MeCN, 80 
oC. i) with Et3NCl (1 eq) 96 h, 78%, 87: 
88 1.8:1. ii) with Tl2CO3, 22 h, 78% 87 only. b) Pd(OAc)2 (0.1 eq), PPh3 (0.2 eq), Li2CO3 (0.2 eq), 
DMF, 80 oC, 24 h, 72%, 90: 91 2:1.  
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Despite the literature precedent, we were concerned that the conditions reported were 
potentially limiting in a library-based approach to the phenanthridine core due to the 
lengthy reaction times (24-96 h) required for the cyclisation reaction, and the varying 
results with regard to the double bond isomer ratios obtained in the product.70-74 Our 
initial aims were thus two-fold; to develop conditions which might overcome these 
practical problems, whilst at the same time promoting the cyclisation of a range of 
functionalised amine precursors to allow access to a diverse library based upon the 
phenanthridine core. 
 
2.3 Catalyst screening studies 
2.3.1 Precursor synthesis 
Our first task was to synthesise suitable cyclisation precursors to test in a catalyst 
screen. To this end, a range of sulfonamide, carbamate and amine cyclisation 
precursors 94a-e were found to be readily accessible through alkylation of 
commercially available 2-bromobenzylamine with 3-bromocyclohexene, followed by 
protection under the appropriate conditions (Scheme 2.7). Sulfonamide 94a provided 
an excellent substrate for catalyst screening studies due to its easy purification and 
characterisation (no amide rotamers). 
 
Scheme 2.7 Cyclisation precursor preparation.  
P = 94a: SO2Me; 94b Boc; 94c Cbz; 94d Bn; 94e PMB. 
ai) iPr2NEt, 3-bromocyclohexene, MeCN, 16 h, r.t.; aii) HCl in Et2O, 99%; b) 94a MeSO2Cl, Et3N, 
CH2Cl2, 16 h, 99%; 94b Boc2O, Et3N, CH2Cl2, 16 h, 90%; 94c NaH, DMF, 0 
oC, 30 min, then 
benzylchloroformate, r.t., 16 h, 86%; 94d NaH, DMF, 0 oC, 30 min, then benzyl bromide, r.t., 16 h, 
81%; 94e NaH, DMF, 0 oC, 30 min, then PMBBr, r.t., 16 h, 84%. 
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2.3.2 Pd(OAc)2 
We chose to use Pd(OAc)2 as a starting point for our catalyst screening studies, as 
this was used in the corresponding phenanthridone synthesis (Scheme 2.6). The 
initial data for the Pd(OAc)2 catalysed intramolecular Heck reaction of sulfonamide 
94a are given in Table 2.1. In related intramolecular Heck cyclisation reactions of 
benzamides, a range of double bond isomers have been reported, including the 
bridgehead ∆10b,1 (95a), ∆1,2 (96a) and ∆2,3 (97a).72-74 In this study, none of the 
bridgehead double bond isomer was formed, and the cis ∆1,2 isomer (96a) was 
observed as the major product, along with trace amounts of the cis ∆2,3 (97a) and cis 
∆3,4 (98a) double bond isomers.φ 
 
Table 2.1 Pd(OAc)2 screening for the intramolecular Heck cyclisation of 
sulfonamide 94a. 
 
Entry Catalysta Base T 
(°C) 




1 Pd(OAc)2/PCy3 MeNCy2 (4 eq) 130 70 DMA 99 77:14:9 
2 Pd(OAc)2/PCy3 MeNCy2 (4 eq) 140 60 DMA 99 96:2:2 
3 Pd(OAc)2/PCy3 MeNCy2 (4 eq) 150 30 DMA 98 95:3:2 
4 Pd(OAc)2/PCy3 Et3N (4 eq) 140 70 DMA 58 90:2:8 
5 Pd(OAc)2/PCy3 
iPr2NEt (4 eq) 140 35 DMA 98 92:5:3 
6 Pd(OAc)2/PCy3 K2CO3 (4 eq) 140 40 DMA 87 55:27:18 
7 Pd(OAc)2/PCy3 2,6-lutidine (4 eq) 140 - DMA - - 
8 Pd(OAc)2/PCy3 MeNCy2 (4 eq) 140 35 DMF 95 94:5:1 
a [5 mol% Pd(0) source] / [10 mol% ligand] b Conversion was determined through analysis of the 1H 
NMR of the crude reaction mixture. 
 
Investigation of a range of bases at the optimum reaction temperature (140 oC) 
showed that iPr2NEt gave comparable results to those obtained in presence of 
MeNCy2, however Et3N, K2CO3 and 2,6-lutidine gave lower conversion levels 
                                                 
φ Unequivocal confirmation of the cis ring junction stereochemistry and the identity of the three 
double bond isomer products, is reported in section 2.5. 
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(entries 4-7). We observed that a switch in solvent from DMA to DMF (entry 8) 
resulted in similar or even enhanced reactivity with almost total conversion in only 
35 minutes.  
Unfortunately however, the results in Table 2.1 do not disclose the truth behind the 
reliability of our reaction. We discovered that regardless of the solvent, base or 
indeed the temperature (130-150 oC) employed, two apparently identical reactions, 
executed side by side, exhibited different colours (yellow vs black) and afforded 
contrasting product yields and ratios. In the reactions where the solution turned 
black, we either observed a significant amount (>50 %) of benzylamine 99a (Scheme 
2.8) in addition to the desired cyclised products 96a-98a, or very little reaction at all. 
The presence of 99a was confirmed by comparison of the 1H and 13C NMR data of 
an authentic sample, synthesised in a similar manner to its bromide counterpart.  
 
Scheme 2.8 Formation of benzylamine 99a. 
a) Pd(OAc)2, MeNCy2, DMA, 160 
oC, 16 h, 99% 96a-98a: 99a 1:3. 
 
2.3.3 Microwave studies 
As previously mentioned, microwave heating has been shown to accelerate many Pd-
mediated cross-coupling reactions and can be effective at suppressing the formation 
of unwanted by-products, providing a generally cleaner reaction than traditional 
heating methods.64 We initially had concerns that the formation of unwanted 
benzylamine by-product 99a was occurring during the initial heating period (r.t.-140 
oC) and we were interested to observe whether the rapid heating period utilised in 
microwave synthesis (typically <30 seconds) would eliminate this unwanted product. 
 
Initial studies showed that a temperature of 180 oC was required to promote the 
Pd(OAc)2 catalysed cyclisation. Performing the reaction in DMF, using either 
MeNCy2 or 
iPr2NEt led to significant amounts of benzylamine 99a being obtained 
(Table 2.2). However, using DMA as the solvent led to a significant reduction in this 
Results and Discussion 1 
37 
unwanted by-product, with ∆1,2 isomer 96a being observed as the exclusive cyclised 
product (entries 3+4). 
 





Entry Base T 
(°C) 




1 MeNCy2 (4 eq) 180 30 DMF 100 57:0:0:43 
2 iPr2NEt (4 eq) 180 30 DMF 100 70:0:0:30 
3 MeNCy2 (4 eq) 180 30 DMA 100 87:0:0:13 
4 iPr2NEt (4 eq) 180 30 DMA 100 86:0:0:14 
5 MeNCy2 (4 eq) 180 15 DMA 100 41:0:0:59 
6 iPr2NEt (4 eq) 180 15 DMA 100 66:0:0:34 
7 MeNCy2 (4 eq) 180 20 DMA 95 80:10:0:10 
8 MeNCy2 (4 eq) 180 20 DMA 100 85:12:0:3 
a [5 mol % Pd(OAc)2] / [10 mol% PCy3] 
b Conversion was determined through  
analysis of the 1H NMR of the crude reaction mixture. 
 
We investigated decreasing the reaction time to determine if this had any influence 
on the formation of by-product 99a, but this gave less favourable results at 15 mins 
(entries 5+6), and only comparable results at 20 mins, and with some loss in 
conversion (entry 7) and double bond isomerism (entry 8). Our optimal conditions 
therefore appeared those of entry 3 or entry 8, however again these results did not 
prove to be consistently reproducible, with variable amounts of 99a being formed. 
We were led to conclude that regardless of the heating induction method employed, 
the catalyst itself was not reliable at the elevated temperatures required for reaction, 
using either heating approach. A survey of the literature led us to attribute this to the 
formation of Pd black.75 
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2.3.4 Pd Black 
Dehalogenated benzylamines such as 99a have been reported to form on the surface 
of Pd black, a colloidal species that is known to result from an excess of Pd(0) in the 
reaction medium (Scheme 2.9).76,77 In the Heck reaction of aryl bromides and 
chlorides the rate-determining step is the oxidative addition, which can result in a 
build up of Pd(0) in solution. Further Pd(0) build up can also occur when electron 
rich aryl substrates which are by nature less reactive toward oxidative addition, are 
employed. Additionally, it is plausible to propose that a catalyst that is rapidly 
converted from Pd(II) to Pd(0) can also lead to a build up of Pd(0) in the reaction 
medium. As a consequence, the formation of soluble nanoparticles of Pd(0) is highly 
likely, and if these grow beyond a certain size the formation of insoluble palladium 
black is observed (Scheme 2.9) giving the reaction a black colour and leading to 
catalyst deactivation and the formation of dehalogenated products such as 99a.75 
 
Scheme 2.9 Pd black formation.75 
It should be noted that the formation of Pd black is thought to be the eventual 
deactivation pathway for all standard Pd catalysed reactions,75 but that in some cases 
such as ours, a combination of the elevated temperature, catalyst and substrate can 
lead to an acceleration of this decomposition mechanism. The capricious nature of 
this particular catalyst system under both standard and microwave heating, led us to 
investigate other possible palladium sources. 
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2.3.5 Herrmann-Beller Palladacycle  
We decided to examine the Herrmann-Beller palladacycle (100, Figure. 2.1) as it is 
well known as a highly effective and stable source of Pd(0) for the arylation of 
alkenes at elevated temperatures.78 Its use also has precedent in intramolecular 
cyclisation reactions.79 
 
Figure 2.1 Herrmann-Beller palladacycle. 
The reactivity of palladacycles is often attributed to high thermal stability, resulting 
in a slow-releasing source of Pd(0) and thus suppression of unwanted deactivation 
processes.80 While it is true that palladacycles are very thermally stable in the solid 
state, in solution they have actually been shown to be highly labile, undergoing facile 
transformations with and without fission of the palladacycle ring. Their ability to act 
as slow releasing reservoirs of Pd(0) is postulated to arise from their slow reaction 
with the other components of the reaction mixture, resulting in heterolytic cleavage 
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The application of 100 in conjunction with the MeNCy2 (the optimum base from our 
Pd(OAc)2 studies), gave relatively rapid cyclisation at a range of temperatures (130-
150 oC), but led to diminished selectivity for the ∆1,2 double bond isomer (Table 2.3, 
entries 1-3). 
Table 2.3 Herrmann-Beller palladacycle screening for the intramolecular Heck 
cyclisation of sulfonamide 94a. 
 
Entry Catalysta Base T (°C) t (min) Solvent Conversion (%)b Ratio 96a:97a:98a 
1 Palladacycle 100 MeNCy2 (4 eq) 130 360 DMF 85 39:38:23 
2 Palladacycle 100 MeNCy2 (4 eq) 140 180 DMF 98 44:31:25 
3 Palladacycle 100 MeNCy2 (4 eq) 150 110 DMF 88 52:16:32 
4 Palladacycle 100 AgF (1 eq) 140 180c DMF 76 65:23:12 
5 Palladacycle 100 Ag3PO4 (1 eq) 140 120 DMF 99 67:18:15 
6 Palladacycle 100 Ag2CO3 (1 eq) 140 70 DMF 99 85:13:2 
a [5 mol % Pd(0) source] b Conversion was determined through analysis of the 1H NMR of the crude 
reaction mixture. c No significant change observed after 180 min, even on leaving reaction for 24 h. 
 
With the aim of finding conditions that suppressed double bond migration through a 
cationic reaction pathway (see section 2.4),82 we screened the use of a range of Ag(I) 
salts (entries 4-6) as additives.83 We were pleased to discover that the use of Ag2CO3 
in conjunction with the Herrmann-Beller catalyst led to rapid conversion (70 min at 
140 oC), good double bond isomer ratios and excellent reproducibility. We found that 
modifying the equivalents of Ag2CO3 salt used as the base made very little difference 
to the double bond isomer ratio or conversion, with one equivalent being optimal. 
The application of the optimal cationic (entry 6) reaction conditions to cyclisation 
precursors 94a-e is reported in section 2.6. 
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2.3.6 Jeffery conditions 
Jeffery pioneered the application of the Heck reaction under aqueous conditions.84 
Most recently these conditions have been successfully applied by Tietze in a double 
Heck reaction using the Herrmann-Beller palladacycle to establish two cis-annelated 
ring junctions (Scheme 2.10) in good yield.85 
 
Scheme 2.10 Application of Jeffery conditions to a double Heck reaction.85 
a) Palladacycle 100, nBu4NOAc, DMF/CH3CN/H2O 1:1:0.2, 130 – 140 
oC, 1.5 h, 80%. 
 
As we had achieved success with palladacycle 100 under organic phase conditions, 
we applied a slightly modified version of these aqueous conditions to the cyclisation 
of sulfonamide 94a (Table 2.4), generating the required nBu4NOAc in situ from 
nBu4NBr and KOAc. 
 
Table 2.4 Application of modified Jeffery conditions to the cyclisation of 
sulfonamide 94a. 
 






1 Palladacycle 100, KOAc, nBu4NBr 140 120 DMF: MeCN: H2O 100 49:30:21 
2 Palladacycle 100, KOAc, nBu4NBr 150 40 DMF: MeCN: H2O 100 37:49:14 
3 Palladacycle 100, Ag2CO3, nBu4NBr 140 200 DMF: MeCN: H2O 74 56:34:10 
a [5 mol % Pd(0) source] b 1:1:0.2 ratio c Conversion was determined through analysis of the 1H NMR 
of the crude reaction mixture. 
 
We were pleased to discover that the aqueous conditions worked well using a neutral 
system (KOAc/nBu4NBr) to give a mixture of double bond isomers. In contrast to 
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the normal phase neutral cyclisation conditions reported in Table 2.3 that reach 
completion in 180 mins at 140 oC, these aqueous conditions take only 40 mins to 
give total conversion at the same temperature (entry 2), offering a significant 
improvement if a mixture of double-bond isomers was desired. However when we 
switched KOAc for Ag2CO3 to test the reaction under conditions that favoured a 
cationic pathway this led to incomplete conversion (entry 3) and a significant degree 
of double bond isomerism. As our initial aim was to obtain conditions for the 
cyclisation of sulfonamide 94a to afford predominantly one double bond isomer 
product, we did not pursue these aqueous conditions any longer. 
 
2.3.7 Pd(dppf)Cl2 
We examined the use of one further catalyst, Pd(dppf)Cl2 (Table 2.5). While this had 
been reported in the literature as a successful catalyst for Pd-catalysed cross-
couplings at 80 oC,86 we found that only low conversions were obtained under both 
neutral and cationic conditions at this temperature (22 - 50%). In addition we had no 
success in obtaining complete conversion of starting material in the presence of 
Ag2CO3 at any temperature (entries 3-5). However, complete conversion was 
achieved by employing Pd(dppf)Cl2 under neutral conditions at 140 
oC, leading to a 
mixture of double bond isomer products (entry 2). 
 








1 MeNCy2 80 2 DMF 22 - 
2 MeNCy2 140 2 DMF 100 37:49:14 
3 Ag2CO3 80 16 DMF 50 47:34:19 
4 Ag2CO3 140 16 DMF 53 69:21:10 
5 Ag2CO3 160 16 DMF 59 85:9:6 
a [5 mol% Pd(0) source] b Conversion was determined through analysis of the 
 1H NMR of the crude reaction mixture. 
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As our optimum conditions for obtaining predominantly the ∆1,2 double bond isomer 
were obtained using palladacycle 100 under cationic conditions (Table 2.3, entry 6), 
these conditions were taken on and applied to the range of amine and carbamate 
substrates in hand (see section 2.6).  
 
2.4 Neutral vs Cationic 
A double catalytic cycle for the Heck reaction, documenting both a neutral and a 
cationic Heck reaction is shown in Scheme 2.11. Both cycles undergo similar 
oxidative addition steps to afford the Pd(II) intermediate 104 as shown. In the case of 
the cationic pathway, the Ag(I) ion abstracts the halide from the surface of 104, 
generating the cationic Pd(II) intermediate 105. Following migratory insertion and 
β–hydride elimination this affords cationic intermediate 106. It is thought this 
undergoes reductive elimination far faster than its neutral counterpart 107, resulting 
in rapid regeneration of Pd(0) and an increased rate of reaction (Table 2.3 entry 2 vs 




Scheme 2.11 The Cationic and Neutral Heck catalytic cycles.82 
 
The rapid reductive elimination step of the cationic cycle also results in decreased 
double bond isomerism. This is because such isomerism occurs via re-addition of the 
Pd(II) intermediate (106 or 107) to the alkene (108 or 109), followed by β-H 
elimination with an alternative proton. If the Pd(II) intermediate 106 rapidly 
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undergoes reductive elimination, as in the case of the cationic cycle, it is not able to 
participate greatly in the re-addition/β-H elimination sequence (Scheme 2.12), and 








2.5 Product identification 
2.5.1 Double bond isomers 
The identity of 96a-98a as double bond isomers was confirmed when a mixture of 
the compounds was treated under hydrogenation conditions to give a single saturated 
product 110 (Scheme 2.13). This process also told us that we had not made any of 
the bridgehead double bond isomer 95a, as hydrogenation could occur at either face 
of this phenanthridine giving rise to both the cis and trans ring junction saturated 
products. 
 
Scheme 2.13 Double bond isomer conversion to a single product. 
a) H2, Pd/C, MeOH, r.t., 16 h, 60 %. 
 
In order to determine the structure of each double bond isomer in the product 
mixture, they were first separated by HPLC, followed by full characterisation using 
1D and 2D NMR techniques. We initially carried out COSY and HSQC NMR 
spectroscopy to identify the carbon backbone of each product. The COSY then 
enabled us to identify the ∆2,3 isomer, as in keeping with its structure, this product did 
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not show any correlations between either of the ring junction protons and the alkene 
protons.  
To distinguish between the ∆1,2 and ∆3,4 isomers we used 2D NOESY spectroscopy 
(Figure 2.2 and Figure 2.3). Key correlations for identifying the ∆1,2 product 96a 
include aromatics - alkene (Ar – a) and benzylic methylene - methylene of the 
cyclohexene ring - (g2 - d). In addition, the absence of the following correlations 
supported our structural assignment: (g – b), (h – d), (e – Ar), (d – Ar). Key 
correlations for identifying the ∆3,4 product 98a include benzylic methylene - alkene 
(g2 – d) and aromatics – cyclohexene ring methylene - (Ar – a1). As above, the 
absence of the following correlations supported our structural assignment: (g – a),  
(g – b), (e – b), (d – Ar), (e – Ar). 
 
 
Figure 2.2. 2D NOESY spectrum for ∆1,2 isomer 96a. 
Key correlations: (Ar – a), (g2 – d). 
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Figure 2.3. 2D NOESY spectrum for ∆3,4 isomer 98a. 
Key correlations: (g2 –- d), (Ar – a1). 
 
Fortunately, each double bond isomer could be clearly identified in the 1H NMR 
spectrum, by the signal of its ring junction proton ‘h’ (Figure 2.4). This allowed 
quantification of the double bond isomer ratio for each reaction without undertaking 









Figure 2.4 Double bond isomer quantification for 96a-98a. 
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2.5.2 Cis ring junction stereochemistry 
As suggested by the phenanthridone literature precedent,70-74 Heck cyclisation of 
precursor 94a gave the cis-ring fused phenanthridine product. Similar selectivity has 
also been reported for the Heck cyclisation of related carbocyclic systems.87a 
Confirmation of the cis-ring junction stereochemistry was gained later in this study 
through the conversion of a mixture of 96b-98b to saturated phenanthridine 112 
(Scheme 2.14), and comparison of its 1H and 13C NMR data with the cis [δ 2.60 (1H, 
m) and 3.12 ppm (1H, m)] and trans [δ 2.36–2.49 ppm (2H, m)] ring junction 
phenanthridines reported in the literature.87b This result was in good accord with the 
strong nOE observed across the ring junction in all the double bond isomer 
phenanthridine products (Figure 2.2 and Figure 2.3 protons h – e). 
 
 
Scheme 2.14 Cis ring junction confirmation. 
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2.6 Application of cationic conditions to protected amines 
Our optimal cationic conditions, reported in section 2.3.5 were tested against our 
range of carbamate and amine cyclisation precursors to probe substrate scope.  
 
Table 2.6 Application of optimal cationic conditions.a 
 
Entry Substrate P t (min) Yield (%) Ratio (96:97:98) 
1 94a SO2Me 70 99 85:13:2 
2 94b Boc 120 99 83:15:2 
3 94c Cbz 120 99 92:6:2 
4 94d Bn 120 92 100:0:0b 
5 94e PMB 160 76 97:3:0 
a Conditions: aryl halide (1 eq), palladacycle 100 (5 mol%), Ag2CO3 (1 eq), DMF, 140 °C. 
b Minor 
isomer peaks could not be quantified. 
 
In all cases our optimum conditions employing the Herrmann-Beller catalyst 100 
gave excellent conversions to the phenanthridine core, strongly favouring the ∆1,2 
isomer (Table 2.6). With the exception of the PMB-protected amine precursor 94e, 
the reactions were complete in <2 h. The Bn and PMB protected analogues in 
particular showed excellent selectivity for the ∆1,2 isomer. 
The identity and ratios of the Boc and Cbz-protected products (96b-98b and 96c-98c 
respectively) were determined by direct correlation of their 1H NMR spectra with 
their sulfonamide counterparts (96a-98a); and the assignment of minor peaks was 
confirmed by TOCSY experiments. For the Bn and PMB products, extensive 2D 
NMR analysis confirmed that the major product in each of these two cases was the 
∆1,2 isomer (96d and 96e respectively), whilst the ∆2,3 and ∆3,4 minor products, where 
visible, were assigned by analogy with their sulfonamide counterparts. 
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2.7 Application to a gem dimethyl analogue 
In order to assess the utility of these cationic conditions on a substrate biased towards 
the formation of a single double bond isomer, we chose to synthesise the gem 
dimethyl phenanthridine analogue, 114. The sulfonamide protected cyclisation 
precursor 115 was readily accessed (Scheme 2.15) through conversion of dimedone 
116 to enol ether 117;88 conversion to known enone 118 via a reduction and 
subsequent reaarrangement on silica;89 reduction of 118 to the corresponding enol 
119 and conversion to allylic bromide 120 using CBr4;
90,91 coupling of bromide 120 
with 2-bromobenzylamine as described in section 2.3.1; and finally sulfonamide 
protection of the amine.  
 
Scheme 2.15 Synthesis and cyclisation of gem dimethyl analogue 114. 
a) CAN, MeOH, r.t., 16 h, 73%; b i) LiAlH4, Et2O 0 
oC → r.t., 1 h; b ii) silica, CH2Cl2, 3 h, 91%; c) 
LiAlH4, Et2O, 0 
oC, 40 min, 72%; d) CBr4, PPh3, Et2O, r.t., 2 h, 67%; e) o-BrPhCH2NH2⋅HCl, 
iPr2NEt, 
MeCN, r.t., 16 h, 63%; f) MeSO2Cl, Et3N, CH2Cl2, r.t., 3 h, 65%; g) 100 (5 mol%), Ag2CO3, DMF, 
140 oC, 2 h, 99%. 
 
Heck cyclisation of 115 employing the Herrmann-Beller catalyst resulted in 
quantitative conversion in 2 h to a colourless solid which was shown to be the 
desired ∆1,2 3,3-dimethyl-tetrahydrophenanthridine 114. This result clearly shows the 
efficiency of our cationic cyclisation conditions, and illustrates their potential utility 
in systems with additional functionality on the cyclohexenyl ring.  
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2.8 Diversity based applications of the phenanthridine cyclisation reaction 
2.8.1 Herrmann-Beller neutral conditions 
As reported in Chapter 1, the synthesis of natural-product-like libraries based on 
strategies which make use of the rapid introduction of stereochemical, structural and 
skeletal diversity,14 is one which has gained prominence in recent years as a means to 
efficiently cover chemical space.6,12 The initial results obtained for the cyclisation of 
sulfonamide 94a under neutral conditions in DMF or DMF:MeCN:H2O using the 
Hermann-Beller catalyst (Table 2.3, entry 2 or Table 2.4 entry 2) offer considerable 
potential in this direction. In one step, the phenanthridine core unit is formed, whilst 
at the same time the potential for further diversification, through reaction of the 
newly-formed double bond at each of the three positions, ∆1,2, ∆2,3 and ∆3,4, is 
introduced. In combination with different amine precursors a large and diverse 
compound library based on the phenanthridine core might be rapidly assembled 
(Scheme 2.16). 
 
Scheme 2.16 Diversity oriented synthesis of a phenanthridine library. 
In order to determine the potential versatility of such an approach we screened the 
use of the Herrmann-Beller catalyst across the full range of precursors 94a-e (Table 
2.7). Although our initial result for the neutral cyclisation of sulfonamide 94a under 
Jeffery conditions offered a more rapid cyclisation than that in DMF, we decided that 
the latter conditions had the advantage of giving a larger proportion of each isomer 
(37:49:14 Jeffery vs 44:31:25 in DMF) and thus used these in our screen.  
We discovered that under these neutral conditions (Table 2.7) the Boc and Cbz 
protected substrates 94b and 94c behaved in a similar manner to 94a, giving a double 
bond isomer profile suitable for diversity-based applications. The Bn and PMB 
protected substrates 94d and 94e however, gave predominantly the ∆1,2 isomer 
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rendering them unsuitable as protecting groups for the synthesis of a DOS library of 
phenanthridines. 
Table 2.7 Application of neutral Herrmann-Beller conditions.a 
 
Entry Substrate P t (h) Yield (%) Ratio (96:97:98) 
1 94a SO2Me 3h 98 44:31:25 
2 94b Boc 3 h 95 36:38:26 
3 94c Cbz 3 h 99 33:39:28 
4 94d Bn 5 h 93 83:8:9 
5 94e PMB 5 h 93 74:13:13 
a Conditions: aryl halide (1 eq), MeNCy2 (4 eq), palladacycle 100 (5 mol%), DMF, 140 °C. 
 
2.8.2 Low temperature alternative 
2.8.2.1 Background information 
Although we were satisfied that the neutral conditions reported above would prove 
suitable for application in a DOS library, we examined one further catalyst system 
during our screening studies that offered an alternative set of low temperature 
conditions. As reported in section 2.1, the highly reactive catalyst (tBu3P)2Pd has 
been used to conduct intermolecular Heck coupling reactions at room temperature.62 
It has limited precedent in intramolecular Heck cyclisations,92,93 with only one 
example of its use at low temperatures (40 oC, Scheme 2.17),94 and no examples of 
its application in a system similar to ours, but we were keen to examine if it could 
offer us a low temperature set of conditions for our cyclisation.  
 
Scheme 2.17 Low temperature intramolecular Heck.94 
a) Pd2(dba)3 (1 mol%), 
tBu3PHBF4 (4 mol%), DABCO (3 eq), 40 
oC, dioxane, 60 h, 92%. 
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We were initially interested in the use of this particular catalyst system as a means of 
accessing predominantly the ∆1,2 double bond isomer. A recent literature report95 
examining the reductive elimination of HCl from L2PdHCl stated that for L = 
tBu3P 
the process was very facile, suggesting to us that double bond isomerism might be 
disfavoured as in a cationic Heck reaction. Upon X-ray crystallographic analysis of 
the hydride species, this was attributed to the steric bulk of the ligands, (Figure 2.5). 
When compared to the corresponding PCy3 hydride species, where the LL angle is 
180o, it can be seen that the tBu3P ligands are forced away from the chlorine, with an 
LL angle of 161o at the cost of increased steric strain between the ligands and the 
hydride. This strain is relieved upon reductive elimination to generate Pd(tBu3P)2 
thus providing a driving force for the process. We anticipated that an even greater 
relief of steric strain might be accomplished if the hydride species contained a 







Figure 2.5 Space-filling models based on the X-ray crystal structures of L2PdHCl 











Results and Discussion 1 
53 
2.8.2.2 Application to protected amine cyclisation precursors 
With this in mind, we explored the use of this catalyst with cyclisation precursors 
94a-e (Table 2.8). The intermolecular reactions are typically conducted in dioxane,61 
but the use of this solvent in our system led to very low conversions. However, a 
simple solvent switch to MeCN gave much more promising results albeit to a 
roughly equal mixture of all three double bond isomers, not to predominantly the ∆1,2 
isomer as predicted from the mechanistic precedent.  
We observed complete conversion of sulfonamide 94a to products 96a-98a at room 
temperature, however, the Boc and Cbz protected precursors 94b and 94c required a 
slightly elevated temperature (50 °C) for the cyclisation reaction to proceed to 
completion. Intriguingly, the Bn and PMB-protected substrates 94d and 94e showed 
little or no reactivity at either temperature. 
Table 2.8 Cyclisation under low-temperature conditions.a 
 
Entry Substrate P Method t (h) Yield (%) Ratio (96:97:98) 
1 94a SO2Me A 9 99 12:65:23 
2 94a SO2Me B 4 99 55:41:4 
3 94b Boc A 40 50 34:43:22 
4 94b Boc B 7 95 34:37:29 
5 94c Cbz A 40 64 53:34:13 
6 94c Cbz B 7 85 36:5:59 
7 94d Bn A 72 no reaction -- 
8 94d Bn B 40 23 n.d.b 
9 94e PMB A 72 no reaction -- 
10 94e PMB B 40 no reaction -- 
a Conditions: Method A: Aryl halide (1 eq), Pd2(dba)3 (5 mol%), 
tBu3PHBF4 (10 mol%), MeNCy2 
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2.8.2.3 Application to aryl iodides 
Aryl iodides are known to undergo oxidative addition more rapidly than their bromo 
or chloro counterparts, so we decided to synthesise the Boc and Cbz aryl iodides to 
determine whether cyclisation could be facilitated at room temperature. As 2-
iodobenzylamine is not commercially available, our synthesis of cyclisation 
precursors 124b and 124c started from 2-iodobenzoic acid 125 (Scheme 2.18). This 
was readily converted into the acid chloride, followed by treatment with aqueous 
ammonia to generate amide 126. Dehydration of amide 126 gave nitrile 127, which 
was converted into amine 128 by a LiAlH4 mediated reduction. Conversion to the 
cyclisation precursors 124b and 124c proceeded in a similar manner to that 
previously shown. 
 
Scheme 2.18 Synthesis of Boc and Cbz aryl iodide cyclisation precursors. 
a i) SOCl2, 60 
oC, 3 h; a ii) NH4OH,  r.t., 16 h, 61%; b) SOCl2, 60 
oC, 3 h, 99%; c) LiAlH4, AlCl3, 
Et2O, 40 
oC, 3 h, 52%; di) iPr2NEt, 3-bromocyclohexene, MeCN, 16 h; ii) HCl in Et2O,  99%; e) 124b 
P=Boc, Boc2O, Et3N, CH2Cl2, 16 h, 49%; f) 124c P=Cbz, NaH, DMF, 0 
oC, 30 min, then 
benzylchloroformate, r.t., 16 h, 82%. 
Surprisingly however, when we subjected aryl iodides 124b and 124c to the room 
temperature cyclisation conditions shown in Table 2.8, we only observed <20% 
conversion in each case after 16 h reaction. We were very surprised by these results 
and can only conclude that the additional steric bulk of the iodine on the Pd hindered 
the cyclisation from going to completion. Further evidence to support the 
incompatibility of (tBu3P)2Pd with bulky substrates comes from the failed cyclisation 
of our 3,3-dimethyl cyclisation precursor 115 at either r.t. or 50 oC using this 
catalyst. 
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2.8.2.4 Rationalising catalyst behaviour 
While we were pleased to have an alternative set of mild conditions for our Heck 
cyclisation, we were puzzled as to the large degree of double bond isomerism 
observed, especially in light of the report illustrating the facile reductive elimination 
of HCl from (tBu3P)2PdHCl.
95 Further examination of the literature suggested that 
when bulky phosphine ligands are employed, sterically-driven dissociation of one 
ligand occurs prior to the oxidative addition, giving rise to a mono-ligated Pd(0) 
(Scheme 2.19).60 If such a mono-ligated Pd(0) is the catalytically active species, then 
clearly the above arguments regarding steric-promoted reductive elimination are not 
valid, perhaps rationalising why double bond isomerism was not minimised. 
 
 
Scheme 2.19 Generation and reaction of a mono-ligated Pd(0).60 
L = Bulky phosphane with high σ-donicity; X= I, Br, Cl, OTs, OTf. 
 
It is clear both from our results and from the literature precedent, that this mono-
ligated Pd(0) species is also a highly reactive catalyst. It has long been proposed that 
high reactivity (TON) in the Heck reaction arises from coordinative unsaturation at 
Pd(II).96 Indeed, pre-dissociation of 16e-Pd(II) complexes to yield coordinatively 
unsaturated 14e-Pd(II) intermediates have been convincingly shown to offer a low 
free-energy pathway to transmetallation.97 It seems plausible therefore to suggest that 
weak σ-donor ligands as opposed to strong σ-donor ligands (such as the 
trialkylphosphines), would lead to more rapid ligand dissociation and coordinative 
unsaturation. However, contrary to this, trialkylphosphine ligands are able to rapidly 
generate mono-ligated Pd(0) species, but this arises not from their σ-donor capability 
but rather from their ability to create coordinative unsaturation by steric bulk. This 
creates a very powerful catalytic species that is further stabilised by the strong σ-
donicity of the ligand.  
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The coordinatively unsaturated nature of the L-Pd(0) species renders it highly 
reactive toward oxidative addition. This permits the successful Pd-mediated cross-
coupling of typically unreactive substrates e.g aryl chlorides, and electron-rich 
aromatics, and also permits the Heck reaction to be performed at non-elevated 
temperatures as we have observed. 
Although we had initially employed the (tBu3P)2Pd catalyst system in an attempt to 
obtain one isomer product, we realised the potential our results offered toward our 
DOS library as complementary set of conditions for the cyclisation of thermally 
unstable and poorly reactive substrates.  
 
2.8.3 Attempted cyclisation of an aryl chloride precursor 
In light of the literature reports illustrating the low temperature (<50 oC) 
intermolecular Heck coupling of aryl chlorides using (tBu3P)2Pd,
61,62 we were 
curious to examine what effect the catalyst system would have on an aryl chloride 
variant of our cyclisation precursor. Aryl chloride 130a was synthesised in a similar 
manner to its bromo and iodo counterparts, via alkylation of commercially available 
2-chlorobenzylamine with 3-bromocyclohexene, followed by methylsulfonylation of 
the secondary amine 132. 
 
Scheme 2.20 Synthesis of an aryl chloride cyclisation precursor 130a. 
a i) iPr2NEt, 3-bromocyclohexene, MeCN, 16 h; a ii) HCl in Et2O, 66%. b) MeSO2Cl, Et3N, CH2Cl2, 
r.t., 16 h, 60%.  
 
We first examined the cyclisation of aryl chloride 130a using dioxane as the solvent, 
but we observed no reaction (Table 2.9) at either r.t. or 120 oC. Switching the solvent 
for MeCN did little to improve the situation, giving only trace conversions (<1%) at 
both r.t. and 50 oC. We decided to employ our Herrmann-Beller palladacycle 
conditions since we had no success with the (tBu3P)2Pd catalyst. Under cationic 
conditions we observed only 8% conversion after 16 h, and using the neutral system 
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we observed 15% conversion, although 11% of this was composed of the 
dehalogenated product 99a.  
 
Table 2.9 Study of Heck cyclisation conditions for aryl chloride 130a. 
 
Entry Conditionsa T 
(°C) 





tBu3PHBF4, MeNCy2 r.t 16 dioxane 0 - 
2 Pd2(dba)3, 
tBu3PHBF4, MeNCy2 120 16 dioxane 0 - 
3 Pd2(dba)3, 
tBu3PHBF4, MeNCy2 r.t 16 MeCN Trace - 
4 Pd2(dba)3, 
tBu3PHBF4, MeNCy2 50 16 MeCN Trace - 
5 Palladacycle 100, Ag2CO3 140 16 DMF 8 n.d 
6 Palladacycle 100, MeNCy2 140 16 DMF 15 27:0:0:73 
7 Palladacycle 100, MeNCy2 
tBuNBr 140 16 DMF - - 
8 Pd2(dba)3, 
tBu3PHBF4, NaOAc 150 16 
tBuNBr - - 
a [5 mol% Pd(0) source] / [10 mol% ligand] b Conversion was determined through analysis of the 1H 
NMR of the crude reaction mixture. 
 
We examined the literature and discovered no reports of (tBu3P)2Pd being 
successfully employed in the intramolecular Heck reaction of an aryl chloride and 
only three examples of different catalyst systems being used for such a purpose.98-100 
Two of these literature reports employed the use of one equivalent of tetra-n-
butylammonium bromide or chloride to achieve poor to moderate conversions (28-
70%), but when we tried this on our palladacycle catalysed neutral conditions we 
observed no trace of cyclisation (entry 7).98 The other report also used tetra-n-
butylammonium bromide, but this time as the solvent.99. However, again we 
observed no conversion using this method (entry 8).  
Therefore we were unable in our short investigation to generate reaction conditions 
for the cyclisation of aryl chloride 130a. The abundance of aryl chloride building 
blocks commercially available (as opposed to iodides and bromides) would make this 
area very worthwhile for further investigation, especially in light of the lack of 
successful conditions in the literature. 
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2.9 Mechanistic studies 
2.9.1 Amine cyclisation precursors 
The first mechanistic issue we wished to address was the minimal double bond 
isomerism observed upon the cyclisation of amine substrates 94d and 94e as opposed 
to sulfonamide and carbamate substrates 94a-c. Under cationic conditions both the 
amine cyclisations showed exceptional selectivity for the ∆1,2 isomer, well in excess 
of the amide substrates. Under the palladacycle catalysed neutral conditions, 94d and 
94e both gave strong selectivity for the ∆1,2 isomer whereas the amide substrates 
gave a spread of the different isomer products. Additionally, they also showed 
minimal reactivity under the (tBu3P)2Pd catalysed conditions, as compared to the 
amide substrates. 
We postulated that perhaps in the cyclisation of these amine precursors, the 
substrates themselves were acting as bases, capable of minimising isomerism. In 
order to test this theory we decided to synthesise dibenzylcyclohexylamine100 133, a 
simplified analogue of the benzyl protected cyclisation precursor 94d and use this 
instead of MeNCy2 as the base in one of our amide Heck cyclisations.  
 
Scheme 2.21 Synthesis of dibenzylcyclohexylamine 133.100 
a i) Benzyl bromide, NaH, 16 h, r.t; a ii) H2, Pd/C, MeOH/EtOAc, 16 h,  r.t., 63%; b) BnBr, NaH, 16 
h,  r.t., 82%.  
 
We chose to test it on the cyclisation of sulfonamide analogue 94a as this gave rise to 
diverse range of double bond isomers under our standard neutral conditions and 
would provide a suitable comparison (Scheme 2.22). However, we discovered that 
while dibenzylcyclohexylamine100 proved to be an excellent base with regard to 
conversion (100%), it furnished significant quantities of each of double bond isomers 
96a-98a.  
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Scheme 2.22 Testing dibenzylcyclohexylamine100 as a base for the Heck reaction. 
a) Palladacycle 100 (5 mol%), Bn2NCy 133 (4 eq), DMF, 140 
oC, 16 h, 99%. 
 
The investigation shown in Scheme 2.22 dismisses the possibility of substrates 94d 
and 94e acting as bases intermolecularly, but not intramolecularly. Following β-
hydride elimination, the Pd-H species ends up on the same face of the cyclohexene 
ring system as the amine nitrogen functionality. The close proximity of the amine 
nitrogen to the Pd-H species means that intramolecular reductive elimination could 
be facilitated rapidly, resulting in minimal double bond isomerism. This hypothesis 
could be examined by studying the cyclisation of substrates 94d or 94e in the 
absence of base. 
 
2.9.2 Sulfonamide and carbamate substrates 
We have shown very different results with regard to the double bond isomer ratio 
obtained for the sulfonamide and carbamate precursor cyclisations, using each of our 
optimised reaction conditions. In the case of the cationic cyclisation this can be 
easily rationalised as arising from the rapid reductive elimination step, as reported in 
section 2.4. However, under the neutral conditions, the double bond isomer profile 
obtained using different catalysts (Pd(OAc)2, palladacycle 100, and (
tBu3P)2Pd) 
shows dramatic variation, (e.g. from 92:6:2 to 33:39:28 for cyclisation of 94a), that 
cannot be so easily rationalised. 
Beller has concluded that in the intermolecular Heck reaction of arylbromides with 
cyclohexene and cyclopentene, double bond migration is predominantly catalysed by 
the base used in the reaction, and not by a HPdX complex (Table 2.10).101 In this 
simple intermolecular study, the choice of solvent (entry 1 vs 3) and base (entries 1 
vs 2 and 5 vs 6) was shown to have an important influence on the extent of C-C 
double bond migration, whilst different catalysts showed no significant changes in 
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selectivity (entries 1 vs 4 and 6 vs 7). It may be argued that the electron-withdrawing 
nature of the acetate group aids base-catalysed isomerism, however similar variation 
in the double bond isomer ratio was also observed for other aryl bromides (m-CF3, p-
OMe, phenyl). 
Table 2.10 Base/Solvent catalysed double bond isomerism of cycloalkenes.101 
 




1 137 DMA Pd(OAc)2/2PPh3 NaOAc 96 4:17:79 
2 137 DMA Pd(OAc)2/2PPh3 
iPr2NEt 63 1:33:66 
3 137 DMSO:DMA (4:1) Pd(OAc)2/2PPh3 NaOAc 59 2:8:90 
4 137 DMA Palladacycle 100 NaOAc 89 7:15:78 
5 138 DMA Pd2(dba)3.dba/PCy3 NaOAc 99 39:45:16 
6 138 DMA Pd2(dba)3.dba/PCy3 Na2CO3 99 91:7:2 
7 138 DMA Pd(OAc)2/2PPh3 Na2CO3 98 83:13:4 
a [5 mol% Pd(0) source]; b  1 eq base, 120-140 oC. 
In sharp contrast, our study demonstrates that in the intramolecular neutral Heck 
reaction where the two components are linked as the protected benzylamine, the 
palladium catalyst plays a pivotal role in double bond isomerism under otherwise 
identical conditions (Pd(OAc)2 vs HB or (
tBu3P)2Pd, with MeNCy2 in DMF). To 
further probe why different catalysts were giving rise to such different results, we 
carried out a series of mechanistic studies. 
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2.9.3 Isomer variation with time 
To determine at what point isomerism occurred, we monitored the double bond 
isomer ratio with time for each of our optimised reactions using sulfonamide 
cyclisation precursor 94a. Aliquots were taken from each reaction at the appropriate 
timepoint and the composition was analysed using 1H NMR spectroscopy. 
Integration of the three double bond isomer peaks highlighted in section 2.5, allowed 
us to plot the following graphs.  






































Figure 2.6 Isomer variation for cationic cyclisation of 94a using palladacycle 100. 
Conditions: 94a (1 eq), palladacycle 100 (5 mol%), Ag2CO3 (1 eq), DMF, 140 °C  
 
First of all we monitored the cationic cyclisation using the Herrmann-Beller 
palladacycle (Figure 2.6). The graph clearly shows that the ∆1,2 isomer is the major 
product at all times, holding true to the theory of rapid reductive elimination. With 
this reaction, no change in double bond isomer ratio is visible after the onset of the 
reaction, suggesting that once decomplexation of the catalyst occurs from the alkene, 
no recomplexation and subsequent isomerism occurs.  
We next examined the Hermann-Beller palladacycle under neutral conditions 
(Figure 2.7). This graph illustrates an initial induction period (0-90 mins) where 
some variation in the ∆1,2 to ∆2,3 ratio occurs. After this point however, no significant 
variation in the ratio of the products is observed even though the reaction takes up to 
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180 minutes to reach completion (Table 2.3, entry 2). This again suggests that once 
the catalyst has decomplexed from the alkene, no further isomerism occurs. 



































Figure 2.7 Isomer variation for neutral cyclisation of 94a using palladacycle 100. 
Conditions: ArBr (1 eq), MeNCy2 (4 eq), palladacycle 100 (5 mol%), DMF, 140 °C. 
 
Finally, we studied the (tBu3P)2Pd catalysed cyclisation (Figure 2.8) at room 
temperature, which clearly shows that the ∆2,3 isomer is the favoured product from 
the outset of the reaction and that there is essentially no change in double bond 
isomer ratio from the outset of the reaction. 





































Figure 2.8 Isomer variation for neutral cyclisation of 94a using (tBu3P)2Pd. 
Conditions: ArBr (1 eq), Pd2(dba)3 (5 mol%), 
tBu3PHBF4 (10 mol %), MeNCy2 (4 eq), MeCN, r.t. 
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2.9.4 Resubmission experiments 
The double bond isomer ratio monitoring experiments all suggest that further 
isomerism does not occur once the catalyst has decomplexed from the alkene. To test 
this hypothesis we decided to execute a series of experiments where the sulfonamide 
∆2,3 isomer 97a was resubmitted to the optimised reaction conditions to observe if 
isomerism had occurred (Table 2.11). In addition to probing our decomplexation 
hypothesis, these studies also gave us the opportunity to observe whether double 
bond isomerism was base-catalysed.101 
 
Table 2.11 Resubmission experiments. 
 
Entry Conditions T 
(oC) 
T (h) Ratio (96a:97a:98a) 
1 Palladacycle 100, MeNCy2, DMF 140 16 0: 100: 0 
2 Palladacycle 100, Ag2CO3, DMF 140 16 0: 100: 0 
3 Pd2(dba)3, 
tBu3PHBF4, MeNCy2 MeCN r.t 72 0: 100: 0 
4 Palladacycle 100, MeNCy2, DMF, HBr (1 eq) 140 72 4: 96: 0 
5 CH3COOH (excess), DMF 140 72 19: 78: 8 
a [5 mol% Pd(0) source] b Conversion was determined through analysis of the 1H NMR of the 
crude reaction mixture. 
Resubmission of sulfonamide ∆2,3 isomer 97a to each of the three optimised 
conditions (entries 1-3) resulted in no double bond isomerism. Each of these 
conditions should have permitted double bond migration to occur if, it were base-
catalysed, so clearly in our case double bond isomerism results from other factors.  
Although entries 1-3 suggest that no isomerism occurs following decomplexation, we 
had concerns that we had not taken into account the equivalent of HBr liberated 
during the reductive elimination process. We wondered if the catalyst system was 
able to turn over without this present, and whether our simple resubmission 
experiment was an accurate reflection of the environment faced by an alkene 
Results and Discussion 1 
64 
following reductive elimination. We repeated the resubmission of sulfonamide ∆2,3 
isomer 97a to the neutral palladacycle catalysed conditions, this time including one 
equivalent of HBr. As indicated in Table 2.11 slight double bond isomerism was 
observed, but the extent of this did not explain the ratios observed under normal 
cyclisation circumstances, especially since the time period of the current experiment 
was significantly longer (72 h vs 6 h).  
Out of interest, we examined the effect of acid on our phenanthridine system (entry 
5) and the results clearly show that a significant proportion of the sulfonamide ∆2,3 
isomer 97a undergoes conversion to the other isomers after 72 hours at elevated 
temperature. Although this has no bearing on our cyclisation reactions, it is an 
interesting result, which is in contrast to the previous report that isomerism in an 
intermolecular reactions is base-catalysed.101 In light of this result we propose that 
the minimal isomerism observed in the HBr resubmission experiment (entry 4) is 
actually a result of acid-catalysed migration. 
Results and Discussion 1 
65 
2.9.5 Decomplexation vs hydro/dehydropalladation 
From these results, it must therefore be concluded that the double bond isomer ratio 
is established at the outset of the reaction, and does not change following 
decomplexation of the catalyst from the alkene. The double bond isomer ratio 
obtained in these intramolecular Heck cyclisation reactions must therefore be a 
product of the differing rates of decomplexation of each catalyst as compared to the 
rate of hydro-palladation/dehydropalladation (Scheme 2.23 and Scheme 2.24).102 
 
 





Scheme 2.24 Hydro-palladation/dehydro-palladation for the neutral reaction. 
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2.10 Conclusions 
We have successfully investigated and developed conditions for the Heck cyclisation 
of various sulfonamide, carbamate and amine precursors to give phenanthridines.49 If 
one double bond isomer is required, the reaction can be performed under cationic 
conditions using the Herrmann-Beller palladacycle 100 to give predominantly the 
∆
1,2 isomer. These conditions have been shown to achieve high yielding conversions 
(76-99%) to the Heck products in less than two hours, and have proved successful in 
a system with additional steric bulk on the cyclohexenyl ring. 
 
We have also developed two sets of conditions for the synthesis of a mixture of 
phenanthridine double bond isomers using the Heck reaction, which we intend to 
utilise in the preparation of a DOS library (Chapters 3 and 4). Palladacycle 100 can 
be employed at elevated temperature using the sulfonamide and carbamate substrates 
to give the desired product mixture in less than 5 hours, with excellent yield (93-
99%). Alternatively, the highly reactive Fu catalyst (tBu3P)2Pd can be used for the 
low temperature (r.t. or 50 oC) cyclisation of the sulfonamide and carbamate 
precursors, to give the double bond isomer mixture in less than 9 hours and with 
excellent conversions (85-99%). 
 
We found that careful choice of the catalyst and reaction conditions employed had a 
significant effect on the outcome of the products, and our mechanistic investigations 
attribute this to either a cationic vs neutral pathway, or differing rates of 
decomplexation as compared to the rate of hydro-palladation/dehydropalladation for 
each catalyst, depending on the particular reaction in question. 
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As discussed in Chapter 2, we realised the potential our two sets of neutral 
cyclisation conditions had toward the development of a DOS library. Each 
cyclisation performed under these conditions furnished three skeletons, each with an 
alkene handle suitable for further functionalisation.49 In addition to this, further 
incorporation of diversity could be accomplished by any of the three means outlined 
in Chapter 1, namely appendage (or building block) variation, introduction of 
stereochemistry, or by further skeletal diversification.  
Building block variation of the A-ring was investigated through the synthesis (and 
subsequent cyclisation) of various aryl and heteroaryl Heck cyclisation precursors. 
We chose to investigate the introduction of stereochemical diversity by examining 
dihydroxylation protocols for the C-ring phenanthridine double-bond isomers. 
Finally, the introduction of skeletal diversity was examined using novel ring-
rearrangement metathesis reactions of the phenanthridine C-ring (Figure 3.1).  
 
 
Figure 3.1 Introducing diversity to the phenanthridine core. 
P= Protecting group. 
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3.2 Building Block Diversity 
We realised that the aromatic part of our phenanthridine core ring structure was an 
excellent component through which to investigate building block diversity. To this 
end we set about synthesising a range of suitable aromatic and heteroaromatic 
cyclisation precursors. 
 
3.2.1 Thiophene analogue 
Initial investigations in the area of building block diversity were based around the 
synthesis of a heteroaromatic thiophene equivalent of our standard sulfonamide 
protected phenanthridines 96a-98a. As a result we developed two synthetic routes to 
incorporate the heteroaromatic building block, both of which warrant discussion 
despite not being used in our final DOS library synthesis. 
 
Our first synthetic strategy started with methylation of 3-bromothiophene 152 to 
afford 2-methylthiophene 153 in excellent yield.103 This was followed by a radical 
bromination using NBS/AIBN to afford thiophenemethyl bromide 154.104 Attempted 
monoalkylation of 3-aminocyclohexene105 with thiophenemethyl bromide 154 
proceeded poorly giving the desired secondary amine in only 18% yield (Scheme 
3.1). This poor yield, coupled with the undesirable use of CCl4 earlier in the synthetic 
route, led us to investigate an alternative synthesis of amine 155. 
 
 
Scheme 3.1 First generation synthesis of a thiophene analogue. 
a) i) LDA, THF, 0 oC → -78 oC, 0.5 h; ii) MeI, -70 oC, 0.5 h, then r.t., 1 h, 99%; b) AIBN, NBS, CCl4, 
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Our second generation synthesis also began using 3-bromothiophene 152, this time 
performing an α-lithiation followed by anion trapping with DMF to afford 
carbaldehyde 156 in excellent yield (Scheme 3.2).106 The initial lithiation step must 
be performed at 0 oC as the competitive formation of the 5-lithiated thiophene is 
known to occur at -78 oC. We next attempted a reductive amination using 3-
aminocyclohexene105 but as in the first generation synthesis, secondary amine 155 
was obtained in very poor yield.107 The 3-aminocyclohexene used in both the 
coupling protocols was difficult to synthesise and purify, and we propose that this 
resulted in the poor conversions we observed in both cases. 
 
Scheme 3.2 Second generation synthesis of a thiophene analogue. 
a) i) LDA, THF, 0 oC, 0.5 h; ii) DMF, 0 oC → r.t., 2.5 h, 94%; b) i) 3-aminocyclohexene, iPr2NEt, 
PhMe, mol. sieves, 110 oC, 16 h; ii) Na(OAc)3BH, MeOH, 16 h, r.t., 16%; c) MeSO2Cl, Et3N, CH2Cl2, 
r.t., 16 h, 68%. 
 
Although neither route had proved to be particularly successful, we did manage to 
obtain sufficient quantities of amine 155 to take on in the synthetic sequence, and so 
sulfonamide 157 was synthesised in good yield using the previously reported 
conditions, giving us material to test our Heck cyclisation upon (Table 3.1). 
 
Table 3.1 Heck cyclisation of thiophene analogues 158-160. 
 








1 Palladacycle 100, Ag2CO3 140 2 DMF 91 77:16:7 
2 Palladacycle 100, MeNCy2 140 4 DMF 74 32:41:27 
3 Pd2(dba)3, 
tBu3PHBF4, MeNCy2 r.t 18 MeCN 25 80:20:n.d.
c 
4 Pd2(dba)3, 
tBu3PHBF4, MeNCy2 50 16 MeCN 55 76:15:9 
a 5 mol% Pd(0) source, 10 mol% ligand. b Conversion was determined through analysis of the 
1H NMR of the crude reaction mixture. c n.d. not determined. 
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We were pleased to discover that both of our palladacycle-catalysed Heck cyclisation 
conditions proved to be robust for this heteroaromatic analogue, giving similar 
reactivities and double bond isomer ratios to the aromatic substrates studied 
previously. Interestingly, (tBu3P)2Pd did not prove to be particularly reactive on 
heteroaromatic analogue 157, despite the success it had shown with the aromatic 
amides (see section 2.8.2), and unfortunately our best result was only 55% 
conversion at 50 oC (entry 4). Additionally, we were surprised to see that the double 
bond isomer ratio for this neutral cyclisation was in keeping with the cationic 
cyclisation, quite unexpected for (tBu3P)2Pd, given the precedent in the previous 
chapter.  
 
Regardless of the (tBu3P)2Pd results, we were confident that both our palladacycle 
100 catalysed conditions would prove successful across a range of aryl/heteroaryl 
analogues, so our next aim was to develop higher yielding route to the synthesis of 
such cyclisation precursors. 
 
3.2.2 Standard synthesis of aryl amines 
We had previously used several standard transformations to synthesise aryl iodides 
124b and 124c from 2-iodobenzoic acid 125 (Scheme 2.18), so we took another look 
at this approach. In order for this to be viable we needed to identify a wide range of 
commercially available 2-bromobenzoic acid starting materials, and fortunately there 
were several available (Figure 3.2). In addition to benzoic acids, we identified two 
suitable heteroaromatic starting materials 161f and 161h, as well as 2-
bromophenylacetic acid 161j that would potentially allow us to examine the 
synthesis of a 7-membered B–ring phenanthridine. 
 
Figure 3.2 Some commercially available benzoic acids. 
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Application of the standard transformations developed in Chapter 2 proved 
compatible with the majority of the substrates (Table 3.2) although there were a few 
exceptions. Unfortunately the 5-NO2 nitrile analogue 163g was not tolerant of the 
harsh LiAlH4 reducing conditions so we did not pursue the synthesis of this analogue 
any further. Both the indole substrate and the phenethyl substrate required direct 
treatment of the amide substrate (162h or 162j) with LiAlH4 to generate the desired 
amine. In the case of the phenethyl substrate this was poorly yielding (14%) and we 
performed the reaction in THF rather than Et2O, to achieve a higher conversion 
(75%). An alternative approach to phenethyl substrate was developed later in this 
work (see section 3.2.5) and the problems associated with the synthesis of the indole 
analogue are addressed in section 3.2.6. 
 




Entry 161 Substrate 
(R= ) 
Yield (% )  
162  




1 a 4-Me 95 73 80 
2 b 4-F 94 97 70 
3 c 5-MeO 73 99 65 
4 d 4,5-MeO 99 88 74 
5 e [Naphthyl]$ 99 95 55 
6 f [Thiophene]$ 93 99 89 
7 g 5-NO2 99 99 - 
8 h [Indole]$ 98 - 55a,b 
9 j [Phenethyl]$ 74 - 75a,c 
 
a) i) SOCl2, 60 
oC, 3 h; ii) NH4OH, r.t., 16 h; b) SOCl2, 60 
oC, 3 h; c) i) LiAlH4, AlCl3, Et2O, ∆, 16 h; 
ii) HCl in Et2O. 
a By direct reduction of the amide. b 3.06:1 ratio amine:debrominated material (see 
section 3.2.6). c In THF, with no AlCl3. 
$ For simplicity, the scheme depicts a benzene ring substrate 
core, however where the substrate core is a hetero- or bicyclo-aromatic ring (cf Figure 3.2) this is 
signified by the parenthesised, italicised core name.  This table and scheme should be read in 
conjunction with Figure 3.2. 
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3.2.3 Synthesis of cyclisation precursors. 
With a range of amine hydrochlorides in hand we next examined construction of the 
cyclisation precursors. We decided to synthesise the Boc–protected analogues 165a-f 
since the parent Boc-cyclisation precursor 94b had proved reliable under both the 
cationic and neutral cyclisation conditions, and we envisaged easy removal of the 
Boc group to give the free amine phenanthridines. In the previous chapter, synthesis 
of the Boc-protected analogue was pursued via the secondary amine, so we 
proceeded to apply this to our range of amine substrates. Intriguingly, we observed 
approximately a 75:25 ratio of the mono-alkylated 166a-f to dialkylated product 
167a-f (Table 3.3), something we had detected no trace of in the simple benzyl 
system. Alternative protocols for the selective mono-alkylation of primary amines 
have been reported, including CsOH promoted conditions,108 however such 
procedures were not pursued due to the success of an alternative strategy discussed 
below. 
 









a) iPr2NEt, 3-bromocyclohexene, MeCN, r.t., 16 h; b) Boc2O, Et3N, CH2Cl2, 16 h. 
$ See footnote to 
Table 3.2. 




Yield (% ) Over 2 steps  
165 
1 a 4-Me 84:16 59 
2 b 4-F 75:25 68 
3 c 5-MeO 75:25 58 
4 d 4,5-MeO 75:25 56 
5 e [Naphthyl]$ 70:30 61 
6 f [Thiophene]$ 80:20 65 
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Although dialkylated material 167a-f could be separated from the Boc-protected 
material 165a-f, we realised that a Boc-protection then alkylation protocol, would 
allow us to circumvent the dialkylation problem. We found this to be a successful 
protocol across all our substrates 164a-f (Table 3.4) giving us higher conversions 
over the two steps in the majority of cases. 
 
Table 3.4 An alternative preparation of cyclisation precursors 165a-f. 
 






1 a 4-Me 99 70 
2 b 4-F 88 71 
3 c 5-MeO 85 72 
4 d 4,5-MeO 99 84 
5 e [Naphthyl]$ 90 86 
6 f [Thiophene]$ 70 91 
a) Boc2O, Et3N, CH2Cl2, 16 h; b) NaH, 3-bromocyclohexene, DMF, 0 
oC- r.t., 16 h. $ See footnote to 
Table 3.2. 
 
3.2.4 Piperonyl analogue 
One additional cyclisation precursor that we were very interested in accessing was 
the piperonyl substrate 165k. Our interest in this target stemmed from the frequent 
observation of the piperonyl motif in biologically active natural products based on 
the phenanthridine core (Figure 1.15), and thus we were keen to include this in our 
DOS library. An alternative route to this substrate was developed as we initially had 
concerns over the stability of the piperonyl bridge toward the LiAlH4 used in the 
standard amine synthesis (Table 3.2).γ We proposed to synthesise the cyclisation 
precursor 165k from Boc-protected piperonyl analogue 168k as previously shown, 
but this time synthesis of the latter substrate would be obtained directly from acid 
169k via a Curtius rearrangement. (Scheme 3.3). 
                                                 
γ Subsequent to our investigation we have discovered two examples of the methylenedioxy bridge 
surviving both LiAlH4 and DIBAL reductive conditions respectively.
109,110 
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Scheme 3.3 Retrosynthetic analysis for piperonyl cyclisation precursor 165k. 
 
The Curtius rearrangement in general involves three major steps, the first of which is 
diphenylphosphorylazide (dppa) 170 promoted conversion of an acid 171 into its 
corresponding acyl azide 173 (Scheme 3.4).111 The second step involves thermal 
decomposition of the azide, with release of N2 to afford an isocyanate 176, via an 
acyl nitrene intermediate 177.112 
 
Scheme 3.4 The Curtius rearrangement. 
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The final step involves the highly electrophillic carbon of the isocyanate,112 that can 
be trapped with a nucleophile to afford a variety of products, both desired and 
undesired (Scheme 3.5). For our purposes, tBuOH was used as the nucleophile as 
this permitted direct access to the desired Boc species 168k, but the reaction can be 
carried out in the presence of water to afford the corresponding amine 179.113 
Commonly two side products are observed, namely the urea 180 or the carbamoyl 




Scheme 3.5 Potential products from nucleophillic attack at the isocyanate. 
 
Our first job was to synthesise the 2-bromo-homopiperonylic acid starting material in 
order that we could trial the Curtius rearrangement. We did this by treatment of 
commercially available homopiperonylic acid 182k with DBDMH (1,3-dibromo-5,5-
dimethylhydantoin) under aqueous conditions which we found to be far superior to 
NBS under aqueous or DMF conditions (Scheme 3.6).114  
We had previously trialled some one-pot115,116 variants of the Curtius reaction on the 
homopiperonylic acid, resulting in low yields (<23%) and a significant amount of 
urea 180k and carbamoyl azide 181k side products being observed (Scheme 3.5, 
R=piperonyl). This led us to choose a two-pot modified Curtius reaction for the 
reaction of 2-bromo-homopiperonylic acid 169k, where the isocyanate intermediate 
was isolated.117  
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Following these two-phase Curtius conditions we discovered that acyl azide 173k 
underwent partial conversion to isocyanate 176k upon purification through a silica 
plug. We could find no previous reports of this occurring in the literature where 
conversion to the isocyanate always requires heating conditions. However, one study 
examining the thermally-induced Curtius rearrangement of ortho-alkyl benzoyl 
azides, reported large rate-accelerations for these substrates as compared to their 
ortho-unsubstituted counterparts.118 The facile decomposition of acyl azide 173k to 
the corresponding isocyanate 176k on silica could therefore be due to a similar 
effect. 
 
Scheme 3.6 Synthesis of piperonyl cyclisation precursor 165k. 
a) DBDMH, 4 M NaOH, H2O, r.t., 16 h, 91%; b) dppa, Et3N, CH2Cl2, 0 
oC → r.t., 0.5 h; c) i) silica 
plug filtration (partial conversion); ii) PhMe, 110 oC, 1 h (total conversion); d) tBuOH, 80 oC, 16 h, 
50% over 3 steps; e) NaH, 3-bromocyclohexene, DMF, 0 oC- r.t., 16 h, 75%. 
 
Total conversion to the isocyanate 176k was achieved after refluxing in toluene for 
1 h, and subsequent treatment of the isocyanate with tBuOH led to the formation of 
the desired Boc-analogue 168k in 50% yield over the three steps. Residual urea and 
carbamoyl azide by-products 180k and 181k were isolated from the product mixture, 
and identified by their carbonyl IR peaks (1579 cm-1 and 2156 cm-1 respectively). 
Subsequent alkylation of 168k under standard conditions afforded cyclisation 
precursor 165k in 75% yield. 
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This Curtius approach clearly offers a comparably yielding and milder route to the 
synthesis of the desired Boc-protected amine analogues, with the advantage of 
essentially two main steps as compared to four using the standard route (Table 3.2 
and 3.4). While we were very pleased with its successful application to the piperonyl 
analogue, our alternative route to the other substrates was more than satisfactory, and 
a lack of commercial availability of other homo benzoic acid starting materials meant 
we did not apply the conditions to any of our other benzyl substrates. 
 
3.2.5 Phenethyl substrate via Curtius rearrangement 
However, we did apply the Curtius conditions to the synthesis of substrate 184j, 
since we had experienced problems accessing this analogue using the standard route, 
and the starting material 3-(2-bromophenyl)propionic acid 183j was commercially 
available (Scheme 3.7). We were delighted to discover that the desired carbamate 
product 184j was obtained in 77% yield, offering a marked improvement over the 3-
step standard synthesis (see Chapter 6 for details).  
 
Scheme 3.7 Curtius rearrangement to afford phenethyl substrate 184j. 
a) i) dppa, Et3N, CH2Cl2, 0 
oC – r.t., 0.5 h; ii) silica plug filtration (partial conversion); b) PhMe, 
110 oC, 1 h (total conversion); c) tBuOH, 80 oC, 16 h, 77% over 3 steps; d) NaH, 3-
bromocyclohexene, DMF, 0 oC- r.t., 16 h, 45%. 
 
Unfortunately however, the final alkylation step to afford cyclisation precursor 185j 
only proceeded in 45% yield, and we were not able to improve upon this using the 
TBAI/Cs2CO3
 protocol developed by Salvatore et al. for the N-alkylation of 
carbamates.119,120 The limitations of this step resulted in insufficient quantities of 
phenethyl analogue 185j for a satisfactory study of the Heck reaction. While it was 
clear from the initial studies that cyclisation occurred to a significant extent, 
identification of the complex mixture of isomeric products obtained, even under 
cationic conditions made the evaluation of this cyclisation a difficult task.  
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3.2.6 Issues with indoles 
We experienced difficulty accessing the desired indole amine buiding block 164h. 
Following the LiAlH4 reduction step in our standard synthetic sequence (Table 3.2), 
treatment of the free amine with HCl in Et2O led to a complex mixture visible by 
1H 
NMR. Although we were confident that a significant proportion was the desired 
bromoindoleamine 164h, we were intrigued as to the identity of the minor 
product(s). We initially considered the formation of an indole-dimer species since 
3-bromoindoles have been reported to undergo dimerisation under acidic 
conditions.121 The driving force for such a reaction is the loss of HBr which enables 
rearomatisation and formation of the 2,3-linked indole dimer (Scheme 3.8).  
 
Scheme 3.8 Synthesis of dimeric indole species.121              
R1=H, Me; R2=H, Me, Bn; R3=H, Me, Ph. 
However, this rearomatisation step was clearly not possible for our substrate due to 
the additional methylamine substituent at the 2-position of bromoindoleamine 164h. 
Additionally, no evidence for the presence of such a dimer was visible in the mass 
spectrum. 
An extra singlet in the 1H NMR spectrum at 6.26 ppm (in DMSO) led us to consider 
that one of the products was the debrominated indole amine 191 (Figure 3.3). 
Additionally, we observed the correct mass for this (m/z 146) in the mass spectrum of 
the mixture. Further evidence for the presence of this product was obtained when 
following a resynthesis, we purified the reaction mixture by flash chromatography on 
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silica, rather than by HCl salt formation. Although the majority of the reaction 
mixture appeared to decompose on the silica, the only isolated product was a trace 
amount of debrominated indole amine 191 (Figure 3.3), which we confirmed by 
comparison of its 1H NMR spectrum with that of the literature.122 We therefore 
proposed that 191 was formed during the LiAlH4 reduction step, and that the 
hydrochloride salt of 191 was the minor contaminant in our product mixture. We 
propose that the remainder of the unassigned signals in the 1H NMR spectrum 
resulted from incomplete formation of the HCl salt of bromo-indole amine 164h. 
 
Figure 3.3 De-brominated indole 191.122 
We continued our studies towards indole cyclisation precursor 165h using the indole-
amine hydrochloride mixture. After conversion of the amine hydrochloride salts to 
the free amines, coupling with 3-bromocyclohexene under standard conditions gave 
an inseparable mixture of products (Scheme 3.9), perhaps not surprising when mono- 
and dialkylation can occur for both the indole amine species.  
 
Scheme 3.9 Attempted synthesis of indole cyclisation precursor.          
a) iPr2NEt, 3-bromocyclohexene, MeCN, 16 h, r.t.; b) Boc2O, Et3N, CH2Cl2, r.t., 16 h, 168h 49%, 192 
24%; c) NaH, 3-bromocyclohexene, DMF, 0 oC → r.t., 16 h. 
We therefore tried Boc-protecting the amine first, which had proved a successful 
method of circumventing the dialkylation issue previously. This gave excellent 
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conversion to a mixture of bromo-carbamate 168h and carbamate 192, and permitted 
us to separate the two compounds. In contrast to an example in the literature,123 we 
observed no Boc-protection of the indole nitrogen, which we have attributed to using 
less equivalents of Boc2O in our case (2 eq vs 5 eq).  
Simple deprotonation of Boc-indole 168h with NaH, and attempted alkylation with 
3-bromocyclohexene led, not surprisingly, to a complex mixture of products due to 
concomitant deprotonation/alkylation of the indole N-H. As a result we could not 
isolate any of the desired cyclisation precursor from the complex product mixture 
following the alkylation reaction. In light of the numerous setbacks we had 
encountered during the attempted synthesis of 165h, we chose not to pursue the 
synthesis of this analogue any further. If the synthesis was to be repeated in future 
studies, it would be favourable to Boc-protect the indole nitrogen and the amine at 
the same time, or even Boc-protect the indole nitrogen at an earlier stage in the 
synthesis. Although Boc-indoles are less susceptible than Boc-amines to acidic 
deprotection conditions, they can be selectively removed under thermolysis at 130 oC 
in DMSO.124 The Heck cyclisation conditions at 140 oC would therefore most likely 
facilitate deprotection of the Boc-indole (Scheme 3.10). 
 
Scheme 3.10 Alternative synthesis of indole analogue.         
a) NaH, 3-bromocyclohexene, DMF, 0 oC → r.t.; b) Palladacycle 100 (5 mol%), Ag2CO3 (1 eq) or 
MeNCy2 (4 eq), DMF, 140 °C. 
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3.2.7 Heck cyclisation of aryl/heteroaryl cyclisation precursors 
With our cyclisation precursors 165a-f,k in hand we studied their reaction under both 
our cationic and neutral palladacycle 100 catalysed conditions. 
 
Table 3.5 Cationic cyclisation of aryl/heteroaryl cyclisation precursors 165a-f,k. 
 








1 94b H 2 99 83:15:2 
2 a 4-Me 2 99 78:17:5 
3 b 4-F 2.5 99 81:14:5 
4 c 5-MeO 4 99 77:19:4 
5 d 4,5-diMeO 1 99 84:13:3 
6 e [Naphthyl]$ 4 88 81:14:5 
7 f [Thiophene]$ 3 99 64:21:15c 
8 k [Piperonyl]$* 2 70 76:18:6 
a Conditions: aryl halide (1 eq), palladacycle 100 (5 mol%), Ag2CO3 (1 eq), DMF, 140 °C. 
b Ratio 
identified from 1H NMR of pure product mixture. c Traces of minor diastereomer peaks visible in the 
1H NMR. $ See footnote Table 3.2. * As in Scheme 3.6. 
 
The cyclisation of all our substrates 165a-f,k was found to proceed rapidly and 
efficiently in all cases, although a slight loss in conversion was observed with the 
piperonyl analogue 165k which was surprising given the excellent reactivity of the 
4,5-dimethoxy analogue. Identification of the isomer ratio was achieved by 
integration of the respective 1H NMR signals (as illustrated in Chapter 2.5.1). As 
expected, the ∆1,2 isomer was obtained as the major product from the cyclisation of 
all the analogues, with a comparable ratio to the cationic cyclisation of standard Boc 
substrate 94b (entry 1). Interestingly, three minor peaks were observed between 3.00 
and 4.00 ppm in the 1H NMR spectra of the thiophene product mixture 195-197f 
where the NCHCH proton is usually observed (proton ‘h’, Figure 2.4, Chapter 2). 
This suggests the possible formation of trace amounts of the trans-ring junction 
diastereomer, although reaction scale did not permit us to isolate any such product. 
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The application of our neutral Heck cyclisation conditions was also applied to 
substrates 165a-f,k as reported in Table 3.6. 
 
Table 3.6 Neutral cyclisation of aryl/heteroaryl cyclisation precursors 165a-f,k. 
 
 








1 94b H 3 95 36:38:26 
2 a 4-Me 12 76 26:57:17 
3 b 4-F 5 72 27:44:29 
4 c 5-MeO 6 73 36:44:20 
5 d 4,5-MeO 12 75 41:32:27 
6 e [Naphthyl]$ 5 74 42:42:16 
7 f [Thiophene]$ 5 79 18:34:30:(18)c 
8 k [Piperonyl]$* 24 59 (32)d 41:26:33 
9 k [Piperonyl]$* 18e 80 (11)f 18:46:36 
10 k [Piperonyl]$* 18 99g 39:37:24 
a Conditions: aryl halide (1 eq), MeNCy2 (4 eq), palladacycle 100 (5 mol%), DMF, 140 °C.
 b Ratio 
identified from 1H NMR of pure product mixture. c Quantifiable minor diastereomer peaks visible in 
the 1H NMR (7:11). d 32% dehalogenated product 198k recovered (see Chapter 6). e Pd2(dba)3 (5 
mol%), tBu3PHBF4 (10 mol%), MeNCy2 (4 eq), MeCN, r.t.
 f Starting material recovered. g as entry 9 
but at 50 oC. $ See footnote Table 3.2. * As in Scheme 3.6. 
 
We found that for the majority of our substrates, the standard neutral palladacycle 
catalysed reaction conditions promoted cyclisation to the expected mixture of isomer 
products 195-197. However, conversions were lower in all cases than that exhibited 
by standard Boc substrate 94b (95% in 3 h), and reaction times were longer, 
especially with the electron rich aromatics (entries 2, 4, 5, 8) where clearly the 
oxidative addition step will be less favoured. For piperonyl substrate 165k (entry 8) a 
significant amount of the dehalogenated product 198k was recovered indicating the 
presence of Pd black (see section 2.3.4). This provides strong evidence for the 
reluctance of this substrate to undergo oxidative addition, since from our experience, 
Pd black is only formed from palladacycle 100 as a result of its standard deactivation 
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pathway, i.e near the end of the catalyst’s lifetime. Fortunately, application of our 
low temperature (tBu3P)2Pd conditions (entry 9) enabled the recovery of the desired 
product mixture 195k-197k in 80% yield at r.t, and 99% yield at 50 oC (entry 10). 
For the cyclisation of thiophene 165f we again observed traces of what we propose to 
be the trans-ring junction minor diastereomers. For the cyclisation of sulfonamide 
protected thiophene analogue 157 (section 3.2.1) under both neutral and cationic 
conditions, no trace of such a product was observed. Additionally, no similar product 
peaks have been observed in the 1H NMR spectra for the cyclisation of any of the 
other Boc-protected analogues. The formation of such a product is therefore unique 
to the combination of the thiophene and the Boc-protecting group.  
We propose that some form of chelation between the thiophene sulfur and the 
carbonyl of the Boc protecting group enables the cyclisation precursor to become 
locked in a conformation that allows subsequent formation of the trans-ring junction 
phenanthridine. However, due to the small scale of the reaction, we have not isolated 
any of the minor products and therefore do not have proof of this hypothesis. 
Additionally, a literature search for similar thiophene carbamates has not highlighted 
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3.3 Stereochemical Diversity 
There are many bioactive phenanthridine natural products that have hydroxylated or 
polyhydroxylated C-rings (Figure 3.4).125 A sensible direction toward converting our 
aryl phenanthridine analogues into a DOS library would therefore be dihydroxylation 
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3.3.1 Cis-dihydroxylation 
Conditions for the cis-dihydroxylation of trans-ring junction phenanthridine 204, 
were reported in the literature, affording diasteromeric diol-products 205a and 206b 
in excellent yield (Scheme 3.11).126 
 
Scheme 3.11 Literature conditions for cis-dihydroxylation.126 
a) OsO4, NMO, THF/H2O, r.t., 18 h, 84%, dr 1:1. 
 
Trans-ring junction phenanthridines sit in a flat conformation in 3D space, so the 
diasteromeric ratio of 1:1 is hardly surprising, since both faces of the C-ring are 
equally accessible by the OsO4 reagent (Figure 3.5). In contrast, cis-ring junction 
phenanthridines occupy a more cupped conformation, rendering the convex face 
more favourable for dihydroxylation, potentially resulting in high diastereomeric 
ratio (Figure 3.6).  
A                            
B   
Figure 3.5 3D models of a typical trans ring junction phenanthridine. 
Angle A illustrating the full molecule. Angle B illustrating the lat planar conformation of molecule.   
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     A  
B  
Figure 3.6 3D models of a typical cis ring junction phenanthridine. 
Angle A illustrating the full molecule. Angle B illustrating the cupped conformation of molecule. 
 
The reaction was tested on all three isolated double bond isomers 96-98b and we 
observed high conversions and diastereomeric ratios (>83:17) for the exo-syn 
product across all substrates (Table 3.7). 
 
Table 3.7 Dihydroxylation test reactions. 
 
Entry Substrate Product Yield 
(%) 
dra 
1 96b (∆1,2) 206m (∆1,2) 99 83:17 
2 97b (∆2,3) 207m (∆2,3) 99 85:15 
3 98b (∆3,4) 208m (∆3,4) 99 85:15 
a) OsO4, NMO, THF/H2O, r.t., 18 h. 
a Diastereomeric ratio determined by integration of the relevent 
peaks in the 1H NMR spectrum. 
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3.3.2 Proof of stereochemistry 
We were confident from the molecular models we had studied that the major product 
would have the hydroxyl groups on the exo-face, however confirmation was 
required. During the application of this methodology to the DOS library synthesis 
(Chapter 4) we isolated both the ∆2,3 piperonyl analogue cis-dihydroxyl products 
207k and 209k and studied them using 2D nOESY NMR. For the major product, 
strong nOE’s were observed between the two ring junction protons, and between the 
two CHOH protons, but there were no cross peaks between the two sets which is 
indicative of structure 207k (Figure 3.7). For the minor product, again strong nOE’s 
were observed between the two ring junction protons, and between the two CHOH 
protons, but this time an additional cross peak was observed between one of the ring 
junction protons and one of the CHOH protons (Figure 3.8). This would be true for 
the minor product where these two sets of protons are on the same face of the 
phenanthridine. 
 
Figure 3.7 2D nOESY NMR for major exo-syn diol product 207k illustrating a lack 
of ring junction (rj) to CHOH cross peaks. 
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Figure 3.8 2D nOESY NMR for minor endo-syn diol product 209k illustrating a ring 
junction (rj) to CHOH cross peak. 
 
3.3.3 Epoxidation using mCPBA or via a bromohydrin 
With conditions for the cis-dihydroxylation of our phenanthridines safely in hand, we 
looked toward developing conditions for accessing the trans-diol, via the epoxide 
intermediate using mCPBA-promoted conditions reported in the literature (Scheme 
3.12.126 Although a mixture of epoxides 210 was formed from the trans-ring-junction 
analogue 204, we expected exo-selectivity for epoxidation of the cis analogue, due to 
the aforementioned cupped conformation adopted by the substrate. 
 
Scheme 3.12 Literature conditions for trans-diol formation via the epoxide.126 
a) mCPBA, CH2Cl2, r.t., 18 h, 73%; b) HClO4, H2O/THF, r.t., 1.5 h, 64%. 
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Application of these conditions to alkene 96b led to the formation of desired epoxide 
212, along with the corresponding phenanthridone epoxide 213 (Scheme 3.13). 
Lowering the temperature (0 oC) or reducing reaction time (3 h) offered no 
improvement. The benzylic position of the phenanthridine is known to be susceptible 
to oxidation under mCPBA conditions,127 and a postulated mechanism involves H-
atom abstraction, followed by benzylic radical trapping by air.128  
 
Scheme 3.13 Epoxidation using mCPBA.                                                                       
a) mCPBA, CH2Cl2, 16 h, r.t., 99% 212:213 59:43; 0 
oC, 16 h, 0%; r.t., 3 h, 50% 212:213 1:1. 
An alternative approach for the epoxidation of alkenes involves a two-step sequence 
via an intermediate bromohydrin 215. This method was successfully applied in the 
synthesis of (+)-homochelidonine where prevention of benzylic oxidation was 
essential (Scheme 3.14).129 
 
Scheme 3.14 Bromohydrin formation in the synthesis of (+)-homochelidonine.129            
a) NBS, THF/H2O, r.t., 1.5 h, 75%; b) KO
tBu, THF, -78 oC, 0.5 h, 99%. 
 
Unfortunately application of the bromohydrin formation conditions to our Boc 
alkene 96b resulted in the formation of multiple products along with considerable 
starting material. The formation of up to four bromohydrins was expected as the 
bromonium ion intermediate can form on either face of the alkene (although we 
would expect the exo to be favoured), and can then open up in either direction. We 
propose that the cupped nature of the cis-ring junction phenanthridine hindered both 
the formation of the bromohydrin on the concave face, and the opening of the exo-
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bromohydrin by attack of H2O from the concave face leading to the large amount of 
alkene 96b being recovered.  
 
 
3.3.4 Epoxidation using DMDO (dimethyldioxirane) 
Another alternative reagent for the preparation of epoxides from alkenes is DMDO 
217 (Scheme 3.15), an oxidising agent derived from acetone.130 DMDO has been 
found to be both a mild and efficient reagent, with the added advantage that only 
acetone is produced as a by-product in the reaction. Although it is highly selective 
for alkenes, it is also capable of oxidising several other functional groups including 
primary amines to nitro compounds131 and sulfides to sulfoxides.132  
We were keen to explore the use DMDO for the epoxidation of our substrate after a 
recent report where the reagent was successfully applied to the synthesis of 
phenanthridine natural product fortucine 218.132 In this example DMDO was used to 
successfully oxidise sulphide 219 to sulfone 220, with no oxidation occurring at the 
benzylic position as we had observed with mCPBA. 
 
Scheme 3.15 Application of DMDO in the synthesis of (±) Fortucine 218.132 
Although DMDO is a very well known reagent, it is very unstable and therefore not 
commercially available. To generate the reagent, a fresh solution must be prepared 
from oxone, sodium bicarbonate and acetone using a complex set-up of glassware 
under vacuum (Figure 3.9).133 The preparation of DMDO is known to be rather 
inefficient, typically yielding a solution of <0.15 M in acetone. Several factors 
account for this low concentration including a large number of possible side 
reactions,134 and inefficient collection of the dioxirane reagent in the cold trap. 
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Figure 3.9 Apparatus for the preparation of DMDO 217 from acetone. 




In agreement with the literature precedent, we also found the preparation of DMDO 
to be extremely inefficient, even after careful repetition a number of times. Although 
the solution concentration was not measured,133 we found that the reaction of just 
80 µmol of alkene with 10 ml of DMDO solution, gave <30% conversion to the 
epoxide, suggesting a concentration of just 0.003 M. Although the conversion was 
poor, no trace of phenanthridone epoxide 213 was observed in the product mixture 
suggesting a more efficient preparation of DMDO would provide the solution to 
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There have been a number of reports of the in situ generation of the reagent under 
phase-transfer conditions.131,135 We trialled these conditions for the epoxidation of 
styrene 221 in order to determine if they would be successful (Scheme 3.16).  
 
Scheme 3.16 In situ generation of dioxirane.131                                                                         
a) oxone, Me2O, CH2Cl2, Na2HPO4 aq. buffer, nBu4NHSO4, pH 7.5-8, 0 
oC, 3 h, 20%; b) oxone, 
(CF3)2O, CH2Cl2, Na2HPO4 aq. buffer, nBu4NHSO4, pH 7.5-8, r.t., 4 h, 20%; 
The conditions for in situ generation of the DMDO, though simpler than the 
traditional method, were still complex, requiring careful monitoring of the pH to 
avoid possible decomposition of the dioxirane at pH>8. Despite our care, we were 
not able to satisfactorily reproduce these conditions and only 20% conversion was 
observed at 0 oC. In an attempt to reduce the electron density of the O-O bond and 
therefore generate a more reactive dioxirane, we switched acetone for 
trifluoromethylacetone.134 However again, only a 20% epoxide was obtained, even 
after raising the reaction temperature from 0 oC to r.t.  
Our studies into the application of DMDO showed that the reagent is selective for 
epoxidation without oxidation at the benzylic position to give the phenanthridone 
212. However, we were not able to satisfactorily replicate the literature methods for 
traditional or in situ generation of the dioxirane. After numerous unsuccessful 
attempts to obtain selective epoxidation, we stopped all investigations into the 
synthesis of epoxides to focus on other areas of the project. 
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3.4 Skeletal Diversity 
3.4.1 Ring-rearrangement metathesis (RRM) 
Olefin metathesis has now become a well-established tool in organic synthesis. 
Originally ring-closing metathesis (RCM) formed the basis of much of the research 
in this field, but more recent efforts have included the development of protocols to 
facilitate ring-opening metathesis (ROM) and cross-metathesis reactions.136 Domino 
metathesis or ring-rearrangement metathesis reactions (RRM), involving 
combinations of these metathesis protocols have also been reported, and 
implemented successfully in complex molecule synthesis.137 These reactions involve 
intramolecular metathesis between an endocyclic olefin and a tethered exocyclic 
C=C or C≡C bond, in such a way that one ring is opening in a ROM process and 
another is formed in a RCM process (Scheme 3.17).138  
 
Scheme 3.17 RRM of 2-aminonorbornenes.138                                                                             
a) Grubbs I (10 mol%), ethylene, CH2Cl2, r.t., 16 h. R= Boc 90%; R= Cbz 90%; R= Ts 99%. 
RRM has previously been used to prepare molecules with carbocyclic and oxocyclic 
skeletons,139 but there are far fewer reports of its successful implementation in the 
synthesis of nitrogen containing systems.140 Indeed, across the whole of metathesis 
chemistry, the presence of amino-functionality is rare (one example is illustrated 
above in Scheme 3.17).138 The reason behind this lies in the ability of the amino 
group to coordinate to the transition metal of the metathesis catalyst, thus leading to 
deactivation and poor reactivity. Successful approaches to counteracting this problem 
include the use of Lewis acids to coordinate the amine;141 the use of amines with 
strongly electron-withdrawing functionality (such as sulfonamides142 or carbamates, 
Scheme 3.17); and the use of ammonium salts.143  
In the above example (Scheme 3.17), the cycloalkene 223 that undergoes ROM is a 
very highly strained norbornene. The drive to achieve a lower energy structural 
conformation makes norbornene units highly effective for ROM, and indeed most of 
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the successful examples of the RRM of amino-containing substrates use norbornene 
as the cycloalkene unit.138 The majority of the other examples use cyclopentene144-146 
or cyclobutene144 which both have more strained ring systems than cyclohexene and 
are thus pre-disposed to undergo ROM. To the best of our knowledge, only three 
successful examples of the ROM or RRM of unstrained cycloalkenes have been 
reported. 
 
3.4.2 ROM/RRM of unstrained cycloalkenes 
RRM of bis-propargyl-N-tosyl amine 225 was found to occur under Grubbs I or 
Grubbs II metathesis (Table 3.8).142,147 However in this example the RRM only 
proceeded with low yields (<22%) and 1,3-diene 227 was recovered as the major 
product along with significant starting material. Formation of the 1,3-diene 227 
occurs from the cross metathesis of the alkyne with ethylene and has been attributed 
to steric hindrance of the ruthenium catalyst at the reaction site.146,148 







T (oC) t (h) Conversion (%) 226:227 
1 Grubbs I (5 mol%), CH2Cl2, CH2=CH2 25 20 63 1:5.3 
2 Grubbs I (10 mol%), CH2Cl2, CH2=CH2 25 20 79 1:3.9 
3 Grubbs I (10 mol%), CH2Cl2, CH2=CH2 50 20 61 1:2.6 
4 Grubbs II (10 mol%), PhMe, CH2=CH2 60 20 81 1:2.7 
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Interestingly, RRM of cycloalkene-ynes 228a-c (Table 3.9),146 was reported to 
proceed under similar conditions to those reported in Table 3.8, but this time 
excellent conversions to the pyrrolidine products 229a-c was obtained in less than 4 
hours at r.t. The 1,3-diene cross metathesis product was not observed though this 
could reasonably be attributed to the lack of steric congestion at the reaction site as 
opposed to bis-propargyl counterpart 225. To the best of our knowledge, this 
example remains the highest yielding RRM of an unstrained cyclohexene.  
 
Table 3.9 RRM of cycloalkene-ynes.146 
         
a) Grubbs I (10 mol%), ethylene, CH2Cl2, r.t. 
 
One final example illustrates how ROM can be used in an elegant manner to generate 
biologically active compounds.143 Exposure of the hydrochloride salt of 
Manzamine A 230 to Grubbs I under ethylene gave a 4:1 mixture of tetraene 231 and 
pentaene 232, formed from ROM of the 13-membered D ring or the 8-membered E 
ring respectively (Scheme 3.18). The high conversion obtained for the ROM of these 
large-ring cycloalkenes shows the power that a simple reaction such as ROM has to 
generate diversity from a common starting material. 
 
Scheme 3.18 ROM of manzamine A 230.143                                                                        
a) i) HCl; ii) Grubbs I, ethylene, CH2Cl2, r.t., 24 h, 71%, 231:232 4:1. 
228 n t (h) Conversion 
(%) 
a 1 4 78 
b 2 1 70 
c 3 1 75 
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3.4.3 RRM in DOS 
Towards the end of our investigation into the RRM of our substrates, an example of 
the application of RRM to a DOS library was reported (Scheme 3.19).149 In this 
example the key step for the generation of molecular scaffold 233 required a RRM of 
highly strained norbornene derivative 234. This generated 1,3-diene 235 that was 
then converted to scaffold 233 using a Diels-Alder reaction. Variation of the N-alkyl 
group and the dienophile would enable the incorporation of further diversity. RRM is 
therefore clearly a powerful tool in DOS library synthesis, and the generation of 
methodology to enable unstrained cycloalkenes to be used for this purpose would be 
of great value.  
 
 
Scheme 3.19 Application of enyne metathesis in DOS library synthesis.149 
a) Grubbs I (10 mol%), ethylene, MW, 60 oC, 1 h; b) Grubbs I (10 mol%), Grubbs II (10 mol%), 
ethylene, MW, 60 oC, 2 h; c) CN-CH2CO2K, MeOH, 1 h, 87% (over 3 steps); d) N-ethylmaleimide, 
PhMe, MW, 160 oC, 6 h. 99%. 
 
3.4.4 Mechanism 
It is postulated for all RRM reactions involving pendant alkynes, that the ruthenium 
catalyst first reacts with the more electron rich alkyne part, rather than facilitating the 
cycloalkene ring-opening immediately. The proposed mechanism for the RRM of a 
cycloalkene-yne has been briefly discussed in the literature, and is represented in 
Scheme 3.20 for the RRM of a substrate whose alkyne tether is connected to the C-3 
position of the cycloalkene.146  
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Scheme 3.20 Proposed mechanism for RRM.146 
The alkyne part of substrate A reacts with the ruthenium complex to generate 
ruthenocyclobutene B. This gives rise to ruthenium-carbene complex C by ring-
opening through cycloreversion. The carbene complex can then react 
intramolecularly with the cycloalkene part to generate the highly-strained ruthenium 
complex D, which then undergoes ring-opening to afford carbene complex E. The 
ruthenium-carbene E is unable to undergo further intramolecular reaction at this 
stage and as a result it will react with another molecule of A to afford a polymer (e.g 
ROMP). However, if the reaction is carried out under an atmosphere of ethylene, 
ruthenium complex E would react with the gas to give RRM product G via 
ruthenacyclobutane F. 
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3.4.5 Proposed RRM of the phenanthridine core 
We were aware from literature examples (section 3.4.2) that the RRM product varies 
depending on the size of the cycloalkene, the length of the alkyne tether, and the 
position of the alkene bond within the cycloalkene. We envisaged using this to our 
advantage in a RRM of our phenanthridine double bond isomer mixture. N-
propargylation of our phenanthridine, followed by RRM would yield three skeletally 
different products using one common reaction (Scheme 3.21). In conjunction with 
aryl variation, a powerful and efficient approach to a DOS library may be realised. 
 
Scheme 3.21 Potential products from the RRM of propargyl phenanthridines 96-98f. 
In addition to the propargyl group, we also proposed to investigate the 
homopropargyl and Poc-protected analogues 96gh-98gh to potentially give us access 
to larger ring cycloalkene and cyclic carbamate products (Scheme 3.22). 
 
Scheme 3.22 Potential products from the RRM of homopropargyl and Poc 
phenanthridine derivatives 96-98g and 96-98h. 
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3.4.6 Synthesis of RRM precursors 
3.4.6.1 Heck cyclisation approach 
In light of the generally poor yields reported in the literature, and to simplify analysis 
of the reaction, we decided to trial the RRM on single double bond isomers. We 
knew that our Heck cyclisation under cationic conditions gave predominantly the ∆1,2 
double bond isomer and so we decided to generate cyclisation precursors with the 
appropriate N-functional groups. To this end we prepared propargyl150 and Poc-
protected151 starting materials 94f and 94h (Scheme 3.23).  
 
Scheme 3.23 Synthesis and attempted cyclisation of propargyl precursors.                 
a) P = CH2C≡CH: propargyl bromide, K2CO3, DMF, r.t., 16 h, 99%; b) P = C(O)OCH2C≡CH: PocCl, 
Et3N, CH2Cl2, 0 
oC → r.t., 16 h, 99%.  
 
Cationic cyclisation of both substrates gave none of the desired product, and in the 
case of the Poc analogue 94h, secondary amine 93 was recovered as the sole product. 
Application of our milder conditions using (tBu3P)2Pd at either r.t. or 50 
oC gave 
similar results. Preparation and cyclisation of a homopropargyl analogue was not 
carried out due to these unsuccessful results. 
 
3.2.6.2 Attempted deprotection of N-Boc 
As the Heck cyclisation of propargyl precursors 94f and 94h had failed, we realised 
that to access the required propargyl phenanthridines we needed to perform a Boc-
deprotection of the appropriate phenanthridine, followed by protection with the 
relevant propargyl reagent. As the desired propargyl and homopropargyl products 
were amines we presumed that separation of the Boc-protected double bond isomers 
would be easier. To this end HPLC separation of 96b-98b furnished us with 
sufficient quantities of the isolated double-bond isomers to take on to the next stage. 
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We had presumed that Boc-deprotection of 96b-98b would be a trivial step, indeed 
we had easily removed the Boc-group from saturated analogue 110b using 
TFA/CH2Cl2 when we proved the cis-ring junction stereochemistry of our 
phenanthridines (see section 2.5.2). However, in this case we had an alkene that was 
capable of unwanted isomerism under acid-catalysis conditions (see section 2.9.4), 
so we were forced to investigate alternative conditions by which to remove the Boc 
group from our phenanthridines (Table 3.10). 
Table 3.10 Conditions for the Boc-deprotection of ∆1,2 phenanthridine 96b.  
 
 
Entries 1 and 2 confirm that double bond isomerism occurred under standard TFA 
Boc-deprotection conditions, even at 0 oC. Lewis acid mediated deprotection using 
ZnBr2
152 gave a mixture of double bond isomers (entry 3) and incomplete 
deprotection/unidentifiable product formation using SnCl4
153 (entry 6). Ceric 
ammonium nitrate (CAN) has been reported as a successful one-electron transfer 
catalyst for the removal of the Boc-group from a range of amines, alcohols and 
thiols.154 However in our case, although complete removal of the Boc-group was 
observed, a mixture of unidentifiable products was obtained, rendering this approach 




1 TFA, CH2Cl2 r.t. 0.5 100 81:18:1 mixture of d.b. isomers 
2 TFA, CH2Cl2 0 1 100 61:19:20 mixture of d.b. isomers 
3 ZnBr2 (2.7 eq), CH2Cl2 r.t. 16 100 77:0:23 mixture of d.b. isomers 
4 CAN (0.2 eq), MeCN 80 16 100 Many products 
5 CAN (2 eq), MeCN 80 16 100 Many products 
6 SnCl4 (4 eq), EtOAc r.t. 16 n.d S.M. + several products 
7 TBAF (10 eq), THF 80 16 n.d S.M. + several products 
8 Na2CO3, DME/H2O 80 72 0 S.M. recovered 
9 FVP 500 0.5 n.d Posible product formation 
10 FVP 600 0.5 60 ∆1,2 isomer only 
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ineffective for our purposes (entries 4 and 5). TBAF has been shown to be an 
effective Boc-deprotecting agent for a range of aryl and heteroaryl substrates,155 
however application of these conditions to ∆1,2 phenanthridine 96b led to incomplete 
conversion and a mixture of unidentifiable products. Na2CO3 in DME/H2O has been 
used for the N-Boc deprotection of various heteroaryl amines,156 but no conversion 
was observed on our system. The conditions we finally used for selective 
deprotection of the Boc-group without double bond isomerism required flash vacuum 
pyrolysis at 600 oC (entry 10).157 
 
3.4.6.3 Flash vacuum pyrrolysis (FVP) deprotection of N-Boc 
Flash vacuum pyrolysis refers to the gas-phase pyrolysis of an organic material under 
low-pressure conditions.158,159 In its simplest form FVP involves vacuum distillation 
of an organic substrate through an empty hot pyrolysis tube, contained within a 
furnace (Figure 3.10). The products are simply collected afterwards in a U-tube 
contained within a cold trap, and generally require no work up and little purification.  
 
Figure 3.10 Diagram of the FVP apparatus and a photograph of a typical FVP 
product collecting in the U-tube.158 
FVP has significant advantages over condensed-phase methods because there are no 
solvent or reagent molecules present to interfere with the reactive intermediate. In 
addition to this, the ultra-high vacuum employed for FVP means that the molecules 
undergoing reaction spend mere milliseconds in the reaction zone (i.e the pyrolysis 
tube) before they are quenched. This means that even thermally unstable reactive 
intermediates usually survive FVP conditions.158,159  
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The use of FVP to facilitate Boc-deprotection has been reported,157,160 and typically 
requires a furnace temperature of 600 oC. As reported in Table 3.10 we found that 
successful Boc-deprotection under these conditions was achieved for ∆1,2 
phenanthridine 96b, and we were pleased to discover that this also held true for the 
∆2,3 and ∆3,4 phenanthridines 97b and 98b (Scheme 3.24). Purification of the reaction 
products was achieved through subsequent Kugelrohr distillation. 
 
Scheme 3.24 FVP mediated Boc-deprotection of isolated phenanthridines 96b-98b.              
a) i) FVP, 600 oC, 0.5 h; ii) Kugelrohr distillation 70 oC, ∆1,2 245 60%, ∆2,3 246 81%, ∆3,4 247 71%. 
 
3.4.6.4 RRM precursors via alkylation/acylation 
With each of the three double-bond isomer amines 245-247 in hand, we set about 
synthesising the corresponding propargyl, homopropargyl and Poc-protected 
analogues. Unfortunately, the conditions we had used previously for the 
propargylation of secondary amine 93 (propargyl bromide, K2CO3, DMF, Scheme 
3.23)150 did not prove to be successful on the phenanthridine substrates 245-247, 
furnishing the desired products in <10% yield. Our group had experience of N-
propargylations, and it was suggested that the formation of side products was 
occurring due to the lengthy reaction time employed. The use of dry acetone and an 
elevated reaction temperature was suggested in order to increase the solubility of the 
K2CO3 and thus accelerate the reaction. After 2 h all three propargylated products 
96f-98f were recovered in good yield (Table 3.11). Similar conditions were 
employed to access homopropargyl phenanthridines 96g-98g, although these 
reactions required heating for 16 h to achieve reasonable conversions. Finally, Poc-
protected phenanthridines 96h-98h were obtained following reaction of a mixture of 
245-247 with propargyl chloroformate as previously. Purification of mixture 96h-
98h was easier as the substrates were carbamates and not amines and therefore less 
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polar. This enabled us to obtain sufficient isolated quantities of Poc-phenanthridines 
96h-98h to use in our RRM studies. 







a) P=CH2C≡CH: propargyl bromide (1.1 eq), K2CO3 (3 eq), acetone (dry); b) P=CH2CH2C≡CH: 
homopropargyl bromide (1.1 eq), K2CO3 (3 eq), acetone (dry); c) P=C(O)OCH2C≡CH: PocCl (4 eq), 
Et3N (4 eq), CH2Cl2, 0 
oC → r.t. a Mixture. 
 
3.4.7 RRM studies – Propargyl analogues 
The majority of recent Grubbs metathesis literature focuses on the use of four main 
catalysts: Grubbs I 248; Grubbs II 249; Hoveyda-Grubbs I 250; and Hoveyda-Grubbs 
II 251 (Figure 3.11). We initially decided to employ Hoveyda-Grubbs II 251 as our 
Ru source as this was the most recent generation catalyst and had precedent in ROM-
polymerisation reactions.161 
 
Figure 3.11 Commercially available Grubbs-metathesis catalysts. 
Entry Substrate Conditions T (oC) t (h) Product Conversion (%) 
1 245 a  60 2 96f 57 
2 246 a 60 2 97f 75 
3 247 a 60 2 98f 91 
4 245 b 60 16 96g 55 
5 246 b 60 16 97g 63 
6 247 b 60 16 98g 73 
7 245-247a c 0 oC→r.t. 16 96h-98ha 74 
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We were delighted to observe that application of catalyst 251 to ∆2,3 propargyl 
phenanthridine 97f under an atmosphere of ethylene, led to formation of 
benzo[b]quinolizine product 237 in excellent yield (Scheme 3.25). We had presumed 
that this particular propargyl substrate would be most likely to undergo a successful 
RRM as it gave rise to a conformationally favoured 6,6,6-ring annulated product.  
 
Scheme 3.25 RRM of ∆2,3 propargyl phenanthridine 97f.                                                       
a) Hoveyda-Grubbs II 251 (15 mol%), ethylene, CH2Cl2, r.t., 40 h, 71%. 
Following the success of this result, we applied these conditions to other propargyl 
phenanthridines 96f and 98f. Disappointingly, we observed quantitative recovery of 
the starting material upon the attempted RRM of ∆1,2 propargyl-phenanthridine 96f. 
Presumably in this instance, the alkene was too far away for the propargyl tether to 
access it for the metathesis reaction. Performing this reaction at elevated temperature 
had no impact on the result. However, we were pleased to discover that ∆3,4 
propargyl-phenanthridine 98f gave total conversion to the benzoindolizine product 
238 (Scheme 3.26). 
 
Scheme 3.26 RRM of ∆3,4 propargyl phenanthridine 98f.                                                         
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3.4.8 RRM of homopropargyl analogues  
The RRM of both ∆2,3 and ∆3,4 propargyl phenanthridines 97f and 98f were 
remarkable results given the lack of similar unstrained cycloalkene examples in the 
literature. However, in order for the reaction to be of use to us in a DOS library 
context, we required an RRM that was applicable to all three double bond isomers. 
We were hopeful that extension of the alkynyl chain by one or two atoms, would 
allow it to be long enough to undergo metathesis with the ∆1,2 alkene.  
To this end, homopropargyl-phenanthridines 96g-98g were subjected to our RRM 
conditions (Table 3.12). Total conversion was observed in all cases, and the product 
exhibited the same mass and the correct number of 1H and 13C signals in the NMR as 
the desired RRM products 239-241. In addition to this, we observed the alkene 
quartet signal at 6.40 ppm that had been very distinctive in the 1H NMR spectrum of 
237 and 238.  
 
 







a) Hoveyda-Grubbs II 251 or Grubbs I 248 (15 mol%), ethylene, CH2Cl2, r.t., 40 h 
a at 45 oC. 
 
However, in one of the literature examples illustrated (Table 3.8),146 two potential 
products from the treatment of an cycloalkene-yne with ethylene in the presence of a 
metathesis catalyst are identified. In addition to the desired RRM product (such as 
benzo[b]quinolizine 237 and benzoindolizine 238), the formation of a 1,3-diene can 
Entry Substrate Catalyst Product Conversion 
(%) 
1 ∆1,2 251 96j 69 
2 ∆2,3 251 97j 54 
3 ∆3,4 251 98j 67 
4 ∆2,3 248 97j 99 
5 ∆2,3 248 97j 89a 
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occur from the metathesis of the alkyne with ethylene, without concommitant RRM. 
This would afford a product with the same mass, number of protons and number of 
carbons as the desired RRM product, leading to easy misinterpretation. We 
eventually assigned products 96j-98j as the undesired 1,3-dienes by careful analysis 
of the splitting pattern in the alkene region of the 1H NMR spectra. 
For benzo[b]quinolizine RRM product 237 (Figure 3.12), each of the four terminal 
alkene signals (a+h) appear as doublets as a result of the proton (b or g) on the 
adjacent carbon. For the 1,3-diene product 97j (Figure 3.13), two of the terminal 
alkene signals appear as doublets (k1+k2) as a result of the proton (j) on the adjacent 
carbon, and the two remaining terminal alkenes appear as broad singlets (indicative 
of h). Proton b of the RRM product 237 is a high order multiplet, strongly indicative 
of its position adjacent to a and c. In addition to this, protons b and c of 1,3-diene 97j 
are positioned where we normally find the ∆2,3 isomer alkene signals of the 
phenanthridine. The two NMR examples given are typical of the other RRM and 1,3-




Figure 3.12 1H NMR of benzo[b]quinolizine RRM product 237. 
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Figure 3.13 1H NMR of ∆2,3 diene 97j. 
 
3.4.9 Other metathesis attempts 
Similarly, the application of our standard metathesis conditions to Poc-
phenanthridines 96h-98h also gave the corresponding 1,3-diene products 96k-98k 
(Table 3.13). Despite substrates 96h-98h failing to undergo RRM, we were pleased 
to observe that the carbamate functionality of the Poc-group had remained in tact. As 
far as we know, this is the first report of such functionality surviving Grubbs-
metathesis conditions, providing evidence to support its application in RCM studies. 




      
a) Hoveyda-Grubbs II 251 (15 mol%), ethylene, CH2Cl2, r.t., 40 h. 
Entry Substrate Product Conversion (%) 
1 ∆1,2 96k 73 
2 ∆2,3 97k 60 
3 ∆3,4 98k 96 
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As suggested in section 3.4.2, the formation of 1,3-diene products has been proposed 
to occur as a result of steric congestion.146 In light of this, we were keen to observe 
what happened when we employed the less sterically hindered Grubbs I catalyst 248, 
which had found success in the literature precedent. However, application of this 
catalyst to the ∆2,3 homopropargyl substrate 97g at room temperature or 45 oC in 
CH2Cl2 (Table 3.12), gave quantitative conversion to the 1,3-diene product 97j, as 
we had previously observed using Hoveyda-Grubbs II 251. 
 
One additional literature example reported the successful manipulation of a butenyl 
tether in the RRM of indolizidine alkaloids.162 As the homopropargyl and Poc-
tethered phenanthridines had both formed the 1,3-diene under RRM conditions, we 
decided to synthesise butenyl-phenanthridine 97m. If this substrate were to undergo 
an alkene cross metathesis with ethylene, it would simply regenerate the starting 
material, thus we were hopeful that an RRM would be promoted under such 
circumstances. However, unfortunately when we attempted this reaction on the ∆2,3 
substrate 97m using catalyst 251, all we recovered was the starting material in 
quantitative yield, suggesting that either a cross alkene metathesis with ethylene had 
occurred, or that the alkene tether was unreactive. 
 
Scheme 3.27 Synthesis and attempted RRM of ∆2,3 butenyl-phenanthridine 97m.         
a) Butenyl bromide (1.1 eq), K2CO3 (3 eq), acetone (anhydrous); b) 251 (15 mol%), ethylene, CH2Cl2, 
r.t., 40 h, 99%.     
 
3.4.10 Conclusions for RRM 
Several interesting points were raised from these preliminary investigations into the 
RRM of our phenanthridine substrates. Firstly, the reaction was clearly possible as 
exemplified by the successful synthesis of benzo[b]quinolizine 237 and 
benzoindolizine 238. As we have seen from the molecular model of a typical cis-
phenanthridine (Figure 3.6), the molecule lies in a very cupped conformation as 
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compared to its flatter trans counterpart. Our working hypothesis as to the success of 
these RRM reactions, is that the relief of steric strain upon opening of the C-ring 
provides a strong driving force for the reaction. In order to test this hypothesis it 
would certainly be interesting to try the same RRM reaction on an analogous trans-
phenanthridine. The formation of the conjugated diene in the RRM product, may also 
contribute to promotion of the RRM reaction. 
The second interesting point is the formation of 1,3-dienes from the longer alkyne-
tethered phenanthridines, rather than the desired RRM product. There are currently 
no reports in the literature comparing the relative abilities of propargyl and 
homopropargyl tethers to undergo RRM. However, instances of both being 
successfully manipulated in RRM are known, as are instances of both acting as 
precursors for formation of the 1,3-diene product.146 As we obtained no improvement 
using a less bulky catalyst (Grubbs I 248) we can only postulate that the reluctance of 
our long-chain alkynyl tethered phenanthridines to undergo RRM may be a result of 
the disfavoured formation of larger C-ring products. This may also have some 
bearing on the failed RRM of the propargyl ∆1,2 analogue as the product here would 
have had a 7-membered C-ring, however it is likely in this case that the tether was 
simply to short to allow the RRM reaction to take place. 
In light of the time constraints for this project we had to be content with limiting our 
skeletal diversification to the successful generation of two RRM products. However, 
the work sets excellent precedent for further investigation into cis vs trans ring-fused 
cyclohexenes as substrates for RRM reactions. 
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3.5 Conclusions 
Methodology for the synthesis of a DOS library of phenanthridines was explored 
from each of the three possible angles, namely building block diversity, 
stereochemical diversity and skeletal diversity. 
i) Building block diversity 
Conditions for the high yielding and efficient synthesis of various 
aromatic/heteroaromatic building blocks were developed, using standard 
transformations, or less standard Curtius methodology. These building blocks were 
readily converted to the corresponding cyclisation precursors 165a-f,k, and shown to 
undergo facile Heck cyclisation under cationic or neutral conditions, to afford the 
expected double bond isomer products 195-197a-f,k in excellent yield (72-99%). 
ii) Stereochemical diversity 
The synthesis of exo-syn dihydroxylated phenanthridines 206m-208m was shown to 
proceed with high dr (>83:17) and excellent yield (99%) across the range of double 
bond isomers. Attempts to introduce epoxide functionality to the C-ring were 
hampered by over-oxidation to the phenanthridone or failure to reproduce reported 
literature conditions. We were therefore unable to generate any trans-diol C-ring 
phenanthridines. 
iii) Skeletal diversity 
Methodology for the RRM of various propargyl-tethered phenanthridines was 
explored. High conversions were obtained for the RRM of ∆2,3 and ∆3,4 propargyl 
phenanthridines 97f and 98f giving a potential route to novel benzo[b]quinolizines 
and benzoindolizine products. Unfortunately the propargyl tether did not react with 
the ∆1,2 alkene, preventing this methodology from being applied to all members of 
the alkene library, and thus limiting its use in a DOS library context. Our attempts to 
lengthen the alkynyl tether led to the formation of unwanted 1,3-diene products 96jk-
98jk. 
Exploration of the amine building block diversity in conjunction with the cis-
dihydroxylation protocol will be the two elements combined in Chapter 4 for the 
DOS library synthesis. 
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LIBRARY SYNTHESIS AND BIOLOGICAL EVALUATION 
 
 
4.1 Library synthesis 
We chose to synthesise a library based upon the phenanthridine core, using the 
building block and stereochemical diversity protocols developed in Chapter 3. To 
this end our aryl and heteroaryl double bond isomer phenanthridine mixtures 195-
197a-f,k were treated under exo cis-dihydroxylation conditions (Table 4.1) to afford 
the corresponding diol mixtures 206-208a-f,k. 
 
Table 4.1 Cis-dihydroxylation of aryl/heteroaryl phenanthridines 195-197a-f,k. 
 










1 a 4-Me 78 - - - 
2 b 4-F 82 18 28 20 
3 c 5-MeO 95 13 12 19 
4 d 4,5-diMeO 70 6 19
c 30 
5 e [Naphthyl]$ 87 14 28 16 
6 f [Thiophene]$ 64 - - - 
7 k [Piperonyl]$* 87  9 23 (2)
d 18 
8  m (96b-98b)e H 70 13 11 12 
 
a) OsO4, NMO, THF/H2O, r.t., 18 h. 
a Isolated yield for mixture following flash chromatography. b 
Isolated yield of each isomer following flash chromatography or additional HPLC separation. c 
comprises approximately 1:1 mixture of ∆1,2:∆2,3 diols. d ∆2,3 endo-syn diol product 209k isolated and 
characterised by 2D NMR studies (see section 3.3.2). e Reaction performed on parent phenanthridines 
96b-98b. $ See footnote Table 3.2. * As in Scheme 3.6. 
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In keeping with the high diasteromeric ratio we obtained for the cis-dihydroxylation 
of carbamates 96b-98b in the previous chapter (Table 3.7), we observed the exo-
diols as the major products. Determination of the exact ratio was not possible due to 
the complex mixture of isomer products. Structural assignment was made by analogy 
with the parent diol analogues 206m-208m (R=H) that were synthesised as isolated 
products in the previous section (Table 3.7). The dihydroxylation of 96b-98b was 
repeated here using the mixture of double bond isomers to give a comparative result 
for the library synthesis (Table 4.1, entry 8). From the dihydroxylation of piperonyl 
phenanthridines 195k-197k (entry 7) we isolated a trace amount of the ∆2,3 endo-syn 
diol 209k that enabled us to confirm the major and minor product structures using 
2D nOESY NMR (see section 3.3.2). 
 
Following dihydroxylation, the three major products 206, 207 and 208 were isolated 
by silica-gel chromatography or HPLC separation, and in the majority of cases 
reasonable amounts of each were recovered (Table 4.1). However, unfortunately we 
were not able to separate the 4-methyl diol products 206a-208a despite repeated 
attempts. Similarly, the ∆1,2 and ∆2,3 dimethoxy analogue fractions 206d and 207d 
overlapped significantly in the HPLC separation and thus the ∆2,3 sample had 
significant ∆1,2 contamination. Additionally, due to the unselective Heck cyclisation 
of thiophene analogue 165f, we did not think it feasible to carry out HPLC separation 
of its diol counterparts. For these three substrates, mixtures of the appropriate 
compounds 206-208a,f,k were carried through to the biological testing stage.  
 
For the last step in our library synthesis, we took the diol mixtures (with the 
exception of 206-208e,m) and isolated compounds and converted each into the 
hydrochloride salts, with yields as summarised in Table 4.2. In general, and where 
available, the diol mixtures were used in preliminary biological investigations, so 
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Table 4.2 Boc deprotection to afford a phenanthridinium hydrochloride library. 
 











1 a 4-Me 69 - - - 
2 b 4-F 99 99 86 74 
3 c 5-MeO 89 82 92 84 
4 d 4,5-diMeO 87 88 60
b 60 
5 e [Naphthyl]$*c - 67 61 69 
6 f [Thiophene]$* 99 - - - 
7 k [Piperonyl]$* 69 61 81 (60)
d 77 
8 m Hc - 86 60 53 
 
a) i) TFA, CH2Cl2, 1 h, r.t.; ii) NaOH, adjust to pH 9; iii) HCl in Et2O, 0 
oC. a Performed on mixture. b 
Approximately 1:1 mixture ∆1,2:∆2,3. c As reasonable quantities of the isolated isomers were available, 
no mixture of hydrochloride salts was synthesised for these analogues. d Yield for deprotection of 
endo-syn piperonyl substrate 209k to afford diol hydrochloride 255k. $ See footnote Table 3.2. * As 
in Scheme 3.6. 
 
We also treated the sulfonamide protected thiophene mixture 158-160 to the cis-
dihydroxylation conditions (Scheme 4.1). Purification by flash chromatography 
afforded isolated quantities of the three major exo-syn products, providing three 
additional compounds 256-258 for our library. 
 
 
Scheme 4.1 Cis-dihydroxylation of thiophene sulfonamides 158-160.                            
a) OsO4, NMO, THF/H2O, r.t., 18 h, 73%. Isolated yields: ∆
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The structures of the 22 isolated compounds and 6 mixtures that were synthesised for 




Figure 4.1 Phenanthridine diol library members for biological testing.
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4.2 Screening of small molecule libraries 
As alluded to in Chapter 1, forward-chemical genetics describes a method of 
identifying small molecules that modulate the function of a biological pathway, 
resulting in an induction or reversion of a specific phenotype.2 The use of whole 
organisms to facilitate phenotypic screening of compound libraries, is an area that 
has received significant attention recently.163 In whole organisms the cells are not 
transformed, and are in their normal physiological environment offering significant 
advantages over traditional cell-based assays. Additionally, because the embryo 
contains many distinct cell-types, the identification of tissue-specific small molecules 
can be made. The use of whole organisms can also enable the screening of processes 
that are not easily replicated in vitro such as organ development. Finally, the 
metabolism of the organism permits the identification of compounds that become 
active as metabolites, something that is not possible in cell-based assays. 
 
Carrying out in vivo screening right from the outset of a project can therefore save 
valuable time by providing a more accurate model in terms of toxicity, tissue-
specificity and bioavailability.163 The validation of drug targets has traditionally been 
performed in mammalian models such as the mouse, however high-throughput 
validation of compound libraries requires smaller organisms that can be easily 
produced, studied and stored in great numbers. In light of this, interest has turned 
towards lower phylogenetic organisms such as Drosophila melanogaster (fruit fly), 
Caenohabditis elegans (nematode worm) and Danio rerio (zebrafish). 
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4.3 Zebrafish 
The zebrafish has been a popular pet for many years, but its use for research has 
increased dramatically over the last 15 years following the demonstration of its 
amenability to chemical genetics screens (Figure 4.2).  
 
Figure 4.2 Adult zebrafish - male (bottom) and female (top). 
 
There are many reasons for the suitability of zebrafish to high-throughput 
phenotyping. For example, following mating, the female adult zebrafish can produce 
up to 300 eggs.50 The breeding process is also very rapid, and a mating pair need 
only be set up the evening before the eggs are required. With multiple breeding pairs, 
sufficient eggs for the screening of large compound collections can be rapidly raised. 
Fertilisation occurs externally to the female’s body meaning that each stage of 
embryonic development can be easily examined, and importantly, the zebrafish 
embryo is transparent for the first five days of development, making it suitable for a 
wide range of optical analysis. This also means that the identification of phenotypes 
can be easily made without the need to kill or dissect the organism. As each embryo 
measures less than 1 mm in diameter they can be easily studied in microwell plates, 
and because the zebrafish is an aquatic organism, compounds can be directly 
aliquoted into the embryo medium.  
One of the most valid reasons for high-throughput screening in zebrafish is their 
close evolutionary relationship to humans. There is a strong homology between the 
genes of mammalians and zebrafish, and phenotypes have been identified that 
closely resemble human diseases.164 In the past few years, several additional tools 
have been developed that greatly aid the use of the zebrafish as a model organism. 
For example, the zebrafish genome has now been fully sequenced, resulting in the 
availability of multiple DNA microarrays for expression-profiling experiments.165 
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Antisense morpholino oligonucleotides can be utilised to knock-down proteins, 
permitting validation in circumstances where the small molecule in question may 
have multiple targets.166,167 Furthermore, transgenic lines168 (Figure 4.3) and targeted 
mutations169 can also be introduced, enabling forward-chemical genetics to be 
performed, where compounds are screened to observe a reversion of phenotype. Of 
additional interest is the ability of the zebrafish to regenerate fins, skin, the heart, and 
the brain in larval stages.164 
 
 





Despite the numerous advantages of performing high-throughput phenotypic 
screening in zebrafish, there are several drawbacks. For true high-throughput 
screening, the number of compounds is limited to a few thousand per week due to the 
number of embryos obtainable. The amount of labour involved is greater than that of 
cell-based assays due to fish husbandry and lower overall throughput. Additionally, 
certain compounds that have proven to be potent in cell lines showed no activity in 
zebrafish.171 The use of zebrafish assays should therefore be used as a 
complementary strategy to cell-based techniques, or as a secondary screening 
platform following a higher throughput primary screen.172  
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4.3.1 Practicalities of high-throughput phenotyping in zebrafish 
In order to set up a small molecule zebrafish screen, a pair of adult zebrafish must 
first be mated to allow the embryos to be collected (Figure 4.4, a).172 This is 
achieved by placing one male and one female in a small covered tank overnight, 
under darkness. When the lights are switched on the next morning the fish will mate 
and the embryos can be collected. Several clutches of embryos from different 
breeding pairs should be combined to minimise any unintended family effects from 
certain parents, or incorrectly genotyped fish. The embryos are washed with and 
stored in E3 medium that sustains their development.φ  The embryos should be 
examined at this stage and any unfertilised eggs or dead embryos should be removed. 
Additionally, if dead embryos are noticed at any point during the screening process, 
they should be removed as they can be detrimental to the development and health of 
all the fish contained in their medium. 
The embryos are incubated at 28.5 oC until they reach the appropriate age of 
development, this is usually between 4 and 24 hours post fertilisation (hpf). 
Typically, two to three embryos are transferred to each well of a 96-well plate using 
a wide-tipped plastic Pasteur pipette (Figure 4.4, b).172 The E3 medium is then 
decanted from the embryos using a Pasteur pipette and the appropriate small 
molecule is added at the relevant concentration in E3 (Figure 4.4, c&d). Drug 
concentrations tend to be in the range 1-100 µM for a preliminary screen, and it is 
standard to use up to 1% v/v DMSO as a vehicle for transporting the small molecule 
across the cell membrane. Control experiments in E3 (plus up to 1% v/v DMSO) are 
also performed so that the identification of phenotypes can be easily performed. 
The development of the zebrafish embryos can then be carefully monitored over a 
period of five days, recording any phenotypes that arise (Figure 4.4, e). Any hits can 
then be traced back to the appropriate library member  (Figure 4.4, f) and further 




                                                 
φ E3 medium is comprised: 5 mM NaCl, 0.17 mM KCl, 0.4 mM CaCl2, and 0.16 mM MgSO4. To 
suppress the growth of mould the medium is supplemented with 10-5% methylene blue.173 







Figure 4.4 Zebrafish small-molecule screens.164 
 
a) Adult zebrafish are mated, producing 200-300 embryos. b) Embryos are distributed to 96-well 
plates, 2-3 per well. c) A small molecule library is acquired or synthesised. d) Small molecules are 
added to the embryonic medium. e) After incubation at 28.5 oC, phenotypes are visually determined. 
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4.3.2 Developmental stages of zebrafish embryos 
The development of embryonic wild-type zebrafish (as used in our screens) is 
illustrated in Figure 4.5.174 At 48 hpf the embryo hatches from its chorion and 
becomes a free swimming larvae that is sensitive to the touch. Anatomical 
terminology for the zebrafish is given in Figure 4.6.173 
 
Figure 4.5 Stages of embryo development in zebrafish.174  
 
 
Figure 4.6 Anatomical terminology for zebrafish at 29 hpf, 48 hpf and 5 dpf.173
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4.3.3 Biological evaluation of our library using zebrafish phenotyping 
In order to assess the applicability of our library to zebrafish screening, we proposed 
to carry out preliminary investigations using the diol hydrochloride mixtures 252-
254. If any activity was apparent then the individual component compounds of the 
mixture could be screened individually. For the substrates where no mixture was in 
hand, the three isolated diols were screened separately (naphthyl analogues 252e-
254e, parent analogues 252m-254m and thiophene sulfonamide 256-258). Using the 
procedure described in section 4.3.1, ‘high stage’ embryos (approximately 3-4 hpf) 
were treated with aliquots of the appropriate drug solution (all 0.5% v/v DMSO in E3 
medium), ranging in concentration from 10-100 µM for the mixtures, and 1-50 µM 
for the isolated compounds.  
Several of the compounds/compound mixtures induced general symptoms of ill 
health in the fish. One such example was 5-methoxy compound mixture 252c-254c 
that induced the bent tail phenotype in 5 dpf larvae at 50 µM (Figure 4.7, a). When 
mixture 252c-254c was split out into its component compounds for a secondary 
assay, compound 254c (∆3,4 isomer) was found to result in extended tail length in 5 
dpf zebrafish, at a concentration of 100 µM (Figure 4.7, c). 













Figure 4.7 Tail modification using 252c-254c at 5 dpf. 
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One other example of general toxicity was shown for parent compound 253m (∆2,3 
isomer) that was screened separately from the outset. This compound reproducibly 
induced oedema in the zebrafish at 50 µM, though no abnormal effects were shown 
above or below this concentration. Figure 4.8 illustrates the enlarged heart and 
hatching gland at 2 dpf (a), increasing to the grossly enlarged yolk sack and heart, 
visible at 5 dpf (c, e). 



















Figure 4.8 Generation of oedema by compound 253m.  
a) 50 µM 253m, 2 dpf; b) control, 2 dpf; c) 50 µM 253m, 5 dpf, side view; d) control, 5 dpf, side 
view; e) 50 µM 253m, 5 dpf, top view; f) control, 5 dpf, top view.  
 
While these symptoms illustrated a level of toxicity associated with the appropriate 
compound/compounds, no dose dependence was shown and no tissue specificity was 
deduced since the general function of the organism was not altered overall. However, 
for fluorinated compound mixture 252b-254b we did observe more severe effects, 
with reproducible embryo death at 50 µM, after 1 dpf (Figure 4.9, a). 
 







Figure 4.9 Dead embryos after exposure to 50 µM 252b-254b. 
a) 50 µM 252b-254b, 1 dpf; b) control, 1 dpf. 
 
Although no effect was observed at the higher dose of 100 µM, the 50 µM results 
prompted us to screen compounds 252b, 253b and 254b individually. For 
compounds 253b and 254b we observed no abnormalities, however compound 252b 
(∆1,2 isomer) appeared to slow down the development of the embryos significantly, 
and in a dose dependent manner (Figure 4.10). 














Figure 4.10 Delayed development of zebrafish embryos treated with 252b at 2 dpf. 
All photos at 2 dpf. a) 100 µM 252b; b) 50 µM  252b; c) 20 µM 252b; d) control. 
 
At 5 dpf, the yolk sack of the fish treated with 100 µM 252b was significantly larger 
than that of the control, providing further evidence for delayed development. 
Additionally the positioning of the melanocytes (pigmentation) on the underside of 
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the yolk sack was noticeably different from that of the control (Figure 4.11, a&b). 
The fish treated with 50 µM 252b showed the bent tail phenotype reported 
previously (Figure 4.7), but no notable difference from the control was observed in 
the fish exposed to lower drug concentrations at 5 dpf. 
 













Figure 4.11 Delayed development of zebrafish embryos treated with 252b at 5 dpf. 
All photos at 5 dpf. a) 100 µM 252b, side view; b) control, side view; c) 100 µM 252b, top view; d) 
control, top view. 
 
The results obtained for compound 252b are preliminary and require further 
investigation and replication on a larger scale to be of statistical significance. 
However, that being said, a decreased rate of embryo development and dose-
dependence was clearly observed in our experiment. This suggests that compound 
252b interferes in some way with the cell division process (mitosis).  This would be 
in agreement with the activity of the benzophenanthridine alkaloid chelidonine 76 
that bears structural similarities to compound 252b (Figure 4.12). Chelidonine 76 is 
known to cause mitotic arrest and inhibition of tubulin polymerisation, as well as 
being the major component of Ukrain™ 259, a selectively toxic agent to malignant 
cells.175 Further studies of compound 252b using both zebrafish assays and cell-
based techniques would enable a more probing identification of its specific mode of 
action.  
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Figure 4.12 Chelidone 76 and Ukrain™ 259.175 
 
The remaining compounds/compound mixtures showed no specific phenotype upon 
application to the zebrafish embryos. However, as previously mentioned, zebrafish 
assays should be used in conjunction with standard cell-based techniques to provide 
a more accurate assessment of any potential bioactivity.171  
 
4.4 Conclusion 
The methodology developed in Chapters 2 and 3 was successfully applied to the 
synthesis of a small library of dihydroxylated phenanthridines. Biological evaluation 
was facilitated using whole organism phenotype screening with zebrafish embryos. 
Preliminary results suggest that 5-methoxy analogue 254c and phenyl analogue 
253m induce signs of ill health in the developing embryos, but the phenotype they 
induce does not indicate any tissue specificity. 4-Fluoro analogue 252b was 
successfully shown to delay the zebrafish embryo development in a dose-dependent 
manner. Further evaluation of compound 252b using more advanced zebrafish assays 







The synthesis of a small library of phenanthridines was successfully achieved using 
the methodology described in Chapters 2, 3 and 4. This methodology could be 
extended to allow the incorporation of greater diversity, as illustrated in Scheme 5.1. 
The synthesis of oxygen and sulfur analogues such as 260 could be investigated 
using benzyl alcohol and benzyl thiol building blocks. Studies into the synthesis of a 
7-membered B-ring derivative could be completed, and this methodology extended 
to incorporate 8- and 9-membered analogues such as 261. Alternatively, the synthesis 
of larger C-ring derivatives such as 262 might be realised by the use of larger 
cycloalkenyl bromide building blocks. Studies into the incorporation of heteroaryl 
building blocks would yield further skeletal variation. In particular, thiophene 
analogues 158-160 and 195f-197f are good precedent for the synthesis of pyrrole and 
furan equivalents such as 263. Finally, further optimisation of the epoxidation step 
would furnish 212 on a scale appropriate for the study a variety of nucleophile-
promoted ring-opening reactions.  
 
Scheme 5.1 Further incorporation of diversity into the phenanthridine library. 




The results obtained for the RRM studies (Chapter 3) also warrant further 
investigation. It would be interesting to examine the application of the RRM reaction 
to less strained ring systems, such as the equivalent trans-ring fused phenanthridines, 
or other trans-ring fused substrates. This would allow us to determine if the 
reactivity of our propargylated phenanthridines 97f and 98f was a result of their 
strained conformation. Additionally, application of the RRM reaction to other cis-
ring fused systems would allow the evaluation of RRM as a general tool for the 
modification of cyclic systems of this type. 
The preliminary results from the biological screening of our phenanthridine library 
using zebrafish are promising (Chapter 4). So far the screening has only been 
performed on a small scale using 2-3 fish per compound, per assay. A larger scale 
experiment using 20 fish would permit a more accurate assessment of the effect of 
our most active analogue 252b. Additionally, the effect of compound 252b could be 
examined using yeast cell assays, which may also allow us to tie down the specific 








6.1 General experimental 
 
1H nuclear magnetic resonance (NMR) spectra were recorded using an internal 
deuterium lock for the indicated reference at the stated temperature on Varian 
Gemini 200 (200 MHz), Bruker AC250 (250 MHz), Bruker DPX360 (360 MHz), 
Bruker DMX500 (500 MHz), Bruker AVA600 (600 MHz) and Bruker AVA800 (800 
MHz) instruments. The data is presented as follows: chemical shift (in ppm on the δ 
scale relative to δTMS = 0), integration, multiplicity (s = singlet, d = doublet, t = 
triplet, q = quartet, m = multiplet, td = triplet of doublets, dd = doublet of doublets, dt 
= doublet of triplets, br = broad), coupling constants (in Hertz, Hz) and 
interpretation. 13C NMR spectra were recorded at the stated temperature on Bruker 
AC250 (62.9 MHz), Bruker DPX360 (90.6 MHz), Bruker DMX500 (125.7 MHz), 
Bruker AVA600 (151.1 Hz) and Bruker AVA800 (201.5 Hz) instruments. 
Assignments are made on the basis of DEPT 135, DEPT 90 and 2D HSQC 
experiments. 
 
Infra-red spectra were recorded using a Biorad FTS-7 or Perkin-Elmer Paragon 1000 
FT-IR spectrometer as thin films unless otherwise stated. The wavelengths of 
maximum absorbance (υmax) are quoted in cm
-1. Electron impact (EI) mass spectra 
were obtained using a Finnigan 4500 mass spectrometer, and electrospray (ESI) and 
fast atom bombardment (FAB) mass spectra were obtained on a Kratos MS50TC 
mass spectrometer. The parent ion, or relevant fragments are quoted, followed by 
significant fragments and their relative intensities. Melting points were determined 
on a Gallenkamp Electrothermal Melting Point apparatus and are uncorrected. TLC 
was carried out using Merk silica gel 60F254 foil-backed plates with visualisation by 
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ultraviolet and KMnO4 (aq)
φ and/or molybdate stain.ϕ Flash chromatography was 
carried out using Merck Kieselgel 60 (Merck 9385) under positive pressure by means 
of an airline or hand pump. Eluent compositions are quoted as v/v ratios. High 
performance liquid chromatography (HPLC) was carried out using a Gilson 
instrument using a Spherisorb column (internal diameter: 20 mm) and fitted with a 
Gilson refractive index detector. Flow rates are a quoted for each separation in 
ml/min. All solvents used for HPLC were filtered prior to use and all HPLC samples 
were filtered through 0.45 µM nylon syringes prior to analysis. 
 
All reactions non-aqueous were carried out under an atmosphere of nitrogen using 
flame- or oven-dried glassware that was cooled in a dessicator prior to use. Unless 
otherwise noted, starting materials and reagents were obtained from commercial 
suppliers and were used without further purification. Dichloromethane (CH2Cl2), 
triethylamine (Et3N) and diisopropylethylamine (
iPr2NEt) were distilled from 
calcium hydride and stored over calcium hydride under a nitrogen atmosphere. When 
used as a reagent, dimethylformamide (DMF) was also distilled from and stored over 
calcium hydride under a nitrogen atmosphere. Tetrahydrofuran (THF) was distilled 
from sodium/benzophenone and stored under a nitrogen atmosphere. Diethyl ether 
(Et2O), toluene and methanol (MeOH) were dried and purified by passage through 
activated alumina columns using a solvent purification system from 
www.glasscontour.com. Anhydrous dimethylacetamide (DMA), DMF (when used as 
a solvent) and acetonitrile (MeCN) were used as supplied by BakerDRY. Extra dry 
acetone was used as supplied by Acros. Anhydrous 1,4-dioxane was used as supplied 
by Aldrich. Saturated aqueous solutions of inorganic salts are represented as 
(volume, sat. aq.) 
                                                 
φ Potassium permanganate dip prepared as follows: To water (1000 ml) was added KMnO4 (10 g), 
K2CO3 (50 g) and NaOH (40 pellets). The mixture was stirred until the solid had dissolved. 
 
ϕ Ammonium molybdate dip prepared as follows: To water (950 ml) was added concentrated 
sulphuric acid (50 ml), ammonium molybdate (50 g) and ceric sulfate (3 g). The mixture was stirred 
until all solid material had disappeared and a bright yellow solution remained. 
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The apparatus used for flash vacuum pyrolysis (FVP) is illustrated in Figure 3.10. 
The system was evacuated by use of an Edwards Model ED100 high capacity oil 
pump to maintain the pressure in the region of 0.030 Torr. A glass Büchi oven was 
used to heat the inlet tube in which the substrate was placed until it volatilises. The 
gaseous substrate passed through a silica tube (30 x 2.5 cm) heated by a Carbolite 
electronically controlled laboratory tube furnace (model number MTF 12/38/250). 
The estimated contact time in the hot zone is of the order of ten milliseconds and the 
gaseous phase of the substrate under vacuum ensures that intramolecular reactions 
are strongly favoured. The products are captured at the exit of the furnace in a U-
shaped trap cooled in liquid nitrogen. Upon completion of the reaction the pump is 
isolated and the trap is allowed to warm to room temperature under a dry nitrogen 
atmosphere. Standard pyrolysis parameters used in this section are furnace 
temperature Tf, inlet temperature Ti, pressure P and time of pyrolysis t. 
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6.2 Experimental for Chapter two 
 
General procedure A - Secondary amine formation 
To a suspension of the appropriate 2-halobenzylamine hydrochloride (1 eq) in MeCN 
at 0 oC was added iPr2NEt (4 eq) and the reaction was stirred for 5 mins. 3-
Bromocyclohexene (1 eq) was added and the reaction stirred for 16 h at r.t. The 
reaction was concentrated under reduced pressure and the residue taken up in CH2Cl2 
(50 ml) and washed with NaCl (3 x 50 ml, sat. aq.). The organics were combined, 
dried (MgSO4) and concentrated under reduced pressure. The residue was taken up in 
CH2Cl2, HCl (excess, 1.0 M in Et2O) added and the resultant suspension filtered to 
afford the desired amine hydrochloride. 
 
General procedure B - Sulfonamide protection 
To a solution of the appropriate amine or amine hydrochloride (1 eq) in CH2Cl2 (10 
ml) at 0 oC was added methanesulfonyl chloride (3 eq) and Et3N (3 eq) and the 
reaction was warmed to r.t. and stirred for 16 h. The reaction was diluted with 
CH2Cl2 (20 ml), and washed with HCl (3 x 20 ml, 1 M aq.). The organics were dried 
(MgSO4), concentrated under reduced pressure and purified by flash chromatography 




N-(2-Bromo-benzyl)-cyclohex-2-enyl-amine hydrochloride 93 
General procedure A was followed using 
2-bromobenzylamine hydrochloride (6.00 g, 27.0 mmol), 
MeCN (100 ml), iPr2NEt (18.8 ml, 108 mmol), 3-
bromocyclohexene (3.10 ml, 27.0 mmol), and HCl (30 ml, 1.0 M in Et2O, 30.0 
mmol) to afford amine hydrochloride 93 as a colourless solid (7.15 g, 99%).  
MP 142 oC (Et2O); 
1H NMR δ (250 MHz, CD3OD) 7.79 (1H, dd, Ј 8.0, 1.3, ArH), 
7.66 (1H, dd, Ј 7.6, ArH), 7.53 (1H, td, Ј 7.6, 1.3, ArH), 7.43 (1H, td, Ј 7.9, 1.7, 
ArH), 6.29-6.23 (1H, m, CH=CH), 5.91-5.87 (1H, m, CH=CH), 4.46 (2H, s, CH2Ar), 
4.06-4.03 (1H, m, CHN), 2.28-2.18 (3H, s, CHAHB+CH2), 1.94-1.87 (3H, m, 
CHAHB+CH2); 
13C NMR δ (250 MHz, CD3OD) 135.4 (CH), 133.0 (CH), 131.6 
(CH), 131.1 (CH), 130.9 (C), 128.0 (CH), 124.5 (C), 120.7 (CH), 54.3 (CH), 46.9 
(CH2), 24.8 (CH2), 23.9 (CH2), 18.8 (CH2); m/z (FAB, THIOG) 266 ([
81BrM-H]+, 86 
%), 264 ([79BrM-H]+, 70), 262 (27), 239 (25), 238 (28.5), 186 (91), 184 (88) ; HRMS 
(FAB, THIOG) Found: [81BrM-H]+, 266.0372. C13H15N
81Br requires 266.0369. 
Found: [79BrM-H]+, 264.0383. C13H15N
79Br requires 264.0388. 
Free Amine: Rf [hexane:EtOAc, 3:1] = 0.90; υmax (CH2Cl2)/cm
-1 3361 (NH), 1466, 
1436, 1010, 747; 1H NMR δ (250 MHz, CDCl3) 7.68 (1H, dd, Ј 7.9, 1.3, ArH), 7.60 
(1H, dd, Ј 7.7, 1.7, ArH), 7.43 (1H, td, Ј 7.4, 1.1, ArH), 7.26 (1H, td, Ј 7.6, 1.8, 
ArH), 5.97-5.87 (2H, m, CHNCH=CH), 4.10 (1H, d, Ј  13.8, CHXHYAr), 4.03 (1H, 
d, Ј  13.8, CHXHYAr), 3.38 (1H, br s, CHN), 2.17-1.66 (6H, m, 3xCH2); 
13C NMR δ 
(62.9 MHz, CDCl3) 139.5 (C), 132.5 (CH), 130.0 (CH), 129.6 (CH), 128.9 (CH), 











General procedure B was followed using amine 
hydrochloride 93 (3.90 g, 14.6 mmol), CH2Cl2 (50 ml), Et3N 
(6.20 ml, 43.8 mmol) and methanesulfonyl chloride (3.40 
ml, 43.8 mmol). Flash chromatography (CH2Cl2-
CH2Cl2:MeOH, 100:1) afforded sulfonamide 94a as a colourless solid (4.95 g, 99%).  
Rf [hexane:EtOAc, 3:1] = 0.46; MP 100 
oC (Et2O); υmax (CHCl3)/cm
-1 1332 (SO2), 
1145 (SO2); 
1H NMR δ (250 MHz, CDCl3) 7.67 (1H, dd, Ј 7.8, 0.8, ArH), 7.49 (1H, 
dd, Ј 7.9, 1.2, ArH), 7.33 (1H, td, Ј 7.7, 1.2, ArH), 7.12 (1H, m, ArH), 5.98-5.93 
(1H, m, NCHCH=CH), 5.53-5.47 (1H, m, NCHCH=CH), 4.66-4.57 (1H, m, NCH), 
4.47 (1H, dd, Ј 17.7, CHXHYAr), 4.33 (1H, d, Ј 17.7, CHXHYAr), 2.97 (3H, s, CH3), 
1.99-1.92 (3H, m, CHAHB+CH2), 1.70-1.34 (3H, m, CHAHB+CH2); 
13C NMR δ 
(62.9 MHz, CDCl3) 137.7 (C), 133.7 (CH), 132.1 (CH), 129.2 (CH), 128.4 (CH), 
127.3 (CH), 126.5 (CH), 121.9 (C), 55.6 (CH), 47.5 (CH2), 39.4 (CH3), 28.7 (CH2), 
24.2 (CH2), 21.4 (CH2); m/z (FAB, THIOG) 346 ([
81BrM+H]+, 64 %), 344 
([79BrM+H]+, 68), 266 (80), 264 (85); HRMS (FAB, THIOG) Found: [81BrM+H]+, 
346.0326. C14H19NO2S
81Br requires 346.0301. Found: [79BrM+H]+ 344.0346. 
C14H19NO2S











(2-Bromo-benzyl)-cyclohex-2-enyl-carbamic acid tert-butyl ester 94b 
To a suspension of amine 93 (500 mg, 1.87 mmol) in CH2Cl2 
(20 ml) was added Et3N (395 µl, 2.81 mmol). After 10 mins, 
the reaction was cooled to 0 oC, Boc2O (613 mg, 2.81 mmol) 
in CH2Cl2 (5 ml) was added and the reaction was stirred for a 
further 10 mins. The reaction was warmed to r.t and stirred 
for 16 h. The reaction was diluted with CH2Cl2 (20 ml), extracted with NaCl (3 x 20 
ml, sat. aq.), dried (MgSO4) and concentrated under reduced pressure. Flash 
chromatography (hexane:EtOAc:Et3N, 10:1:0.1) afforded Boc amine 94b as a 
colourless solid (685 mg, 90%). 
 Rf [hexane:EtOAc, 3:1] = 0.8; MP 81 
oC (hexane); υmax (CHCl3)/cm
-1 3057, 3021, 
1695 (C=O), 1274, 1253; 1H NMR δ (360 MHz, 318 K, CDCl3) 7.51 (1H, d, Ј 7.7, 
ArH), 7.29-7.26 (2H, m, 2xArH), 7.11-7.07 (1H, m, ArH), 5.83 (1H, br s, CH=CH), 
5.50 (1H, d, Ј 10.1, CH=CH), 4.90 (1H, br s, NCH), 4.38 (2H, br s, CH2Ar), 2.10-
1.81 (3H, m, CH2+CHAHB), 1.81-1.70 (1H, m, CHAHB), 1.55-1.46 (2H, m, CH2), 
1.35 (9H, s, 3CH3); 
13C NMR δ (90.6 MHz, 318 K, CDCl3) 155.6 (C), 132.2 (CH), 
131.7 (CH), 130.8 (C), 128.0 (CH), 127.7 (CH), 127.3 (CH), 126.9 (CH), 121.9 (C), 
79.7 (C), 53.0 (CH), 52.6 (CH2), 28.0 (3xCH3), 27.3 (CH2), 24.4 (CH2), 21.2 (CH2); 
m/z (FAB, THIOG) 368 ([81BrM+H]+, 12 %), 366 ([79BrM+H]+, 15), 313 (33), 312 
(68), 311 (39), 310 (70), 266 (28), 232 (57), 230 (51); HRMS (FAB, THIOG) 
Found: [81BrM+H]+ 368.1046. C18H25NO2
81Br requires 368.1050. Found: [79BrM+H]+ 
366.1067. C18H25NO2










(2-Bromo-benzyl)-cyclohex-2-enyl-carbamic acid benzyl ester 94c 
To a suspension of NaH (143 mg, 60% dispersion in mineral 
oil, 3.62 mmol) in DMF (10.0 ml) at 0 oC was added amine 
93 (500 mg, 1.65 mmol) in DMF (10.0 ml). The solution was 
stirred for 30 mins then benzyl chloroformate (302 µl, 2.15 
mmol) was added dropwise and the reaction was warmed to 
r.t. and stirred for 16 h. The reaction was diluted with Et2O 
(20 ml), extracted with NaCl (3 x 20.0 ml, sat. aq.), dried 
(MgSO4) and concentrated under reduced pressure to give the crude product. Flash 
chromatography (hexane:EtOAc:Et3N, 100:1:0.1–100:5:0.1) afforded Cbz amide 94c 
as a colourless solid (570 mg, 86%).  
Rf [hexane:EtOAc, 10:1] = 0.54; MP 48 
oC (hexane); υmax (CHCl3)/cm
-1 3064, 3021, 
1699, 1407, 1258; 1H NMR δ (360 MHz, 323K, CDCl3) 7.52 (1H, d, Ј 5.8, ArH), 
7.40 – 7.22 (7H, m, 7xArH), 7.11-7.08 (1H, m, ArH), 5.87-5.85 (1H, m, CH=CH), 
5.48 (1H, d, Ј 10.2, CH=CH), 5.16 (2H, br s, OCH2Ar), 4.89 (1H, br s, CHN), 4.51 
(1H, d, Ј 17.4, CHXHYAr), 4.44 (1H, d, Ј 17.4, CHXHYAr), 2.11-1.84 (3H, m, 
CH2+CHAHB), 1.80-1.70 (1H, m, CHAHB), 1.70-1.47 (2H, m, CH2); 
13C NMR δ 
(90.6 MHz, 323K, CDCl3) 156.4 (C), 138.4 (C), 136.7 (C), 132.4 (2xCH), 128.3 
(CH), 127.9 (CH), 127.7 (3xCH), 127.6 (3xCH), 127.1 (CH), 122.1 (C), 67.3 (CH2), 
53.8 (CH), 47.7 (CH2), 28.1 (CH2), 24.5 (CH2), 21.2 (CH2); m/z (FAB, 3-NOBA) 
402 ([81BrM+H]+, 35 %), 400 ([79BrM+H]+, 38), 310 (22), 308 (22), 171 (69), 169 (50) 
; HRMS (FAB, THIOG) Found: [81BrM+H]+ 402.0821. C21H23O2
81BrN requires 









To a suspension of amine 93 (750 mg, 2.47 mmol) in DMF 
(20 ml) at 0 oC, was added NaH (217 mg, 60% dispersion in 
mineral oil, 5.43 mmol) and the reaction stirred for 30 mins. 
Benzyl bromide (382 µl, 3.21 mmol) was added dropwise and 
the reaction warmed to r.t and stirred for 16 h. Et2O (20 ml) 
was added and the organics washed with NaCl (3 x 30 ml, sat. 
aq.), dried (MgSO4), concentrated under reduced pressure and purified by flash 
chromatography (hexane:EtOAc:NH3, 100:1:0.1) to afford benzylamine 94d as a 
colourless oil (712 mg, 81%). 
Rf [hexane] = 0.29; υmax (CHCl3)/cm
-1 3057, 3019, 1026; 1H NMR δ (360 MHz, 
CDCl3) 7.71 (1H, dd, Ј 7.7, 1.6, ArH), 7.49 (1H, dd, Ј 8.0, 1.2, ArH), 7.40 (2H, d, Ј 
7.4, 2xArH), 7.31-7.27 (3H, m, 3xArH), 7.27-7.21 (1H, m, ArH), 7.07 (1H, td, Ј 7.9, 
1.8, ArH), 5.89-5.84 (1H, m, CH=CH), 5.79 (1H, d, Ј 10.4, CH=CH), 3.81 (1H, d, Ј 
15.3, CHPHQAr), 3.78 (1H, d, Ј 14.0, CHXHY), 3.75 (1H, d, Ј 15.3, CHPHQ), 3.63 
(1H, d, Ј 14.0, CHXHY), 3.39-3.36 (1H, m, NCH), 2.08-1.95 (3H, m, CH2+CHAHB), 
1.85-1.76 (1H, m, CHAHB), 1.64-1.42 (2H, m, CH2); 
13C NMR δ (90.6 MHz, CDCl3) 
140.3 (C), 139.5 (C), 132.3 (CH), 130.4 (CH), 130.3 (CH), 130.2 (CH), 128.4 
(2xCH), 128.0 (2xCH), 127.8 (CH), 127.2 (CH), 126.6 (CH), 124.0 (C), 55.2 (CH), 
54.0 (CH2), 53.1 (CH2), 25.2 (CH2), 23.5 (CH2), 21.7 (CH2) ; m/z (FAB, THIOG) 
356 ([81BrM+H]+, 52 %), 354 ([79BrM+H]+, 47 %), 329 (35), 327 (35), 276 (75), 274 
(53), 184 (34), 171 (69), 169 (71); HRMS (FAB, THIOG) Found: [81BrM+H]+ 
356.0838. C20H23NO2
81Br requires 356.0838. Found: [79BrM+H]+ 354.0856. 
C20H23N








To a suspension of amine 93 (750 mg, 2.81 mmol) in DMF 
(20 ml) at 0 oC was added NaH (246 mg, 60% dispersion in 
mineral oil, 6.18 mmol) and the reaction was stirred until 
homogeneous. The reaction was warmed to r.t. and stirred for 
30 mins, then cooled to 0 oC, p-methoxybenzyl bromide (614 
µl, 4.21 mmol) was added and the reaction stirred for 15 
mins. The reaction was warmed to r.t. and stirred for 16 h. Et2O (30 ml) was added, 
the organics washed with NaCl (3 x 20 ml, sat. aq.), concentrated under reduced 
pressure and purified by flash chromatography (hexane:EtOAc:NH3, 100:1.5:0.1) to 
afford PMB protected amine 94e as a colourless oil (912 mg, 84%). 
Rf [hexane: EtOAc, 3:1] = 0.81; υmax (CHCl3)/cm
-1 2857, 1541, 1508, 1457, 1248, 
750; 1H NMR δ (360 MHz, CDCl3) 7.69 (1H, d, Ј 7.8, ArH), 7.47 (1H, dd, Ј 7.8, 
ArH), 7.31-7.25 (3H, m, 3xArH), 7.04 (1H, td, Ј 7.8, 1.7, ArH), 6.83 (2H, dd, Ј 6.7, 
1.8, 2xArH), 5.85-5.82 (1H, m,CH=CH), 5.76 (1H, d, Ј 10.5, CH=CH), 3.76 (3H, s, 
OCH3), 3.75 (2H, m, CH2Ar), 3.70 (1H, d, Ј 13.8, CHXHYAr), 3.55 (1H, d, Ј 13.8, 
CHXHYAr), 3.34 (1H, br s, CHN), 2.04-1.93 (3H, m, CH2CHAHB), 1.83-1.75 (1H, m, 
CHAHB), 1.58-1.48 (2H, m, CH2); 
13C NMR δ (90.6 MHz, CDCl3) 158.3 (C), 139.6 
(C), 132.2 (C), 132.1 (CH), 130.4 (CH), 130.1 (2xCH), 129.4 (2xCH), 127.7 (CH), 
127.0 (CH), 123.9 (C), 113.4 (2xCH), 55.0 (CH3), 54.9 (CH), 53.3 (CH2), 52.9 
(CH2), 25.2 (CH2), 23.4 (CH2), 21.7 (CH2) ; m/z (FAB, THIOG) 389 ([
81BrM+H]+, 15 
%), 387 ([79BrM+H]+, 43), 359 (53), 357 (54), 306 (43.9), 304 (41.2), 280 (21.8), 278 
(24.4), 216 (35.9), 214 (21.0); HRMS (FAB, THIOG) Found: [81BrM+H]+ 388.1068. 
C21H24NO








General Procedures for Heck cyclisations 
General procedure C 
Cationic protocol: To a degassed solution of the aryl halide (1 eq) in DMF was 
added palladacycle 100 (5 mol%) and Ag2CO3 (1 eq), and the reaction was heated at 
140 °C. At the conclusion of the reaction (as judged by TLC), the mixture was 
allowed to cool and then diluted with Et2O (20 ml) and washed with NaCl (3 x 20 
ml, sat. aq.). The organics were combined, dried (MgSO4) and concentrated under 
reduced pressure to afford the crude product, which was purified by column 
chromatography to give the stated mixture of double bond isomers. 
 
General procedure D 
Neutral protocol (140 oC): To a degassed solution of the aryl halide (1 eq) in DMF 
was added palladacycle 100 (5 mol%) and MeNCy2 (4 eq), and the reaction was 
heated at 140 °C. At the conclusion of the reaction (as judged by TLC), the mixture 
was allowed to cool and then diluted with Et2O (20 ml) and washed with NaCl (3 x 
20 ml, sat. aq.). The organics were combined, dried (MgSO4) and concentrated under 
reduced pressure to afford the crude product, which was purified by column 
chromatography to give the stated mixture of double bond isomers. 
General procedure E 
Neutral protocol (Low temperature):  To a degassed solution of the aryl halide (1 
eq) and MeNCy2 (4 eq) in MeCN was added Pd2(dba)3 (5 mol%) and 
tBu3PHBF4 (10 
mol %), and the reaction mixture stirred at r.t. (Method A) or or 50 oC (Method B) 
for the indicated time. At the conclusion of the reaction (as judged by TLC), the 
mixture was allowed to cool and then diluted with Et2O (20 ml) and washed with 
NaCl (3 x 20 ml, sat. aq.). The organics were combined, dried (MgSO4) and 
concentrated under reduced pressure to afford the crude product, which was purified 







Application of optimised methods in Table 2.6, 2.7 and 2.8 
Sulfonamide-functionalised phenanthridine 96a-98a 
(Table 2.6, Entry 1) General procedure C was employed using sulfonamide 94a (50 
mg, 0.144 mmol), palladacycle 100 (8.1 mg, 8.6 µmol) and Ag2CO3 (40 mg, 0.144 
mmol) in DMF (3 ml). After 70 mins at 140 °C, work up and column 
chromatography (hexane:EtOAc, 10:1–4:1) afforded the phenanthridine as a 
colourless oil (38 mg, 99%). 1H NMR of this oil showed it to be an 85:13:2 mixture 
of double bond isomers (96a:97a:98a).  
(Table 2.7, Entry 1) General procedure D was employed using sulfonamide 94a (50 
mg, 0.144 mmol), palladacycle 100 (8.1 mg, 8.6 µmol) and MeNCy2 (122 µl, 0.576 
mmol) in DMF (3 ml). After 3h at 140 °C, work up and column chromatography 
(hexane:EtOAc, 10:1–4:1) afforded the phenanthridine as a colourless oil (37 mg, 
99%). 1H NMR of this oil showed it to be an 44:31:25 mixture of double bond 
isomers (96a:97a:98a). 
(Table 2.8, Entry 1) General procedure E (Method A) were employed using 
sulfonamide 94a (50 mg, 0.144 mmol), Pd2(dba)3 (6.6 mg, 7.2 µmol), 
tBu3PHBF4 
(4.2 mg, 14.4 µmol) and MeNCy2 (122 µl, 0.576 mmol) in MeCN (3 ml). After 9 h at 
r.t, work up and column chromatography (hexane:EtOAc, 10:1–5:1) afforded the 
phenanthridine as a colourless oil (38 mg, 99%). 1H NMR of this oil showed it to be 
a 12:65:23 mixture of double bond isomers (96a:97a:98a). 
(Table 2.8, Entry 2) General procedure E (Method B) was employed using 
sulfonamide 94a (50 mg, 0.144 mmol), Pd2(dba)3 (6.6 mg, 7.2 µmol), 
tBu3PHBF4 
(4.2 mg, 14.4 µmol) and MeNCy2 (122 µl, 0.576 mmol) in MeCN (3 ml). After 4 h at 
50 °C, work up and column chromatography (hexane:EtOAc, 10:1–5:1) afforded the 
phenanthridine as a colourless oil (38 mg, 99%). 1H NMR of this oil showed it to be 




Boc-functionalised phenanthridine 96b-98b 
(Table 2.6, Entry 2) General procedure C was employed using amide 94b (96 mg, 
0.26 mmol), palladacycle 100 (15 mg, 15.7 µmol) and Ag2CO3 (72 mg, 0.26 mmol) 
in DMF (6 ml). After 2 h at 140 °C, work up and column chromatography 
(hexane:EtOAc, 25:1) afforded the phenanthridine as a colourless oil (74 mg, 99%). 
1H NMR of this oil showed it to be an 83:15:2 mixture of double bond isomers 
(96b:97b:98b).  
(Table 2.7, Entry 2) General procedure D was employed using amide 94b (53 mg, 
0.144 mmol), palladacycle 100 (7 mg, 7.2 µmol) and MeNCy2 (122 µl, 0.576 mmol) 
in DMF (3 ml). After 3 h at 140 °C, work up and column chromatography 
(hexane:EtOAc, 25:1) afforded the phenanthridine as a colourless oil (39 mg, 95%). 
1H NMR of this oil showed it to be an 38:36:28 mixture of double bond isomers 
(96b:97b:98b).  
(Table 2.8, Entry 3) General procedure E (Method B) was employed using amide 
94b (53 mg, 0.144 mmol), Pd2(dba)3 (6.6 mg, 7.2 µmol), 
tBu3PHBF4 (4.2 mg, 14.4 
µmol) and MeNCy2 (122 µl, 0.576 mmol) in MeCN (3 ml). After 7 h at 50 °C, work 
up and column chromatography (hexane:EtOAc, 25:1) afforded the phenanthridine 
as a colourless oil (39 mg, 95%). 1H NMR of this oil showed it to be a 34:37:29 




Cbz-functionalised phenanthridine 96c-98c 
(Table 2.6, Entry 3) General procedure C was employed using amide 94c (100 mg, 
0.25 mmol), palladacycle 100 (11.7 mg, 12.5 µmol) and Ag2CO3 (69 mg, 0.25 mmol) 
in DMF (6 ml). After 2 h at 140 °C, work up and column chromatography 
(hexane:EtOAc, 25:1) afforded the phenanthridine as a colourless oil (86 mg, 99%). 
1H NMR of this oil showed it to be a 92:6:2 mixture of double bond isomers 
(96c:97c:98c) .  
(Table 2.7, Entry 3) General procedure D was employed using amide 94c (58 mg, 
0.144 mmol), palladacycle 100 (7 mg, 7.2 µmol) and MeNCy2 (122 µl, 0.576 mmol) 
in DMF (3 ml). After 3 h at 140 °C, work up and column chromatography 
(hexane:EtOAc, 25:1) afforded the phenanthridine as a colourless oil (44 mg, 99%). 
1H NMR of this oil showed it to be a 33:29:28 mixture of double bond isomers 
(96c:97c:98c). 
(Table 2.8, Entry 6) General procedure E (Method B) was employed using amide 
94c (58 mg, 0.144 mmol), Pd2(dba)3 (6.6 mg, 7.2 µmol), 
tBu3PHBF4 (4.2 mg, 14.4 
µmol) and MeNCy2 (122 µl, 0.576 mmol) in MeCN (3 ml). After 7 h at 50 °C, work 
up and column chromatography (hexane:EtOAc, 25:1) afforded the phenanthridine 
as a colourless oil (39 mg, 85%). 1H NMR of this oil showed it to be a 36:5:59 
mixture of double bond isomers (96c:97c:98c). 
 
Benzyl-functionalised phenanthridine 96d-98d 
(Table 2.6, Entry 4) General procedure C was employed using amine 94d (100 mg, 
0.29 mmol), palladacycle 100 (13.5 mg, 14.4 µmol) and Ag2CO3 (79 mg, 0.29 mmol) 
in DMF (6 ml). After 2 h at 140 °C, work up and column chromatography 
(hexane:EtOAc:Et3N, 100:1:0–100:1:0.1) afforded the phenanthridine 96d as a 
colourless oil (73 mg, 92%).  
(Table 2.7, Entry 4) General procedure D was employed using amine 94d (50 mg, 
0.148 mmol), palladacycle 100 (7 mg, 7.4 µmol) and MeNCy2 (126 µl, 0.592 mmol) 
in DMF (3 ml). After 5 h at 140 °C, work up and column chromatography 
(hexane:EtOAc:Et3N, 100:1:0–100:1:0.1) afforded the phenanthridine as a colourless 
oil (37 mg, 93%). 1H NMR of this oil showed it be a 83:8:9 mixture of double bond 
isomers (96d:97d:98d).  
Experimental 
142 
PMB-protected phenanthridine 96e-98e 
(Table 2.6, Entry 5) General procedure C was employed using amine 94e (112 mg, 
0.29 mmol), palladacycle 100 (13.5 mg, 14.4 µmol) and Ag2CO3 (79 mg, 0.29 mmol) 
in DMF (6 ml). After 160 mins at 140 °C, work up and column chromatography 
(hexane:EtOAc, 50:1-10:1) afforded the phenanthridine as a colourless oil (67 mg, 
76%). 1H NMR of this oil showed it to be a 97:3:0 mixture of double bond isomers 
(96e:97e:98e). 
(Table 2.7, Entry 5) General procedure D was employed using amine 94e (56 mg, 
0.144 mmol), palladacycle 100 (7 mg, 7.2 µmol) and MeNCy2 (122 µl, 0.576 mmol) 
in DMF (3 ml). After 5 h at 140 °C, work up and column chromatography 
(hexane:EtOAc, 50:1-10:1) afforded the phenanthridine as a colourless oil (41 mg, 






96a (∆1,2 isomer) 
Rf [hexane:EtOAc, 3:1] = 0.38; Rt [hexane:EtOAc, 11:9] 15.9 
mins; υmax (CHCl3)/cm
-1 3029, 1671, 1328, 1152; 1H NMR δ 
(360 MHz, CDCl3) 7.31 (1H, d, Ј 7.5, ArH), 7.26 (1H, t, Ј 7.8, 
ArH), 7.19 (1H, t, Ј 7.3, ArH), 7.10 (1H, d, Ј 7.5, ArH), 5.58 
(1H, ddt, Ј 10.0, 4.8, 1.9, CHCH=CH), 5.86 (1H, dtd, Ј 10.0, 
3.9, 1.7, CH=CHCH2), 4.59 (1H, d, Ј 16.2, CHXHYAr), 4.43 (1H, d, Ј 16.2, 
CHXHYAr), 4.19 (1H, dt, Ј 8.4, 5.8, NCHCH), 3.66 (1H, br s, CHCH=CH), 2.74 (3H, 
s, CH3), 2.27-2.20 (2H, m, CH2), 1.87-1.81 (2H, m, CH2); 
13C NMR δ (90.0 MHz, 
CDCl3) 136.9 (C), 131.1 (C), 128.5 (CH), 127.7 (CH), 127.6 (CH), 126.7 (CH), 
126.3 (CH), 125.9 (CH), 52.1 (CH), 44.1 (CH2), 38.2 (CH3), 37.4 (CH), 25.1 (CH2), 
24.0 (CH2); m/z (FAB, THIOG) 264 ([M+H]
+, 19 %), 217 (25), 130 (79), 109 (38); 
HRMS (FAB, THIOG) Found: [M+H]+ 264.1050. C14H18NO2S requires 264.1058. 




(97a) (∆2,3 isomer) 
Rf [hexane:EtOAc, 3:1] = 0.32; Rt [hexane:EtOAc, 11:9] 18.1 
mins; MP 140 oC (hexane); 1H NMR δ (360 MHz, CDCl3) 
7.29-7.23 (3H, m, 3xArH), 7.17 (1H, dd, Ј 6.5, 1.8, ArH), 
5.69-5.66 (1H, m, CHCH2CH=), 5.42(1H, ddt, Ј 10.0, 5.1, 2.3, 
NCHCH2CH=), 4.53 (2H, s, CH2Ar), 4.29 (1H, ddd, Ј 10.4, 
4.0, 2.4, NCHCH2), 3.26-3.22 (1H, m, CHCH2), 2.94 (3H, s, CH3), 2.92-2.85 (1H, m, 
CHAHB), 2.69-2.58 (1H, m, CHAHB), 2.28-2.23 (1H, m, CHCHD), 1.80-1.71 (1H, m, 
CHCHD); 
13C NMR δ (90.0 MHz, CDCl3) 135.6 (C), 128.5 (C), 127.3 (CH), 126.5 
(CH), 126.4 (CH), 125.3 (CH), 124.9 (CH), 123.8 (CH), 51.7 (CH), 45.0 (CH2), 37.7 
(CH3), 35.8 (CH), 27.9 (CH2), 26.5 (CH2). This compound was also fully 


















(98a) (∆3,4 isomer) 
 
Rf [hexane:EtOAc, 3:1] = 0.39; Rt [hexane:EtOAc, 11:9] 15.4 
mins; 1H NMR δ (360 MHz, CDCl3) 7.37 (1H, d, Ј 7.8, ArH), 
7.26 (1H, t, Ј 7.2, ArH), 7.19 (1H, t, Ј 7.3, ArH), 7.07 (1H, d, 
Ј 7.4, ArH), 5.83-5.80 (1H, m, CH2CH=CH), 5.61 (1H, dt, Ј 
10.2, 1.0, CH=CHCH), 4.87-4.83 (1H, m, NCH), 4.59 (1H, d, Ј 16.5, CHXHYAr), 
4.26 (1H, d, Ј 16.5, CHXHYAr), 3.39 (1H, br s, CHCH2), 2.83 (3H, s, CH3), 2.43-
2.38 (1H, m, CHAHB), 2.05-1.97 (1H, m, CHAHB), 1.94-1.76 (2H, m, CH2CH); 
13C 
NMR δ (90.6 MHz, CDCl3) 134.5 (C), 133.0 (CH), 132.4 (C), 127.3 (CH), 126.9 
(CH), 126.1 (2xCH), 125.8 (CH), 52.4 (CH), 43.3 (CH2), 39.8 (CH3), 34.1 (CH), 
25.3 (CH2), 20.1 (CH2). This compound was also fully characterised by COSY, 




butyl ester 96b (∆1,2 isomer) 
Rf [hexane:EtOAc, 10:1] = 0.42; Rt [hexane:EtOAc, 92:8] 
17 min; υmax (CHCl3)/cm
-1 3026, 1693 (C=O), 1258, 913, 
745;  1H NMR δ (360 MHz, 323 K, CDCl3) 7.30 (1H, d, Ј 
7.5, ArH), 7.25-7.17 (2H, m, 2xArH), 7.12 (1H, d, Ј 7.2, 
ArH), 6.17-6.13 (1H, m, CHCH=CH), 5.87-5.83 (1H, m, 
CH=CHCH2), 4.71 (1H, d, Ј 16.5, CHXHYAr), 4.41 (1H, br s, NCHCH), 4.39 (1H, d, 
Ј 16.5, CHXHYAr), 3.57 (1H, br s, NCHCH), 2.31-2.27 (1H, m, CHAHB), 2.15-2.05 
(1H, m, CHAHB), 1.79-1.69 (1H, m, CHCHD), 1.61-1.40 (10H, m, 3 x CH3+CHCHD); 
13C NMR δ (90.0 MHz, 323 K, CDCl3) 155.0 (C), 137.8 (C), 132.5 (C), 128.3 (CH), 
128.1 (C), 127.6 (CH), 127.3 (CH), 126.8 (CH), 126.1 (CH), 125.9 (CH), 79.6 (C), 
43.5 (CH2), 37.3 (CH), 28.5 (3xCH3), 25.3 (CH2), 24.2 (CH2); m/z (FAB, THIOG) 
284 ([M-H]+, 44 %), 228 (66), 184 (49), 130 (25); HRMS (FAB, THIOG) Found: 



















butyl ester 97b (∆2,3 isomer) 
Rf [hexane:EtOAc, 10:1] = 0.39; Rt [hexane:EtOAc, 92:8] 18 
min; υmax (CHCl3)/cm
-1 3352, 1699 (C=O), 1392, 1367, 1167;  
1H NMR δ (250 MHz, CDCl3) 7.24-7.16 (4H, m, 4xArH), 
5.70-5.66 (1H, m, CHCH2CH=), 5.45-5.37 (1H, m, 
NCHCH2CH=), 4.68-4.66 (3H, m, CH2Ar+NCHCH2), 3.32-
3.18 (1H, m, CHCH2), 2.86 (1H, dd, Ј 18.0, 4.5, CHAHB), 2.67-2.54 (1H, m, 
CHAHB), 2.28-2.16 (1H, m, CHCHD), 1.65-1.52 (10H, m, 3xCH3+CHCHD); 
13C 
NMR δ (62.9 MHz, CDCl3) 154.8 (C), 136.4 (C), 133.9 (C), 126.6 (CH), 126.4 
(CH), 126.1 (CH), 125.4 (CH), 124.8 (CH), 123.7 (CH), 79.6 (C), 50.3 (CH), 44.6 
(CH2), 35.5 (CH), 28.5 (3xCH3), 26.2 (CH2); m/z (EI) 285 ([M]
+, 2 %), 231 (32), 175 




butyl ester 98b (∆3,4 isomer) 
Rf [hexane:EtOAc, 10:1] = 0.44; Rt [hexane:EtOAc, 92:8] 16 
min; υmax (CHCl3)/cm
-1 3359, 1695 (C=O), 1400, 1367;  1H 
NMR δ (250 MHz, CDCl3) 7.37 (1H, d, Ј 7.5, ArH), 7.26-7.13 
(2H, m, 2xArH), 7.07 (1H, d, Ј 7.0, ArH), 5.72-5.65 (1H, m, 
CH2CH=CH), 5.52 (1H, d, Ј 11.0, CH=CHCH), 5.08 (1H, br 
s, NCH), 4.86 (1H, d, Ј 17.0, CHXHYAr), 4.24 (1H, d, Ј 17.0, CHXHYAr), 3.30 (1H, 
br s, CHCH2), 2.45-2.37 (1H, m, CHACHB), 2.08-1.94 (1H, m, CHAHB), 1.95-1.81 
(2H, m, CH2), 1.50 (9H, s, 3xCH3); 
13C NMR δ (62.9 MHz, CDCl3) 154.8 (C), 135.1 
(C), 133.9 (C), 130.8 (CH), 127.6 (CH), 126.5 (2xCH), 125.8 (CH), 125.6 (CH), 79.8 
(C), 50.0 (CH), 42.6 (CH2), 34.5 (CH), 28.4 (3xCH3), 25.0 (CH2), 20.2 (CH2); m/z 
(EI) 285 ([M]+, 2 %), 229 (77), 228 (100), 184 (32), 175 (48); HRMS (EI) Found: 


















benzyl ester 96c (∆1,2 isomer) 
Rf [hexane:EtOAc, 10:1] = 0.34; υmax (CHCl3)/cm
-1 3030, 
1698 (C=O), 1410, 1263; 1H NMR δ (360 MHz, 323 K, 
CDCl3) 7.29-7.22 (6H, m, 6xArH), 7.19-7.07 (2H, m, 
2xArH), 7.01 (1H, d, Ј 6.1, ArH), 6.06-6.02 (1H, m, 
CH=CH), 5.77-5.73 (1H, m, CH=CH), 5.12 (2H, s, CH2Ph), 
4.72 (1H, d, Ј 16.6, CHXHYAr), 4.41 (1H, br s, NCHCH), 
4.36 (1H, d, Ј 16.6, CHXHYAr), 3.49 (1H, br s, CHCH=CH), 
2.24-2.09 (1H, m, CHAHB), 2.07-1.95 (1H, m, CHAHB), 
1.67-1.63 (1H, m, CHCHD), 1.56-1.48 (1H, m, CHCHD); 
13C NMR δ (90.6 MHz, 323 
K, CDCl3) 155.5 (C), 137.6 (C), 136.9 (C), 132.0 (C), 128.4 (2xCH), 128.3 (CH), 
127.9 (CH), 127.8 (2xCH), 127.6 (CH), 127.1 (CH), 127.0 (CH), 126.0 (CH), 126.0 
(CH), 67.1 (CH2), 50.7 (CH), 43.6 (CH2), 37.2 (CH), 25.1 (CH2), 24.2 (CH2) ; m/z 
(FAB, THIOG) 320 ([M+H]+, 24 %), 318 ([M-H]+, 51), 274 (37), 228 (26), 154 (61); 
HRMS (FAB, THIOG) Found: [M-H]+ 318.1483. C21H20NO2 requires 318.1494. 
 
Diagnostic 1H NMR data for 97c (∆2,3 isomer)   
1H NMR δ (360 MHz, 323 K, CDCl3) 5.69-5.65 (1H, m, CH=CH), 5.41-5.37 (1H, 
m, CH=CH), 4.65 (1H, d, Ј 16.6, CHXHYAr), 4.59 (1H, d, Ј 16.6, CHXHYAr), 3.20 
(1H, br s, CHCH2), 2.88-2.81 (1H, m, CHAHB), 2.63-2.55 (1H, m, CHAHB). 
 
Diagnostic 1H NMR data for 98c (∆3,4 isomer)   
1H NMR δ (360 MHz, 323 K, CDCl3) 5.75-5.71 (1H, m, CH=CH), 5.55 (1H, d, Ј 
9.7, CH=CH), 4.95 (1H, d, Ј 16.6, CHXHYAr), 4.33 (1H, d, Ј 16.6, CHXHYAr), 3.33 












 96d (∆1,2 isomer) 
Rf [hexane:EtOAc, 10:1] = 0.44; υmax (CHCl3)/cm
-1 3025, 
1642, 1602, 1260; 1H NMR δ (360 MHz, CDCl3) 7.35 (2H, d, 
Ј 7.0, 2xArH), 7.29-7.20 (4H, m, 4xArH), 7.19 (1H, t, Ј 7.6, 
ArH), 7.10 (1H, t, Ј 7.6, ArH), 6.89 (1H, d, Ј 7.6, ArH),  6.06-
6.02 (1H, ddt, Ј 9.8, 4.2, 1.8, CHCH=CH), 5.73-5.70 (1H, ddt, 
Ј 9.8, 5.5, 2.4, CH=CHCH2), 3.89 (1H, d, Ј 13.3, CHXHYAr), 
3.75 (1H, d, Ј 15.6, CHPHQAr), 3.66 (1H, d, Ј 13.3, CHXHYAr), 3.58 (1H, br s, 
CHCH=CH), 3.54 (1H, d, Ј 15.6, CHPHQ), 3.14 (1H, ddd, Ј 10.6, 5.2, 2.5, 
NCHCH2), 2.21-2.07 (2H, m, =CHCH2), 1.86-1.77 (1H, m, CHAHB), 1.69-1.61 (1H, 
m, CHAHB); 
13C NMR δ (90.0 MHz, CDCl3) 139.0 (C), 137.7 (C), 133.4 (C), 128.8 
(CH), 128.7 (2xCH), 128.2 (2xCH), 127.7 (CH), 127.4 (CH), 126.9 (CH), 126.4 
(2xCH), 125.2 (CH), 58.4 (CH2), 56.1 (CH), 50.9 (CH2), 37.8 (CH), 24.3 (CH2), 19.4 
(CH2); m/z (FAB, THIOG) 276 ([M+H]
+, 76 %), 200 (35), 184 (55), 154 (93), 136 
(83); HRMS (FAB, THIOG) Found: [M+H]+ 276.1755. C20H22N requires 276.1754. 
This compound was also fully characterised by COSY, HSQC and NOESY 2D NMR 
studies.  
 
Diagnostic 1H NMR data for 97d (∆2,3 isomer) 
1H NMR δ (360 MHz, CDCl3) 5.70-5.67 (1H, m), 5.58-5.55 (1H, m), 2.74-2.65 (1H, 
m).  
 
Diagnostic 1H NMR data for 98d (∆3,4 isomer) 










 96e (∆1,2 isomer) 
Rf [hexane:EtOAc, 10:1] = 0.23; υmax (CHCl3)/cm
-1 3024, 
1647, 1609, 1511; 1H NMR δ (360 MHz, CDCl3) 7.33-7.29 
(3H, m, 3xArH), 7.18 (1H, t, Ј 7.3, ArH), 7.10 (1H, t, Ј 7.6, 
ArH), 6.96 (1H, d, Ј 7.6, ArH), 6.90-6.88 (2H, m, 2xArH),  
6.12-6.08 (1H, m, CHCH=CH), 5.79-5.76 (1H, m, 
CH=CHCH2), 3.89 (1H, d, Ј 13.0, CHXHYAr), 3.82 (3H, s, 
OCH3), 3.80 (1H, d, Ј 16.1, CHPHQAr), 3.67 (1H, d, Ј 13.0, 
CHXHYAr), 3.62 (1H, br s, CHCH=), 3.59 (1H, d, Ј 16.1, CHPHQ), 3.12 (1H, ddd, Ј 
10.6, 5.4, 2.6, NCH), 2.20-2.00 (2H, m, CH2), 1.90-1.63 (2H, m, CH2); 
13C NMR δ 
(90.0 MHz, CDCl3) 158.6 (C), 137.7 (C), 133.4 (C), 130.9 (C), 129.9 (2xCH), 128.8 
(CH), 127.6 (CH), 127.4 (CH), 126.4 (CH), 126.3 (CH), 125.2 (CH), 113.6 (2xCH), 
57.7 (CH2), 55.9 (CH), 55.1 (CH3), 50.8 (CH2), 37.8 (CH), 24.4 (CH2), 19.2 (CH2); 
m/z (FAB, THIOG) 306 ([M+H]+, 56 %), 305 ([M]+, 58), 304 ([M-H]+, 69), 251 
(12.4), 184 (46.1); HRMS (FAB, 3-NOBA) Found: [M]+ 305.1779. C21H23NO 
requires 305.1780. This compound was also fully characterised by COSY, HSQC 
and NOESY 2D NMR studies.  
 
Diagnostic 1H NMR data for 97e (∆2,3 isomer) 
1H NMR δ (360 MHz, CDCl3) 5.68-5.65 (1H, m), 5.56-5.53 (1H, m), 3.98 (1H, d, J 
13.2), 3.18 (1H, br s), 2.71-2.65 (1H, m). 
 
Diagnostic 1H NMR data for 98e (∆3,4 isomer) 
1H NMR δ (360 MHz, CDCl3) 5.96-5.91 (1H, m), 5.90-5.84 (1H, m), 4.05 (1H, J 















General procedure B was followed using N-Benzyl-cyclohex-
2-enyl amine176 (590 mg, 3.15 mmol), CH2Cl2 (15 ml), Et3N 
(1.33 ml, 3.47 mmol) and methanesulfonyl chloride (0.73 ml, 
9.45 mmol). Flash chromatography (hexane:EtOAc, 10:1–
2:1) afforded colourless solid 99a (300 mg, 63%).  
Rf [hexane:EtOAc, 3:1] = 0.47; MP 89 
oC (Et2O); υmax (CHCl3)/cm
-11334 (SO2), 
1143 (SO2); 
1H NMR δ (250 MHz, CDCl3) 7.40-7.25 (5H, m, 5xArH), 5.97-5.91 
(1H, m, CHNCH=CH), 5.57-5.51 (1H, m, CHNCH=CH), 4.63-4.53 (1H, m, CHN), 
4.47 (1H, d, Ј 16.1, CHXHYPh), 4.25 (1H, d, Ј 16.1, CHXHYPh), 2.79 (3H, s, CH3), 
1.98-1.93 (3H, m, CHAHB+CH2), 1.72-1.48 (3H, m, CHAHB+CH2); 
13C NMR δ 
(62.9 MHz, CDCl3) 138.4 (C), 132.8 (CH), 128.2 (2xCH), 127.7 (2xCH), 127.5 
(CH), 127.1 (CH), 55.5 (CH), 47.2 (CH2), 40.4 (CH3), 28.9 (CH2), 24.2 (CH2), 21.5 
(CH2); m/z (FAB, THIOG) ([2M+H]
+, 571, 21.3 %), ([M+H]+ , 266, 70.1), 250 
(33.2), 237 (35.6), 214 (49.5); HRMS (FAB, THIOG) Found: [M+H]+, 266.1218. 












To a solution of phenanthridines 96a-98a (316 mg, 1.18 mmol) 
in ethanol (10 ml) was added EtOAc (1 ml) and Pd/C (35 mg, 
10% by weight). The reaction was stirred vigorously and 
exposed to an atmosphere of hydrogen for 12 h. The reaction 
was filtered through celite and concentrated under reduced 
pressure to afford phenanthridine 110 as a colourless solid (190 mg, 60%). 
Rf [hexane:EtOAc, 3:1] = 0.33; MP 103 
oC (EtOH); υmax (CHCl3)/cm
-1 3029, 1684, 
1325 (SO2), 1153 (SO2); 
1H NMR δ (360 MHz, CDCl3) 7.39 (1H, d, Ј 7.7, ArH), 
7.25 (1H, t, Ј 6.0, ArH), 7.21 (1H, t, Ј 6.1, ArH), 7.11 (1H, d, Ј 6.7, ArH), 4.64 (1H, 
d, Ј 16.3, CHXHYAr), 4.42 (1H, d, Ј 16.3, CHXHYAr), 4.14-4.09 (1H, m, CHN), 3.26 
(1H, br s, CHCHN), 2.89 (3H, s, CH3), 2.55-2.49 (1H, m, CHAHB), 1.83-1.65 (3H, 
m, CH2+CHAHB), 1.48-1.42 (3H, m, CH2+CHCHD), 1.26-1.15 (1H, m, CHCHD); 
13C 
NMR δ (90.6 MHz, CDCl3) 134.7 (C), 131.8 (C), 127.1 (CH), 126.2 (CH), 126.1 
(CH), 126.0 (CH), 54.0 (CH), 43.6 (CH2), 38.8 (CH3), 37.1 (CH), 27.6 (CH2), 26.3 
(CH2), 25.0 (CH2), 19.6 (CH2); m/z (FAB, THIOG) 529 (2M+H]
+, 10 %), 266 
([M+H]+, 83), 264 (94), 262 (29), 234 (17), 222 (18); HRMS (FAB, THIOG) Found: 












tert-butyl ester 111 
To a solution of phenanthridines 96b-98b (200 mg, 0.71 
mmol) in methanol (20 ml) was added Pd/C (20 mg, 10% by 
weight). The reaction was stirred vigorously and exposed to 
an atmosphere of hydrogen for 16 h. The reaction was filtered 
through celite, concentrated under reduced pressure and 
purified by flash chromatography (CH2Cl2:EtOAc, 1:1) to afford phenanthridine 111 
as a colourless oil (179 mg, 88%). 
Rf [hexane:EtOAc, 10:1] = 0.47; υmax (CHCl3)/cm
-1 2927, 1693 (C=O), 1366, 1174; 
1H NMR δ (360 MHz, 323 K, CDCl3) 7.37 (1H, d, Ј 7.6, ArH), 7.28-7.14 (2H, m, 
2xArH), 7.13 (1H, d, Ј 6.5, ArH), 4.72 (1H, d, Ј 17.1, CHXHYAr), 4.39 (1H, d, Ј 
17.1, CHXHYAr), 4.32-4.29 (1H, m, NCHCH), 3.20 (1H, br s, NCHCH), 2.57-2.52 
(1H, m, CHAHB), 1.84-1.72 (1H, m, CHAHB), 1.72-1.60 (2H, m, CH2), 1.60-1.20 
(13H, m, 3 x CH3+CH2CH2); 
13C NMR δ (90.6 MHz, 323 K, CDCl3) 154.8 (C), 
135.7 (C), 133.8 (C), 126.6 (CH), 126.3 (CH), 125.8 (CH), 125.7 (CH), 79.5 (C), 
52.4 (CH), 43.8 (CH2), 36.8 (CH), 28.5 (3xCH3), 27.4 (CH2), 26.5 (CH2), 25.5 
(CH2), 19.9 (CH2); m/z (FAB, THIOG) 286 ([M-H]
+, 31 %), 230 (75), 186 (55), 184 
(18), 156 (12), 130 (17), 57 (100); HRMS (FAB, THIOG) Found: [M-H]+ 286.1812. 










(4aSR,10bSR)-1,2,3,4,4a,5,6,10b-Octahydro-phenanthridinium; chloride 11287 
To a solution of Boc-protected amine 111 (154 mg, 0.54 mmol) 
in CH2Cl2 (10 ml) was added Trifluoroacetic acid (15.0 ml). 
After 10 minutes no starting material remained by TLC so the 
solution was adjusted to pH 9 using KOH pellets and extracted 
with CH2Cl2 (3 x 15 ml). The combined organics were dried (MgSO4) and 
concentrated under reduced pressure. The residue was taken up in CH2Cl2 (1 ml), 
HCl added (1 ml, 1.0 M in Et2O, 1 mmol) and the resultant suspension filtered to 
afford octahydrophenanthridinium chloride 112 as a pale yellow solid (106 mg, 
88%). 
MP 173 oC (Et2O); υmax (CHCl3)/cm
-1 3421 (NH); 1H NMR δ (360 MHz, CD3OD) 
9.19 (1H, brs, NH), 7.97 (1H, d, Ј 7.5, ArH), 7.91 (1H, t, Ј 7.6, ArH), 7.63 (1H, d, Ј 
7.6, ArH), 7.59 (1H, d, Ј 7.9, ArH), 4.90 (2H, s, CH2Ar), 4.33 (1H, brs, NCHCH), 
3.30 (1H, m, NCHCH), 2.30-2.15 (1H, m, CHAHB), 2.08-1.90 (1H, m, CHAHB), 
1.89-1.70 (2H, m, CH2), 1.56 (2H, brs, CH2); 
13C NMR δ (90.0 MHz, CD3OD) 142.9 
(C), 138.0 (CH), 133.6 (CH), 127.7 (CH), 127.3 (CH), 122.8 (C), 53.4 (CH), 48.0 
(CH2), 36.0 (CH), 27.7 (CH2), 25.9 (CH2), 22.3 (CH2), 20.0 (CH2); m/z (FAB, 
THIOG) 188 ([M+H]+, 100 %), 156 (54), 144 (57), 130 (68); HRMS (FAB, THIOG) 
Found: [M+H]+ 188.1436. C13H18N requires 188.1439. 
Free Amine: Rf [EtOAc] = 0.29; 
1H NMR δ (360 MHz, CDCl3) 7.02 (1H, d, Ј 6.5, 
ArH), 7.16-7.08 (3H, m, 3xArH), 4.16 (1H, d, Ј 16.2, CHXHY), 4.10 (1H, d, Ј 16.2 
CHXHY), 3.16 (1H, d, Ј 3.3, NCHCH), 2.65-2.62 (1H, m, NCHCH), 2.16 (1H, br s, 
NH), 1.97-1.91 (1H, d, Ј 23.1, CHAHB), 1.86-1.69 (3H, m, CHAHB+CH2), 1.65-1.36 
(4H, m, CH2+CH2); 
13C NMR δ (90.6 MHz, CDCl3) 140.7 (C), 134.6 (C), 128.7 
(CH), 126.9 (CH), 125.8 (CH), 125.7 (CH), 52.0 (CH), 48.7 (CH2), 39.0 (CH), 31.7 
(CH2), 31.2 (CH2), 25.8 (CH2), 20.4 (CH2). 
 







 3-Methoxy-5,5-dimethyl-cyclohex-2-enone 117177 
To a solution of dimedone (4.90 g, 34.9 mmol) in MeOH (100 
ml) was added cerium(IV) ammonium nitrate (1.91 g, 3.49 
mmol) and the reaction stirred for 16 h at r.t. The reaction was 
concentrated under reduced pressure and the organics taken up 
in Et2O (200 ml) and washed with NaCl (3 x 100 ml, sat. aq.). 
The organics were dried (MgSO4), concentrated under reduced pressure, and purified 
using flash chromatography (hexane:EtOAc, 10:1-2:1) to afford enol ether 117 as a 
pale yellow oil (3.90 g, 73%). 
Rf [hexane:EtOAc, 3:1] = 0.15; υmax (CHCl3)/cm
-1 1656 (C=O), 1608, 1376, 1226, 
1155; 1H NMR δ (250 MHz, CDCl3) 5.35 (1H, s, C=CH), 3.67 (3H, s, OCH3), 2.25 
(2H, s, CH2), 2.19 (2H, s, CH2), 1.04 (6H, s, 2xCH3); 
13C NMR δ (62.9 MHz, 
CDCl3) 199.4 (C), 176.9 (C), 100.9 (CH), 55.5 (CH3), 50.5 (CH2), 42.5 (CH2), 32.3 
(C), 28.1 (2xCH3); m/z (FAB, THIOG) 155 ([M+H]
+, 100 %), 139 (28), 124 (12), 
110 (16); HRMS (FAB, THIOG) Found: [M+H]+ 155.1073. C9H15O2 requires 
155.1072. 
 










To a solution of enol ether 117 (900 mg, 5.84 mmol) in Et2O (12 
ml) at 0 oC was added LiAlH4 (255 mg, 6.72 mmol) portionwise. 
The reaction was warmed to r.t. and stirred for 1 h. The LiAlH4 was 
quenched by adding Na2SO4.5H2O portionwise, then the reaction 
was filtered and the filtrate concentrated under reduced pressure. The residue was 
taken up in CH2Cl2 (10 ml) and stirred with silica (cat.) for 3 h to afford enone 118 as 
a colourless oil (661 mg, 91%). 
Rf [hexane:EtOAc, 3:1] = 0.55; υmax (CHCl3)/cm
-1 1678 (C=O), 1609, 1389, 1161; 
1H NMR δ (250 MHz, CDCl3) 6.75 (1H, dt, Ј 10.1, 4.2, CH=CH), 5.88 (1H, dt, Ј 
10.1, 2.1, CH=CH), 2.14 (2H, s, CH2), 2.13 (2H, dd, Ј 4.2, 2.1, CH2CH=), 0.89 (6H, 
s, 2xCH3); 
13C NMR δ (62.9 MHz, CDCl3) 199.8 (C), 148.2 (CH), 128.9 (CH), 51.6 
(CH2), 39.8 (CH2), 33.7 (C), 28.2 (2xCH3); m/z (FAB, THIOG) 125 ([M+H]
+, 96 %), 
122 (43), 120 (35) 116 (33), 111 (73), 109 (92); HRMS (FAB, THIOG) Found: 
[M+H]+ 125.0968. C8H13O requires 125.0966. 
 











To a solution of enone 118 (661 mg, 5.32 mmol) in Et2O (12 ml) at 
0 oC was added portionwise LiAlH4 (201 mg, 5.32 mmol). The 
reaction was stirred for at 0 oC for 40 mins then quenched by the 
addition of Na2SO4.5H2O portionwise. The reaction was filtered and 
the filtrate vigorously stirred with potassium sodium tartate (50 ml, 
sat. aq.) for 1 h. The organic phase was separated and the aqueous phase washed with 
Et2O (3 x 40 ml). The combined organics were dried (MgSO4) and concentrated 
under reduced pressure to afford alcohol 119 as a colourless oil (525 mg, 72%). 
 Rf [hexane:EtOAc, 3:1] = 0.37; υmax (CHCl3)/cm
-1 3336 (OH), 2952, 1650, 1454, 
1089; 1H NMR δ (250 MHz, CDCl3) 5.71 (2H, s, CH=CH), 4.29-4.22 (1H, m, 
CHOH), 1.88-1.57 (3H, m, CH2+CHAHB), 1.31 (1H, dd, Ј 12.3, 8.7, CHAHB), 1.00 
(3H, s, CH3), 0.92 (3H, s, CH3); 
13C NMR δ (62.9 MHz, CDCl3) 129.1 (CH), 128.0 
(CH), 66.2 (CH), 45.3 (CH2), 38.9 (CH2), 31.2 (CH3), 30.7 (C), 26.0 (CH3); m/z 
(FAB, THIOG) 149 ([M+Na]+, 33 %), 127 ([M+H]+, 5), 125 ([M-H]+, 12), 124 (18), 
111 (53); HRMS (FAB, THIOG) Found: [M-H]+ 125.0968. C8H13O requires 
125.0966. 
 








To a stirred solution of alcohol 119 (2.00 g, 15.8 mmol) and CBr4 (11.1 
g, 33.3 mmol) in Et2O (75 ml) at 0 
oC was added PPh3 (8.00 g, 33.3 
mmol). The reaction was warmed to r.t. and stirred for 2 h. The reaction 
was filtered and the filtrate concentrated under reduced pressure to 
afford a colourless solid and a yellow oil. These were washed with pentane (2 x 100 
ml) and the combined washings dried (MgSO4) and concentrated under reduced 
pressure to afford bromide 120 as a pale yellow oil (2.00 g, 67%). This material was 
found to be unstable to flash chromatography and thus was used without further 
purification.  
Rf [hexane:EtOAc, 3:1] = 0.46; υmax (CHCl3)/cm
-1 1437, 1120, 723, 694; 1H NMR δ 
(250 MHz, CDCl3) 5.90-5.84 (1H, m, CH=CH), 5.75-5.71 (1H, m, CH=CH), 4.79-
4.77 (1H, m, CHBr), 2.14-1.88 (3H, m, CHAHB+CH2), 1.80-1.70 (1H, m, CHAHB), 
1.02 (3H, s, CH3), 0.96 (3H, s, CH3); 
13C NMR δ (62.9 MHz, CDCl3) 129.0 (CH), 









To a suspension of 2-bromobenzylamine hydrochloride 
(412 mg, 1.85 mmol) in MeCN (20 ml) was added iPr2NEt 
(1.30 ml, 7.40 mmol) and the reaction stirred for 10 mins. 
Cyclohexenyl bromide 120 (700 µl, 3.70 mmol) was 
added dropwise and the reaction stirred at r.t. for 16 h. The reaction was concentrated 
under reduced pressure and the residue taken up in CH2Cl2 (20 ml) and washed with 
NaCl (3 x 20 ml, sat. aq.). The combined organics were dried (MgSO4) and 
concentrated under reduced pressure to afford amine 121 as a brown oil (340 mg, 
63%). 
Rf [hexane:EtOAc, 3:1] = 0.37; υmax (CHCl3)/cm
-1 3307 (NH), 1776, 1651, 1466; 1H 
NMR δ (360 MHz, CDCl3) 7.53 (1H, dd, Ј 7.9, 1.2, ArH), 7.46 (1H, dd, Ј 6.1, 1.6, 
ArH), 7.28 (1H, t, Ј 7.4, 6.1, ArH), 7.11 (1H, td, Ј 7.8, 1.6, ArH), 5.76-5.70 (2H, m, 
CH=CH), 3.92 (2H, s, CH2Ar), 3.31-3.24 (1H, m, CHN), 1.92 (1H, dd, Ј 17.8, 3.4, 
CHAHB), 1.79-1.71 (2H, m, CHAHB+CHCHD), 1.23 (1H, dd, CHCHD), 1.00 (3H, s, 
CH3), 0.92 (3H, s, CH3); 
13C NMR δ (90.6 MHz, CDCl3) 139.6 (C), 132.5 (CH), 
130.0 (CH), 128.4 (CH), 128.3 (CH), 127.3 (CH), 127.2 (CH), 123.7 (C), 52.0 (CH), 
50.7 (CH2), 43.2 (CH2), 39.0 (CH2), 31.8 (CH3), 30.2 (C), 25.4 (CH3); m/z (FAB, 
THIOG) 296 ([81BrM+H]+, 96 %), 294 ([79BrM+H]+, 100), 239 (25), 188 (33), 186 
(51), 171 (42), 169 (48) ; HRMS (FAB, THIOG) Found: [81BrM+H]+ 296.0845. 
C15H21N










General procedure B was followed using amine 
hydrochloride 121 (180 µl, 0.62mmol), CH2Cl2 (5 ml), 
Et3N (262 µl, 1.87 mmol) and methanesulfonyl chloride 
(214 µl, 1.87 mmol). Flash chromatography 
(hexane:EtOAc, 10:1–5:1) afforded sulfonamide 115 as a colourless oil (150 mg, 
65%). 
 Rf [hexane:EtOAc, 3:1] = 0.77; υmax (CHCl3)/cm
-1 1335 (SO2), 1159 (SO2), 913, 
745; 1H NMR δ (360 MHz, CDCl3) 7.66 (1H, d, Ј 7.0, ArH), 7.50 (1H, dd, Ј 8.0, 1.2, 
ArH), 7.32 (1H, td, Ј 7.6, 0.7, ArH), 7.11 (1H, Ј 7.6, 1.8, ArH), 5.89-5.83 (1H, dddd, 
Ј 10.3, 5.2, 2.7, 2.5, CH=CH), 5.49 (1H, dd, Ј 10.3, 1.3, CH=CH), 4.63-4.47 (1H, m, 
CHN), 4.45 (1H, d, Ј 17.6, CHXHY), 4.31 (1H, d, Ј 17.6, CHXHY), 2.98 (3H, s, CH3), 
1.92-1.83 (1H, m, CHAHB), 1.75-1.68 (1H, m, CHAHB), 1.68-1.60 (1H, m, CHCHD), 
1.30-1.25 (1H, m, CHCHD), 0.95 (3H, s, CH3), 0.91 (3H, s, CH3) ; 
13C NMR δ (90.6 
MHz, CDCl3) 137.7 (C), 132.1 (2xCH), 129.3 (CH), 128.5 (CH), 127.4 (CH), 125.1 
(CH), 122.0 (C), 54.9 (CH), 47.7 (CH2), 40.8 (CH2), 39.5 (CH3), 38.2 (CH2), 31.7 
(CH3), 31.0 (C), 24.8 (CH3); m/z (FAB, THIOG) 374 ([
81BrM+H]+, 80 %), 372 
([79BrM+H]+, 93), 294 (49), 292 (53), 264 (23), 262 (12), 171 (100), 169 (100); 
HRMS (FAB, THIOG) Found: [81BrM+H]+, 374.0612. C16H23O2NS
81Br requires 
374.0612. Found: [79BrM+H]+, 372.0628. C16H23O2NS










General procedure C was employed using sulfonamide 115 
(40 mg, 0.11 mmol), palladacycle 100 (5.0 mg, 5.4 µmol) and 
Ag2CO3 (30 mg, 0.11 mmol) in DMF (3 ml). After 2 h at 140 
oC, work up and column chromatography (hexane:EtOAc, 
10:1-5:1) afforded phenanthridine 114 as a colourless solid (31 
mg, 99%).  
Rf [hexane:EtOAc, 3:1] = 0.48; MP 104 
oC (hexane); υmax (CHCl3)/cm
-1 2957, 1332 
(SO2), 1153 (SO2); 
1H NMR δ (360 MHz, CDCl3) 7.32 (1H, d, Ј 7.5, ArH), 7.24 
(1H, t, Ј 7.3, ArH), 7.20 (1H, t, Ј 7.9, ArH), 7.10 (1H, d, Ј 7.3, ArH), 6.03 (1H, dd, Ј 
10.0, 5.6, CH=CH), 5.59 (1H, d, Ј 10.0, CH=CH), 4.60 (1H, d, Ј 16.2, CHXHY), 4.43 
(1H, d, Ј 16.2, CHXHY), 4.41 (1H, dd, Ј 15.5, 6.2, CHN), 3.59 (1H, tr, Ј 5.6, 
CHCH=CH), 2.87 (3H, s, CH3), 1.64-1.60 (2H, m, CH2), 1.15 (3H, s, CH3), 0.94 
(3H, s, CH3); 
13C NMR δ (90.6 MHz, CDCl3) 138.7 (CH), 136.3 (C), 130.3 (C), 
127.9 (CH, C10), 127.3 (CH), 126.1 (CH), 126.0 (CH, C7), 123.7 (CH, C1), 49.8 (CH, 
C4a), 43.3 (CH2, C6), 39.0 (CH3, SO2Me), 38.2 (CH2, C4), 36.6 (CH), 34.0 (C, C3), 
30.3 (CH3), 28.3 (CH3); m/z (FAB, THIOG) 292 ([M+H]
+, 100 %), 291 ([M]+, 82), 
213 (44), 197 (40), 165 (12), 130 (15), 94 (89); HRMS (FAB, THIOG) Found: 













N-(2-Iodo-benzyl)-cyclohex-2-enyl-amine hydrochloride 129 
General procedure A was followed using 2-iodobenzylamine 
hydrochloride (200 mg, 0.742 mmol), MeCN (5 ml) at 0 oC 
iPr2NEt (517 µl, 2.97 mmol), 3-bromocyclohexene (86.0 µl, 
0.742 mmol) and HCl (2 ml, 1 M in Et2O, 2.00 mmol) to 
afford amine hydrochloride 129 as a colourless solid (287 mg, 100%). 
MP 241 oC; 1H NMR δ (360 MHz, CD3OD) 8.05 (1H, dd, Ј 8.0, 1.1, ArH), 7.65 
(1H, dd, Ј 7.7, 1.6, ArH), 7.55 (1H, td, Ј 7.5, 1.1, ArH), 7.23 (1H, td, Ј 7.9, 1.6, 
ArH), 6.29 (1H, m, CH=H), 5.91 (1H, dd, Ј 9.6, 1.4, CH=CH), 4.45 (2H, s, CH2Ar), 
4.10-4.04 (1H, m, CHN), 2.29-2.18 (3H, m, CH2+CHAHB), 1.99-1.91 (2H, m, CH2), 
1.83-1.70 (1H, m, CHAHB); 
13C NMR δ (90.6 MHz, CD3OD) 141.9 (C), 136.8 (CH), 
135.9 (C), 132.6 (CH), 132.5 (CH), 130.4 (CH), 122.7 (CH), 101.9 (C), 55.8 (CH), 
54.0 (CH2), 26.6 (CH2), 25.6 (CH2), 20.6 (CH2); m/z (FAB, 3-NOBA) 314 ([M+H]
+, 
99 %), 234 (51), 217 (53), 167 (39), 154 (63), 149 (100), 130 (92) ; HRMS (FAB, 3-
NOBA) Found: [M+H]+ 314.0409. C13H17NI requires 314.0406. 
Free Amine: Rf [hexane:EtOAc, 3:1] = 0.60; υmax (CH2Cl2)/cm
-1 3361 (NH), 1562, 







(2-Iodo-benzyl)-cyclohex-2-enyl-carbamic acid tert-butyl ester 124b 
To a suspension of amine hydrochloride 129 (120 mg, 0.34 
mmol) in CH2Cl2 (5 ml) was added Et3N (72 µl, 0.52 mmol). 
After 10 mins, the reaction was cooled to 0 oC, Boc2O (112 
mg, 0.52 mmol) in CH2Cl2 (1 ml) was added and the reaction 
was stirred for a further 10 mins. The reaction was warmed to 
r.t. and stirred for 16 h. The reaction was diluted with CH2Cl2 (10 ml), extracted with 
NaCl (3 x 10 ml, sat. aq.), dried (MgSO4) and concentrated under reduced pressure. 
Flash chromatography (hexane:EtOAc, 100:1) afforded Boc-protected amine 124b as 
a colourless oil (60 mg, 49%). 
 Rf [hexane:EtOAc, 3:1] = 0.82; υmax (CHCl3)/cm
-1 2930, 1694 (C=O), 1167; 1H 
NMR δ (360 MHz, 323 K, CDCl3) 7.80 (1H, d, Ј 7.9, ArH), 7.31 (1H, tr, Ј 7.3, 
ArH), 7.22 (1H, d, Ј 7.6, ArH), 6.92 (1H, t, Ј 7.3, ArH), 5.83 (1H, br s, CH=CH), 
5.48 (1H, d, Ј 10.0, CH=CH), 4.88 (1H, br s, NCH), 4.28 (2H, br s, CH2Ar), 2.10-
1.81 (3H, m, CH2+CHAHB), 1.81-1.70 (1H, m, CHAHB), 1.55-1.46 (2H, m, CH2), 
1.35 (9H, s, 3CH3); 
13C NMR δ (90.6 MHz, 323 K, CDCl3) 155.7 (C), 140.9 (C), 
139.0 (2xCH), 128.1 (2xCH), 127.9 (CH), 127.1 (CH), 97.2 (C), 79.8 (C), 53.2 (CH), 
52.9 (CH2), 28.2 (3xCH3), 24.5 (2xCH2), 21.3 (CH2); m/z (FAB, THIOG) 414 
([M+H]+, 20 %), 359 (100), 232 (22), 217 (41); HRMS (FAB, THIOG) Found: 









(2-Iodo-benzyl)-cyclohex-2-enyl-carbamic acid benzyl ester 124c 
To a suspension of NaH (15 mg, 60% dispersion in mineral 
oil, 0.37 mmol) in DMF (4 ml) at 0 oC was added amine 
hydrochloride 129 (58.0 mg, 0.17 mmol) in DMF (1 ml). The 
solution was stirred for 30 mins then benzyl chloroformate 
(31 µl, 0.22 mmol) was added dropwise and the reaction was 
warmed to r.t. and stirred for 16 h. The reaction was diluted 
with Et2O (10 ml), extracted with NaCl (3 x 10 ml, sat. aq.), 
dried (MgSO4) and concentrated under reduced pressure to give the crude product. 
Flash chromatography (hexane:EtOAc, 100:3) afforded Cbz protected amide 124c as 
a colourless oil (61 mg, 82%).  
Rf [hexane:EtOAc, 10:1] = 0.78; υmax (CHCl3)/cm
-1 1699 (C=O); 1H NMR δ (360 
MHz, 323 K, CDCl3) 7.80 (1H, d, Ј 7.9, 1.5, ArH), 7.40 – 7.21 (7H, m, 7xArH), 7.18 
(1H, td, Ј 7.6, 1.5, ArH), 5.87-5.80 (1H, m, CH=CH), 5.47 (1H, d, Ј 10.2, CH=CH), 
5.15 (2H, br s, OCH2Ar), 4.90 (1H, br s, CHN), 4.40 (1H, d, Ј 16.9, CHXHYAr), 4.33 
(1H, d, Ј 16.9, CHXHYAr),  2.10-1.85 (3H, m, CH2+CHAHB), 1.80-1.70 (1H, m, 
CHAHB), 1.70-1.42 (2H, m, CH2) ; 
13C NMR δ (90.6 MHz, 323 K, CDCl3) 156.5 
(C), 141.1 (C), 139.1 (2xCH), 131.8 (C), 129.9 (C), 128.2 (3xCH), 128.0 (CH), 127.7 
(3xCH), 127.6 (CH), 127.2 (CH), 67.1 (CH2), 53.8 (CH), 45.9 (CH2), 28.1 (CH2), 
24.5 (CH2), 21.2 (CH2); m/z (FAB, THIOG) 448 ([M+H]
+, 14  %), 217 (13), 171 (4), 













N-(2-Chloro-benzyl)-cyclohex-2-enyl-amine hydrochloride 132 
General procedure A was followed using 2-
chlorobenzylamine (1.00 g, 8.28 mmol), MeCN (20 ml) 
iPr2NEt (4.20 ml, 24.9 mmol), 3-bromocyclohexene (952 µl, 
8.28 mmol) and HCl (10 ml, 1 M in Et2O, 10 mmol) to 
afford amine hydrochloride 132 as a colourless solid (1.20 g, 66%).  
MP 161 oC (Et2O); 
1H NMR δ (250 MHz, CD3OD) 7.72-7.69 (1H, m, ArH), 7.62-
7.47 (3H, m, 3xArH), 6.28-6.23 (1H, m, CH=CH), 5.90 (1H, dd, Ј 10.3, 1.5, 
CH=CH), 4.45 (2H, s, CH2Ar), 4.25-4.22 (1H, br s, CHN), 2.26-2.17 (3H, m, 
CH2+CHAHB), 1.96-1.72 (3H, m, CH2+CHAHB); 
13C NMR δ (62.9 MHz, CD3OD) 
136.9 (CH), 136.0 (C), 133.4 (CH), 132.6 (CH), 131.2 (CH), 130.8 (C), 129.0 (CH), 
122.4 (CH), 55.8 (CH), 46.6 (CH2), 26.4 (CH2), 25.5 (CH2), 20.5 (CH2); m/z (FAB, 
THIOG) 224 ([37ClM+H]+, 39 %), 222 ([35ClM+H]+, 100), 144 (11), 142 (34), 127 
(16), 125 (47) ; HRMS (FAB, THIOG) Found: [37ClM+H]+, 224.1026. C13H17N
37Cl 
requires 224.1020. Found: [35ClM+H]+ 222.1057. C13H17N
35Cl requires 222.1050.  
Free amine: Rf [hexane:EtOAc, 3:1] = 0.33; υmax (MeOH/CH2Cl2)/cm
-1 2937, 2707, 















General procedure B was followed using amine 
hydrochloride 132 (1.10 g, 4.96 mmol), CH2Cl2 (30 ml), 
Et3N (2.10 ml, 14.9 mmol) and methanesulfonyl chloride 
(1.15 ml, 14.9 mmol). Flash chromatography 
(hexane:EtOAc, 10:1-3:1) afforded sulfonamide 130a as a colourless solid (890 mg, 
60%).  
Rf [hexane:EtOAc, 3:1] = 0.59; MP 89 
oC (Et2O); υmax (CHCl3)/cm
-1 2932, 1333 
(SO2), 1145 (SO2); 
1H NMR δ (250 MHz, CDCl3) 7.68 (1H, dt, Ј 7.2, 1.7, ArH), 
7.33-7.19 (3H, m, 3xArH), 5.99-5.93 (1H, m, CH=CH), 5.51 (1H, dt, Ј 10.1, 1.6, 
CH=CH), 4.66-4.59 (1H, m, NCH), 4.50 (1H, d, Ј 17.5, CHXHYAr), 4.38 (1H, d,  Ј 
17.5, CHXHYAr),  2.96 (3H, s, CH3), 2.00-1.93 (3H, m, CHAHB+CH2), 1.80-1.33 
(3H, m, CHAHB+CH2); 
13C NMR δ (62.9 MHz, CDCl3) 137.0 (C), 133.7 (CH), 
132.5 (C), 129.1 (CH), 128.9 (CH), 128.1 (CH), 126.8 (CH), 126.6 (CH), 55.6 (CH), 
44.9 (CH2), 39.4 (CH3), 28.7 (CH2), 24.2 (CH2), 21.4 (CH2); m/z (FAB, THIOG) 302 
([37ClM+H]+, 5 %),  300 ([35ClM+H]+), 220 (17), 127 (34), 125 (100), 109 (12); 
HRMS (FAB, THIOG) Found: [37ClM+H]+, 302.0805. C14H19NO2S
37Cl requires 
302.0800. Found: [35ClM+H]+, 300.0836. C14H19NO2S
















 To a suspension of amine 135178 (4.62 g, 24.4 mmol) in 
DMF (100 ml) at 0 oC, was added NaH (2.14 g, 60% 
dispersion in mineral oil, 54.0 mmol) and the reaction stirred 
for 30 mins. Benzyl bromide (3.77 ml, 3.77 mmol) was 
added dropwise and the reaction warmed to r.t and stirred for 
16 h. Et2O (100 ml) was added and the organics washed with NaCl (3 x 100 ml, sat. 
aq.), dried (MgSO4), concentrated under reduced pressure and purified by flash 
chromatography (hexane:EtOAc, 25:1). The resultant solid was recrystallised from 
EtOH (10 ml) to afford dibenzylamine 133 as a colourless solid (4.52 g, 61%). 
Rf [hexane:EtOAc, 10:1] = 0.87; MP 63 
oC (lit 62 oC)100; υmax (CHCl3)/cm
-1 2927, 
2852, 2796, 1493, 1452; 1H NMR δ (360 MHz, CDCl3) 7.41 (4H, d, Ј 6.9, 4xArH), 
7.31 (4H, t, Ј 7.3, 4xArH), 7.23 (2H, t, Ј 7.3, 2xArH), 3.67 (4H, s, 2xCH2Ar), 2.51 
(1H, tt, Ј 11.6, 3.4, NCH), 1.93 (2H, br d, Ј 12.6, CH2), 1.81-1.78 (2H, m, CH2), 
1.64-1.62 (1H, m, CHAHB), 1.42-1.29 (2H, m, CH2), 1.23-1.06 (3H, m, 
CH2+CHAHB); 
13C NMR δ (90.6 MHz, CDCl3) 141.2 (2xC), 128.2 (4xCH), 127.9 
(4xCH), 126.3 (2xCH), 57.6 (CH), 53.7 (2xCH2), 28.5 (2xCH2), 26.4 (CH2), 26.1 
(2xCH2); m/z (EI) 279 ([M]
+, 10 %), 236 (18), 181 (7), 138 (11); HRMS (EI) Found: 
[M]+ 279.1979. C20H25N requires 279.1982.  
 









6.3 Experimental for Chapter three 
 
3-Bromo-2-methyl-thiophene 153180 
To a solution of diisopropylamine (6.00 ml, 42.6 mmol) in THF (20 ml) 
at 0 oC was added nBuLi (26.6 ml, 42.6 mmol, 1.6 M in hexanes). After 
addition was complete the reaction temperature was maintained at 0 oC 
for 30 mins. The flask was cooled to –78 oC, 3-bromothiophene (4.00 ml, 42.6 
mmol) was added dropwise and the reaction warmed to 0 oC and stirred for 30 mins. 
The reaction was cooled again to –78 oC and methyl iodide (2.68 ml, 42.6 mmol) 
was added. After 30 mins the reaction was warmed to r.t. and stirred for 1 h. The 
reaction was diluted with Et2O (100 ml) and washed with H2O (3 x 50 ml). The 
organic phase was dried (MgSO4) and concentrated under reduced pressure to afford 
methyl thiophene 153 as a grey oil (7.2 g, 99%). 
Rf [hexane:EtOAc, 3:1] = 0.80; υmax (CHCl3)/cm
-1 3110, 2919, 2856, 1527, 1439, 
1341; 1H NMR δ (360 MHz, CDCl3) 7.08 (1H, d, Ј  5.4, HetH), 6.91 (1H, d, Ј  5.4, 
HetH), 2.43 (3H, s, CH3); 
13C NMR δ (90.6 MHz, CDCl3) 134.0 (C), 129.7 (CH), 
127.4 (CH), 109.2 (C), 14.4 (CH3). 




To a solution of methyl thiophene 153 (600 mg, 2.82 mmol) in CCl4 
(15 ml) was added NBS (503 mg, 2.82 mmol) and AIBN (20 mg, 
cat.). The reaction was heated at 80 oC for 3 h and then cooled and 
filtered to remove the succinimide. The crude organics concentrated under reduced 
pressure and purified by flash chromatography (hexane:EtOAc, 100:2.5–100:5) to 
afford thiophenemethyl bromide 154 as a yellow oil (384 mg, 53%). 
Rf [CH2Cl2:MeOH, 9:1] = 0.43; υmax (CHCl3)/cm
-1 2927, 1613, 1508; 1H NMR δ 
(250 MHz, CDCl3) 7.32 (1H, d, Ј  5.4, HetH), 6.95 (1H, d, Ј  5.4, HetH), 4.69 (2H, s, 
CH2); 
13C NMR δ (62.9 MHz, CDCl3) 134.5 (C), 130.3 (CH), 126.6 (CH), 112.6 (C), 
25.1 (CH3). 











To a solution of diisopropylamine (7.03 ml, 50.0 mmol) in THF (80 
ml) at 0 oC was added nBuLi (3.87 ml, 62.0 mmol, 1.6 M in 
hexanes) and the reaction stirred for 30 mins. 3-Bromothiophene 
(4.63 ml, 50.0 mmol) was added dropwise and the reaction was 
stirred for 30 mins. Freshly distilled DMF (3.87 ml, 50.0 mmol) was added dropwise 
and the reaction allowed to warm to r.t. and stirred for 2.5 h. The reaction was 
diluted with Et2O (80 ml) and the organics washed with NH4Cl (3 x 50 ml, sat. aq.), 
dried (MgSO4), and concentrated under reduced pressure to afford aldehyde 156 as a 
yellow oil (8.85 g, 94%). 
Rf [hexane:EtOAc, 3:1] = 0.64; υmax (CHCl3)/cm
-1 1665 (C=O), 1498, 1416, 1213, 
737; 1H NMR δ (250 MHz, CDCl3) 9.99 (1H, d, Ј  1.4, COH), 7.75 (1H, dd, Ј  5.1, 
1.4, HetH), 7.16 (1H, d, Ј  5.1, HetH); 13C NMR δ (62.9 MHz, CDCl3) 182.9 (C), 
136.8 (C), 134.7 (CH), 131.9 (CH), 120.2 (C); m/z (FAB, THIOG) 283 (95), 281 
(93), ([81BrM+H]+ 193, 96 %), ([79BrM+H]+ 191, 100), 177 (19), 175 (18), 109 (17); 
HRMS (FAB, THIOG) (Found: [81BrM+H]+, 192.9147. C5H3N
81BrOS requires 
192.9147). (Found: [79BrM+H]+ 190.9166. C5H3N
79BrOS requires 190.9166). 
 









Alkylation: To a suspension of 3-aminocyclohexene 
hydrochloride105 (53 mg, 0.39 mmol) in MeCN (5 ml) at 0 oC 
was added iPr2NEt (272 µl, 1.56 mmol), and the reaction was 
stirred for 5 mins. 3-Bromo-2-bromomethyl-thiophene 154 (100 mg, 0.39 mmol) was 
added and the reaction stirred for 16 h at r.t. The reaction was concentrated under 
reduced pressure and the residue taken up in CH2Cl2 (5 ml) and washed with NaCl (3 
x 5 ml, sat. aq.). The organics were combined, dried (MgSO4), concentrated under 
reduced pressure and purified by flash chromatography (hexane:EtOAc, 10:1-5:1) to 
afford amine 155 as a brown oil (19 mg, 18%). 
Reductive amination: To a suspension of 3-aminocyclohexene hydrochloride105 
(5.64 g, 31.7 mmol) in toluene (150 ml) was added iPr2NEt (6.90 ml, 26.5 mmol) and 
the reaction was stirred for 10 mins. Aldehyde 156 (5.00 g, 26.5 mmol) and 
molecular sieves (5.00 g) were added and the reaction was heated at reflux for 16 h. 
The reaction was concentrated under reduced pressure, and the crude imine was 
dissolved in methanol (150 ml), cooled to 0 oC and Na(OAc)3BH (33.6 g, 158.7 
mmol) was added portionwise. The reaction was stirred at r.t. for 16 h then diluted 
with CH2Cl2 (150 ml) and washed with NaCl (3 x 50 ml, sat. aq.). The organics were 
dried (MgSO4), concentrated under reduced pressure and purified by flash 
chromatography (hexane:EtOAc:NH3, 100:10:0.1) to afford amine 155 as a brown 
oil (1.18 g, 16%). 
Rf [hexane:EtOAc, 3:1] = 0.76; υmax (CHCl3)/cm
-1 3416 (NH), 1464, 1382, 1364; 1H 
NMR δ (250 MHz, CDCl3) 7.20 (1H, d, Ј 5.3, HetH), 6.93 (1H, d, Ј 5.2, HetH), 5.82-
5.70 (2H, m, CH=CH), 4.02 (1H, d, Ј 15.1, CHXHYHet), 3.96 (1H, d, Ј 15.1, 
CHXHYHet), 3.24 (1H, br s, CHN), 2.13-1.84 (3H, m, CH2+CHAHB), 1.82-1.72 (1H, 
m, CHAHB), 1.61-1.49 (2H, m, CH2); 
13C NMR δ (62.9 MHz, CDCl3) 139.3 (C), 
129.7 (CH), 129.5 (CH), 129.2 (CH), 124.2 (CH), 107.9 (C), 52.0 (CH), 44.6 (CH2), 
29.3 (CH2), 25.2 (CH2), 20.0 (CH2); m/z (FAB, 3-NOBA) 274 ([
81BrM+H]+, 63 %), 
272 ([79BrM+H]+, 69), 192 (78), 190 (46), 177 (80), 175 (78); HRMS (FAB, 3-
NOBA) Found: [81BrM+H]+, 274.0086. C11H15N








General procedure B was followed using amine 155 (300 mg, 
1.10 mmol), CH2Cl2 (10 ml), methanesulfonyl chloride (256 
µl, 3.31 mmol) and Et3N (465 µl, 3.31 mmol). Flash 
chromatography (hexane:EtOAc, 10:1–3:1) afforded 
sulfonamide 157 as a yellow oil (262 mg, 68%). 
Rf [hexane: EtOAc, 3:1] = 0.46; υmax (CHCl3)/cm
-1 1325, 1152, 745 1H NMR δ (360 
MHz, CDCl3) 7.26 (1H, d, Ј 5.4, HetH), 6.88 (1H, d, Ј 5.4, HetH), 6.01-5.95 (1H, m, 
CH=CH), 5.54-5.49 (1H, m, CH=CH), 4.56 (1H, d, Ј 16.8, CHXHYHet), 4.55-4.50 
(1H, br s, CHN), 4.49 (1H, d, Ј 16.8, CHXHYHet), 2.94 (3H, s, CH3), 2.06-1.94 (3H, 
m, CH2+CHAHB), 1.84-1.72 (1H, m, CHAHB), 1.62-1.59 (2H, m, CH2); 
13C NMR δ 
(90.6 MHz, CDCl3) 137.8 (C), 133.6 (CH), 129.5 (CH), 126.8 (CH), 125.5 (CH), 
108.8 (C), 55.6 (CH), 42.2(CH2), 40.3 (CH3), 28.6 (CH2), 24.3 (CH2), 21.6 (CH2); 
m/z (FAB, THIOG) 352([81BrM+H]+, 12 %), 350 ([79BrM+H]+, 15), 272 (25), 270 
(37), 190 (34), 188 (56), 177 (73), 175 (74); HRMS (FAB, THIOG) Found: 
[81BrM+H]+, 351.9860. C12H17N
81BrO2S2 requires 351.9864. Found: [
79BrM+H]+ 
349.9848. C12H17N
79BrO2S2 requires 349.9884. 
 
(5aSR,9aSR)-5-Methanesulfonyl-3a,4,5,5a,6,7,9a,9b-octahydro-thieno[2,3-
c]quinoline 158 (∆1,2 isomer) 
Cationic: To a solution of cyclohexene 157 (50.0 mg, 0.14 
mmol) in DMA (5 ml) was added Pd(OAc)2 (1.6 mg, 7.0 µmol), 
PCy3 (4.1 mg, 14.3 µmol) and MeNCy2 (122 µl, 0.57 mmol) 
and the reaction was heated at 160 oC for 2 h. Flash 
chromatography (hexane:EtOAc, 10:1) afforded the quinoline 
as a colourless oil (23 mg, 60 %). 1H NMR of this oil showed it to be 77:16:7 
mixture of double bond isomers (158:159:160).  Neutral: General procedure D was 
followed using cyclohexene 157 (30 mg, 0.090 mmol), palladacycle 100 (4.0 mg, 4.3 
µmol) and MeNCy2 (73 µl, 0.34 mmol). Flash chromatography (hexane:EtOAc, 
100:1-10:1) afforded the quinoline as a colourless oil (17 mg, 74 %). 1H NMR of this 















Rf [hexane:EtOAc, 3:1] = 0.41; υmax (CHCl3)/cm
-1 1447, 1325, 1151; 1H NMR δ 
(360 MHz, CDCl3) 7.21 (1H, d, Ј 5.1, HetH), 6.93 (1H, d, Ј 5.1, HetH), 6.05-6.01 
(1H, m, CH=CH), 5.83-7.78 (1H, m, CH=CH), 4.82 (1H, dd, Ј 16.9, 0.9, 
CHXHYHet), 4.42 (1H, dd, Ј 16.8, 1.8, CHXHYHet), 4.36-4.32 (1H, m, CHN),  3.56 
(1H, br s, NCHCH), 2.86 (3H, s, CH3), 2.38-2.26 (1H, m, CHAHB), 2.22-2.10 (1H, 
m, CHAHB), 1.84-1.78 (2H, m, CH2); 
13C NMR δ (90.6 MHz, CDCl3) 135.8 (C), 
127.8 (CH), 126.4 (CH), 125.9 (CH), 123.9 (CH), 111.28 (C), 51.4 (CH), 40.4 (CH2), 
39.9 (CH3), 35.8 (CH), 25.2 (CH2), 23.2 (CH2); m/z (FAB, THIOG) 270 ([M+H]
+, 50 
%), 268 (73), 214 (32), 190 (69), 188 (72), 175 (32), 163 (33); HRMS (FAB, 3-
NOBA) Found: [M+H]+, 270.0628. C12H16O2NS2 requires 270.0623. 
Diagnostic 1H NMR data for 159 (∆2,3 isomer)   
1H NMR δ (360 MHz, CDCl3) 7.22 (1H, d, Ј 5.2, HetH), 6.92 (1H, d, Ј 5.2, HetH), 
5.65-5.61 (1H, m, CH=CH), 5.52-5.48 (1H, m, CH=CH), 4.83 (1H, d, Ј 16.3, 
CHxHYHet), 4.51 (1H, dd, Ј 16.3, 2.2, CHXHYHet), 4.45-4.39 (1H, m, NCH), 3.29-
3.25 (1H, m, NCHCH), 2.94 (3H, s, CH3), 2.75-2.65 (2H, m, CH2), 2.22-2.18 (2H, 
m, CH2). 
Diagnostic 1H NMR data for 160 (∆3,4 isomer) 
1H NMR δ (360 MHz, CDCl3) 5.87-5.80 (1H, m, CH=CH), 5.55-5.50 (1H, m, 
CH=CH), 4.86 (1H, br s, NCH), 4.73 (1H, d, Ј 16.6, CHxHYHet), 3.34 (1H, br s, 




General procedure F - Synthesis of aryl amide analogues  
A mixture of the appropriate benzoic acid (approx. 1.00 g) and thionyl chloride (15 
ml) was refluxed at 60 oC for 3 h. The thionyl chloride was removed under reduced 
pressure and the residue was dissolved in NH4OH (15 ml, conc.) and stirred for 16 h 
at r.t. The reaction was filtered and the precipitate dried on the high vacuum line for 
several hours to afford the desired amide. 
 
2-Bromo-4-methylbenzamide 162a181 
General procedure F was followed using 2-bromo-4-methyl 
benzoic acid (800 mg, 3.70 mmol) and thionyl chloride (12 
ml) to afford amide 162a as a colourless solid (750 mg, 95%). 
Rf [CH2Cl2:MeOH, 95:5] = 0.45; MP 171 
oC (H2O), lit 175 
oC181; υmax (CHCl3)/cm
-1 3419 (NH), 1636 (C=O); 1H NMR δ (250 MHz, CD3OD) 
7.46 (1H, s, ArH), 7.33 (1H, d, Ј 8.0, ArH), 7.19 (1H, dd, Ј 7.5, 0.8, ArH), 2.33 (3H, 
s, CH3); 
13C NMR δ (62.9 MHz, CD3OD) 173.4 (C), 143.1 (C), 136.6 (C), 134.7 
(CH), 129.7 (CH), 129.2 (CH), 120.0 (C), 20.9 (CH3); m/z (FAB, 3-NOBA) 216 
([81BrM+H]+, 75 %), 214 ([79BrM+H]+, 77), 199 (10), 197 (10), 154 (100), 136 (100), 
121 (27); HRMS (EI) Found: [81BrM]+, 214.9760. C8H8ON
81Br requires 214.9763. 
Found: [79BrM]+, 212.9779. C8H8ON
79Br requires 212.9784. 
 
2-Bromo-4-fluorobenzamide 162b 
General procedure F was followed using 2-bromo-4-fluoro 
benzoic acid (1.00 g, 4.57 mmol) and thionyl chloride (15 ml) 
to afford amide 162b as a colourless solid (940 mg, 94%). 
Rf [CH2Cl2:MeOH, 95:5] = 0.4; MP 155 
oC (H2O); υmax 
(CHCl3)/cm
-1 3400 (NH), 1639 (C=O); 1H NMR δ (360 MHz, CD3OD) 7.50 (1H, dd, 
Ј 8.4, 5.8, ArH), 7.46 (1H, dd, Ј 8.6, 2.6, ArH), 7.22 (1H, td, Ј 8.4, 2.6, ArH); 13C 
NMR δ (90.6 MHz, CD3OD) 172.6 (C), 164.4 (1C, d, Ј 252.1, C), 136.5 (C), 131.7 
(1C, d, Ј 9.0, CH), 121.7 (1C, d, Ј 25.1, CH), 121.2 (1C, d, Ј 9.9, C), 115.9 (1C, d, Ј 
21.7, CH); m/z (FAB, 3-NOBA) 220 ([81BrM+H]+, 64 %), 218 ([79BrM+H]+, 66), 167 
(12), 165 (11), 136 (100); HRMS (EI) Found: [81BrM]+, 218.9511. C7H5ON
81BrF 
requires 218.9513. Found: [79BrM]+, 216.9528. C7H5ON












General procedure F was followed using 2-bromo-5-
methoxy benzoic acid (1.00 g, 4.53 mmol) and thionyl 
chloride (15 ml) to afford amide 162c as a colourless solid 
(650 mg, 65%). 
Rf [CH2Cl2:MeOH, 95:5] = 0.45; MP 154 
oC, lit 157 oC182; υmax (CHCl3)/cm
-1 3415 
(NH), 1635 (C=O); 1H NMR δ (250 MHz, CD3OD) 7.53 (1H, d, Ј 8.8, ArH), 7.04 
(1H, d, Ј 3.3, ArH), 6.95 (1H, dd, Ј 8.8, 3.3, ArH), 3.84 (3H, s, CH3); 
13C NMR δ 
(62.9 MHz, CD3OD) 160.1 (C), 150.8 (C), 134.7 (CH), 128.8 (C), 117.7 (CH), 115.0 
(CH), 109.8 (C), 55.8 (CH3); m/z (FAB, 3-NOBA) 232 ([
81BrM+H]+, 65 %), 230 
([79BrM+H]+, 67), 154 (100), 136 (100), 121 (26), 109 (42); HRMS (EI) Found: 
[81BrM]+, 230.9715. C8H8O2N
81Br requires 230.9713. Found: [79BrM]+, 228.9733. 
C8H8O2N
79Br requires 228.9733. 
 
2-Bromo-4,5-methoxybenzamide 162d183 
General procedure F was followed using 2-bromo-4,5-
methoxy benzoic acid (2.00 g, 7.66 mmol) and thionyl 
chloride (30 ml) to afford amide 162d as a colourless solid 
(1.45 g, 73%). 
Rf [CH2Cl2:MeOH, 95:5] = 0.49; MP 178 
oC, lit 178 oC183; υmax (CHCl3)/cm
-1 3442 
(NH), 1676 (C=O); 1H NMR δ (250 MHz, (CD3)2SO) 7.73 (1H, br s, NH), 7.48 (1H, 
br s, NH), 7.14 (1H, s, ArH), 7.02 (1H, s, ArH), 3.80 (3H, s, CH3), 3.78 (3H, s, CH3); 
13C NMR δ (62.9 MHz, (CD3)2SO) 167.9 (C), 149.1 (C), 147.0 (C), 129.9 (C), 115.1 
(CH), 111.4 (CH), 108.6 (C), 55.3 (CH3), 55.1 (CH3); m/z (FAB, 3-NOBA) 262 
([81BrM+H]+, 100 %), 260 ([79BrM+H]+, 83), 245 (100), 243 (71), 204 (23), 202 (34), 
200 (24), 181 (37), 180 (26), 167 (27), 166 (30); HRMS (EI) Found: [81BrM]+, 
260.9825. C9H10O3N
79Br requires 260.9818. Found: [79BrM]+, 258.9838. 
C9H10O3N

















General procedure F was followed using 1-bromo-2-naphthoic  
acid (1.00 g, 3.98 mmol) and thionyl chloride (15 ml) to afford 
amide 162e as a colourless solid (995 mg, 99%). 
Rf [CH2Cl2:MeOH, 95:5] = 0.67; MP 202 
oC (H2O); υmax 
(CHCl3)/cm
-1 3440 (NH), 1678 (C=O); 1H NMR δ (250 MHz, (CD3)2SO) 8.20 (1H, 
d, Ј 7.5, ArH), 8.17 (1H, br s, NH), 8.14 (2H, br s, 2xArH), 7.88 (1H, br s, NH), 7.84 
(1H, td, Ј 6.8, 1.5, ArH), 7.79 (1H, td, Ј 6.8, 1.5, ArH), 7.62 (1H, d, Ј 6.8, ArH); 13C 
NMR δ (62.9 MHz, (CD3)2SO) 169.4 (C), 137.7 (C), 133.4 (C), 130.8 (C), 128.1 
(2xCH), 127.7 (CH), 127.0 (CH), 126.4 (CH), 124.6 (CH), 117.8 (C); m/z (FAB, 3-
NOBA) 252 ([81BrM+H]+, 76 %), 250 ([79BrM+H]+, 90), 235 (12), 233 (13), 154 
(100), 149 (26), 138 (41), 136 (97), 107 (46); HRMS (EI +ve) Found: [81BrM]+, 
250.9765. C11H8
81BrNO requires 250.9763. Found: [79BrM]+, 248.9782. 
C11H8
79BrNO requires 248.9784. 
 




General procedure F was followed using 3-bromothiophene-2-
carboxylic acid (1.00 g, 4.88 mmol) and thionyl chloride (15 ml) 
to afford amide 162f as a beige solid (923 mg, 93%). 
Rf [CH2Cl2:MeOH, 95:5] = 0.59; MP 102 
oC, lit 103 oC185; υmax 
(CHCl3)/cm
-1 3432 (NH), 1642 (C=O), 1429; 1H NMR δ (250 MHz, CD3OD) 7.71 
(1H, d, Ј 5.5, HetH), 7.16 (1H, d, Ј 5.5, HetH); 13C NMR δ (62.9 MHz, CD3OD) 
167.0 (C), 143.0 (C), 134.1 (C), 132.7 (CH), 131.0 (CH); m/z (FAB, 3-NOBA) 208 
([81BrM+H]+, 66 %), 206 ([79BrM+H]+, 65), 154 (100), 138 (32), 137 (70), 136 (85); 
HRMS (EI) Found: [81BrM]+, 206.9169. C5H4ON
81BrS requires 206.9171. Found: 
[79BrM]+, 204.9190. C5H4ON
79BrS requires 204.9191. 
 












General procedure F was followed using 2-bromo-5-
nitrobenzoic acid (2.00 g, 8.13 mmol) and thionyl chloride 
(30 ml) to afford amide 162g as a colourless solid (1.99 g, 
99%). 
Rf [CH2Cl2:MeOH, 95:5] = 0.63; MP 168 
oC, lit 197-198 oC (EtOH)186; υmax 
(CHCl3)/cm
-1 3420 (NH), 1654 (C=O); 1H NMR δ (250 MHz, (CD3)2SO) 8.19 (1H, 
s, ArH), 8.17 (1H, dd, Ј 8.7, 2.8, ArH), 8.16 (1H, br s, NH), 7.98 (1H, td, Ј 8.8, 1.4, 
ArH), 7.88 (1H, br s, NH); 13C NMR δ (62.9 MHz, (CD3)2SO) 167.5 (C), 146.8 (C), 
140.6 (C), 134.9 (CH), 126.8 (C), 125.4 (CH), 123.4 (CH); m/z (FAB, 3-NOBA) 247 
([81BrM+H]+, 32 %), 245 ([79BrM+H]+, 33), 167 (22), 154 (100); HRMS (EI) Found: 
[81BrM]+, 245.9461. C7H5
81BrN2O3 requires 245.9458. Found: [
79BrM]+, 243.9485. 
C7H5
79BrN2O3 requires 243.9478. 
 
1H and 13C spectroscopic data in agreement with literature.186 
 
3-Bromoindole-2-carboxylic acid amide 162h 
General procedure F was followed using 3-bromo-2-
carboxylic acid (1.00 g, 4.17 mmol) and thionyl chloride (15 
ml) to afford amide 162h as a yellow solid (885 mg, 89%). 
Rf [CH2Cl2:MeOH, 95:5] = 0.66; MP 173 
oC; υmax 
((CH3)2SO)/cm
-1 3452 (NH), 1672 (C=O), 1619 (C=O); 1H NMR δ (250 MHz, 
(CD3)2SO) 12.0 (1H, br s, NH), 7.88 (1H, br s, NH), 7.46 (2H, t, Ј 7.8, 2xArH), 7.31 
(1H, br s, NH), 7.33-7.27 (1H, m, ArH), 7.17 (1H, t, 8.1, ArH); 13C NMR δ (62.9 
MHz, (CD3)2SO) 161.2 (C), 134.9 (C), 128.3 (C), 126.6 (C), 124.8 (CH), 120.8 
(CH), 119.5 (CH), 112.7 (CH), 90.7 (C); m/z (FAB, 3-NOBA) 241 ([81BrM+H]+, 61 
%),  239 ([79BrM+H]+, 61), 223 (46), 221 (44), 165 (37), 152 (55), 138 (64), 125 (43), 



















General procedure F was followed using 2-bromophenethyl 
carboxylic acid (3.00 g, 14.0 mmol) and thionyl chloride (30 
ml) to afford amide 162j as a colourless solid (2.20 g, 74%). 
Rf [CH2Cl2: MeOH, 95:5] = 0.65; MP 184 
oC (lit 184-186 oC)187; υmax 
((CH3)2SO)/cm
-1  3452 (NH), 1683 (C=O), 1635 (C=O); 1H NMR δ (250 MHz, 
(CD3)2SO) 7.58 (1H, d, Ј 7.5, ArH), 7.47 (1H, br s, NH), 7.38-7.29 (2H, m, 2xArH), 
7.19 (1H, dd, Ј 8.0, 2.8, ArH), 7.17 (1H, dd, Ј 7.8, 2.5, ArH), 7.00 (1H, br s, NH); 
13C NMR δ (62.9 MHz, (CD3)2SO) 170.2 (C), 135.4 (C), 131.5 (CH), 131.3 (CH), 
127.8 (CH), 126.8 (CH), 123.8 (C), 41.4 (CH2); m/z (FAB, 3-NOBA) 216 
([81BrM+H]+,  72 %),  214 ([79BrM+H]+, 72 ), 180 (21), 171 (52), 169 (61), 154 (77), 





2-Bromo-4-methyl benzonitrile 163a188 
A mixture of amide 162a (750 mg, 3.50 mmol) and thionyl 
chloride (5 ml) was refluxed at 60 oC for 3 h. The reaction was 
concentrated under reduced pressure to afford nitrile 163a as a 
colourless solid (500 mg, 73%). 
Rf [hexane:EtOAc, 3:1] = 0.75; MP 55 
oC, lit 56 oC188; υmax (CHCl3)/cm
-1 3408, 
2230 (CN); 1H NMR δ (250 MHz, CD3OD) 7.38-7.37 (2H, m, 2xArH), 7.34 (1H, dq, 
Ј 8.0, 1.5, ArH), 2.43 (3H, s, CH3); 
13C NMR δ (62.9 MHz, CD3OD) 146.8 (C), 
134.6 (CH), 134.2 (CH), 129.3 (CH), 124.9 (C), 117.5 (C), 112.9 (C), 20.8 (CH3); 
m/z (FAB, 3-NOBA) 198 ([81BrM+H]+, 47 %), 196 ([79BrM+H]+, 48), 167 (13), 165 
(12), 154 (100); HRMS (ES, 3-NOBA) Found: [81BrM]+, 196.9656. C8H6 
81BrN 
requires 196.9658. Found: [79BrM]+, 194.9678. C8H6 












A mixture of amide 162b (940 mg, 4.30 mmol) and thionyl 
chloride (6 ml) was refluxed at 60 oC for 3 h. The reaction was 
concentrated under reduced pressure to afford nitrile 163b as a 
colourless solid (840 mg, 97%). 
Rf [hexane:EtOAc, 3:1] = 0.78; MP 76 
oC (EtOH); υmax (CHCl3)/cm
-1 2228 (CN); 1H 
NMR δ (360 MHz, CD3OD) 7.88 (1H, dd, Ј 8.6, 5.4, ArH), 7.69 (1H, dd, Ј 8.3, 2.5, 
ArH), 7.35 (1H, td, Ј 8.6, 2.5, ArH); 13C NMR δ (90.6 MHz, CD3OD) 166.4 (1C, d, 
Ј 259.3, C), 138.0 (1C, d, Ј 10.1, CH), 127.6 (1C, d, Ј 10.3, C), 122.5 (1C, d, Ј 26.1, 
CH), 117.6 (C), 117.3 (1C, d, Ј 22.9, CH), 113.5 (C); m/z (FAB, 3-NOBA)  202 
([81BrM+H]+, 3 %), 200 ([79BrM+H]+, 2), 154 (64), 121 (11); HRMS (EI) Found: 
[81BrM]+, 200.9407. C7H3
81BrFN requires 200.9407. Found: [79BrM]+, 198.9422. 
C7H3
79BrFN requires 198.9427. 
 
2-Bromo-5-methoxybenzonitrile 163c189 
A mixture of amide 162c (630 mg, 2.74 mmol) and thionyl 
chloride (3 ml) was refluxed at 60 oC for 3 h. The reaction was 
concentrated under reduced pressure to afford nitrile 163c as a 
colourless solid (510 mg, 88%). 
Rf [hexane:EtOAc, 3:1] = 0.74; MP 95 
oC, lit 98.5-99.5 oC189; υmax (CHCl3)/cm
-1 
3420, 2229 (CN); 1H NMR δ (250 MHz, CD3OD) 7.67 (1H, d, Ј 9.0, ArH), 7.38 
(1H, d, Ј 3.1, ArH), 7.18 (1H, dd, Ј 9.0, 3.1, ArH), 3.89 (3H, s, CH3); 
13C NMR δ 
(62.9 MHz, CD3OD) 161.3 (C), 134.9 (CH), 121.9 (CH), 120.0 (CH), 117.6 (C), 
116.7 (C), 115.7 (C), 56.2 (CH3); m/z (FAB, 3-NOBA) 214 ([
81BrM+H]+, 8 %), 212 
([79BrM+H]+, 8), 167 (20), 165 (26), 154 (100); HRMS (EI) Found: [81BrM]+, 
212.9604. C8H6














A mixture of amide 162d (1.25 g, 4.81 mmol) and thionyl 
chloride (30 ml) was refluxed at 60 oC for 3 h. The reaction was 
concentrated under reduced pressure to afford nitrile 163d as a 
colourless solid (1.15 g, 99%). 
Rf [hexane:EtOAc, 3:1] = 0.5; MP 113 
oC (EtOH), lit 117 oC190; υmax (CHCl3)/cm
-1 
2229 (CN); 1H NMR δ (250 MHz, (CD3)2SO) 7.49 (1H, s, ArH), 7.39 (1H, s, ArH), 
3.87 (3H, s, CH3), 3.81 (3H, s, CH3); 
13C NMR δ (90.6 MHz, (CD3)2SO) 153.4 (C), 
148.5 (C), 117.9 (C), 116.9 (C), 116.2 (CH), 115.9 (CH), 105.4 (C), 56.8 (CH3), 56.3 
(CH3); m/z (FAB, 3-NOBA) 244 ([
81BrM+H]+, 27 %), 242 ([79BrM+H]+, 42), 167 
(16), 154 (98), 152 (17), 150 (15), 149 (49), 137 (82), 136 (74); HRMS (EI) Found: 
[81BrM]+, 242.9708. C9H8
81BrNO2 requires 242.9713. Found: [
79BrM]+, 240.9726. 
C9H8




A mixture of amide 162e (950 mg, 3.80 mmol) and thionyl 
chloride (6 ml) was refluxed at 60 oC for 3 h. The reaction was 
concentrated under reduced pressure to afford nitrile 163e as a 
colourless solid (839 mg, 95%). 
Rf [hexane:EtOAc, 3:1] = 0.83; MP 91 
oC (EtOH), lit 93 oC191; υmax (CHCl3)/cm
-1 
2226 (CN), 1580 (C=C), 1560 (C=C); 1H NMR δ (250 MHz, CD3OD) 8.33-8.29 
(1H, m, ArH), 8.04-7.98 (2H, m, 2xArH), 7.80-7.72 (2H, m, 2xArH), 7.66 (1H, d, Ј 
8.5, ArH); 13C NMR δ (62.9 MHz, CD3OD) 136.3 (C), 132.1 (C), 130.2 (CH), 129.6 
(CH), 129.5 (CH), 129.2 (CH), 128.3 (CH), 128.2 (C), 127.9 (CH), 118.2 (C), 113.9 
(C); m/z (FAB, 3-NOBA)  234 ([81BrM+H]+, 27 %), 232 ([79BrM+H]+, 27), 154 (99), 
138 (48), 136 (100); HRMS (EI +ve) Found: [81BrM]+, 232.9656. C11H6N
81Br 
requires 232.9658. Found: [79BrM]+, 230.9680. C11H6N














A mixture of amide 162f (920 mg, 4.48 mmol) and thionyl chloride (3 
ml) was refluxed at 60 oC for 3 h. The reaction was concentrated 
under reduced pressure to afford nitrile 163f as a brown oil (840 mg, 
99%). 
Rf [hexane:EtOAc, 3:1] = 0.52; υmax (CHCl3)/cm
-1 3109, 2221 (CN), 1407; 1H NMR 
δ (250 MHz, CDCl3) 7.53 (1H, d, Ј 5.3, HetH), 7.07 (1H, d, Ј 5.3, HetH); 
13C NMR 
δ (62.9 MHz, CDCl3) 132.7 (CH), 130.7 (CH), 121.7 (C), 112.6 (C), 108.5 (C); m/z 
(FAB, 3-NOBA) 189 ([81BrM+H]+, 3 %), 187 ([79BrM+H]+, 1), 165 (12), 154 (100), 
149 (30), 138 (80), 137 (98), 136 (100), 125 (29); HRMS (FAB, 3-NOBA) Found: 
[81BrM+H]+, 188.9066. C5H2
81BrNS requires 188.9065. Found: [79BrM+H]+, 
186.9086. C5H2
79BrNS requires 186.9086. 
 
1H NMR data in good agreement with the literature.192  
 
2-Bromo-5-nitro-benzonitrile 163g193 
A mixture of amide 162g (1.30 g, 5.29 mmol) and thionyl 
chloride (30 ml) was refluxed at 60 oC for 3 h. The reaction 
was concentrated under reduced pressure to afford nitrile 163g 
as a colourless solid (1.20 g, 99%). 
Rf [CH2Cl2:MeOH, 95:5] = 0.91; MP 108 
oC, lit 117 oC (H2O)
193; υmax (CHCl3)/cm
-1 
2253 (CN); 1H NMR δ (250 MHz, (CD3)2SO) 8.85 (1H, d, Ј 2.7, ArH), 8.42 (1H, dd, 
Ј 8.9, 2.7, ArH), 8.20 (1H, d, Ј 8.9, ArH); 13C NMR δ (90.6 MHz, (CD3)2SO) 147.8 










General procedure G - Reduction of aryl nitrile analogues 
To a suspension of LiAlH4 (2 eq) in Et2O (10 ml) was added AlCl3 (2 eq) and the 
reaction stirred for 10 mins at r.t. The mixture was cooled to 0 oC and the appropriate 
nitrile (1 eq) was added portionwise. The reaction was stirred at r.t for 30 mins then 
heated at 40 oC for 18 h. The reaction was quenched by the addition of Na2SO4.5H2O 
portionwise, then it was filtered and the filtrate stirred vigorously with potassium 
sodium tartrate (100 ml, sat. aq.) for 1 h. The Et2O layer was separated and the 
aqueous phase extracted with Et2O (3 x 60 ml). The combined organic phases were 
dried (MgSO4) and concentrated under reduced pressure. The residue was taken up in 
CH2Cl2 (1 ml), and HCl in Et2O (20.0 ml, 1 M in Et2O) added. The precipitate was 
removed by filtration and dried to afford the desired amine hydrochloride. 
 
2-Bromo-4-methylbenzylamine hydrochloride 164a 
General procedure G was followed using LiAlH4 (186 mg, 
4.90 mmol), Et2O (5 ml), AlCl3 (654 mg, 4.90 mmol) and 
nitrile 163a (480 mg, 2.45 mmol), to afford amine 
hydrochloride 164a as a colourless solid (465 mg, 80%). 
MP 249 oC (Et2O); 
1H NMR δ (250 MHz, CD3OD) 7.53 (1H, s, ArH), 7.43 (1H, d, Ј 
8.0, ArH), 7.27 (1H, d, Ј 8.0, ArH), 4.23 (2H, s, CH2), 2.35 (3H, s, CH3); 
13C NMR δ 
(62.9 MHz, CD3OD) 142.8 (C), 134.4 (CH), 131.5 (CH), 130.5 (C), 129.9 (CH), 
124.7 (C), 43.6 (CH2), 20.5 (CH3); m/z (FAB, 3-NOBA) 202 ([
81BrM+H]+, 91 %), 
200 ([79BrM+H]+, 93), 185 (95), 183 (95),154 (51); HRMS (EI) Found: [81BrM]+, 
200.9969. C8H10
81BrN requires 200.9971. Found: [79BrM]+, 198.9985 C8H10
79BrN 
requires 198.9991. Free Amine: Rf [CH2Cl2:MeOH, 95:5] = 0.46; υmax (CHCl3)/cm
-1 
3371 (NH), 3304 (NH), 2922, 1605, 1488; 1H NMR δ (250 MHz, CDCl3) 7.33 (1H, 
s, ArH), 7.19 (1H, d, Ј 7.7, ArH), 7.05 (1H, d, Ј 7.7, ArH), 3.81 (2H, s, CH2), 2.27 
(3H, s, CH3); 
13C NMR δ (62.9 MHz, CDCl3) 138.4 (C), 137.6 (C), 132.4 (CH), 









2-Bromo-4-fluorobenzylamine hydrochloride 164b  
General procedure G was followed using LiAlH4 (95 mg, 
2.50 mmol), Et2O (5 ml), AlCl3 (334 mg, 2.50 mmol) and 
nitrile 163b (249 mg, 1.25 mmol) to afford amine 
hydrochloride 164b as a colourless solid (210 mg, 70%). 
MP 251 oC (Et2O); 
1H NMR δ (250 MHz, CD3OD) 7.63 (1H, dd, Ј 8.8, 6.0, ArH), 
7.58 (1H, dd, Ј 8.3, 2.8, ArH), 7.28 (1H, td, Ј 8.5, 2.8, ArH), 4.29 (2H, s, CH2); 
13C 
NMR δ (62.9 MHz, CD3OD) 163.5 (1C, d, Ј 252.4, C), 133.1 (1C, d, Ј 9.0, CH), 
129.6 (C), 125.3 (1C, d, Ј 10.3, C), 120.9 (1C, d, Ј 25.1, CH), 115.9 (1C, d, 21.6, 
CH), 42.8 (CH2); m/z (FAB, 3-NOBA) 206 ([
81BrM+H]+, 14 %), 204 ([79BrM+H]+, 
17), 189 (37), 187 (40), 149 (47); HRMS (ESI, +, CH2Cl2/MeOH/NH4OAc) Found: 
[M+H]+, 203.9820. C7H8NF
79Br requires 203.9819. Free Amine: Rf 
[CH2Cl2:MeOH, 95:5] = 0.46; υmax (CHCl3)/cm
-1 3285 (NH), 2926, 1597, 1484; 1H 
NMR δ (250 MHz, CDCl3) 7.33 (1H, dd, Ј 8.5, 6.0, ArH), 7.26 (1H, dd, Ј 8.3, 2.5, 
ArH), 6.98 (1H, td, Ј 8.3, 2.5, ArH), 3.85 (2H, s, CH2); 
13C NMR δ (62.9 MHz, 
CDCl3) 160.6 (1C, d, Ј 249.3, C), 137.4 (C), 129.1 (1C, d, Ј 7.9, CH), 122.6 (1C, d, Ј 







2-Bromo-5-methoxybenzylamine hydrochloride 164c 
General procedure G was followed using LiAlH4 (36.0 
mg, 0.94 mmol), Et2O (1.00 ml), AlCl3 (432 mg, 0.94 
mmol) and nitrile 163c (100 mg, 0.47 mmol), to afford 
amine hydrochloride 164c as a colourless solid (301 mg, 74%). 
MP 201 oC; 1H NMR δ (250 MHz, CD3OD) 7.62 (1H, d, Ј 8.9, ArH), 7.19 (1H, d, Ј 
3.0, ArH), 6.99 (1H, dd, Ј 8.9, 3.0, ArH), 4.27 (2H, s, CH2), 3.87 (3H, s, CH3); 
13C 
NMR δ (62.9 MHz, CD3OD) 160.6 (C), 146.3 (C), 134.7 (CH), 117.2 (CH), 117.1 
(CH), 114.5 (C), 55.7 (CH3), 43.7 (CH2); m/z (FAB, 3-NOBA) 218 ([
81BrM+H]+, 51 
%), 216 ([79BrM+H]+, 62), 201 (39), 199 (40), 154 (100), 149 (43), 137 (59); HRMS 
(EI) Found: [81BrM]+, 216.9915. C8H10ON
81Br requires 216.9920. Found: [79BrM]+, 
214.9935. C8H10ON
79Br requires 214.9940. Free Amine: Rf [CH2Cl2:MeOH, 95:5] 
= 0.36; υmax (CHCl3)/cm
-1 3370 (NH), 1593, 1573, 1470, 1242; 1H NMR δ (250 
MHz, CDCl3) 7.40 (1H, d, Ј 8.7, ArH), 6.93 (1H, d, Ј 3.0, ArH), 6.66 (1H, dd, Ј 8.7, 
3.0, ArH), 3.84 (2H, s, CH2), 3.78 (3H, s, CH3); 
13C NMR δ (62.9 MHz, CDCl3) 








2-Bromo-4,5-methoxybenzylamine hydrochloride 164d194 
General procedure G was followed using LiAlH4 (345 
mg, 4.50 mmol), Et2O (20 ml), AlCl3 (1.21 g, 9.00 
mmol) and nitrile 163d (1.10 g, 4.50 mmol), to afford 
amine hydrochloride 164d as a colourless solid (829 mg, 65%). 
MP 194 oC; 1H NMR δ (250 MHz, CD3OD) 7.25 (1H, s, ArH), 7.21 (1H, s, ArH), 
4.25 (2H, s, CH2), 3.90 (3H, s, CH3), 3.88 (3H, s, CH3); 
13C NMR δ (62.9 MHz, 
CD3OD) 151.8 (C), 150.2 (C), 125.2 (C), 116.8 (CH), 115.4 (C), 114.9 (CH), 56.5 
(2xCH3), 43.7 (CH2); m/z (FAB, 3-NOBA) 248 ([
81BrM+H]+, 11 %), 246 
([79BrM+H]+, 20), 231 (37), 229 (37), 154 (82), 149 (64), 136 (100); HRMS (EI) 
Found: [81BrM]+, 247.0016. C9H12O2N
81Br requires 247.0026. Found: [79BrM]+, 
245.0034. C9H12O2N
79Br requires 245.0046. Free Amine: Rf [CH2Cl2:MeOH, 95: 5] 
= 0.54; υmax (CHCl3)/cm
-1 3368 (NH), 2935, 2841, 1602, 1505; 1H NMR δ (250 
MHz, CDCl3) 7.20 (1H, s, ArH), 7.11 (1H, s, ArH), 4.08 (3H, s, CH3), 4.05 (3H, s, 
CH3), 4.03 (2H, s, CH2), 1.75 (2H, br s, NH2); 
13C NMR δ (62.9 MHz, CDCl3) 148.2 
(C), 148.0 (C), 133.9 (C), 115.3 (CH), 112.8 (C), 111.7 (CH), 55.8 (CH3), 55.7 
(CH3), 46.2 (CH2). 
 
















(1-Bromo-2-naphthalen-2-yl) methyl amine hydrochloride 164e 
General procedure G was followed using LiAlH4 (261 mg, 
6.89 mmol), Et2O (10 ml), AlCl3 (920 mg, 6.89 mmol) and 
nitrile 163e (800 mg, 3.45 mmol), to afford amine 
hydrochloride 164e as a colourless solid (504 mg, 55%). 
MP 270 oC (Et2O); 
1H NMR δ (250 MHz, CD3OD) 8.37 (1H, d, Ј 9.3, ArH), 8.01 
(1H, t, Ј 8.5, ArH), 7.98 (1H, d, Ј 9.5, ArH), 7.75-7.63 (3H, m, 3xArH), 4.54 (2H, s, 
CH2); 
13C NMR δ (62.9 MHz, CD3OD) 136.5 (C), 133.9 (C), 132.3 (C), 130.4 (CH), 
130.0 (CH), 129.9 (CH), 129.3 (CH), 128.8 (CH), 128.4 (CH), 126.4 (C) 45.7 (CH2); 
m/z (FAB, 3-NOBA) 238 ([81BrM+H]+, 77 %), 236 ([79BrM+H]+, 43), 221 (97), 219 
(97)167 (37), 165 (28), 154 (100); HRMS (EI +ve) Found: [81BrM]+, 236.9974. 
C11H10N
81Br requires 236.9971. Found: [79BrM]+, 235.0001. C11H10N
79Br requires 
234.9991. Free Amine: Rf [CH2Cl2:MeOH, 95:5] = 0.94; υmax (CHCl3)/cm
-1 3364 
(NH), 1596 (NH2); 
1H NMR δ (250 MHz, CDCl3) 8.15 (1H, d, Ј 8.5, ArH), 7.62 
(2H, t, Ј 7.5, 2xArH), 7.42-7.29 (3H, m, 3xArH), 3.96 (2H, s, CH2); 
13C NMR δ 
(62.9 MHz, CDCl3) 140.0 (C), 133.5 (C), 132.2 (C), 127.9 (CH), 127.8 (CH), 127.2 






(3-Bromo-2-thiophen-2-yl) methylamine hydrochloride 164f 
General procedure G was followed using LiAlH4 (263 mg, 
6.92 mmol), Et2O (7 ml), AlCl3 (924 mg, 6.92 mmol) and 
nitrile 163f (651 mg, 3.46 mmol) to afford amine 
hydrochloride 164f as a beige solid (700 mg, 89%). 
MP 187 oC; 1H NMR δ (250 MHz, CD3OD) 7.68 (1H, d, Ј 5.3, HetH), 7.14 (1H, d, Ј 
5.3, ArH), 4.36 (2H, s, CH2); 
13C NMR δ (62.9 MHz, CD3OD) 130.9 (CH), 130.4 
(C), 128.8 (CH), 113.7 (C), 37.2 (CH2); m/z (FAB, 3-NOBA) 194 ([
81BrM+H]+, 20 
%), 192 ([79BrM+H]+, 28), 177 (33), 175 (32), 154 (96), 138 (34), 137 (59), 136 (81); 
HRMS (EI) Found: [81BrM]+, 192.9376. C5H6
81BrNS requires 192.9378. Found: 
[79BrM]+, 190.9393. C5H6
79BrNS requires 190.9399. Free Amine: Rf 
[CH2Cl2:MeOH, 95:5] = 0.80; υmax (CHCl3)/cm
-1 3370 (NH), 1594, 1344; 1H NMR 
δ (250 MHz, CDCl3) 7.30 (1H, d, Ј 5.3, HetH), 7.06 (1H, d, Ј 5.3, HetH), 4.09 (2H, s, 
CH2), 1.86 (2H, br s, NH2); 
13C NMR δ (62.9 MHz, CDCl3) 140.7 (C), 129.5 (CH), 









2-(2’-Bromophenyl) ethylamine hydrochloride 164j195 
To a suspension of LiAlH4 (709 mg, 18.7 mmol) in THF 
(15 ml) at 0 oC was added a solution of amide 162j in THF 
(2 ml) dropwise. The reaction was stirred at r.t. for 30 mins 
then heated at 70 oC for 18 h. The reaction was quenched 
by the addition of Na2SO4.5H2O portionwise, then it was filtered and the filtrate 
stirred vigorously with potassium sodium tartrate (50 ml, sat. aq.) for 1 h. The Et2O 
layer was separated and the aqueous phase extracted with Et2O (3 x 20 ml). The 
combined organic phases were dried (MgSO4) and concentrated under reduced 
pressure. The residue was taken up in CH2Cl2 (1 ml), and HCl in Et2O (10.0 ml, 1 M 
in Et2O) added. The precipitate was filtered and dried to afford amine hydrochloride 
164j as a colourless solid (698 mg, 75%). 
MP 203 oC; 1H NMR δ (360 MHz, CD3OD) 7.66 (1H, dd, Ј 7.8, 0.6, ArH), 7.44-
7.38 (2H, m, 2xArH), 7.24-7.23 (1H, m, ArH), 3.22-3.16 (4H, m, 2xCH2); 
13C NMR 
δ (90.6 MHz, CD3OD) 135.4 (C), 132.4 (CH), 130.3 (CH), 128.5 (CH), 127.5 (CH), 
123.3 (C) 38.4 (CH2), 33.0 (CH2); m/z (FAB, 3-NOBA) 202 ([
81BrM+H]+, 85 %), 200 
([79BrM+H]+, 91), 185 (33), 183 (34), 165 (47),  154 (100), 137 (100); HRMS (ESI+) 
Found: [79BrM]+, 200.0070. C8H11N






General procedure H - Boc protection of aryl analogues 
To a suspension of the appropriate amine hydrochloride (1 eq) in CH2Cl2 (10 ml) 
was added Et3N (1.5 eq) and the reaction stirred for 10 mins. The reaction was 
cooled to 0 oC, Boc2O (1.1 eq) added and the reaction allowed to warm to r.t. and 
stirred for 4 h. The reaction was diluted with CH2Cl2 (15 ml) and washed with NaCl 
(3 x 15 ml, sat. aq.). The organics were combined, dried (MgSO4), concentrated 
under reduced pressure and purified by flash chromatography to afford the desired 
carbamate.  
 
2-Bromo-4-methylbenzyl-tert-butylcarboxamide 168a  
General procedure H was followed using amine 
hydrochloride 164a (170 mg, 0.72 mmol), CH2Cl2 (10 ml), 
Et3N (222 µl, 1.58 mmol) and Boc2O (173 mg, 0.79 mmol). 
Flash chromatography (hexane:EtOAc, 10:1) afforded 
carbamate 168a as a colourless oil (217 mg, 100%).  
Rf [3: 1 hexane: EtOAc] = 0.78; υmax (CHCl3)/cm
-1 3346 (NH), 2978, 2928, 1700 
(C=O), 1506, 1365, 1250, 1172; 1H NMR δ (360 MHz, 323 K, CDCl3) 7.36 (1H, s, 
ArH), 7.25 (1H, d, Ј 7.8, ArH), 7.07 (1H, dd, Ј 7.8, 0.9, ArH), 4.98 (1H, br s, CHN), 
4.34 (2H, d, Ј 6.2, CH2Ar), 2.30 (3H, s, CH3), 1.43 (9H, s, 3xCH3); 
13C NMR δ (90.6 
MHz, 323 K, CDCl3) 155.6 (C), 138.9 (C), 135.0 (C), 133.0 (CH), 129.4 (CH), 128.2 
(CH), 123.2 (C), 79.3 (C), 44.6 (CH2), 28.3 (3xCH3), 20.4 (CH3); m/z (EI) 302 
([81BrM+H]+, 2 %), 300 ([79BrM+H]+, 2), 244 (7), 242 (7); HRMS (EI) Found: 
[79BrM]+, 299.0516. C13H18 









2-Bromo-4-fluorobenzyl tertbutylcarboxamide 168b 
General procedure H was followed using amine 
hydrochloride 164b (167 mg, 0.69 mmol), CH2Cl2 (8 ml), 
Et3N (195 µl, 1.39 mmol) and Boc2O (167 mg, 0.76 mmol). 
Flash chromatography (hexane:EtOAc, 10:1) afforded 
carbamate 168b as a colourless oil (184 mg, 88%).  
Rf [hexane:EtOAc, 3:1] = 0.85; υmax (CHCl3)/cm
-1 3343 (NH), 1696 (C=O); 1H 
NMR δ (250 MHz, CDCl3) 7.35 (1H, dd, Ј 8.3, 6.0, ArH), 7.27 (1H, dd, Ј 8.3, 2.5, 
ArH), 6.99 (1H, dt, Ј 8.3, 2.5, ArH), 5.11 (1H, br s, CHN), 4.33 (2H, d, Ј 6.3, 
CH2Ar), 1.44 (9H, s, 3xCH3); 
13C NMR δ (62.9 MHz, CDCl3) 163.4 (C), 157.5 (1C, 
d, Ј 245.8, C), 133.8 (C), 130.5 (1C, d, Ј 7.8, CH), 123.2 (1C, d, Ј 9.6, C), 119.8 (1C, 
d, Ј 24.5, CH), 114.4 (1C, d, Ј 20.9, C), 79.6 (C), 44.0 (CH2), 28.2 (3xCH3); m/z (EI)  
306 ([81BrM+H]+, 1 %), 304 ([79BrM+H]+, 1), 248 (14), 246 (13), 189 (17), 187 (18) 






General procedure H was followed using amine 
hydrochloride 164c (218 mg, 0.86 mmol), CH2Cl2 (10 
ml), Et3N (182 µl, 1.30 mmol) and Boc2O (207 mg, 0.95 
mmol). Flash chromatography (hexane:EtOAc, 10:1) 
afforded carbamate 168c as a colourless oil (230 mg, 
85%).  
Rf [hexane:EtOAc, 3:1] = 0.77; υmax (CHCl3)/cm
-1 3350 (NH), 2977, 1698 (C=O), 
1506, 1471; 1H NMR δ (360 MHz, CDCl3) 7.40 (1H, d, Ј 8.7, ArH), 6.93 (1H, d, Ј 
3.1, ArH), 6.68 (1H, dd, Ј 8.7, 3.1, ArH), 5.00 (1H, br s, NH), 4.33 (2H, d, Ј 6.3, 
CH2Ar), 3.77 (3H, s, CH3),1.46 (9H, s, 3xCH3); 
13C NMR δ (90.6 MHz, CDCl3) 
159.2 (C), 155.6 (C), 139.0 (C), 133.1 (CH), 115.2 (CH), 114.6 (CH), 113.6 (C), 79.5 
(C), 55.4 (CH3), 45.0 (CH2), 28.3 (3xCH3); m/z (EI) 317 ([
81BrM]+, 1 %), 315 
([79BrM]+, 1), 261 (3), 259 (3), 201 (9), 199 (10), 180 (100); HRMS (EI) Found: 
[79BrM]+, 315.0461. C13H18
















(2-Bromo-4,5-dimethoxy-benzyl)-carbamic acid tert-butyl ester 168d 
General procedure H was followed using amine 
hydrochloride 164d (200 mg, 0.710 mmol), CH2Cl2 
(10 ml), Et3N (219 µl, 1.56 mmol) and Boc2O (155 
mg, 0.710 mmol). Flash chromatography 
(hexane:EtOAc, 10:1) afforded carbamate 168d as a 
colourless oil (267 mg, 100%).  
Rf [hexane:EtOAc, 3:1] = 0.63; υmax (CHCl3)/cm
-1 3377 (NH), 1701 (C=O); 1H 
NMR δ (360 MHz, CDCl3) 6.93 (1H, s, ArH), 6.85 (1H, s, ArH), 5.07 (1H, br s, 
CHN), 4.24 (2H, d, Ј 6.0, CH2Ar), 3.79 (6H, s, 2xCH3), 1.39 (9H, s, 3xCH3); 
13C 
NMR δ (90.6 MHz, CDCl3) 155.7 (C), 149.1 (C), 148.7 (C), 130.4 (CH), 115.9 
(CH), 113.4 (C), 113.2 (C), 79.5 (C), 56.2 (CH3), 56.1 (CH3),  44.7 (CH2), 28.3 
(3xCH3); m/z (EI) 347 ([
81BrM]+, 4 %), 345 ([79BrM]+, 4), 290 (27), 288 (27), 242 




(1-Bromo-naphthalen-2-ylmethyl) carbamic acid tert-butyl ester 168e 
General procedure H was followed using amine 
hydrochloride 164e (200 mg, 0.73 mmol), CH2Cl2 (10 ml), 
Et3N (155 µl, 1.10 mmol) and Boc2O (176 mg, 0.81 mmol). 
Flash chromatography (hexane:EtOAc, 10:1) afforded 
carbamate 168e as a colourless solid (222 mg, 90%).  
Rf [hexane:EtOAc, 3:1] = 0.64; MP 96 
oC; υmax (CHCl3)/cm
-
1 3346 (NH), 1699 (C=O), 1503, 1172; 1H NMR δ (250 MHz, CDCl3) 8.21 (1H, d, Ј 
8.5, ArH), 7.72 (1H, d, Ј 7.3, ArH), 7.69 (1H, d, Ј 8.3, ArH), 7.53-7.39 (3H, m, 
3xArH), 5.09 (1H, br s, NH), 4.54 (2H, d, Ј 6.3, CH2), 1.37 (9H, s, 3xCH3);
13C 
NMR δ (62.9 MHz, CDCl3) 155.7 (C), 136.0 (C), 133.7 (C), 132.2 (C), 128.0 (CH), 
127.8 (CH), 127.4 (CH), 127.0 (CH), 126.8 (CH), 126.3 (CH), 123.4 (C), 79.6 (C), 
45.7 (CH2), 28.3 (3xCH3); m/z (EI) 337 ([
81BrM+H]+, 1 %),  335 ([79BrM+H]+,1), 200 
(100); HRMS (EI) Found: [79BrM]+, 335.0506. C16H18
















(3-Bromo-thiophen-2-ylmethyl)-carbamic acid tert-butyl ester 168f 
General procedure H was followed using amine hydrochloride 
164f (183 mg, 0.80 mmol), CH2Cl2 (10 ml), Et3N (169 µl, 1.20 
mmol) and Boc2O (192 mg, 0.88 mmol). Flash chromatography 
(hexane:EtOAc, 20:1–10:1) afforded carbamate 168f as a 
colourless solid (164 mg, 70%).  
Rf [hexane:EtOAc, 3:1] = 0.85; υmax (CHCl3)/cm
-1 3341 (NH), 2978, 1699 (C=O), 
1505, 1167; 1H NMR δ (250 MHz, CDCl3) 7.18 (1H, d, Ј 5.4, HetH), 6.89 (1H, d, Ј 
5.4, HetH), 5.12 (1H, br s, NH), 4.41 (2H, d, Ј 6.0, CH2), 1.44 (9H, s, 3xCH3); 
13C 
NMR δ (62.9 MHz, CDCl3) 155.3 (C), 136.3 (C), 129.7 (CH), 124.7 (CH), 109.0 
(C), 79.7 (C), 38.5 (CH2), 28.2 (3xCH3); m/z (EI) 293 ([
81BrM]+, 1 %), 291 ([79BrM]+, 
1), 236 (26), 234 (24), 177 (28), 175 (27), 156 (100); HRMS (EI) Found: [79BrM]+, 
290.9917. C10H14










General procedure J - Dialkylation  
To a suspension of the appropriate amine hydrochloride (1 eq) in MeCN (5 ml) at 0 
oC was added iPr2NEt (4 eq) and the reaction was stirred for 5 mins. 3-
Bromocyclohexene (1 eq) was added and the reaction stirred for 16 h at r.t. The 
reaction was concentrated under reduced pressure and the residue taken up in CH2Cl2 
(5 ml) and washed with NaCl (3 x 5 ml, sat. aq.). The organics were combined, dried 
(MgSO4) and concentrated under reduced pressure. The crude residue was taken up 
in CH2Cl2 (10 ml), Et3N (1 eq) was added, and the reaction was stirred for 10 mins. 
The reaction was cooled to 0 oC, Boc2O (1.5 eq) was added and the reaction was 
stirred for a further 10 mins and then allowed to warm to r.t. and stirred for 16 h. The 
reaction was diluted with CH2Cl2 (20 ml), extracted with NaCl (3 x 20 ml, sat. aq.), 
dried (MgSO4) and concentrated under reduced pressure. Flash chromatography 
afforded the desired Boc amide. 
 
General procedure K – Monoalkylation 
 To a solution of Boc carbamate (87 mg, 0.23 mmol) in DMF (1.5 ml) at 0 oC was 
added NaH (2 eq, 60% dispersion in mineral oil) and the reaction warmed to r.t. for 
40 mins. The reaction was then cooled to 0 oC and 3-bromocyclohexene (2 eq) was 
added dropwise. The reaction allowed to warm to r.t. and stirred for 16 h. Et2O (10 
ml) was added and the organics washed with NaCl (3 x 15 ml, sat. aq.). The organics 
were dried (MgSO4), concentrated under reduced pressure and purified by flash 




2-Bromo-4-methylbenzyl cyclohex-2-enyl-carbamic acid tert-butyl ester 165a 
General procedure J was followed using amine 
hydrochloride 164a (150 mg, 0.63 mmol), MeCN (3 ml), 
iPr2NEt (442 µl, 2.54 mmol), 3-Bromocyclohexene (73 
µl, 0.63 mmol), CH2Cl2 (10 ml), Et3N (134 µl, 0.95 
mmol) and Boc2O (208 mg, 0.95 mmol). Flash 
chromatography (hexane:EtOAc, 100:1) afforded Boc 
amide 165a as a colourless oil (140 mg, 59%). 
General procedure K was followed using Boc carbamate 168a (198 mg, 0.659 
mmol), DMF (5 ml), NaH (53 mg, 60% dispersion in mineral oil, 1.32 mmol) and 3-
bromocyclohexene (153 µl, 1.32 mmol). Flash chromatography (hexane-
hexane:EtOAc, 100:1) afforded cyclohexenyl amine 165a as a colourless oil (175 
mg, 70%). 
Rf [hexane:EtOAc, 3:1] = 0.76; υmax (CHCl3)/cm
-1 2978, 2927, 1640 (C=O), 1362, 
1190; 1H NMR δ (360 MHz, 323 K, CDCl3) 7.33 (1H, s, ArH), 7.14 (1H, d, Ј 7.9, 
ArH), 7.07 (1H, d, Ј 7.9, ArH), 5.82-5.80 (1H, m, CH=CH), 5.47 (1H, d, Ј 10.2, 
CH=CH), 4.84 (1H, br s, CHN), 4.39-4.34 (2H, m, CH2Ar), 2.30 (3H, s, CH3), 2.04-
1.84 (3H, m, CH2+CHAHB), 1.80-1.68 (1H, m, CHAHB), 1.65-1.25 (11H, m, 
CH2+3xCH3); 
13C NMR δ (90.6 MHz, 323 K, CDCl3) 155.7 (C), 137.6 (C), 135.9 
(C), 132.6 (CH), 131.1 (CH), 128.2 (CH), 127.8 (CH), 127.3 (CH), 121.8 (C), 79.5 
(C), 53.0 (CH), 47.3 (CH2), 28.2 (3xCH3), 28.1 (CH2), 24.4 (CH2), 21.3 (CH2), 20.3 
(CH3); m/z (FAB, 3-NOBA) 382 ([
81BrM+H]+, 12 %), 380 ([79BrM+H]+, 15), 326 
(100), 324 (100), 185 (96), 183 (97); HRMS (EI) Found: [79BrM]+, 379.1142. 
C19H26










2-Bromo-4-fluorobenzyl cyclohex-2-enyl-carbamic acid tert-butyl ester 165b 
General procedure J was followed using amine 
hydrochloride 164b (150 mg, 0.62 mmol), MeCN (3 ml), 
iPr2NEt (435 µl, 2.50 mmol), 3-Bromocyclohexene (72 µl, 
0.62 mmol), CH2Cl2 (10 ml), Et3N (132 µl, 0.94 mmol) 
and Boc2O (205 mg, 0.94 mmol). Flash chromatography 
(hexane:EtOAc, 100:1) afforded Boc amide 165b as a 
colourless oil (161 mg, 67%). 
General procedure K was followed using Boc carbamate 168b (175 mg, 0.56 mmol), 
DMF (4 ml), NaH (46 mg, 60% dispersion in mineral oil, 1.15 mmol) and 3-
bromocyclohexene (133 µl, 1.15 mmol). Flash chromatography (hexane:EtOAc, 
100:1) afforded cyclohexenyl amine 165b as a colourless oil (157 mg, 71%). 
Rf [hexane:EtOAc, 3:1] = 0.75; υmax (CHCl3)/cm
-1 2975, 2932, 1694 (C=O), 1485, 
1169; 1H NMR δ (360 MHz, 323 K, CDCl3) 7.29-7.22 (2H, m, 2xArH), 7.01 (1H, dt, 
Ј 8.4, 2.6, ArH), 5.86-5.84 (1H, m, CH=CH), 5.46 (1H, d, Ј 10.2, CH=CH), 4.83 
(1H, br s, CHN), 4.30-4.26 (2H, m, CH2Ar), 2.06-1.85 (3H, m, CH2+CHAHB), 1.79-
1.73 (1H, m, CHAHB), 1.70-1.55 (1H, m, CHCHD), 1.55-1.20 (10H, m, 
CHCHD+3xCH3); 
13C NMR δ (90.6 MHz, 323 K, CDCl3) 161.0 (1C, d, Ј 249.0, C), 
155.7 (C), 135.0 (C), 131.4 (CH), 128.5 (CH), 128.0 (CH), 121.7 (1C, d, Ј 9.5, C), 
119.4 (1C, d, Ј 24.5, CH), 114.1 (1C, d, Ј 20.9, CH), 79.9 (C), 53.1 (CH), 47.0 
(CH2), 28.2 (3xCH3), 28.1 (CH2), 24.5 (CH2), 21.3 (CH2); m/z (FAB, 3-NOBA)  386 
([81BrM+H]+, 86 %), 384 ([79BrM+H]+, 95), 330 (98), 328 (98), 301 (47), 299 (49), 
284 (96), 282 (97), 250 (96), 248 (97), 246 (94), 204 (77), 202 (87); HRMS (FAB, 
3-NOBA) Found: [79BrM]+, 384.0969. C18H24










(2-Bromo-5-methoxybenzyl)-(cyclohex-2-enyl)-carbamic acid tert-butyl ester 
165c 
General procedure J was followed using amine 
hydrochloride 164c (200 mg, 0.79 mmol), MeCN (5 
ml), iPr2NEt (552 µl, 3.17 mmol), 3-
Bromocyclohexene (92 µl, 0.79 mmol), CH2Cl2 (10 
ml), Et3N (167 µl, 1.19 mmol) and Boc2O (260 mg, 
1.19 mmol). Flash chromatography (hexane:EtOAc, 100:1–20:1) afforded Boc amide 
165c as a colourless oil (181 mg, 58%). 
General procedure K was followed using Boc carbamate 168c (222 mg, 0.703 
mmol), DMF (5 ml), NaH (56 mg, 60% dispersion in mineral oil, 1.41 mmol) and 3-
bromocyclohexene (163 µl, 1.41 mmol). Flash chromatography (hexane:EtOAc, 
100:1) afforded cyclohexenyl amine 165c as a colourless oil (201 mg, 72%). 
Rf [hexane:EtOAc, 3:1] = 0.74; υmax (CHCl3)/cm
-1 2975, 2929, 1694 (C=O), 1168; 
1H NMR δ (360 MHz, 323 K, CDCl3) 7.45 (1H, d, Ј 8.8, ArH), 6.85 (1H, d, Ј 3.1, 
ArH), 6.66 (1H, dd, Ј 8.8, 3.1, ArH), 5.89-5.80 (1H, m, CH=CH), 5.49 (1H, d, Ј 
10.1, CH=CH), 4.88 (1H, br s, CHN), 4.37 (1H, d, Ј 17.4, CHXHYAr), 4.30 (1H, d, Ј 
17.4, CHXHYAr), 3.77 (3H, s, OCH3), 2.08-1.87 (3H, m, CH2+CHAHB), 1.80-1.71 
(1H, m, CHAHB), 1.70-1.29 (11H, m, CH2+3xCH3); 
13C NMR δ (90.6 MHz, 323 K, 
CDCl3) 159.1 (C), 155.7 (C), 132.8 (CH), 131.4 (C), 128.2 (2xCH), 113.8 (CH), 
113.4 (CH), 112.5 (C), 79.8 (C), 55.3 (CH3), 53.4 (CH), 47.7 (CH2), 28.3 (CH2), 28.2 
(3xCH3), 24.5 (CH2), 21.3 (CH2); m/z (EI) 398 ([
81BrM+H]+, 7 %), 396 ([79BrM+H]+, 
9), 342 (100), 340 (100), 260 (100), 201 (41), 199 (42); HRMS (EI) Found: [79BrM]+, 
395.1090. C19H26









2-Bromo-4,5-dimethoxybenzyl-(cyclohex-2-enyl)-carbamic acid tert-butyl ester 
165d 
General procedure J was followed using amine 
hydrochloride 164d (200 mg, 0.710 mmol), MeCN (5 
ml), iPr2NEt (493 µl, 2.83 mmol), 3-
Bromocyclohexene (82 µl, 0.710 mmol), CH2Cl2 (10 
ml), Et3N (149 µl, 0.71 mmol) and Boc2O (927 mg, 
4.25 mmol). Flash chromatography 
(hexane:EtOAc:Et3N, 100:5:0.5) afforded the Boc amide 165d as a colourless oil 
(170 mg, 56%). 
General procedure K was followed using Boc carbamate 168d (87 mg, 0.23 mmol), 
DMF (1.5 ml), NaH (18 mg, 60% dispersion in mineral oil, 0.46 mmol) and 3-
bromocyclohexene (53 µl, 0.46 mmol). Flash chromatography (hexane:EtOAc:Et3N, 
100:5:0.5) afforded cyclohexenyl amine 165d as a colourless oil (81 mg, 84%). 
Rf [hexane:EtOAc, 3:1] = 0.49; υmax (CHCl3)/cm
-1 1640 (C=O), 1362, 1190, 1177; 
1H NMR δ (360 MHz, 323 K, CDCl3) 6.97 (1H, s, ArH), 6.82 (1H, s, ArH), 5.85-
5.77 (1H, m, CH=CH), 5.44 (1H, d, Ј 10.0, CH=CH), 4.80 (1H, br s, CHN), 4.35 
(1H, d, Ј 16.5, CHXHYAr), 4.26 (1H, d, Ј 16.5, CHXHYAr), 3.83 (3H, s, CH3), 3.81 
(3H, s, CH3), 2.05-1.92 (2H, m, CH2), 1.91-1.80 (1H, m, CHAHB), 1.74-1.65 (1H, m, 
CHAHB), 1.65-1.30 (11H, m, CH2+3xCH3); 
13C NMR δ (90.6 MHz, 323 K, CDCl3) 
155.7 (C), 148.6 (C), 148.3 (C), 131.3 (C), 131.1 (CH), 128.2 (CH), 115.6 (CH), 
111.8 (C), 111.2 (CH), 79.6 (C), 56.1 (CH3), 55.9 (CH3), 53.1 (CH), 47.1 (CH2), 28.2 
(3xCH3), 28.1 (CH2), 24.4 (CH2), 21.3 (CH2); m/z (FAB, 3-NOBA) 428 ([
81BrM+H]+, 
6 %), 426 ([79BrM+H]+, 9), 372 (34), 370 (40), 346 (16), 326 (10), 290 (100), 231 













1-Bromo-naphthalen-2-ylmethyl-(cyclohex-2-enyl)-carbamic acid tert-butyl 
ester 165e 
General procedure J was followed using amine 
hydrochloride 164e (150 mg, 0.55 mmol), MeCN (3 ml), 
iPr2NEt (383 µl, 2.20 mmol), 3-Bromocyclohexene (64 µl, 
0.55 mmol), CH2Cl2 (10 ml), Et3N (116 µl, 0.83 mmol) 
and Boc2O (180 mg, 0.83 mmol). Flash chromatography 
(hexane:EtOAc, 100:1) afforded the Boc amide 165e as a 
colourless oil (140 mg, 61%). 
General procedure K was followed using Boc carbamate 168e (165 mg, 0.49 mmol), 
DMF (5 ml), NaH (40 mg, 60% dispersion in mineral oil, 0.982 mmol) and 3-
bromocyclohexene (114 µl, 0.98 mmol). Flash chromatography (hexane:EtOAc, 
100:1) afforded cyclohexenyl amine 165e as a colourless oil (175 mg, 86%). 
Rf [hexane:EtOAc, 3:1] = 0.80; υmax (CHCl3)/cm
-1 1652 (C=O); 1H NMR δ (360 
MHz, 323 K, CDCl3) 8.33 (1H, d, Ј 8.7, ArH), 7.82 (1H, d, Ј 7.4, ArH), 7.80 (1H, d, 
Ј 8.4, ArH), 7.58 (1H, t, Ј 6.9, ArH), 7.48 (1H, ddd, Ј 8.3, 7.2, 1.1, ArH), 7.43 (1H, 
d, Ј 8.6, ArH),  5.83 (1H, br s, CH=CH), 5.52 (1H, d, Ј 10.0, CH=CH), 4.95 (1H, br 
s, CHN), 4.66 (2H, br s, CH2Ar), 2.10-1.88 (3H, m, CH2+CHAHB), 1.80-1.71 (1H, m, 
CHAHB), 1.70-1.30 (11H, m, CH2+3xCH3);
13C NMR δ (90.6 MHz, 323 K, CDCl3) 
155.9 (C), 137.3 (C), 133.6 (C), 132.2 (C), 131.3 (CH), 128.2 (CH), 127.9 (CH), 
127.2 (2xCH), 126.7 (CH), 125.9 (CH), 125.0 (CH), 121.5 (C), 79.8 (C) 53.0 (CH), 
48.6 (CH2), 28.2 (3xCH3), 28.1 (CH2), 24.5 (CH2), 21.3 (CH2); m/z (FAB, 3-NOBA)  
418 ([81BrM+H]+, 2 %), 416 ([79BrM+H]+, 3), 362 (80), 360 (85), 221 (100), 219 
(100), 200 (33), 141 (41), 139 (36); HRMS (EI) Found: [79BrM]+, 415.1140. 
C22H26N









(3-Bromo-thiophen-2-ylmethyl)-(cyclohex-2-enyl)-carbamic acid tert-butyl ester 
165f 
General procedure J was followed using amine 
hydrochloride 164f (150 mg, 0.66 mmol), MeCN (3 ml), 
iPr2NEt (457 µl, 2.62 mmol), 3-Bromocyclohexene (76 µl, 
0.66 mmol), CH2Cl2 (10 ml), Et3N (138 µl, 0.98 mmol) and 
Boc2O (215 mg, 0.98 mmol). Flash chromatography 
(hexane:EtOAc, 100:1 – 100:2) afforded Boc amide 165f as a colourless oil (160 mg, 
65%). 
General procedure K was followed using Boc carbamate 168f (155 mg, 0.53 mmol), 
DMF (5 ml), NaH (42 mg, 60% dispersion in mineral oil, 1.06 mmol) and 3-
bromocyclohexene (123 µl, 1.06 mmol). Flash chromatography (hexane:EtOAc, 
100:1) afforded cyclohexenyl amine 165f as a yellow oil (180 mg, 91%). 
Rf [hexane:EtOAc, 3:1] = 0.85; υmax (CHCl3)/cm
-1 1696 (C=O); 1H NMR δ (360 
MHz, 323 K, CDCl3) 7.17 (1H, d, Ј 5.3, HetH), 6.87 (1H, d, Ј 5.3, HetH), 5.91-5.84 
(1H, m, CH=CH), 5.49 (1H, dt, Ј 10.2, 1.2, CH=CH), 4.74 (1H, s, CHN), 4.51-4.41 
(2H, m, CH2Ar), 2.16-1.99 (2H, m, CH2), 1.91-1.81 (1H, m, CHAHB), 1.80-1.68 (1H, 
m, CHAHB), 1.68-1.50 (2H, m, CH2), 1.46 (9H, s, 3xCH3); 
13C NMR δ (90.6 MHz, 
323 K, CDCl3) 155.3 (C), 139.4 (C), 131.4 (CH), 129.2 (CH), 128.3 (CH), 124.2 
(CH), 107.7 (C), 80.2 (C), 53.3 (CH), 42.6 (CH2), 28.3 (3xCH3), 27.4 (CH2), 24.6 
(CH2), 21.5 (CH2); m/z (FAB, 3-NOBA) 374 ([
81BrM+H]+, 18 %), 372 ([79BrM+H]+, 
22), 318 (99), 316 (99), 236 (51), 234 (43), 177 (98), 175 (49), 154 (58), 140 (31), 












(6-Bromo-benzo[1,3]dioxol-5-yl)-acetic acid 169k196 
To a solution of 1,3-benzodioxole-5-acetic acid (700 mg, 3.89 
mmol) and NaOH (1.0 ml, 5 M aq.) in H2O (7 ml) was added 
DBDMH (600 mg, 2.10 mmol) and the reaction stirred at r.t. 
under an air atmosphere for 48 h. The reaction was diluted 
with H2O (50 ml), acidified to pH 1 with HCl (6 M, aq.) and 
extracted into Et2O (3 x 30 ml). The organics were dried (MgSO4) and concentrated 
under reduced pressure to afford acid 169k as a colourless crystalline powder (909 
mg, 91% yield).  
Rf [CH2Cl2:MeOH, 95:5] = 0.23; MP 191 °C (EtOH), lit. 190 
oC196; υmax 
(NUJOL)/cm-1 1699 (C=O); 1H NMR δ (250 MHz, DMSO) 7.21 (1H, s, ArH), 7.02 
(1H, s, ArH), 6.07 (2H, s, OCH2O), 3.63 (2H, s, ArCH2);
 13C NMR δ (62.9 MHz, 
DMSO), 171.4 (C), 147.0 (C), 146.8 (C), 127.9 (C), 114.7 (C), 111.9 (CH), 111.4 
(CH), 101.7 (CH2), 40.6 (CH2); m/z (EI) 260 ([
81BrM]+, 49 %), 258 ([81BrM]+, 48), 
215 (97), 213 (100), 179 (92), 135 (38), 113 (27); HRMS (EI) Found: [79BrM]+, 
257.9521. C9H7O4











6-Bromo-benzo[1,3]dioxol-5-ylmethyl)-carbamic acid tert-butyl ester 168k 
To a suspension of acid 169k (1.72 g, 6.64 mmol) and 
Et3N (1.31 ml, 9.40 mmol) in CH2Cl2 (50 ml) at 0 °C was 
added diphenylphosphoryl azide (2.00 ml, 9.30 mmol) and 
the reaction stirred at 0 °C for 30 mins. The reaction was 
warmed to r.t. and stirred for 30 mins before being filtered 
through a silica gel plug. The crude organics were 
concentrated under reduced pressure and refluxed in toluene (50 ml) at 80 °C for 1 h. 
The reaction was concentrated under reduced pressure and then refluxed at 80 °C in 
tBuOH (50 ml) for 19 h. The reaction was concentrated under reduced pressure and 
purified by flash chromatography (hexane:EtOAc, 100:2–100:8) to afford carbamate 
168k as a colourless oil (1.09 g, 50%). 
Rf [hexane:EtOAc, 10:1] = 0.21; υmax (CHCl3)/cm
-1 3346 (NH), 1694 (C=O), 1470; 
1H NMR δ (250 MHz, CDCl3) 6.99 (1H, s, ArH), 6.95 (1H, s, ArH), 5.97 (2H, s, 
OCH2O), 4.99 (1H, br s, NH), 4.28 (2H, d, Ј 6.2, CH2Ar), 1.46 (9H, s, 3xCH3);
 13C 
NMR δ (90.6 MHz, CDCl3), 155.6 (C), 147.4 (C), 147.3 (C), 131.1 (C), 113.6 (C), 
112.5 (CH), 109.5 (CH), 101.6 (CH2), 79.4 (C), 44.5 (CH2), 28.2 (3xCH3); m/z (EI) 
331 ([81BrM]+, 1 %), 329 ([79BrM]+, 1), 274 (1), 272 (1), 194 (7), 49 (100). HRMS 
(EI) Found: [79BrM]+, 329.0258. C13H16O4N













butyl ester 165k 
General procedure K was followed using Boc carbamate 
168k (140 mg, 0.42 mmol), DMF (4 ml), NaH (34 mg, 
60% dispersion in mineral oil, 0.84 mmol) and 3-
bromocyclohexene (100 µl, 0.84 mmol). Flash 
chromatography (hexane:EtOAc, 100:1–100:3) afforded 
cyclohexene 165k as a colourless oil (130 mg, 75%). 
Rf [hexane:EtOAc, 3:1] = 0.69; υmax (CHCl3)/cm
-1 1693 (C=O), 1479; 1H NMR δ 
(360 MHz, 323 K, CDCl3) 6.95 (1H, s, ArH), 6.78 (1H, s, ArH), 5.93 (2H, s, 
OCH2O), 5.83-5.81 (1H, m, CH=CH), 5.45 (1H, br d, Ј 10.2, CH=CH), 4.76 (1H, br 
s, CHN), 4.34-4.15 (2H, m, CH2Ar), 2.01-1.97 (2H, m, CH2), 1.90-1.88 (1H, m, 
CHAHB), 1.75-1.73 (1H, m, CHAHB), 1.63-1.59 (2H, m, CH2), 1.44-1.41 (9H, s, 
3xCH3); 
13C NMR δ (90.6 MHz, 323 K, CDCl3), 155.7 (C), 147.4 (C), 146.8 (C), 
132.6 (C), 131.0 (CH), 128.2 (CH), 112.3 (CH), 112.0 (C), 107.7 (CH), 101.4 (CH2), 
79.8 (C), 53.2 (CH), 47.5 (CH2), 28.3 (3xCH3), 28.0 (CH2), 24.5 (CH2), 21.3 (CH2); 
m/z (EI) 411 ([81BrM]+, 1 %), 409 ([79BrM]+, 1), 274 (92), 215 (65), 213 (69), 194 
(100); HRMS (EI) Found: [79BrM]+, 409.0889. C19H24O4N










2-(2’-Bromophenyl) ethyl-tert-butyl ester 184j 
General procedure H was followed using amine hydrochloride 
164j (100 mg, 0.42 mmol), CH2Cl2 (5 ml), Et3N (89 µl, 0.64 
mmol) and Boc2O (102 mg, 0.47 mmol). Flash chromatography 
(hexane:EtOAc, 25:1–5:1)  afforded carbamate 184j as a 
colourless oil (71 mg, 56%).  
Curtius: To a suspension of 3-(2-bromo-phenyl)-propionic 
acid (200 mg, 0.87 mmol) and Et3N (172 µl, 1.22 mmol) in CH2Cl2 (10 ml) at 0 °C 
was added diphenylphosphoryl azide (263 µl, 1.22 mmol) and the reaction was 
stirred at 0 °C for 30 mins. The reaction was warmed to r.t. and stirred for 30 mins 
before being filtered through a silica gel plug. The crude organics were concentrated 
under reduced pressure and heated in toluene (10 ml) at 80 °C for 1 h. The reaction 
was concentrated under reduced pressure and then heated at 80 °C in tBuOH (10 ml) 
for 19 h. The reaction was concentrated under reduced pressure and purified by flash 
chromatography (hexane:EtOAc, 25:1–5:1) to afford carbamate 184j as a colourless 
oil (201 mg, 77%). 
Rf [3: 1 hexane: EtOAc] = 0.65; υmax (CHCl3)/cm
-1 3300 (NH), 2977, 1700 (C=O), 
1507, 1472, 1364; 1H NMR δ (360 MHz, CDCl3) 7.55 (1H, d, Ј 7.7, ArH), 7.27-7.22 
(2H, m, 2xArH), 7.10-7.06 (1H, m, ArH), 4.55 (1H, br s, NH), 3.41 (2H, q, Ј 6.7, 
CH2NH), 2.96 (2H, t, Ј 7.1, CH2Ar), 1.45 (9H, s, 3xCH3); 
13C NMR δ (90.6 MHz, 
CDCl3) 155.7 (C), 138.4 (C), 132.9 (CH), 130.9 (CH), 128.0 (CH), 127.4 (CH), 
124.6 (C), 79.2 (C), 40.4 (CH2), 36.4 (CH2), 28.3 (3xCH3); m/z (EI) 301 ([
81BrM]+, 2 
%), 299 ([79BrM]+, 2), 286 (2), 284 (2), 245 (14), 243 (14), 172 (19), 170 (19), 164 
(100); HRMS (EI) Found: [79BrM]+, 299.0512. C13H18








[2-(2’-Bromophenyl) ethyl]–cyclohex-2-enyl-carbamic acid tert-butyl ester 185j  
General procedure K was followed using Boc carbamate 
184j (67 mg, 0.223 mmol), DMF (2 ml), NaH (18 mg, 
60% dispersion in mineral oil, 0.446 mmol) and 3-
bromocyclohexene (52 µl, 0.446 mmol). Flash 
chromatography (hexane:EtOAc, 100:1–10:1) afforded 
cyclohexene 185j as a colourless oil (38 mg, 45%). 
Rf [hexane:EtOAc, 3:1] = 0.79; υmax (CHCl3)/cm
-1 2931, 1689 (C=O); 1H NMR δ 
(360 MHz, CDCl3) 7.53 (1H, d, Ј 7.9, ArH), 7.27-7.21 (2H, m, 2xArH), 7.09-7.04 
(1H, m, ArH), 5.84-5.82 (1H, m, CH=CH), 5.43 (1H, d, Ј 9.7, CH=CH), 4.66 (1H, br 
s, CHN), 3.30 (2H, dd, Ј 8.1, 6.2, CH2), 3.04 (2H, m, CH2), 2.10-1.93 (2H, m, CH2), 
1.85-1.78 (2H, m, CH2), 1.63-1.58 (2H, m, CH2), 1.52 (9H, s, 3xCH3); 
13C NMR δ 
(90.6 MHz, CDCl3) 155.7 (C), 139.4 (C), 132.8 (CH), 131.0 (CH), 130.9 (CH), 129.0 
(CH), 127.8 (CH), 127.4 (CH), 124.5 (C), 79.4 (C), 53.3 (CH), 44.1 (CH2), 37.0 
(CH2), 28.5 (3xCH3), 28.1 (CH2), 24.6 (CH2), 21.6 (CH2); m/z (EI) 381 ([
81BrM]+, 2 
%), 379 ([79BrM]+, 2), 325 (9), 323 (9), 271 (6), 273 (6), 184 (22), 182 (22); HRMS 
(EI) Found: [79BrM]+, 379.1137. C19H26







3-Bromoindole-2-methylamine hydrochloride 164h 
 To a suspension of LiAlH4 (587 mg, 15.5 mmol) in THF 
(20 ml) at 0 oC was added dropwise a solution of amide 
162h (920 mg, 3.87 mmol) in THF (2 ml). The reaction 
was allowed to warm to r.t. and then heated at 70 oC for 
18 h. The reaction was quenched by the addition of 
Na2SO4.5H2O portionwise, then it was filtered and the filtrate stirred vigorously with 
potassium sodium tartrate (100 ml, sat. aq.) for 1 h. The THF layer was separated and 
the aqueous phase extracted with Et2O (3 x 60 ml). The combined organic phases 
were dried (MgSO4) and concentrated under reduced pressure. The residue was taken 
up in CH2Cl2 (1 ml), and HCl in Et2O (20.0 ml, 1 M in Et2O) added. The brown 
precipitate was filtered and dried to afford a mixture of two products: amine 
hydrochloride 164h (528 mg, 52 %) and debrominated amine hydrochloride 191 
(118 mg, 17%). The full reduction protocol above was also repeated and crude 
reaction mixture purified by flash chromatography (CH2Cl2:MeOH, 9:1) rather than 
HCl salt formation. This led to the recovery of a minor amount of the free amine of 
debrominated amine 191.  
Rf [CH2Cl2:MeOH, 9:1] = 0.27; 
1H NMR δ (360 MHz, CD3OD) 7.51 (1H, dt, Ј 7.9, 
1.1, ArH), 7.47 (1H, dt, Ј 8.3, 1.1 ArH), 7.29 (1H, ddd, Ј 8.3, 7.2, 1.4, ArH), 7.19 
(1H, ddd, Ј 7.9, 7.2, 1.1, ArH), 4.38 (2H, s, CH2); 
13C NMR δ (90.6 MHz, (CD3OD) 
135.5 (C), 126.4 (C), 126.2 (C), 123.2 (CH), 119.9 (CH), 118.1 (CH), 111.1 (CH), 
91.9 (C), 33.9 (CH2); m/z (EI) 226 ([
81BrM(164h)]+, 62 %),  224 ([79BrM(164h)]+, 64), 












Data for Indole-2-methylamine hydrochloride 191.122 
 Rf [CH2Cl2:MeOH, 9:1] = 0.14; 
1H NMR δ (360 MHz, 
CD3OD) 7.56 (1H, dt, Ј 7.9, 1.1, ArH), 7.41 (1H, dd, Ј 
7.6, 0.7, ArH), 7.17 (1H, ddd, Ј 8.3, 7.2, 1.1, ArH), 7.06 
(1H, ddd, Ј 7.9, 7.2, 1.1, ArH), 6.60 (1H, s, =CH), 4.32 (2H, s, CH2); 
13C NMR δ 
(90.6 MHz, (CD3OD) 121.6 (CH), 119.6 (CH), 118.9 (CH), 110.4 (CH), 101.6 (CH), 
35.7 (CH2). Free amine: 
1H NMR δ (250 MHz, (CD3)2SO) 10.93 (1H, br s, NH), 
7.44 (1H, dd, Ј 7.1, 1.0, ArH), 7.32 (1H, dd, Ј 8.0, 1.0, ArH), 7.03 (1H, td, Ј 7.8, 1.3, 
ArH), 6.94 (1H, td, Ј 7.1, 1.3, ArH), 6.26 (1H, s, =CH), 3.88 (2H, s, CH2); 
13C NMR 
δ (62.9 MHz, (CD3)2SO) 136.1 (C), 128.1 (C), 120.4 (CH), 119.5 (CH), 118.7 (CH), 
110.9 (CH), 98.1 (CH), 48.6 (CH2). 
 









(3-Bromo-1H-indol-2-ylmethyl)-carbamic acid tert-butyl ester 168h 
General procedure H was followed using 3.06:1 
mixture of bromoindole 164h and debromoindole 191 
(130 mg), CH2Cl2 (6 ml), Et3N (141 µl, 1.00 mmol) 
and Boc2O (218 mg, 1.00 mmol). Flash 
chromatography (hexane:EtOAc, 10:1) afforded  bromoindole carbamate 168h as a 
yellow oil (87 mg, 49 %) and indole carbamate 192 as a colourless solid (32 mg, 
24%).  
Rf [hexane:EtOAc, 3:1] = 0.57; υmax (CHCl3)/cm
-1 3401, 2979, 1696 (C=O), 1507, 
1165; 1H NMR δ (360 MHz, CDCl3) 9.20 (1H, br s, NH), 7.57 (1H, d, Ј 7.8, ArH), 
7.37 (1H, d, Ј 7.6, ArH), 7.30-7.19 (2H, m, 2xArH), 5.19 (1H, br s NH), 4.49 (2H, d, 
Ј 6.2, CH2), 1.54 (9H, s, 3xCH3); 
13C NMR δ (90.6 MHz, (CDCl3) 157.3 (C), 135.1 
(C), 133.8 (C), 126.9 (C), 123.1 (CH), 120.4 (CH), 119.0 (CH), 111.3 (CH), 90.1 
(C), 80.4 (C), 36.4 (CH2), 28.3 (3xCH3); m/z (EI) 326 ([
81BrM(168h)]+, 25 %), 324 
([79BrM(168h)]+, 25), 270 (25), 268 (26), 246 ([M(192)]+, 6), 210 (34), 208 (35), 189 




 (1H-Indol-2-ylmethyl)-carbamic acid tert-butyl ester 192 (Diagnostic data) 
 Rf [hexane:EtOAc, 3:1] = 0.48; 
1H NMR δ (360 
MHz, CDCl3) 8.77 (1H, br s, NH), 7.57 (1H, dd, Ј 7.8, 
1.1, ArH), 7.37 (1H, dd, Ј 8.0, 0.9, ArH), 7.18 (1H, td, 
Ј 7.1, 1.2, ArH), 7.10 (1H, td, Ј 7.9, 1.1, ArH), 6.34 














Application of optimised methods in Table 3.5 and 3.6 
9-Methyl phenanthridine 195a-197a 
(Table 3.5, Entry 2) General procedure C was followed using cyclohexene 165a (20 
mg, 53 µmol), palladacycle 100 (3 mg, 2.6 µmol) and Ag2CO3 (15 mg, 5.3 µmol). 
After 2 h at 140 oC, flash chromatography (hexane:EtOAc, 100:1-100:2) afforded the 
phenanthridine as a colourless solid (18 mg, 99%).  1H NMR of this oil showed it to 
be a 78: 17: 5 mixture of double bond isomers (195a:196a:197a).  
(Table 3.6, Entry 2) General procedure D was followed using cyclohexene 165a 
(110 mg, 0.289 mmol), palladacycle 100 (14 mg, 14.5 µmol) and MeNCy2 (245 µl, 
1.16 mmol). After 12 h at 140 oC, flash chromatography (hexane:EtOAc, 100:1-
100:2) afforded the phenanthridine as a colourless solid (65 mg, 76%). 1H NMR of 
this oil showed it to be 26: 57: 11 mixture of double bond isomers (195a:196a:197a). 
 
9-Fluoro phenanthridine 195b-197b 
(Table 3.5, Entry 3) General procedure C was followed using cyclohexene 165b (20 
mg, 0.052 mmol), palladacycle 100 (2.5 mg, 2.6 µmol) and Ag2CO3 (14.5 mg, 0.052 
mmol). After 2.5 h at 140 oC, flash chromatography (hexane:EtOAc, 100:1-10:1) 
afforded the phenanthridine as a colourless oil (16 mg, 99%).  1H NMR of this oil 
showed it to be an 81: 14: 5 mixture of double bond isomers. (195b:196b:197b).  
(Table 3.6, Entry 3) General procedure D was followed using cyclohexene 165b (80 
mg, 0.21 mmol), palladacycle 100 (10 mg, 10 µmol) and MeNCy2 (175 µl, 0.84 
mmol). After 5 h at 140 oC, flash chromatography (hexane:EtOAc, 100:1-100:6) 
afforded the phenanthridine as a colourless oil (46 mg, 72%). 1H NMR of this oil 




8-Methoxy phenanthridine 195c-197c 
(Table 3.5, Entry 4) General procedure C was followed using cyclohexene 165c (23 
mg, 0.058 mmol), palladacycle 100 (3 mg, 2.9 µmol) and Ag2CO3 (16 mg, 0.058 
mmol). After 4 h at 140 oC, flash chromatography (hexane: EtOAc 100: 1) afforded 
the phenanthridine as a colourless oil (18 mg, 99%).  1H NMR of this oil showed it to 
be a 77: 19: 4 mixture of double bond isomers (195c:196c:197c).  
(Table 3.6, Entry 4) General procedure D was followed using cyclohexene 165c 
(110 mg, 0.278 mmol), palladacycle 100 (13 mg, 14.0 µmol) and MeNCy2 (236 µl, 
1.11 mmol). After 6 h at 140 oC, flash chromatography (hexane:EtOAc, 100:1) 
afforded the phenanthridine as a colourless oil (64 mg, 73%). 1H NMR of this oil 
showed it to be a 36: 44: 20 mixture of double bond isomers (195c:196c:197c). 
 
 
8,9-Dimethoxy phenanthridine 195d-197d 
(Table 3.5, Entry 5) General procedure C was followed using cyclohexene 165d (50 
mg, 0.12 mmol), palladacycle 100 (6 mg, 5.9 µmol) and Ag2CO3 (33 mg, 0.12 
mmol). After 1 h at 140 oC, flash chromatography (hexane:EtOAc, 100:15) afforded 
the phenanthridine as a colourless oil (40 mg, 99%).  1H NMR of this oil showed it to 
be an 84: 13: 3 mixture of double bond isomers (195d:196d:197d).  
(Table 3.6, Entry 5) General procedure D was followed using cyclohexene 165d (50 
mg, 0.12 mmol), palladacycle 100 (6 mg, 5.9 µmol) and MeNCy2 (100 µl, 0.47 
mmol). After 12 h at 140 oC, flash chromatography (hexane:EtOAc, 100:5–100:15) 
afforded the phenanthridine as a colourless oil (30 mg, 75%). 1H NMR of this oil 





(Table 3.5, Entry 6) General procedure C was followed using cyclohexene 165e (20 
mg, 0.05 mmol), palladacycle 100 (2.3 mg, 2.4 µmol) and Ag2CO3 (14 mg, 0.05 
mmol). After 4 h at 140 oC, flash chromatography (hexane: EtOAc 100:2 – 100: 4) 
afforded the phenanthridine as a colourless oil (14 mg, 88%). 1H NMR of this oil 
showed it to be an 81: 14: 5 mixture of double bond isomers (195e:196e:197e).  
(Table 3.6, Entry 6) General procedure D was followed using cyclohexene 165e 
(110 mg, 0.26 mmol), palladacycle 100 (13 mg, 13 µmol) and MeNCy2 (224 µl, 1.06 
mmol). After 5 h at 140 oC, flash chromatography (hexane:EtOAc, 100:2–100:3) 
afforded the phenanthridine as a colourless oil (65 mg, 74%). 1H NMR of this oil 
showed it to be a 44: 42: 16 mixture of double bond isomers (195e:196e:197e). 
 
Thieno[2,3-c]quinoline 195f-197f 
(Table 3.5, Entry 7) General procedure C was followed using cyclohexene 165f (20 
mg, 0.054 mmol), palladacycle 100 (3 mg, 2.7 µmol) and Ag2CO3 (15 mg, 0.054 
mmol). After 3 h at 140 oC, flash chromatography (hexane:EtOAc, 100:1–100:5) 
afforded the phenanthridine as a colourless oil (15 mg, 99%).  1H NMR of this oil 
showed it to be a 64:21:15 mixture of double bond isomers (195f:196f:197f), with 
unquantifiable possible traces of the corresponding trans-ring junction diastereomers.  
(Table 3.6, Entry 7) General procedure D was followed using cyclohexene 165f (85 
mg, 0.23 mmol), palladacycle 100 (11 mg, 11.4 µmol) and MeNCy2 (194 µl, 0.913 
mmol). After 5 h at 140 oC, flash chromatography (hexane:EtOAc, 100:1) afforded 
the phenanthridine as a colourless oil (52 mg, 79%). 1H NMR of this oil showed it to 
be a 18:34:30 mixture of double bond isomers (195f:196f:197f), with possible traces 





(Table 3.5, Entry 8) General procedure C was followed using cyclohexene 165k (65 
mg, 0.16 mmol), palladacycle 100 (8 mg, 8 µmol), Ag2CO3 (44 mg, 0.16 mmol) and 
DMF (2.5 ml). After 2 h at 140 oC, flash chromatography (hexane:EtOAc, 100:1–
100:5) afforded the phenanthridine as a colourless oil (47 mg, 91%).  1H NMR of this 
oil showed it to be an 76:18:6 mixture of double bond isomers (195k:196k:197k).  
(Table 3.6, Entry 8) General procedure D was followed using cyclohexene 165k (24 
mg, 59 µmol), palladacycle 100 (3 mg, 3.0 µmol), MeNCy2 (52 µl, 0.24 mmol) and 
DMF (2 ml). After 24 h at 140 oC, flash chromatography (hexane:EtOAc, 20:1) 
afforded the phenanthridine as a colourless oil (12 mg, 59%). 1H NMR of this oil 
showed it to be a 41:26:33 mixture of double bond isomers (195k:196k:197k). 
Additionally, 32% of the dehalogenated product 198k was recovered. 
(Table 3.6, Entry 9) General procedure E (Method A) was followed using 
cyclohexene 165k (85 mg, 0.21 mmol), Pd2(dba)3 (9.6 mg, 11 µmol), P(
tBu)3HBF4 
(6.1 mg, 21 µmol) and MeNCy2 (176 µl, 0.83 mmol). After 18 h at r.t., flash 
chromatography (hexane:EtOAc, 100:4) afforded the phenanthridine as a colourless 
oil (55 mg, 80%). 1H NMR of this oil showed it to be a 18:46:36 mixture of double 
bond isomers (195k:196k:197k). Additionally, 11% of the dehalogenated product 
198k was recovered. 
(Table 3.6, Entry 10) General procedure E (Method B) was followed using 
cyclohexene 165k (844 mg, 2.06 mmol), Pd2(dba)3 (94 mg, 0.10 mmol), 
P(tBu)3HBF4 (56 mg, 0.21 mmol) and MeNCy2 (1.75 ml, 8.24 mmol). After 18 h at 
50 oC, flash chromatography (hexane:EtOAc, 100:4) afforded the phenanthridine as a 
colourless oil (676 mg, 99%). 1H NMR of this oil showed it to be a 37:39:24 mixture 








acid tert-butyl ester 195a (∆1,2 isomer) 
 Rf [hexane:EtOAc, 10:1] = 0.46; MP 105 
oC; υmax 
(CHCl3)/cm
-1 2972, 1692 (C=O), 1398, 1364, 1169;  1H 
NMR δ (360 MHz, 323 K, CDCl3) 7.11 (1H, d, ArH), 
7.00 (2H, m, 2xArH), 6.18-6.12 (1H, m, CHCH=CH), 
5.88-5.83 (1H, m, CH=CHCH2), 4.68 (1H, d, Ј 16.3, 
CHXHYAr), 4.41 (1H, br s, NCHCH), 4.35 (1H, d, Ј 
16.3, CHXHYAr), 3.54 (1H, br s, NCHCH), 2.34 (3H, s, CH3), 2.29-2.16 (1H, m, 
CHAHB), 2.15-2.05 (1H, m, CHAHB), 1.74-1.69 (1H, m, CHCHD), 1.61-1.50 (10H, m, 
3 x CH3+CHCHD); 
13C NMR δ (90.0 MHz, 323 K, CDCl3) 155.0 (C), 137.6 (C), 
136.3 (C), 128.2 (CH), 128.1 (CH), 127.4 (CH), 126.6 (CH), 125.9 (CH), 123.8 (C), 
79.6 (CH), 50.5 (CH), 43.3 (CH2), 37.2 (CH), 28.5 (CH2), 28.5 (3xCH3), 25.3 (CH2), 
21.1 (CH3); m/z (EI) 299 ([M]
+, 1 %), 242 (100), 198 (15), 189 (26), 144 (11); 
HRMS (EI) Found: [M]+ 299.1880. C19H25NO2 requires 299.1880. 
 
Diagnostic 1H NMR data for 196a (∆2,3 isomer)   
1H NMR δ (360 MHz, 323 K, CDCl3) 7.04 (3H, m, 3xArH), 5.70-5.66 (1H, m, 
CH=CH), 5.45-5.40 (1H, m, CH=CH), 4.55 (1H, d, Ј 16.2, CHXHY), 4.48 (1H, d, Ј 
16.2, CHXHY), 4.43 (1H, br s, NCH), 3.18 (1H, br s, NCHCH), 2.86 (1H, dd, Ј 18.1, 
4.9, CHAHB), 2.63-2.56 (1H, m, CHAHB), 2.35 (3H, s, CH3), 2.24-2.19 (1H, m, 
CHCHD), 1.57-1.48 (10H, m, CHCHD+3xCH3). 
  
Diagnostic 1H NMR data for 197a (∆3,4 isomer) 
1H NMR δ (360 MHz, 323 K, CDCl3); 5.70-5.68 (1H, m, CH=CH), 5.53 (1H, dd, Ј 
8.5, CH=CH), 5.06 (1H, br s, NCH), 4.82 (1H, d, Ј 16.7, CHXHY), 4.21 (1H, d, Ј 











acid tert-butyl ester 195b (∆1,2 isomer) 
Rf [hexane:EtOAc, 3:1] = 0.57; υmax (CHCl3)/cm
-1 2974, 
2928, 1692 (C=O), 1498, 1400, 1365;  1H NMR δ (360 
MHz, 323 K, CDCl3) 7.07 (1H, dd, Ј 8.4, 5.7, ArH), 7.00 
(1H, dd, Ј 9.9, 2.6, ArH), 6.88 (1H, td, Ј 8.4, 2.6, ArH), 
6.12-6.06 (1H, m, CHCH=CH), 5.89-5.87 (1H, m, 
CH=CHCH2), 4.65 (1H, d, Ј 16.3, CHXHYAr),  4.40 (1H, 
br s, NCHCH), 4.36 (1H, d, Ј 16.3, CHXHYAr), 3.53 (1H, br s, NCHCH), 2.31-2.18 
(1H, m, CHAHB), 2.17-2.08 (1H, m, CHAHB), 1.77-1.68 (1H, m, CHCHD), 1.53-1.46 
(10H, m, 3xCH3+CHCHD); 
13C NMR δ (90.0 MHz, 323 K, CDCl3) 161.9 (1C, d, Ј 
244.1, C), 154.6 (C), 140.0 (1C, d, Ј 6.8, C), 129.0 (CH), 127.5 (1C, d, Ј 8.0, CH),  
126.5 (CH), 123.4 (C), 114.4 (1C, d, Ј 22.1, CH), 113.0 (1C, d, Ј 21.8, CH), 79.8 
(C), 50.2 (CH), 43.0 (CH2), 37.3 (CH), 28.5 (3xCH3), 25.4 (CH2), 24.0 (CH2); m/z 
(EI) 303 ([M]+, 8 %), 247 (95), 246 (90), 202 (27), 193 (100), 148 (36); HRMS (EI) 
Found: [M]+ 303.1626. C18H22FNO2 requires 303.1629. 
 
Diagnostic 1H NMR data for 196b (∆2,3 isomer)   
1H NMR δ (360 MHz, 323 K, CDCl3) 7.12 (1H, dd, Ј 8.3, 5.7, ArH), 6.94 (1H, d, Ј 
10.5, ArH), 6.92-6.87 (1H, m, ArH), 5.69-5.66 (1H, m, CH=CH), 5.46-5.41 (1H, m, 
CH=CH), 4.57 (1H, d, Ј 16.2, CHXHY), 4.46 (1H, br s, NCH), 4.45 (1H, d, Ј 16.1, 
CHXHY), 3.18 (1H, s, NCHCH), 2.79-2.73 (1H, m, CHAHB), 2.67-2.60 (1H, m, 
CHAHB), 2.27-2.20 (1H, m, CHCHD), 1.53-1.45 (10H, m, CHCHD+3xCH3)  
 
Diagnostic 1H NMR data for 197b (∆3,4 isomer) 
1H NMR δ (360 MHz, 323 K, CDCl3); 5.69-5.66 (1H, m, CH=CH), 5.52 (1H, dd, Ј 
10.2, 1.0, CH=CH), 5.08 (1H, br s, NCH), 4.84 (1H, d, Ј 16.4, CHXHY), 4.19 (1H, d, 
Ј 16.4, CHXHY), 3.28 (1H, br s, NCHCH), 2.40-2.30 (1H, m, CHAHB), 2.12-2.00 












carboxylic acid tert-butyl ester 195c (∆1,2 isomer) 
Rf [hexane:EtOAc, 3:1] = 0.71; υmax (CHCl3)/cm
-1 
2974, 1691 (C=O);  1H NMR δ (360 MHz, 323 K, 
CDCl3) 7.19 (1H, d, Ј 8.5, ArH), 6.79 (1H, dd, Ј 8.5, 
2.7, ArH), 6.66 (1H, d, Ј 2.7, ArH), 6.14-6.09 (1H, m, 
CHCH=CH), 5.84-5.80 (1H, m, CH=CHCH2), 4.69 
(1H, d, Ј 16.6, CHXHYAr), 4.34 (1H, br s, NCHCH), 
4.30 (1H, d, Ј 16.6, CHXHYAr), 3.79 (3H, s, CH3), 3.51 (1H, br s, NCHCH), 2.27-
2.16 (1H, m, CHAHB), 2.12-2.04 (1H, m, CHAHB), 1.74-1.65 (1H, m, CHCHD), 1.58-
1.47 (10H, m, CHCHD+3 x CH3); 
13C NMR δ (90.0 MHz, 323 K, CDCl3) 157.9 (C), 
154.9 (C), 130.0 (C), 128.5 (CH), 128.0 (CH), 127.6 (CH), 125.4 (CH), 113.0 (CH), 
111.1 (CH), 79.6 (C), 55.2 (CH3), 50.5 (CH), 43.7 (CH2), 36.6 (CH), 28.6 (3xCH3), 
26.5 (CH2), 25.3 (CH2); m/z (EI) 315 ([M]
+, 2 %), 259 (77), 242 (100), 205 (47); 
HRMS (EI) Found: [M]+ 315.1831. C29H25NO3 requires 315.1829. 
 
Diagnostic 1H NMR data for 196c (∆2,3 isomer)   
1H NMR δ (360 MHz, 323 K, CDCl3) 7.14 (1H, d, Ј 8.6, ArH), 6.73 (1H, d, Ј 2.3, 
ArH), 5.70-5.62 (1H, m, CH=CH), 5.44-5.40 (1H, m, CH=CH), 4.52 (2H, s, CH2Ar), 
3.15 (1H, br s, NCHCH), 2.81 (1H, dd, Ј 22.9, 4.7, CHAHB), 2.62-2.54 (1H, m, 
CHAHB).  
 
Diagnostic 1H NMR data for 197c (∆3,4 isomer) 
1H NMR δ (360 MHz, 323 K, CDCl3) 7.26 (1H, d, Ј 8.6, ArH), 6.60 (1H, s, ArH), 
5.51 (1H, d, Ј 10.2, CH=CH), 5.05 (1H, br s, NCH), 4.83 (1H, d, Ј 17.1, CHXHY), 











carboxylic acid tert-butyl ester 195d (∆1,2 isomer) 
Rf [hexane:EtOAc, 3:1] = 0.44; MP 124 
oC; υmax 
(CHCl3)/cm
-1 2973, 1692 (C=O);  1H NMR δ (360 
MHz, 323 K, CDCl3) 6.77 (1H, s, ArH), 6.60 (1H, s, 
ArH), 6.12-6.07 (1H, m, CHCH=CH), 5.84-5.81 (1H, 
m, CH=CHCH2), 4.62 (1H, d, Ј 16.3, CHXHYAr), 4.37 
(1H, br s, NCHCH), 4.27 (1H, d, Ј 16.3, CHXHYAr), 
3.85 (3H, s, CH3), 3.83 (3H, s, CH3), 3.47 (1H, br s, NCHCH), 2.25-2.20 (1H, m, 
CHAHB), 2.11-2.03 (1H, m, CHAHB), 1.69-1.65 (1H, m, CHCHD), 1.57 (1H, td, Ј 
16.8, 5.8, CHCHD), 1.50-1.48 (9H, m, 3 x CH3); 
13C NMR δ (90.0 MHz, 323 K, 
CDCl3) 155.0 (C), 148.2 (C), 147.6 (C), 129.8 (C), 128.3 (CH), 127.2 (CH), 124.4 
(C), 111.2 (CH), 109.5 (CH), 79.7 (C), 56.0 (2xCH3), 50.2 (CH), 43.0 (CH2), 36.6 
(CH), 28.4 (3xCH3), 25.3 (CH2), 23.9 (CH2); m/z (FAB, 3-NOBA) 346 ([M+H]
+, 26 
%), 289 (100), 244 (82), 216 (36), 190 (52), ; HRMS (FAB, 3-NOBA) Found: 
[M+H]+ 346.2017. C20H28NO4 requires 346.2013. 
 
Diagnostic 1H NMR data for 196d (∆2,3 isomer)   
1H NMR δ (360 MHz, 323 K, CDCl3) 6.75 (1H, s, ArH), 6.66 (1H, s, ArH), 5.67-
5.63 (1H, m, CH=CH), 5.44-5.40 (1H, m, CH=CH), 4.46 (2H, s, CH2Ar), 3.13 (1H, 
br s, NCHCH), 2.77-2.73 (1H, m, CHAHB), 2.61-2.56 (1H, m, CHAHB).  
 
Diagnostic 1H NMR data for 197d (∆3,4 isomer) 
1H NMR δ (360 MHz, 323 K, CDCl3); 6.82 (1H, s, ArH), 6.53 (1H, s, ArH), 5.72-
5.66 (1H, m, CH=CH), 5.48 (1H, dd, Ј 10.1, CH=CH), 5.03 (1H, br s, NCH), 4.75 












acid tert-butyl ester 195e (∆1,2 isomer) 
 Rf [hexane:EtOAc, 3:1] = 0.80; υmax (CHCl3)/cm
-1 2926, 
1688 (C=O), 1400, 1166; 1H NMR δ (360 MHz, 323 K, 
CDCl3) 8.08 (1H, d, Ј 8.4, ArH), 7.87 (1H, dd, Ј 8.1, 0.7, 
ArH), 7.71 (1H, d, Ј 8.3, ArH), 7.55 (1H, ddd, Ј 8.3, 6.8, 
1.4, ArH), 7.48 (1H, ddd, Ј 8.1, 6.8, 1.3, ArH), 7.29 (1H, 
d, Ј 8.3, ArH),  5.97-5.92 (1H, m, CH=CH), 5.43 (1H, ddd, 
Ј 9.9, 1.6, 0.8, CH=CH), 5.11 (1H, d, Ј 15.1, CHXHYAr), 4.62-4.59 (1H, m, 
CHCH=CH), 4.29-4.26 (1H, m, NCH), 4.23 (1H, d, Ј 15.1, CHXHYAr), 2.56-2.21 
(1H, m, CHCHD), 2.37-2.25 (1H, m, CHAHB), 2.17-2.07 (1H, m, CHAHB), 1.91-1.84 
(1H, dddd, Ј 13.6, 11.3, 5.2, 2.5, CHCHD), 1.49 (9H, m, 3xCH3); 
13C NMR δ (90.6 
MHz, 323 K, CDCl3) 155.2 (C), 133.7 (C), 133.4 (C), 130.6 (2xC), 129.2 (CH), 
129.0 (CH), 126.8 (CH), 126.6 (CH), 126.2 (CH), 125.1 (CH), 124.7 (CH), 122.4 
(CH), 79.6 (C) 49.8 (CH), 45.2 (CH2), 35.2 (CH), 28.5 (3xCH3), 26.9 (CH2), 20.6 
(CH2); m/z (EI)  335 ([M]
+, 4 %), 307 (30), 242 (35), 136 (100); HRMS (EI) Found: 
[M]+,335.1880. C22H25NNO2 requires 335.1880. 
 
Diagnostic data for 196e (∆2,3 isomer). 
1H NMR δ (360 MHz, 323 K, CDCl3) 4.98 (1H, d, Ј 16.1, CHXHYAr), 4.56 (1H, d, Ј 
16.1, CHXHYAr), 4.11 (1H, td, Ј 5.7, 2.6, CHCH2), 3.95-3.88 (1H, m, NCHCH2), 
2.97-2.92 (1H, m, CHAHB). 
 
Diagnostic data for 197e (∆3,4 isomer). 
1H NMR δ (360 MHz, 323 K, CDCl3) 4.96 (1H, d, Ј 16.0, CHXHYAr), 4.81-4.76 



















tert-butyl ester 195f (∆1,2 isomer) 
Rf [hexane:EtOAc, 3:1] = 0.79; υmax (CHCl3)/cm
-1 3361, 2974, 
2928, 1692 (C=O), 1400, 1365; 1H NMR δ (360 MHz, 323 K, 
CDCl3)  7.16 (1H, d, Ј 5.1, HetH), 6.90 (1H, d, Ј 5.1, HetH), 
6.09-6.05 (1H, m, CH=CH), 5.80-5.76 (1H, m, CH=CH), 4.98 
(1H, d, Ј 16.8, CHXHYAr), 4.60 (1H, br s, CHN), 4.24 (1H, d, Ј 
16.8, 2.0, CHXHYAr), 3.48 (1H, br s, NCHCH), 2.33-2.20 (1H, 
m, CHAHB), 2.15-2.06 (1H, m, CHAHB), 1.75-1.60 (2H, m, CH2), 1.51 (9H, s, 
3xCH3); 
13C NMR δ (90.6 MHz, 323 K, CDCl3) 154.7 (C), 129.5 (C), 127.6 (CH), 
127.3 (CH), 125.8 (CH), 123.9 (C), 123.1 (CH), 80.0 (C), 49.3 (CH), 39.9 (CH2), 
35.9 (CH), 28.4 (3xCH3), 25.5 (CH2), 22.9 (CH2); m/z (EI) 292 ([M+H]
+, 3 %), 236 
(100), 234 (55), 177 (31), 175 (30); HRMS (EI) Found: [M]+ 291.1298. C16H21O2NS 
requires 291.1288.  
 
Diagnostic 1H NMR data for 196f (∆2,3 isomer)   
1H NMR δ (360 MHz, 323 K, CDCl3) 5.65-5.58 (1H, m, CH=CH), 5.52-5.45 (1H, 
m, CH=CH), 4.89 (1H, d, Ј 17.6, CHXHYAr), 4.40 (1H, d, Ј 17.2, CHXHYAr), 3.17 
(1H, br s, NCHCH), 2.72-2.65 (2H, m CH2). 
 
Diagnostic 1H NMR data for 197f (∆3,4 isomer) 
1H NMR δ (360 MHz, 323 K, CDCl3) 5.90-5.81 (1H, m, CH=CH), 5.50-5.42 (1H, 
m, CH=CH), 4.88 (1H, d, Ј 17.3, CHXHYAr), 4.18 (1H, d, Ј 17.3, CHXHYAr),  3.24 




















carboxylic acid tert-butyl ester 195k (∆1,2 isomer) 
Rf [hexane:EtOAc, 3:1] = 0.65; υmax (CHCl3)/cm
-1 1692 
(C=O), 1484, 1166; 1H NMR δ (360 MHz, 323 K, 
CDCl3) 6.77 (1H, s, ArH), 6.59 (1H, s, ArH), 6.08-6.03 
(1H, m, CH=CH), 5.92 (2H, s, OCH2O), 5.86-5.83 (1H, 
m, CH=CH), 4.58 (1H, d, Ј 16.2, CHXHYAr), 4.36 (1H, 
br s, CHCH=CH), 4.29 (1H, d, Ј 16.2, CHXHYAr), 3.46 
(1H, m, NCH), 2.26-2.19 (1H, m, CHAHB), 2.16-2.12 (1H, m, CHAHB), 2.72-1.68 
(1H, m, CHCHD), 1.60-1.55 (1H, m, CHCHD), 1.51 (1H, s, 3xCH3); 
13C NMR δ (90.6 
MHz, 323 K, CDCl3) 154.9 (C), 146.7 (C), 145.8 (C), 131.0 (C), 128.5 (CH), 127.2 
(CH), 125.7 (C), 107.7 (CH), 106.2 (CH), 100.7 (CH2), 79.6 (C), 50.4 (CH), 43.6 
(CH2), 37.1 (CH), 28.5 (3xCH3), 25.3 (CH2), 24.1 (CH2); m/z (EI) 329 ([M]
+, 1 %),  
272 (100); HRMS (EI) Found: [M]+, 329.1621. C19H23O4N requires 329.1622. 
 
Diagnostic 1H NMR data for 196k (∆2,3 isomer) 
1H NMR δ (360 MHz, 323 K, CDCl3) 6.74 (1H, s, ArH), 6.65 (1H, s, ArH), 5.92 
(2H, s, OCH2O), 5.69-5.65 (1H, m, CH=CH), 5.47-5.42 (1H, m, CH=CH), 4.41 (2H, 
s, CH2Ar), 3.10 (1H, br s, NCHCH), 2.72 (1H, dd, Ј 18.3, 4.9, CHAHB), 2.63-2.56 
(1H, m, CHAHB), 2.25-2.20 (1H, m, CHCHD), 1.63-1.55 (1H, m, CHCHD), 1.52 (9H, 
s, 3xCH3). 
 
Diagnostic 1H NMR data for 197k (∆3,4 isomer) 
1H NMR δ (360 MHz, 323 K, CDCl3) 6.82 (1H, s, ArH), 6.52 (1H, s, ArH), 5.90 
(2H, s, OCH2O), 5.73-5.70 (1H, m, CH=CH), 5.52-5.48 (1H, m, CH=CH), 5.02 (1H, 












(Benzo[1,3]dioxol-5-ylmethyl)-(cyclohex-2-enyl)-carbamic acid tert-butyl ester 
198k 
Rf [hexane:EtOAc, 3:1] = 0.69; υmax (CHCl3)/cm
-1 
1686 (C=O), 1490, 1245, 1166; 1H NMR δ (360 MHz, 
323 K, CDCl3) 6.77 (1H, br s, ArH), 6.73 (1H, d, Ј 8.0, 
ArH), 6.69 (1H, br d, Ј 8.6, ArH), 5.93 (2H, s, 
OCH2O), 5.82-5.80 (1H, m, CH=CH), 5.49 (1H, d, Ј 
10.2, CH=CH), 4.71 (1H, br s, CHN), 4.34 (1H, d, Ј 16.0, CHXHYAr), 4.20 (1H, d, Ј 
16.0, CHXHYAr), 1.99-1.97 (2H, m, CH2), 1.90-1.82 (1H, m, CHAHB), 1.79-1.71 
(1H, m, CHAHB), 1.66-1.43 (11H, m, CH2+3xCH3); 
13C NMR δ (90.6 MHz, 323 K, 
CDCl3), 155.9 (C), 147.6 (C), 146.1 (C), 134.6 (C), 130.5 (CH), 129.0 (CH), 119.8 
(CH), 107.8 (CH), 107.5 (CH), 100.7 (CH2), 79.6 (C), 53.3 (CH), 47.3 (CH2), 28.4 
(3xCH3), 28.1 (CH2), 24.6 (CH2), 21.5 (CH2); m/z (EI) 331 ([M]
+, 13 %), 275 (38), 
194 (100), 150 (14), 140 (14), 136 (28), 135 (46); HRMS (EI) Found: [M]+, 











cyclopropa[c]phenanthrene-4-carboxylic acid tert-butyl ester 212 
 To a solution of mCPBA (42 mg, 0.22 mmol) in CH2Cl2 
(4 ml) at r.t. was added dropwise ∆1,2 phenanthridine 96b 
(20 mg, 0.07 mmol) in CH2Cl2 (1 ml). The reaction was 
stirred for 2 h at r.t. then diluted with CH2Cl2 (15 ml) and 
washed with Na2CO3 (3 x 15 ml, sat. aq.). The organics 
were dried, concentrated under reduced pressure and 
purified by flash chromatography (hexane:EtOAc, 10:1) to afford epoxy 
phenanthridine 212 as a colourless oil (12 mg, 57%) and epoxy phenanthridone 213 
as a colourless oil (8 mg, 36%). 
Rf [hexane:EtOAc, 3:1] = 0.54; υmax (CHCl3)/cm
-1 2976, 1693 (C=O), 1234 (C-O); 
1H NMR δ (360 MHz, CDCl3) 7.42 (1H, d, Ј 6.9, ArH), 7.30-7.25 (2H, m, 2xArH), 
7.19 (1H, d, Ј 7.2, ArH), 4.77 (1H, d, Ј 16.4, CHXHYAr), 4.29 (1H, br s, NCHCH2), 
4.26 (1H, d, Ј 16.4, CHXHYAr), 3.60-3.57 (2H, m, CHOCH+CHCH2), 3.23 (1H, t, Ј 
3.7, CHOCH), 2.12-2.03 (1H, m, CHAHB), 1.97-1.89 (1H, m, CHAHB), 1.51-1.40 
(11H, m, CH2+3xCH3); 
13C NMR δ (90.6 MHz, CDCl3) 157.3 (C), 134.7 (C), 134.3 
(C), 127.1 (CH), 126.7 (CH), 126.3 (CH), 126.1 (CH), 79.8 (C), 55.3 (CH), 51.8 
(CH), 47.2 (CH), 43.9 (CH2), 37.1 (CH), 28.4 (3xCH3), 21.7 (CH2), 21.6 (CH2); m/z 
(EI) 301 ([M]+, 1 %), 244 ([M-tBu]+, 100), 228 (18), 172 (22); HRMS (EI) Found: 
[M]+, 301.1672. C18H23NO3 requires 301.1673. This compound was also fully 





















cyclopropa[c]phenanthrene-4-carboxylic acid tert-butyl ester 213 
 Rf [hexane:EtOAc, 3:1] = 0.38; υmax (CHCl3)/cm
-1 2979, 
1715 (C=O), 1691 (C=O), 1244 (C-O); 1H NMR δ (360 
MHz, CDCl3) 8.21 (1H, d, Ј 7.8, 1.4, ArH), 7.58 (1H, td, Ј 
7.5, 1.5, ArH), 7.73 (1H, d, Ј 7.7, ArH), 7.42 (1H, t, Ј 7.7, 
ArH), 4.56 (1H, ddd, Ј 12.2, 5.1, 3.2, NCHCH2), 3.97-3.96 
(1H, m, CHCH2), 3.91 (1H, t, Ј 5.8, CHOCH), 3.27 (1H, t, Ј 
4.1, CHOCH), 2.16-2.07 (1H, m, CHAHB), 1.98-1.89 (1H, m, CHAHB), 1.63-1.39 
(11H, m, CH2+3xCH3); 
13C NMR δ (90.6 MHz, CDCl3) 162.9 (C), 152.7 (C), 136.9 
(C), 133.2 (CH), 129.8 (CH), 128.9 (C), 127.5 (CH), 124.7 (CH), 83.4 (C), 77.1 
(CH), 55.2 (CH), 51.2 (CH), 35.5 (CH), 27.9 (3xCH3), 22.2 (CH2), 21.6 (CH2); m/z 
(EI) 315 ([M]+, 7 %), 260 (59), 216 (43), 146 (69), 57 (100); HRMS (EI) Found: 












To a suspension of amine hydrochloride 93 (100 mg, 0.330 
mmol) in DMF (5 ml) at r.t. was added K2CO3 (137 mg, 1.00 
mmol) and the reaction stirred for 10 mins. Propargyl bromide 
(148 µl, 80 % by w/w. in toluene, 1.66 mmol) was added 
dropwise and the reaction stirred for 16 h. The reaction was 
diluted with Et2O (20 ml) and washed with NaCl (3 x 20 ml, sat. aq.), and the 
combined organics were dried (MgSO4) and concentrated under reduced pressure. 
The resultant oil was purified using flash chromatography (hexane:EtOAc, 100:15) 
to afford propargyl amine 94f as a colourless oil (103 mg, 99%). 
Rf [hexane:EtOAc, 3: 1] = 0.89; υmax (CHCl3)/cm
-1 3299(C≡C-H), 2931, 1439, 1025; 
1H NMR δ (250 MHz, CDCl3) 7.59 (1H, d, Ј 7.6, ArH), 7.56 (1H, dd, Ј 7.9, 1.2, 
ArH), 7.29 (1H, td, Ј 7.4, 1.2, ArH), 7.10 (1H, td, Ј 7.8, 1.4, ArH), 5.89-5.76 (2H, m, 
CH=CH), 3.91 (1H, d, Ј 15.0, CHXHYAr), 3.82 (1H, d, Ј 15.0, CHXHYAr), 3.56-3.53 
(1H, m, CHN), 3.38 (2H, d, Ј 2.4, CH2C≡CH), 2.23 (1H, t, Ј 2.4, ≡CH), 2.03-1.84 
(4H, m, 2xCH2), 1.69-1.44 (2H, m, CH2); 
13C NMR δ (62.9 MHz, CDCl3) 138.7 (C), 
132.5 (CH), 130.6 (CH), 130.4 (CH), 129.7 (CH), 128.1 (C), 127.1 (CH), 124.2 (C), 
81.4 (C), 72.2 (CH), 57.6 (CH), 52.9 (CH2), 39.3 (CH2), 25.2 (CH2), 24.8 (CH2), 21.2 
(CH2); m/z (EI) 305 ([
81BrM]+, 19 %), 303 ([79BrM]+, 19), 277 (64), 275 (65), 251 
(33), 249 (35), 213 (42), 171 (97), 169 (100), 106 (85); HRMS (EI) Found: [79BrM]+, 
303.0618. C16H18N







(2-Bromo-benzyl)-cyclohex-3-enyl-carbamic acid prop-2-ynyl ester 94h 
To a suspension of amine hydrochloride 93 (100 mg, 
0.33 mmol) in CH2Cl2 (10 ml) at 0 
oC was added Et3N 
(182 µl, 1.32 mmol) and propargyl chloroformate (130 
µl, 1.32 mmol). The reaction was allowed to warm to 
r.t. and stirred for 16 h. The reaction was diluted with 
CH2Cl2 (10 ml) and washed with HCl (3 x 10 ml, 1 M aq.). The combined organics 
were concentrated under reduced pressure to afford Poc-amine 94h as a colourless 
oil (130 mg, 99%). 
Rf [hexane:EtOAc, 3:1] = 0.73; υmax (CHCl3)/cm
-1 3298 (C≡C-H), 2937, 1703 
(C=O), 1442, 1409; 1H NMR δ (360 MHz, 323 K, CDCl3) 7.52 (1H, d, Ј 7.7, ArH), 
7.30-7.24 (2H, m, 2xArH), 7.10 (1H, td, Ј 7.3, 2.2, ArH), 5.87-5.84 (1H, m, 
CH=CH), 5.48-5.43 (1H, m, CH=CH), 4.86 (1H, br s, CHN), 4.77-4.71 (2H, m, 
CH2C≡CH), 4.50 (1H, d, Ј 17.3, CHXHYAr), 4.44 (1H, d, Ј 17.3, CHXHYAr), 2.45-
2.37 (1H, m, ≡CH), 2.02-1.90 (3H, m, CH2 +CHAHB), 1.80-1.70 (1H, m, CHAHB), 
1.70-1.49 (2H, m, CH2); 
13C NMR δ (90.6 MHz, 323 K, CDCl3) 155.8 (C), 138.1 
(C), 132.4 (CH), 131.9 (CH), 128.0 (CH), 127.7 (CH), 127.3 (CH), 127.2 (CH), 
122.1 (C), 78.4 (C), 74.2 (CH), 54.0 (CH), 52.9 (CH2), 47.6 (CH2), 28.0 (CH2), 24.4 
(CH2), 21.2 (CH2); m/z (EI) 349 ([
81BrM]+, 13 %), 347 ([79BrM]+, 14), 310 (99), 308 
(100), 178 (57), 171 (88), 169 (93); HRMS (EI) Found: [79BrM]+, 347.0513. 
C17H18O2N










Flash vacuum pyrolysis of Boc-protected ∆1,2 isomer 
phenanthridine 96b [500 mg, Tf 600 
oC, Ti 140 
oC, P 3.2 x 10-2 
Torr, t 0.5 h], followed by Kugelrohr distillation (70 oC, 0.7 
Torr) gave amine 245 as a yellow oil (193 mg, 60%). 
Rf [CH2Cl2:MeOH, 9:1] = 0.36; υmax (CHCl3)/cm
-1 3274 (NH), 3019, 2920, 1671 
(C=C), 1449, 1260 (CN); 1H NMR δ (360 MHz, CDCl3) 7.22-7.21 (2H, m, 2xArH), 
7.17-7.14 (1H, m, ArH), 7.03 (1H, d, Ј 7.5, ArH), 5.74-5.71 (1H, m, CH=CH), 5.66-
5.62 (1H, m, CH=CH), 4.12 (1H, d, Ј 16.3, CHXHYAr), 4.04 (1H, d, Ј 16.3, 
CHXHYAr), 3.36 (1H, br s, NCHCH), 3.32-3.28 (1H, m, NCHCH), 2.25-2.03 (2H, m, 
CH2), 2.03-1.89 (2H, m, CH2); 
13C NMR δ (90.6 MHz, CDCl3) 138.4 (C), 135.7 (C), 
130.2 (CH), 129.1 (CH), 126.4 (CH), 125.8 (CH), 125.7 (2xCH), 50.4 (CH), 48.3 
(CH2), 38.0 (CH), 27.4 (CH2), 20.0 (CH2); m/z (EI) 185 ([M]
+, 77 %), 170 (21), 168 




Flash vacuum pyrolysis of Boc-protected ∆2,3 isomer 
phenanthridine 97b [900 mg, Tf 600 
oC, Ti 140 
oC, P 3.2 x 10-2 
Torr, t 0.5 h], followed by Kugelrohr distillation (70 oC, 0.7 Torr) 
gave amine 246 as a yellow oil (500 mg, 81%). 
Rf [CH2Cl2:MeOH, 9:1] = 0.34; υmax (CHCl3)/cm
-1 3284 (NH), 3021, 2902, 1654 
(C=C), 1453, 1260 (CN); 1H NMR δ (360 MHz, CDCl3) 7.17-7.13 (2H, m, 2xArH), 
7.09-7.02 (2H, m, ArH), 5.73-5.66 (2H, m, CH=CH), 4.24 (1H, d, Ј 16.5, 
CHXHYAr), 4.15 (1H, d, Ј 16.5, CHXHYAr), 3.23 (1H, br d, Ј 4.0, NCHCH), 2.81 
(1H, ddd, Ј 10.1, 6.4, 2.7, NCHCH), 2.65-2.59 (1H, m, CHAHB), 2.34-2.28 (1H, m, 
CHAHB), 2.15-2.10 (2H, m, CH2); 
13C NMR δ (90.6 MHz, CDCl3) 141.0 (C), 134.2 
(C), 128.2 (CH), 126.0 (CH), 125.9 (CH), 125.8 (CH), 124.7 (CH), 124.1 (CH), 49.9 
(CH), 48.5 (CH2), 35.3 (CH), 31.9 (CH2), 30.1 (CH2); m/z (EI) 185 ([M]
+, 10 %), 














Flash vacuum pyrolysis of Boc-protected ∆3,4 isomer 
phenanthridine 98b [320 mg, Tf 600 
oC, Ti 140 
oC, P 3.2 x 10-2 
Torr, t 0.5 h], followed by Kugelrohr distillation (70 oC, 0.7 Torr) 
gave amine 247 as a yellow oil (190 mg, 71%). 
Rf [CH2Cl2:MeOH, 9:1] = 0.37; υmax (CHCl3)/cm
-1 3283 (NH), 3020, 2902, 1654 
(C=C), 1453, 1260 (CN); 1H NMR δ (360 MHz, CDCl3) 7.23-7.13 (3H, m, 3xArH), 
7.03 (1H, d, Ј 7.2, ArH), 5.96-5.85 (2H, m, CH=CH), 4.05 (1H, d, Ј 16.6, 
CHXHYAr), 4.00 (1H, d, Ј 16.9, CHXHYAr), 3.46 (1H, br s, NCHCH), 2.74 (1H, dt, Ј 
12.6, 3.6, NCHCH), 2.22-1.62 (4H, m, 2xCH2); 
13C NMR δ (90.6 MHz, CDCl3) 
139.3 (C), 135.8 (C), 130.0 (CH), 129.2 (CH), 128.3 (CH), 126.1 (CH), 125.7 (CH), 
125.5 (CH), 50.7 (CH), 48.2 (CH2), 36.5 (CH), 27.5 (CH2), 25.8 (CH2); m/z (EI) 185 








General procedure L - Propargylation 
To a solution of the appropriate phenanthridine (1 eq) in acetone (5 ml) was added 
K2CO3 (3 eq) followed by relevant alkylating agent (1.1 eq). The reaction was heated 
at 60 oC for the stated time and then concentrated under reduced pressure. The crude 
product was purified by flash chromatography to the desired alkyl amine. 
 
(4aSR,10bSR)-5-(Prop-2’-ynyl)-3,4,4a,5,6,10b-hexahydro-phenanthridine 96f 
General procedure L was followed using amine 245 (150 mg, 
0.81 mmol), acetone (5 ml), K2CO3 (368 mg, 2.67 mmol), and 
propargyl bromide (100 µl, 80 % w/w in toluene, 0.89 mmol). 
After 2 h, flash chromatography (CH2Cl2) afforded propargyl 
amine 96f as a yellow oil (103 mg, 57%). 
Rf [CH2Cl2:MeOH, 95:5] = 0.83; υmax (CHCl3)/cm
-1 3290 
(C≡C-H), 2925, 1696; 1H NMR δ (250 MHz, CDCl3) 7.27-7.10 (3H, m, 3xArH), 
7.10 (1H, d, Ј 7.2, ArH), 5.79 (2H, s, CH=CH), 4.01 (1H, d, Ј 15.0, CHXHYAr), 3.83 
(1H, dd, Ј 17.4, 2.4, CHPHQC≡CH), 3.81 (1H, d, Ј 15.0, CHXHYAr), 3.56 (1H, dd, Ј 
17.4, 2.4, CHPHQC≡CH), 3.56 (1H, br s, NCHCH), 3.16 (1H, br s, NCHCH), 2.28 
(1H, t, Ј 2.4, ≡CH), 2.14-2.00 (3H, m, CH2+CHAHB), 1.87-1.75 (1H, m, CHAHB); 
13C NMR δ (62.9 MHz, CDCl3) 137.3 (C), 133.8 (C), 129.8 (CH), 128.0 (CH), 126.5 
(CH), 126.4 (CH), 126.1 (CH), 125.6 (CH), 78.3 (C), 73.4 (CH), 53.8 (CH), 53.4 
(CH2), 42.3 (CH2), 39.2 (CH), 23.2 (CH2), 21.9 (CH2); m/z (EI) 223 ([M]
+, 59 %), 
222 (100), 208 (16), 184 (17), 168 (36), 140 (34); HRMS (EI) Found: [M]+, 









General procedure L was followed using amine 246 (50 mg, 0.27 
mmol), acetone (2 ml), K2CO3 (112 mg, 0.81 mmol) and 
propargyl bromide (33 µl, 80 % w/w in toluene, 0.30 mmol). After 
2 h, flash chromatography (CH2Cl2) afforded propargyl amine 97f 
as a colourless oil (45 mg, 75%). 
Rf [CH2Cl2:MeOH, 95:5] = 0.89; υmax (CHCl3)/cm
-1 3292 (C≡C-H), 2925, 1663, 
1604, 1430; 1H NMR δ (360 MHz, CDCl3) 7.17-7.14 (2H, m, 2xArH), 7.12-7.08 
(2H, m, 2xArH), 5.76-5.72 (1H, m, CH=CH), 5.67-5.63 (1H, m, CH=CH), 4.10 (1H, 
d, Ј 15.2, CHXHYAr), 3.88 (1H, d, Ј 15.2, CHXHYAr), 3.75 (1H, dd, Ј 15.3, 2.3, 
CHPHQC≡CH), 3.49 (1H, dd, Ј 15.3, 2.3, CHPHQC≡CH), 3.08-3.05 (1H, m, 
NCHCH), 2.99 (1H, td, Ј 7.9, 2.4, NCHCH), 2.53-2.43 (1H, m, CHAHB), 2.38-2.13 
(3H, m, CH2+CHAHB), 2.26 (1H, t, Ј 2.3, ≡CH); 
13C NMR δ (90.6 MHz, CDCl3) 
140.2 (C), 134.0 (C), 127.0 (CH), 126.5 (CH), 126.3 (CH), 125.8 (CH), 125.7 (CH), 
122.9 (CH), 78.3 (C), 73.4 (CH), 54.4 (CH2), 53.3 (CH), 42.2 (CH2), 37.6 (CH), 31.4 
(CH2), 26.4 (CH2); m/z (EI) 223 ([M]
+, 6 %), 222 (6), 168 (100), 129 (25); HRMS 








General procedure L was followed using amine 247 (52 mg, 0.18 
mmol), acetone (5 ml), K2CO3 (76 mg, 0.55 mmol) and propargyl 
bromide (18 µl, 80% w/w in toluene, 0.20 mmol). After 2 h, flash 
chromatography (CH2Cl2) afforded propargyl amine 98f as a 
yellow oil (37 mg, 91%). 
Rf [CH2Cl2:MeOH, 95:5] = 0.84; υmax (CHCl3)/cm
-1 3291 (C≡C-H), 3027, 2925, 
1663; 1H NMR δ (360 MHz, CDCl3) 7.20-7.04 (3H, m, 3xArH), 7.05 (1H, d, Ј 7.3, 
2xArH), 6.02-5.93 (2H, m, CH=CH), 3.98 (1H, d, Ј 15.1, CHXHYAr), 3.82 (1H, dd, Ј 
17.2, 2.3, CHPHQC≡CH), 3.78 (1H, d, Ј 15.1, CHXHYAr), 3.51 (1H, dd, Ј 17.2, 2.4, 
CHPHQC≡CH), 3.26 (1H, br s, NCHCH), 2.84 (1H, dt, Ј 11.2, 3.5, NCHCH), 2.27 
(1H, t, Ј 2.3, ≡CH), 2.16-2.04 (3H, m, CH2+CHAHB), 1.85-1.76 (1H, m, CHAHB); 
13C NMR δ (90.6 MHz, CDCl3) 138.8 (C), 134.5 (C), 132.1 (CH), 128.2 (CH), 126.2 
(CH), 126.0 (CH), 125.6 (CH), 125.5 (CH), 78.5 (C), 73.1 (CH), 54.0 (CH2), 54.0 
(CH), 42.3 (CH2), 38.0 (CH), 27.7 (CH2), 25.7 (CH2); m/z (EI) 223 ([M]
+, 30 %), 








General procedure L was followed using amine 245 (150 mg, 
0.81 mmol), acetone (5 ml), K2CO3 (368 mg, 2.67 mmol) 
and 4-bromo-1-butyne (84 µl, 0.89 mmol). After 16 h flash 
chromatography (CH2Cl2) afforded homopropargyl amine 
96g as a yellow oil (105 mg, 55%). 
Rf [CH2Cl2:MeOH, 9:1] = 0.9; υmax (CHCl3)/cm
-1 3295 (C≡C-H), 3023, 2929; 1H 
NMR δ (360 MHz, CDCl3) 7.29 (1H, d, Ј 7.6, ArH), 7.19 (1H, t, Ј 7.5, ArH), 7.13 
(1H, t, Ј 7.4, ArH), 7.03 (1H, d, Ј 7.5, ArH), 6.10-6.04 (1H, m, CH=CH), 5.82-5.77 
(1H, m, CH=CH), 3.87 (1H, d, Ј 15.3, CHXHYAr), 3.74 (1H, d, Ј 15.3, CHXHYAr), 
3.60 (1H, br s, NCHCH), 3.18-3.11 (1H, m, NCHCH), 2.97-2.92 (2H, m, CH2), 2.52-
2.47 (2H, m, CH2), 2.17-2.10 (2H, m, CH2), 2.01 (1H, t, Ј 2.6, ≡CH), 1.83-1.75 (1H, 
m, CHAHB), 1.71-1.61 (1H, m, CHAHB); 
13C NMR δ (90.6 MHz, CDCl3) 137.4 (C), 
133.1 (C), 128.7 (CH), 127.6 (CH), 127.4 (CH), 126.5 (CH), 126.3 (CH), 125.3 
(CH), 82.8 (C), 69.0 (CH), 56.2 (CH), 52.9 (CH2), 51.0 (CH2), 37.8 (CH), 24.2 
(CH2), 20.0 (CH2), 17.3 (CH2); m/z (EI) 237 ([M]
+, 5 %), 198 (100), 141 (18), 128 








General procedure L was followed using amine 246 (40 mg, 
0.216 mmol), acetone (1.5 ml), K2CO3 (90 mg, 0.65 mmol) 
and 4-bromo-1-butyne (22 µl, 0.24 mmol). After 16 h flash 
chromatography (CH2Cl2–CH2Cl2:MeOH, 95:5) afforded 
homopropargyl amine 97g as a yellow oil (32 mg, 63%). 
Rf [CH2Cl2:MeOH, 9:1] = 0.65; υmax (CHCl3)/cm
-1 3294 (C≡C-H), 2925, 1649 
(C=C), 1452; 1H NMR δ (360 MHz, CDCl3) 7.18-7.14 (3H, m, 3xArH), 7.07-7.05 
(1H, m, ArH), 5.69-5.66 (1H, m, CH=CH), 5.60-5.56 (1H, m, CH=CH), 3.92 (2H, s, 
CH2Ar), 3.16-3.12 (2H, m, 2xCH), 2.97-2.92 (2H, m, CH2), 2.62-2.53 (1H, m, 
CHAHB), 2.49-2.42 (3H, m, CH2+CHAHB), 2.21-2.19 (2H, m, CH2), 2.00 (1H, t, Ј 
2.7, ≡CH); 13C NMR δ (90.6 MHz, CDCl3) 138.4 (C), 134.2 (C), 126.2 (2xCH), 
126.0 (CH), 125.6 (CH), 125.5 (CH), 124.1 (CH), 82.8 (C), 69.0 (CH), 54.8 (CH), 
52.9 (CH2), 52.8 (CH2), 36.8 (CH), 29.3 (CH2), 24.0 (CH2), 16.8 (CH2); m/z (EI) 237 
([M]+, 6 %), 198 (56), 182 (100), 144 (65), 128 (21); HRMS (EI) Found: [M]+, 








General procedure L was followed using amine 247 (70 mg, 
0.38 mmol), acetone (4 ml), K2CO3 (156 mg, 1.13 mmol) 
and 4-bromo-1-butyne (38 µl, 0.42 mmol). After 16 h flash 
chromatography (CH2Cl2) afforded homopropargyl amine 
98g as a yellow oil (65 mg, 73 %). 
Rf [CH2Cl2:MeOH, 9:1] = 0.9; υmax (CHCl3)/cm
-1 3294 (C≡C-H), 3022, 2925, 1648 
(C=C); 1H NMR δ (360 MHz, CDCl3) 7.28 (1H, d, Ј 7.4, ArH), 7.19 (1H, t, Ј 7.3, 
ArH), 7.12 (1H, t, Ј 7.3, ArH), 7.01 (1H, d, Ј 7.4, ArH), 5.88 (1H, d, Ј 10.7, 
CH=CH), 5.82 (1H, d, Ј 11.9, CH=CH), 3.91 (1H, d, Ј 15.3, CHXHYAr), 3.69 (1H, d, 
Ј 15.3, CHXHYAr), 3.48 (1H, br s, NCHCH), 3.08-3.02 (1H, m, NCHCH), 3.00-2.89 
(2H, m, CH2), 2.46 (2H, t, Ј 7.1, CH2), 2.24-2.18 (1H, m, CHAHB), 2.01-1.93 (3H, m, 
CH2+≡CH), 1.90-1.85 (1H, m, CHAHB); 
13C NMR δ (90.6 MHz, CDCl3) 137.3 (C), 
134.6 (C), 131.7 (CH), 127.3 (CH), 126.3 (CH), 126.2 (CH), 125.7 (CH), 125.4 
(CH), 82.8 (C), 68.9 (CH), 56.3 (CH), 52.0 (2xCH2), 35.9 (CH), 26.5 (CH2), 23.4 
(CH2), 17.6 (CH2); m/z (EI) 237 ([M]
+, 8 %), 199 (100), 169 (62), 167 (65), 164 (35), 







Tetrahydro-phenanthridine-5-carboxylic acid prop-2-ynyl ester 96h-98h 
To a solution of amines 245-247 (271 mg, 1.46 mmol) at 0 oC in CH2Cl2 (15 ml) was 
added Et3N (822 µl, 5.85 mmol) and propargyl chloroformate (573 µl, 5.85 mmol) 
dropwise. The reaction was allowed to warm to r.t. and stirred for 16 h. The reaction 
was diluted with CH2Cl2 (15 ml) and washed with HCl (3 x 15 ml, 1 M aq.). The 
combined organics were concentrated under reduced pressure to afford Poc-amide 
isomer mixture 96h-98h as a colourless oil (290 mg, 74 %). Flash chromatography 
(hexane:EtOAc, 100:5) afforded 96h (54 mg, 14%), 97h (48 mg, 12%), 98h (38 mg, 
10%) and mixture 96h-98h (130 mg, 33%) all colourless oils. 
  
(4aSR,10bSR)-4,4a,6,10b-Tetrahydro-3H-phenanthridine-5-carboxylic acid 
prop-2-ynyl ester 96h 
Rf [hexane:EtOAc, 3:1] = 0.64; υmax (CHCl3)/cm
-1 3291 
(C≡C-H), 1700 (C=O); 1H NMR δ (360 MHz, 323 K, 
CDCl3) 7.30 (1H, d, Ј 7.6, ArH), 7.24 (1H, td, Ј 7.2, 
1.8, ArH), 7.18 (1H, tdd, Ј 7.2, 1.4, 0.7, ArH), 7.12 (1H, 
d, Ј 7.6, ArH), 6.16-6.11 (1H, m, CH=CH), 5.88-5.84 
(1H, m, CH=CH), 4.81 (1H, d, Ј 16.5, CHXHYAr), 4.76 (2H, s, CH2C≡CH), 4.48 
(1H, br s, NCHCH), 4.46 (1H, d, Ј 16.5, CHXHYAr), 3.60 (1H, br s, NCH), 2.46 (1H, 
t, Ј 1.2, ≡CH), 2.34-2.22 (1H, m, CHAHB), 2.17-2.07 (1H, m, CHAHB), 1.76-1.74 
(1H, m, CHCHD), 1.67-1.55 (1H, m, CHCHD); 
13C NMR δ (90.6 MHz, 323 K, 
CDCl3) 154.6 (C), 137.4 (C), 131.7 (C), 128.3 (CH), 127.6 (CH), 127.0 (2xCH), 
126.0 (2xCH), 78.5 (C), 74.3 (CH), 52.8 (CH2), 50.7 (CH), 43.6 (CH2), 37.1 (CH), 
25.0 (CH2), 24.0 (CH2); m/z (EI) 267 ([M]
+, 34 %), 228 (100), 213 (50), 187 (37), 











prop-2-ynyl ester 97h 
Rf [hexane:EtOAc, 3:1] = 0.60; υmax (CHCl3)/cm
-1 3289 
(C≡C-H), 1703 (C=O), 1695; 1H NMR δ (360 MHz, 
323 K, CDCl3) 7.27-7.13 (4H, m, ArH), 5.71-5.68 (1H, 
m, CH=CH), 5.45-5.40 (1H, m, CH=CH), 4.84-4.80 
(2H, m, CH2), 4.66 (1H, d, Ј 16.2, CHPHQC≡CH), 4.59 (1H, d, Ј 16.2, 
CHPHQC≡CH), 4.51 (1H, br s, NCH), 3.23 (1H, t,  Ј 4.8, NCHCH), 2.88 (1H, dd, Ј 
18.3, 5.2, CHAHB), 2.67-2.59 (1H, m, CHAHB), 2.47 (1H, t, Ј 2.4, ≡CH), 2.32-2.22 
(1H, m, CHCHD), 1.56-1.45 (1H, m, CHCHD); 
13C NMR δ (90.6 MHz, 323 K, 
CDCl3) 154.5 (C), 136.2 (C), 133.5 (C), 127.0 (CH), 126.4 (CH), 126.3 (CH), 125.2 
(CH), 125.0 (CH), 123.8 (CH), 78.7 (C), 74.3 (CH), 52.8 (CH2), 50.5 (CH), 45.0 
(CH2), 35.6 (CH), 27.1 (CH2), 26.3 (CH2); m/z (EI) 267 ([M]
+, 17 %), 228 (100), 184 




prop-2-ynyl ester 98h 
Rf [hexane:EtOAc, 3:1] = 0.64; υmax (CHCl3)/cm
-1 3292 
(C≡C-H), 1703 (C=O), 1433; 1H NMR δ (360 MHz, 
323 K, CDCl3) 7.36 (1H, d, Ј 7.6, ArH), 7.28-7.15 (2H, 
m, 2xArH), 7.07 (1H, d, Ј 7.3, ArH), 5.75-5.72 (1H, m, 
CH=CH), 5.54 (1H, d, Ј 10.1, CH=CH), 5.17 (1H, br s, NCHCH), 4.92 (1H, d, Ј 
16.6, CHXHYAr), 4.78-4.77 (2H, m, CH2C≡CH), 4.33 (1H, d, Ј 16.6, NCHCH), 3.35 
(1H, br s, NCH), 2.47-2.40 (2H, m, ≡CH+CHAHB), 2.04-1.99 (1H, m, CHAHB), 1.95-
1.72 (2H, m, CH2); 
13C NMR δ (90.6 MHz, 323 K, CDCl3) 154.6 (C), 135.0 (C), 
133.4 (C), 131.4 (CH), 127.0 (CH), 126.8 (CH), 126.6 (CH), 125.9 (CH), 125.8 
(CH), 78.5 (C), 74.3 (CH), 53.0 (CH2), 50.8 (CH), 42.8 (CH2), 34.2 (CH), 25.1 
(CH2), 20.3 (CH2); m/z (EI) 267 ([M]
+, 14 %), 228 (100), 184 (33), 167 (40); HRMS 














General procedure M - RRM reactions of amines 
To a solution of the appropriate amine (1 eq) in CH2Cl2 (1 ml) was added HCl (1-2 
ml, 1 M in Et2O) and the solvent removed under reduced pressure. The resultant 
hydrochloride salt was dissolved in CH2Cl2 (10 ml) and degassed with ethylene for 
10 mins. Hoveyda-Grubbs catalyst 2nd generation (0.15 eq) was added and the 
reaction stirred under an atmosphere of ethylene for 40 h at r.t. The crude product 
was washed with NaOH (3 x 20 ml, 1 M aq.) and the combined organics dried 
(MgSO4), concentrated under reduced pressure and purified by flash chromatography 




General procedure M was followed using propargyl amine 
97f (50 mg, 0.22 mmol), CH2Cl2 (1 ml) and HCl (2 ml, 1 
M in Et2O), then CH2Cl2 (10 ml) and Hoveyda-Grubbs 
catalyst 2nd generation (21 mg, 33.6 µmol). Flash 
chromatography (CH2Cl2:MeOH, 100-100:1) afforded 
isoquinoline 237 as a colourless oil (40 mg, 71%). 
Rf [CH2Cl2:MeOH, 95:5] = 0.31; υmax (CHCl3)/cm
-1 2925, 1655, 1636; 1H NMR δ 
(360 MHz, CDCl3) 7.33 (1H, d, Ј 6.6, ArH), 7.18-7.14 (2H, m, 2xArH), 7.04-7.02 
(1H, m, ArH), 6.34 (1H, dd, Ј 17.8, 10.9, CCH=CH2), 6.00-5.88 (1H, dddd,  Ј 17.1, 
10.3, 8.4, 5.6, CH2CH=CH2), 5.86-5.82 (1H, m, CH2CH=C), 5.16 (1H, dq, Ј 17.1, 
1.2, CH2CH=CHCHD), 5.12 (1H, br d, Ј 10.3, CH2CH=CHCHD), 5.06 (1H, d, Ј 17.8, 
CCH=CHEHF), 4.97 (1H, d, Ј 10.9, CCH=CHEHF), 4.07 (1H, d, Ј 15.8, CHXHYAr), 
3.78 (1H, d, Ј 15.8, CHXHYAr), 3.77 (1H, d, Ј 17.0, NCHPHQ), 3.46 (1H, d, Ј 17.0, 
NCHPHQ), 3.34-3.30 (2H, m, NCHCH), 2.91-2.84 (1H, m, CH2=CHCHAHB), 2.19-
2.10 (1H, m, CH2=CHCHAHB), 2.06-1.94 (2H, m, CHCH2); 
13C NMR δ (90.6 MHz, 
CDCl3) 137.6 (CH), 136.8 (CH), 135.6 (C), 134.4 (C), 131.8 (C), 126.9 (CH), 126.3 
(CH), 126.2 (CH), 126.0 (CH), 125.7 (CH), 116.4 (CH2), 110.6 (CH2), 53.8 (CH), 
52.3 (CH2), 50.0 (CH2), 40.6 (CH), 34.2 (CH2), 20.1 (CH2); m/z (ESI+) 252 
([M+H]+, 98 %), 211 (15), 172 (100), 145 (8), 131 (100); HRMS (EI) Found: [M]+, 
251.1675. C18H21N requires 251.1669. This compound was also fully characterised 






b]isoquinoline 238  
General procedure M was followed using propargyl amine 
98f (10 mg, 45 µmol), CH2Cl2 (1 ml) and HCl (1 ml, 1 M in 
Et2O), then CH2Cl2 (5 ml) and Hoveyda-Grubbs catalyst 2
nd 
generation (4.2 mg, 6.7 µmol). Flash chromatography 
(CH2Cl2:MeOH, 100-100:5) afforded isoquinoline 238 as a 
yellow oil (9 mg, 80%). This compound was not stable therefore full characterisation 
was not possible. 
Rf [CH2Cl2:MeOH, 95:5] = 0.36; 
1H NMR δ (360 MHz, CDCl3) 7.18-7.16 (3H, m, 
3xArH), 7.15-7.10 (1H, m, ArH), 6.52 (1H, dd, Ј 17.5, 10.9, CCH=CH2), 5.89-5.77 
(2H, m, CHCH=C+CH2CH=CH2), 5.14 (1H, br d, Ј 10.9, CCH=CHCHT), 5.08 (1H, 
br d, Ј 17.5, CCH=CHCHT), 5.03 (1H, dq, Ј 17.1, 1.5, CH2CH=CHCHT), 4.94 (1H, 
dq, Ј 11.2, 1.9, CH2CH=CHCHT), 4.08 (1H, d, Ј 14.6, CHXHYAr), 3.93-3.84 (4H, m, 
CHXHYAr+NCH2+CH), 2.96-2.92 (1H, m, CH), 2.24-2.15 (2H, m, CH2), 1.86-1.78 
(2H, m, CH2); 
13C NMR δ (90.6 MHz, CDCl3) 131.0 (CH), 128.9 (CH), 128.1 
(2xCH), 126.6 (CH), 126.0 (CH), 125.6 (CH), 114.8 (CH2), 114.2 (CH2), 58.2 (CH), 
55.5 (CH2), 53.6 (CH2), 41.3 (CH), 32.0 (CH2), 30.7 (CH2). 
13C data was assigned 
using HSQC data, therefore four quaternary carbons remain unassigned. 








General procedure M was followed using homopropargyl 
amine 96g (41 mg, 0.17 mmol), CH2Cl2 (1 ml) and HCl (2 
ml, 1 M in Et2O) then CH2Cl2 (10 ml) and Hoveyda-
Grubbs catalyst 2nd generation (16 mg, 26 µmol). Flash 
chromatography (CH2Cl2–CH2Cl2:MeOH, 100:0.5) 
afforded phenanthridine 96j as a colourless oil (31 mg, 69%). 
Rf [CH2Cl2:MeOH, 95:5] = 0.48; υmax (CHCl3)/cm
-1 3854, 3745, 2925, 1653, 1457; 
1H NMR δ (250 MHz, CDCl3) 7.30 (1H, d, Ј 7.3, ArH), 7.20 (1H, td, Ј 7.0, 1.5, 
ArH), 7.13 (1H, td, Ј 6.3, 1.8, ArH), 7.05 (1H, d, Ј 7.3, ArH), 6.41 (1H, dd, Ј 17.6, 
10.3, CCH=CH2), 6.12-6.05 (1H, m, CHCH=CH), 5.85-5.77 (1H, m, CH=CHCH2), 
5.32 (1H, d, Ј 17.6, CH=CHUHV), 5.13-5.08 (3H, m, CH=CHUHV+CH2), 3.91 (1H, d, 
Ј 15.5, CHXHYAr), 3.77 (1H, d, Ј 15.3, CHXHYAr), 3.62 (1H, br s, NCHCH), 3.16 
(1H, ddd, Ј 10.0, 5.3, 2.8, NCHCH), 2.94-2.75 (2H, m, CH2CH2), 2.59-2.52 (2H, m, 
CH2CH2), 2.17-2.08 (2H, m, =CHCH2), 1.86-1.76 (1H, m, CHNCHAHB), 1.71-1.58 
(1H, m, CHNCHAHB); 
13C NMR δ (62.9 MHz, CDCl3) 144.6 (C), 138.7 (CH), 137.5 
(C), 133.3 (C), 128.8 (CH), 127.6 (CH), 127.4 (CH), 126.4 (CH), 126.3 (CH), 125.3 
(CH), 116.5 (CH2), 113.3 (CH2), 56.5 (CH), 53.4 (CH2), 51.2 (CH2), 37.8 (CH), 29.6 
(CH2), 29.4 (CH2), 24.3 (CH2); m/z (EI) 265 ([M]
+, 6 %), 198 (100); HRMS (EI) 
Found: [M]+, 265.1827. C19H23N requires 265.1825. This compound was also 









General procedure M was followed using homopropargyl 
amine 97g (41 mg, 0.17 mmol), CH2Cl2 (1 ml) and HCl (2 
ml, 1 M in Et2O), then CH2Cl2 (10 ml) Hoveyda-Grubbs 
catalyst 2nd generation (16 mg, 26 µmol). Flash 
chromatography (CH2Cl2–CH2Cl2:MeOH, 100:0.5) 
afforded phenanthridine 97j as a colourless oil (25 mg, 54%). 
Rf [CH2Cl2:MeOH, 95:5] = 0.51; υmax (CHCl3)/cm
-1 2907, 1646 (C=C); 1H NMR δ 
(360 MHz, CDCl3) 7.19-7.13 (3H, m, 3xArH), 7.09-7.07 (1H, m, ArH), 6.40 (1H, dd, 
Ј 17.5, 10.7, CCH=CH2), 5.69-5.66 (1H, m, CH=CH), 5.58-5.55 (1H, m, CH=CH), 
5.32 (1H, d, Ј 17.5, CH=CHUHV), 5.31 (1H, br s, C=CHRHS), 5.11-5.07 (2H, m, 
CH=CHUHV+C=CHRHS), 5.12 (2H, s, CH2), 3.94 (2H, s, CH2Ar), 3.20-3.10 (2H, m, 
NCHCH), 2.92-2.81 (2H, m, CH2), 2.60-2.43 (4H, m, 2xCH2), 2.22-2.18 (2H, m, 
CH2); 
13C NMR δ (90.6 MHz, CDCl3) 144.7 (C), 138.8 (CH), 138.4 (C), 134.6 (C), 
126.3 (CH), 126.1 (CH), 126.0 (CH), 125.6 (CH), 125.4 (CH), 124.5 (CH), 116.5 
(CH2), 113.3 (CH2), 55.0 (CH), 53.3 (CH2), 53.0 (CH2), 36.8 (CH), 29.2 (CH2), 28.8 
(CH2), 23.6 (CH2); m/z (EI) 265 ([M]
+, 7 %), 198 (16), 197 (100), 169 (12); HRMS 









General procedure M was followed using homopropargyl 
amine 98g (12 mg, 50.6 µmol), CH2Cl2 (1 ml) and HCl (1 
ml, 1 M in Et2O), then CH2Cl2 (10 ml) and Hoveyda-
Grubbs catalyst 2nd generation (5 mg, 7.6 µmol). Flash 
chromatography (CH2Cl2–CH2Cl2:MeOH, 100:0.5) 
afforded phenanthridine 98j as a colourless oil (9 mg, 67%).   
Rf [CH2Cl2:MeOH, 95:5] = 0.42; υmax (CHCl3)/cm
-1 3022, 2925, 1453; 1H NMR δ 
(360 MHz, 323 K, CDCl3) 7.29 (1H, d, Ј 9.9, ArH), 7.21 (1H, t, Ј 7.5, ArH), 7.14 
(1H, t, Ј 7.5, ArH), 7.03 (1H, d, Ј 7.5, ArH), 6.38 (1H, dd, Ј 17.6, 10.6, CCH=CH2), 
5.89 (2H, br s, CH=CH), 5.32 (1H, d, Ј 17.6, CH=CHUHW), 5.12-5.07 (3H, m, 
CH2+CH=CHUHW), 4.01 (1H, d, Ј 15.2, CHXHYAr), 3.76 (1H, d, Ј 15.5, CHXHYAr), 
3.63 (1H, br s, NCHCH), 3.14 (1H, br s, NCHCH), 2.99-2.94 (1H, m, CHAHB), 2.91-
2.83 (1H, m, CHAHB), 2.62-2.50 (2H, m, CH2), 2.36-2.26 (1H, m, CHCHD), 1.99-
1.90 (3H, m, CHCHD+CH2); 
13C NMR δ (62.9 MHz, CDCl3) 144.6 (C), 138.8 (CH), 
137.2 (C), 134.9 (C), 131.4 (CH), 127.2 (CH), 126.3 (CH), 126.2 (CH), 125.7 (CH), 
125.4 (CH), 116.4 (CH2), 113.3 (CH2), 56.5 (CH), 52.4 (CH2), 52.0 (CH2), 35.8 
(CH), 29.5 (CH2), 26.5 (CH2), 23.2 (CH2); m/z (EI) 265 ([M]
+, 8 %), 212 (70), 198 








General procedure N - RRM reactions of Poc analogues 
A solution of the appropriate amide (1 eq) in CH2Cl2 (10 ml) was degassed with 
ethylene for 10 mins. Hoveyda-Grubbs catalyst 2nd generation (0.15 eq) was added 
and the reaction stirred under an atmosphere of ethylene for 40 h at r.t. The crude 
product was concentrated under reduced pressure and purified by flash 
chromatography to afford the appropriate product. 
 
(4aSR,10bSR)-4,4a,6,10b-Tetrahydro-3H-phenanthridine-5-carboxylic acid 2-
methylene-but-3-enyl ester 96k 
General procedure N was followed using Poc amide 
96h (25 mg, 93.5 µmol), CH2Cl2 (5 ml) and Hoveyda-
Grubbs catalyst 2nd generation (9 mg, 14.0 µmol). Flash 
chromatography (hexane:EtOAc, 20:1) afforded 
phenanthridine 96k as a colourless oil (20 mg, 73%).   
Rf [hexane:EtOAc, 3:1] = 0.79; υmax (CHCl3)/cm
-1 2929, 1695 (C=O), 1418; 1H 
NMR δ (360 MHz, 323 K, CDCl3) 7.30 (1H, d, Ј 7.4, ArH), 7.23 (1H, td, Ј 7.6, 1.4, 
ArH), 7.18 (1H, td, Ј 7.9, 1.1, ArH), 7.12 (1H, d, Ј 6.8, ArH), 6.41 (1H, dd, Ј 18.1, 
11.1, CCH=CH2), 6.11-6.11 (1H, m, CHCH=CH), 5.88-5.85 (1H, m, CH=CHCH2), 
5.33 (1H, d, Ј 18.1, CCH=CHUHV), 5.29 (1H, br s, C=CHRHS), 5.23 (1H, br s, 
C=CHRHS), 5.15 (1H, d, Ј 11.1, CCH=CHUHV), 4.87 (2H, s, OCH2), 4.80 (1H, d, Ј 
16.4, CHXHYAr), 4.48 (1H, br s, NCH), 4.46 (1H, d, Ј 16.4, CHXHYAr), 3.60 (1H, br 
s, NCHCH), 2.31-2.22 (1H, m, CHCHAHB), 2.15-2.08 (1H, m, CHCHAHB), 1.78-
1.73 (1H, m, NCHCHCHD), 1.66-1.64 (1H, m, NCHCHCHD); 
13C NMR δ (62.9 
MHz, CDCl3) 155.2 (C), 141.7 (C), 137.4 (C), 136.1 (2xCH), 131.9 (C), 128.3 
(2xCH), 127.6 (CH), 126.9 (2xCH), 125.9 (CH), 117.3 (CH2), 114.5 (CH2), 64.5 
(CH2), 50.5 (CH), 43.6 (CH2), 36.8 (CH), 25.1 (CH2); m/z (EI) 295 ([M]
+, 48 %), 
268 (50), 228 (100), 184 (43), 167 (40); HRMS (EI) Found: [M]+, 295.1567. 











methylene-but-3-enyl ester 97k 
General procedure N was followed using Poc amide 
96h (24 mg, 89.9 µmol),CH2Cl2 (4 ml) and Hoveyda-
Grubbs catalyst 2nd generation (8.5 mg, 13.5 µmol). 
Flash chromatography (hexane:EtOAc, 20:1) afforded 
phenanthridine 97k as a colourless oil (16 mg, 60%).   
Rf [hexane:EtOAc, 3:1] = 0.66; υmax (CHCl3)/cm
-1 3026, 2929, 1699 (C=O), 1412; 
1H NMR δ (360 MHz, 323 K, CDCl3) 7.27-7.17 (4H, m, 4xArH), 6.42 (1H, dd, Ј 
18.1, 11.1, CCH=CH2), 5.71-5.67 (1H, m, CH=CH), 5.44-5.40 (1H, m, CH=CH), 
5.34 (1H, d, Ј 18.1, CCH=CHUHW), 5.30 (1H, br s, C=CHRHS), 5.25 (1H, br s, 
C=CHRHS), 5.16 (1H, d, Ј 11.1, CCH=CHUHW), 4.92 (1H, d, Ј 13.3, OCHPHQ), 4.85 
(1H, d, Ј 13.3, OCHPHQ), 4.66 (1H, d, Ј 16.1, CHXHYAr), 4.60 (1H, d, Ј 16.1, 
CHXHYAr), 4.35 (1H, br s, NCH), 3.23 (1H, br s, NCHCH), 2.88 (1H, dd, Ј 18.2, 
5.3, CHCHAHB), 2.64-2.55 (1H, m, CHCHAHB), 2.28-2.23 (1H, m, CHNCHCHD), 
1.61-1.49 (1H, m, CHNCHCHD); 
13C NMR δ (62.9 MHz, CDCl3) 155.1 (C), 141.3 
(C), 136.1 (C+CH), 133.4 (C), 126.8 (CH), 126.4 (CH), 126.2 (CH), 125.0 (CH), 
124.9 (CH), 123.7 (CH), 117.3 (CH2), 114.5 (CH2), 64.4 (CH2), 53.3 (CH), 50.2 
(CH2), 44.8 (CH2), 35.5 (CH), 26.1 (CH2); m/z (EI) 295 ([M]
+, 12 %), 241 (100), 228 
(13), 198 (13), 196 (25), 174 (12), 167 (10), 130 (69); HRMS (EI) Found: [M]+, 
295.1567. C19H21NO2 requires 295.1567. This compound was also characterised by 










methylene-but-3-enyl ester 98k 
General procedure N was followed using Poc amide 98h 
(19 mg, 71.0 µmol), CH2Cl2 (4 ml) and Hoveyda-Grubbs 
catalyst 2nd generation (7 mg, 10.7 µmol). Flash 
chromatography (CH2Cl2) to afford phenanthridine 98k as 
a colourless oil (20 mg, 96%).   
Rf [hexane:EtOAc, 3:1] = 0.63; υmax (CHCl3)/cm
-1 3025, 2927, 1700 (C=O), 1430; 
1H NMR δ (360 MHz, 323 K, CDCl3) 7.36 (1H, d, Ј 7.5, ArH), 7.27-7.17 (2H, m, 
2xArH), 7.06 (1H, d, Ј 7.3, ArH), 6.39 (1H, dd, Ј 17.8, 10.8, CCH=CH2), 5.76-5.68 
(1H, m, CH=CHCH2), 5.54 (1H, br d, Ј 10.8, NCHCH=CH), 5.31 (1H, d, Ј 17.8, 
CCH=CHUHV), 5.26 (1H, s, C=CHRHS), 5.22 (1H, s, C=CHRHS), 5.14 (1H, d, Ј 10.5, 
CCH=CHUHV), 5.13 (1H, br s, NCHCH), 4.93 (1H, d, Ј 16.8, CHXHYAr), 4.86 (2H, 
s, OCH2), 4.32 (1H, d, Ј 16.8, CHXHYAr), 3.33 (1H, br s, NCHCH), 2.44-2.39 (1H, 
m, CHCHAHB), 2.04-1.99 (1H, m, CHCHAHB), 1.88-1.81 (2H, m, =CHCH2); 
13C 
NMR δ (90.6 MHz, 323 K, CDCl3) 155.3 (C), 141.8 (C), 136.2 (CH), 135.1 (C), 
133.7 (C), 131.3 (CH), 127.3 (CH), 126.7 (CH), 126.6 (CH), 125.8 (2xCH), 117.1 
(CH2), 114.5 (CH2), 64.7 (CH2), 50.7 (CH), 42.8 (CH2), 34.2 (CH), 25.2 (CH2), 20.3 
(CH2); m/z (EI) 295 ([M]
+, 28 %), 228 (93), 199 (90), 184 (27), 167 (41); HRMS 
(EI) Found: [M]+, 295.1567. C19H21NO2 requires 295.1567. This compound was also 










General procedure L was followed using amine 246 (70 mg, 
0.38 mmol), acetone (4 ml), K2CO3 (157 mg, 1.13 mmol) and 4-
bromo-1-butene (46 µl, 0.45 mmol). After 16 h, flash 
chromatography (CH2Cl2) afforded butenyl amine 97m (84 mg, 
93%) as a yellow oil. 
Rf [hexane:EtOAc, 3:1] = 0.68; υmax (CHCl3)/cm
-1 3024, 2924, 1647, 1446; 1H NMR 
δ (250 MHz, CDCl3) 7.22-7.11 (3H, m, 3xArH), 7.08-7.05 (1H, m, ArH), 5.87 (1H, 
ddt, Ј 17.1, 10.2, 6.8,  CH=CH2), 5.71-5.64 (1H, m, CH=CH), 5.61-5.54 (1H, m, 
CH=CH), 5.10 (1H, dq, Ј 17.1, 1.7, CH=CHTHC), 5.02 (1H, dq, Ј 10.2, 1.0, 
CH=CHTHC), 3.90 (2H, s, CH2Ar), 3.18-3.11 (2H, m, NCHCH), 2.87-2.56 (3H, m, 
CH2+CHAHB), 2.46-2.29 (3H, m, CH2+CHAHB), 2.17 (2H, br s, CH2); 
13C NMR δ 
(69.2 MHz, CDCl3) 138.4 (C), 136.7 (CH), 134.7 (C), 126.3 (CH), 126.1 (CH), 125.9 
(CH), 125.5 (CH), 125.4 (CH), 124.4 (CH), 115.4 (CH2), 54.8 (CH), 53.6 (CH2), 
52.9 (CH2), 36.8 (CH), 31.3 (CH2), 29.2 (CH2), 23.5 (CH2); m/z (EI) 239 ([M]
+, 2 
%), 212 (10), 198 (100), 185 (36), 144 (37); HRMS (EI) Found: [M]+, 239.1671. 
C17H21N requires 239.1669. 
 
6.4 Experimental for Chapter four  
 
 
General procedure P - Dihydroxylation  
To a solution of the appropriate phenanthridines (1 eq) in THF and H2O at r.t was 
added OsO4 (0.07 eq, 2.5% 
w/w in 
tBuOH) and NMO (3 eq) and the reaction was 
stirred for 16 h. The reaction mixture was poured onto Na2SO3 (30 ml, sat. aq.) and 
extracted with EtOAc (3 x 30 ml). The combined organics were dried (MgSO4), 
concentrated under reduced pressure and purified to afford the appropriate mixture of 
diols. Purification by flash chromatography afforded either a mixture of the isolated 
isomers/diol mixture, or purely the diol mixture. In cases where the isolated isomers 










acid tert-butyl ester 206a-208a (∆1,2, ∆2,3, ∆3,4  isomer) 
General procedure P was followed using phenanthridines 
195a-197a (84 mg, 0.282 mmol), THF (165 µl), H2O 
(820 µl), OsO4 (247 µl, 2.5% 
w/w in 
tBuOH, 19.7 µmol) 
and NMO (132 mg, 0.846 mmol). Flash chromatography 
(CH2Cl2-CH2Cl2:MeOH, 100:2) afforded mixture of 
diols 206a-208a (73 mg, 78%). Further isolation of the 
individual diol products 206a-208a was not found to be possible by HPLC so these 
compounds were taken on as a mixture.  
Rf [CH2Cl2:MeOH, 9:1] = 0.57; υmax (CHCl3)/cm
-1 3421 (OH), 1664 (C=O); m/z (EI) 
319 ([M]+, 2 %), 262 ([M-tBu]+, 100), 218 ([M-Boc]+, 22), 184 (75). 
 
9-Fluoro-3,4-dihydroxy-2,3,4,4a,6,10b-hexahydro-1H-phenanthridine-5-
carboxylic acid tert-butyl ester 206b-208b 
General procedure P was followed using phenanthridines 
195b-197b (50 mg, 0.165 mmol), THF (920 µl), H2O (184 
µl), OsO4 (144 µl, 2.5% 
w/w in 
tBuOH, 11.5 µmol) and 
NMO (58 mg, 0.495 mmol). Flash chromatography 
(CH2Cl2:MeOH, 100:2) afforded mixture of diols 206b-
208b (46 mg, 82%). HPLC (EtOAc:hexane, 3:1) of this 
mixture afforded ∆1,2 diol 206b (10 mg, 18%), ∆ 2,3 diol 207b (15.3 mg, 2 %), ∆ 3,4 
diol 208b (11.4 mg, 20%), and mixed diol fractions (9 mg, 16%) giving an overall 























phenanthridine-5-carboxylic acid tert-butyl ester 206b (∆1,2 isomer) 
Rf [CH2Cl2:MeOH, 9:1] = 0.43; Rt (EtOAc:hexane, 3:1, 
flow rate: 10 ml/min) = 15 min; υmax (CHCl3)/cm
-13425 
(OH), 2976, 2931, 1664 (C=O), 1367, 1167; 1H NMR δ 
(360 MHz, 323 K, CDCl3) 7.13-7.04 (2H, m, 2xArH), 
6.92 (1H, td, Ј 10.9, 2.6, ArH), 4.70-4.62 (3H, m, 
2xCH+CHXHYAr), 4.31 (1H, d, Ј 16.9, CHXHYAr), 3.73-
3.68 (1H, m, CH), 3.37 (1H, br s, CH), 2.51 (1H, br s, 
OH), 1.92-1.84 (1H, m, CHAHB), 1.70-1.52 (2H, m, CHAHB+CHCHD), 1.51 (9H, s, 
3xCH3), 1.91-1.82 (1H, m, CHCHD); 
13C NMR δ (90.6 MHz, 323 K, CDCl3)  161.9 
(1C, d, Ј 245.2, C), 154.8 (C), 135.3 (1C, d, Ј 6.9, C), 129.1 (C), 128.1 (1C, d, Ј 8.2, 
CH), 113.5 (1C, d, Ј 21.7, CH), 112.5 (1C, d, Ј 22.4, CH), 80.1 (C), 71.1 (CH), 67.4 
(CH), 46.9 (CH), 43.0 (CH2), 42.9 (CH), 28.4 (3xCH3), 27.3 (CH2), 24.2 (CH2) ; m/z 
(EI)  337 ([M]+, 1 %), 280 ([M-tBu]+, 100), 236 ([M-Boc]+, 61), 192 (19), 162 (26). 
 
(2RS,3SR,4aSR,10bSR)-9-Fluoro-2,3-dihydroxy-2,3,4,4a,6,10b-hexahydro-1H-
phenanthridine-5-carboxylic acid tert-butyl ester 207b (∆2,3 isomer) 
Rf [CH2Cl2:MeOH, 9:1] = 0.53; Rt (EtOAc:hexane, 3:1, 
flow rate: 10 ml/min) = 20 min; υmax (CHCl3)/cm
-1 3421 
(OH), 2935, 1670 (C=O), 1412, 1167; 1H NMR δ (360 
MHz, 323 K, CDCl3) 7.17 (1H, d, Ј 10.1, ArH), 7.11-7.07 
(1H, m, ArH), 6.91 (1H, td, Ј 8.3, 1.8, ArH), 4.80-4.72 
(1H, m, CH), 4.66 (1H, d, Ј 17.1, CHXHYAr),  4.31 (1H, d, 
Ј 17.0, CHXHYAr), 3.93 (1H, br s, CH), 3.64-3.60 (1H, m, CH), 3.23 (1H, br s, CH), 
2.40-2.23 (2H, m, CH2), 1.92-1.89 (1H, m, CHAHB), 1.52 (9H, s, 3xCH3), 1.45-1.42 
(1H, m, CHAHB); 
13C NMR δ (62.9 MHz, CDCl3) 164.9 (1C, d, Ј 133.4, C), 154.7 
(C), 136.8 (C), 128.6 (C), 127.9 (1C, d, Ј 8.3, CH), 113.4 (1C, d, Ј 21.6, CH), 112.5 
(1C, d, Ј 21.9, CH), 80.2 (C), 69.1 (CH), 66.6 (CH), 46.3 (CH), 42.8 (CH2), 36.4 
(CH), 31.3 (CH2), 29.1 (CH2), 28.4 (3xCH3); m/z (EI) 337 ([M]
+, 1 %), 280 ([M-




















phenanthridine-5-carboxylic acid tert-butyl ester 208b (∆3,4 isomer) 
Rf [CH2Cl2:MeOH, 9:1] = 0.47; Rt (EtOAc:hexane, 3:1, 
flow rate: 8 ml/min) = 17 min; υmax (CHCl3)/cm
-1 3404 
(OH), 2937, 1670 (C=O), 1421, 1169; 1H NMR δ (360 
MHz, 323 K, CDCl3) 7.11 (1H, dd, Ј 8.5, 5.7, ArH), 7.03 
(1H, dd, Ј 10.0, 1.7, ArH), 6.92 (1H, m, ArH), 4.73-4.61 
(2H, m, CH+CHXHYAr), 4.41 (1H, d, Ј 16.4, CHXHYAr), 
3.96 (1H, d, Ј 2.7, CH), 3.30-3.25 (2H, m, 2xCH), 2.85-2.72 (1H, m, CHAHB), 2.17-
2.12 (1H, m, CHAHB), 1.87-1.82 (1H, m, CHCHD), 1.60-1.50 (10H, m, 
CHCHD+3xCH3); 
13C NMR δ (90.6 MHz, 323 K, CDCl3) 162.1 (1C, d, Ј 245.1, C), 
155.2 (C), 137.1 (1C, d, Ј 2.8, C), 128.9 (C), 128.0 (1C, d, Ј 8.2, CH), 113.4 (1C, d, Ј 
21.7, CH), 112.3 (1C, d, Ј 22.1, CH), 81.0 (C), 69.5 (2xCH), 52.7 (CH), 42.1 (CH2), 
37.1 (CH), 28.4 (3xCH3), 25.4 (CH2), 20.1 (CH2); m/z (EI) 337 ([M]
+, 1 %), 281 
(36), 280 ([M-tBu])+, 9), 236 ([M-Boc]+, 100), 218 (11), 206 (12), 192 (13), 162 (40). 
 
Dihydroxy-8-methoxy-2,3,4,4a,6,10b-hexahydro-1H-phenanthridine-5-
carboxylic acid tert-butyl ester 206c-208c 
General procedure P was followed using 
phenanthridines 195c-197c (152 mg, 0.482 mmol), 
THF (2.70 ml), H2O (541 µl), OsO4 (423 µl, 2.5% 
w/w 
in tBuOH, 33.8 µmol) and NMO (226 mg, 1.93 mmol). 
Flash chromatography (CH2Cl2:MeOH, 100:1-10:1) 
afforded mixture of diols 195c-197c (159 mg, 95%). 
HPLC (EtOAc:hexane, 4:1) of this mixture afforded ∆1,2 diol 206c (21 mg, 13%), ∆ 
2,3 diol 207c (20 mg, 12%), ∆3,4 diol 208c (32 mg, 19%), and mixed diol fractions (32 






















phenanthridine-5-carboxylic acid tert-butyl ester 206c (∆1,2 isomer) 
Rf [CH2Cl2:MeOH, 9:1] = 0.49; Rt (EtOAc:hexane, 4:1, 
flow rate: 10 ml/min) = 21 min; υmax (CHCl3)/cm
-1 3423 
(OH), 2933, 1687 (C=O); 1H NMR δ (360 MHz, 323 
K, CDCl3) 7.24 (1H, d, Ј 8.6, ArH), 6.79 (1H, dd, Ј 8.6, 
2.7, ArH), 6.68 (1H, d, Ј 2.7, ArH), 4.72-4.63 (3H, m, 
2xCH+CHXHYAr), 4.30 (1H, d, Ј 17.1, CHXHYAr), 
3.80 (3H, s, CH3),  3.75-3.69 (1H, m, CH), 3.35 (1H, br 
s, CH), 2.60 (1H, br s, OH), 1.93-1.87 (1H, m, CHAHB), 1.69-1.64 (1H, m, CHAHB), 
1.57-1.41 (11H, m, CH2+3xCH3); 
13C NMR δ (62.9 MHz, CDCl3) 157.9 (C), 154.8 
(C), 134.6 (C), 126.5 (CH), 124.8 (C), 112.9 (CH), 111.5 (CH), 79.9 (C), 71.1 (CH), 
67.3 (CH), 55.2 (CH3), 46.8 (CH), 43.5 (CH2), 42.0 (CH), 28.4 (3xCH3), 27.3 (CH2), 
23.9 (CH2); m/z (EI) 349 ([M]




phenanthridine-5-carboxylic acid tert-butyl ester 207c (∆2,3 isomer) 
Rf [CH2Cl2:MeOH, 9:1] = 0.49; Rt (EtOAc:hexane, 4:1, 
flow rate: 10 ml/min) = 24 min; υmax (CHCl3)/cm
-1 3392 
(OH), 2935, 1672 (C=O); 1H NMR δ (360 MHz, 323 
K, CDCl3) 7.37 (1H, d, Ј 8.5, ArH), 6.82 (1H, dd, Ј 8.5, 
2.7, ArH), 6.67 (1H, d, Ј 2.6, ArH), 4.76-4.67 (2H, m, 
CH+CHXHYAr), 4.31 (1H, d, Ј 17.4, CHXHYAr), 3.92 
(1H, d, Ј 3.1, CH), 3.81 (3H, s, CH3), 3.66-3.61 (1H, m, 
CH), 3.21 (1H, m, CH), 2.45-2.42 (1H, m, CHAHB), 2.26-2.17 (1H, m, CHAHB), 
1.91-1.86 (1H, m, CHCHD), 1.52 (9H, s, 3xCH3), 1.41 (1H, t, Ј 7.3, CHCHD); 
13C 
NMR δ (90.6 MHz, 323 K, CDCl3) 158.2 (C), 154.7 (C), 134.5 (C), 126.8 (CH), 
126.5 (C), 113.0 (CH), 111.5 (CH), 79.9 (C), 69.6 (CH), 66.7 (CH), 55.2 (CH3), 46.5 
(CH), 43.7 (CH2), 35.7 (CH), 31.3 (CH2), 29.5 (CH2), 28.5 (3xCH3); m/z (EI)  349 



















phenanthridine-5-carboxylic acid tert-butyl ester 208c (∆3,4 isomer) 
Rf [CH2Cl2:MeOH, 9:1] = 0.49; Rt (EtOAc:hexane, 4:1, 
flow rate: 10 ml/min) = 17 min; υmax (CHCl3)/cm
-1 3492 
(OH), 2935, 1668 (C=O); 1H NMR δ (360 MHz, 323 
K, CDCl3) 7.23 (1H, d, Ј 8.7, ArH), 6.82 (1H, dd, Ј 5.9, 
2.7, ArH), 6.69 (1H, d, Ј 2.7, ArH), 4.80-4.62 (2H, m, 
CH+CHXHYAr), 4.41 (1H, d, Ј 16.7, CHXHYAr), 3.94 
(1H, d, Ј 2.8, CH), 3.81 (3H, s, CH3), 3.34-3.31 (1H, m, CH), 3.24-3.22 (1H, m, CH), 
2.23-2.21 (1H, m, CHAHB), 1.85-1.80 (1H, m, CHAHB), 1.57-1.52 (10H, s, 
CHCHD+3xCH3), 1.43-1.39 (1H, m, CHCHD); 
13C NMR δ (90.6 MHz, 323 K, 
CDCl3) 158.2 (2xC), 134.5 (C), 126.4 (CH), 123.4 (CH), 113.0 (CH), 111.6 (CH), 
80.8 (C), 69.6 (2xCH), 55.3 (CH3), 53.3 (CH), 46.8 (CH2), 36.2 (CH), 28.4 (3xCH3), 
25.3 (CH2), 20.1 (CH2); m/z (EI) 349 ([M]
+, 21 %), 292 ([M-tBu)]+, 100), 257 (56), 
248 ([M-Boc]+, 33), 230 (61), 204 (55). 
 
Dihydroxy-8,9-dimethoxy-2,3,4,4a,6,10b-hexahydro-1H-phenanthridine-5-
carboxylic acid tert-butyl ester 206d-208d 
General procedure P was followed using 
phenanthridines 195d-197d (30 mg, 87 µmol), THF 
(488 µl), H2O (98 µl), OsO4 (76 µl, 2.5% 
w/w in 
tBuOH, 6.1 µmol) and NMO (31 mg, 0.26 mmol). 
Flash chromatography (CH2Cl2:MeOH, 100:5) 
afforded mixture of diols 206d-208d (23 mg, 70 %). 
HPLC (EtOAc:hexane, 84:16) afforded ∆1,2 diol 206d (2 mg, 6%), diol mixture 206d 
and 207d (6.2 mg, 19%) and ∆ 3,4 diol 208d (10 mg, 30%), giving an overall yield 






















1H-phenanthridine-5-carboxylic acid tert-butyl ester 206d (∆1,2 isomer) 
Rf [CH2Cl2:MeOH, 9:1] = 0.48; Rt (EtOAc:hexane, 
84:16, flow rate: 10 ml/min) = 38 min; υmax 
(CHCl3)/cm
-13423 (OH), 2937, 1670 (C=O), 1520, 
1406; 1H NMR δ (360 MHz, CDCl3) 6.83 (1H, s, ArH), 
6.61 (1H, s, ArH), 4.70-4.64 (3H, m, 
2xCH+CHXHYAr), 4.24 (1H, d, Ј 16.8, CHXHYAr), 
3.87 (6H, s, 2xCH3), 3.70-3.67 (1H, m, CH), 3.34 (1H, 
br s, CH), 1.93-1.89 (1H, m, CHAHB), 1.67-1.61 (2H, m, CHAHB+CHCHD), 1.53-1.45 
(10H, m, CHCHD+3xCH3); 
13C NMR δ (90.6 MHz, CDCl3) 154.8 (C), 147.9 (C), 
147.6 (C), 125.3 (C), 124.5 (C), 109.3 (CH), 108.6 (CH), 80.0 (C), 71.3 (CH), 67.5 
(CH), 56.1 (CH3), 55.8 (CH3), 46.7 (CH), 42.9 (CH2), 42.2 (CH), 28.4 (3xCH3), 27.2 
(CH2), 23.8 (CH2); m/z (EI)  379 ([M]




1H-phenanthridine-5-carboxylic acid tert-butyl ester 207d (∆2,3 isomer) 
NMR Data for ∆2,3 isomer 207d was deduced from 1H 
and 13C NMR of 206d and 207d mixture. 
Rf [9: 1 CH2Cl2:MeOH] = 0.48; Rt (EtOAc:hexane, 
84:16, flow rate: 10 ml/min) = 38 min; υmax 
(CHCl3)/cm
-1 3425 (OH), 2935, 1664 (C=O), 1520, 
1259; 1H NMR δ (360 MHz, CDCl3) 6.94 (1H, s, ArH), 
6.60 (1H, s, ArH), 4.75-4.63 (2H, m, CH+CHXHYAr), 4.25 (1H, d, Ј 16.8, 
CHXHYAr), 3.94 (1H, br s, CH), 3.89 (3H, s, CH3), 3.87 (3H, s, CH3), 3.63-3.60 (1H, 
m, CH), 3.20 (1H, br s, CH), 2.43-2.40 (1H, m, CHAHB), 2.28-2.19 (1H, m, CHAHB), 
1.89-1.85 (1H, m, CHCHD), 1.66-1.61 (1H, m, CHCHD), 1.50 (9H, m, 3xCH3); 
13C 
NMR δ (90.6 MHz, CDCl3) 154.7 (C), 148.1 (C), 147.6 (C), 128.5 (C), 126.1 (C), 
109.2 (CH), 108.6 (CH), 79.9 (C), 69.3 (CH), 66.8 (CH), 56.1 (CH3), 55.8 (CH3), 
45.8 (CH), 42.9 (CH2), 35.7 (CH), 31.1 (CH2), 29.6 (CH2), 28.4 (3xCH3); m/z (EI)  




















1H-phenanthridine-5-carboxylic acid tert-butyl ester 208d (∆3,4 isomer) 
Rf [9: 1 CH2Cl2:MeOH] = 0.51; Rt (EtOAc:hexane, 
84:16, flow rate: 10 ml/min) = 23 min; υmax 
(CHCl3)/cm
-1 3404 (OH), 2931, 1668 (C=O), 1518, 
1419; 1H NMR δ (250 MHz, CDCl3) 6.80 (1H, s, ArH), 
6.63 (1H, s, ArH), 4.66-4.60 (2H, m, CH+CHXHYAr), 
4.37 (1H, d, Ј 16.8, CHXHYAr), 3.96 (1H, br s, CH), 
3.88 (3H, s, OCH3), 3.87 (3H, s, OCH3), 3.35-3.31 (1H, m, CH), 3.22 (1H, br s, CH), 
2.26-2.13 (2H, m, CH2), 1.86-1.78 (1H, m, CHAHB), 1.53-1.42 (10H, m, 
CHAHB+3xCH3); 
13C NMR δ (62.9 MHz, CDCl3) 157.7 (C), 148.0 (C), 147.6 (C), 
127.6 (C), 125.2 (C), 109.4 (CH), 108.5 (CH), 80.8 (C), 71.2 (CH), 69.4 (CH), 56.0 
(CH3), 55.9 (CH3), 52.7 (CH), 43.9 (CH2), 36.3 (CH), 28.4 (3xCH3), 25.4 (CH2), 
20.2 (CH2); m/z (EI) 379 ([M]
+, 1 %), 322 ([M-tBu]+, 2), 278 ([M-Boc]+, 10). 
 
Dihydroxy-2,3,4,4a,6,12c-hexahydro-1H-benzo[k]phenanthridine-5-carboxylic 
acid tert-butyl ester 206e-208e  
General procedure P was followed using phenanthridines 
195e-197e (130 mg, 0.39 mmol), THF (2.17 ml), H2O 
(434 µl), OsO4 (338 µl, 2.5% 
w/w in 
tBuOH, 27.1 µmol) 
and NMO (136 mg, 1.16 mmol). Flash chromatography 
(CH2Cl2:MeOH, 100:0.5) afforded ∆
1,2 diol 206e (20 mg, 
14%), ∆ 2,3 diol 207e (40 mg, 28%), ∆ 3,4 diol 208e (23 





















benzo[k]phenanthridine-5-carboxylic acid tert-butyl ester 206e (∆1,2 isomer) 
Rf [CH2Cl2:MeOH, 9:1] = 0.65; υmax (CHCl3)/cm
-1 3418 
(OH), 2932, 1668 (C=O), 1393, 1163; 1H NMR δ (360 
MHz, 323 K, CDCl3) 8.08 (1H, d, Ј 8.5, ArH), 7.85 (1H, d, 
Ј 7.9, ArH), 7.70 (1H, d, Ј 8.3, ArH), 7.54 (1H, t, Ј 7.9, 
ArH), 7.47 (1H, t, Ј 7.9, ArH), 7.26 (1H, d, Ј 8.3, ArH), 
5.11 (1H, d, Ј 15.9, CHXHYAr), 4.41 (1H, m, CH), 4.30 
(1H, d, Ј 15.9, CHXHYAr), 4.17-4.28 (2H, m, 2xCH), 3.98-3.95 (1H, m, CH), 2.79 
(1H, br s, OH), 2.27 (1H, br s, OH), 2.01-1.93 (2H, m, CH2), 1.75-1.69 (2H, m, 
CH2), 1.49 (9H, m, 3xCH3); 
13C NMR δ (90.6 MHz, 323 K, CDCl3) 156.0 (C), 134.8 
(C), 133.3 (C), 132.6 (C), 130.6 (C), 128.8 (CH), 126.6 (CH), 126.2 (CH), 125.4 
(CH), 124.6 (CH), 122.6 (CH), 80.6 (C), 71.2 (CH), 68.9 (CH), 56.7 (CH), 45.3 
(CH2), 30.9 (CH), 28.4 (3xCH3), 26.6 (CH2), 26.5 (CH2); m/z (EI)  369 ([M]
+, 4 %), 





benzo[k]phenanthridine-5-carboxylic acid tert-butyl ester 207e (∆2,3 isomer) 
Rf [CH2Cl2:MeOH, 9:1] = 0.52; υmax (CHCl3)/cm
-1 3418 
(OH), 2927, 1685 (C=O), 1393, 1366, 1163; 1H NMR δ 
(360 MHz, 323 K, CDCl3) 8.11 (1H, d, Ј 8.5, ArH), 7.85 
(1H, d, Ј 8.1, ArH), 7.71 (1H, d, Ј 8.3, ArH), 7.55 (1H, t, Ј 
8.4, ArH), 7.48 (1H, t, Ј 6.8, ArH), 7.27 (1H, d, Ј 8.3, 
ArH), 5.10 (1H, d, Ј 16.1, CHXHYAr), 4.37 (1H, d, Ј 16.1, 
CHXHYAr), 4.17-4.02 (4H, m, 4xCH), 2.71-2.66 (1H, m, 
CHAHB), 2.44 (1H, br s, OH), 2.15-2.10 (2H, m, CH2), 1.86-1.78 (1H, m, CHAHB), 
1.60 (1H, br s, OH), 1.52 (9H, m, 3xCH3); 
13C NMR δ (90.6 MHz, 323 K, CDCl3) 
155.9 (C), 135.0 (C), 133.1 (C), 131.9 (C), 130.3 (C), 128.7 (CH), 126.7 (CH), 126.4 
(CH), 125.4 (CH), 124.7 (CH), 122.4 (CH), 80.2 (C), 68.5 (CH), 67.9 (CH), 52.3 
(CH), 46.6 (CH2), 33.5 (CH2), 31.9 (CH2), 29.9 (CH), 28.5 (3xCH3); m/z (EI)  369 

















benzo[k]phenanthridine-5-carboxylic acid tert-butyl ester 208e (∆3,4 isomer) 
Rf [CH2Cl2:MeOH, 9:1] = 0.66; υmax (CHCl3)/cm
-1 3409 
(OH), 2949, 1662 (C=O), 1393, 1033, 1017; 1H NMR δ 
(360 MHz, 323 K, CDCl3) 8.20 (1H, d, Ј 8.5, ArH), 7.85 
(1H, d, Ј 8.1, ArH), 7.76 (1H, d, Ј 8.3, ArH), 7.55 (1H, t, Ј 
8.4, ArH), 7.48 (1H, t, Ј 8.1, ArH), 7.33 (1H, d, Ј 8.3, 
ArH), 5.23 (1H, d, Ј 16.0, CHXHYAr), 4.37 (1H, d, Ј 16.0, 
CHXHYAr), 4.18-4.09 (2H, m, 2xCH), 4.01-4.00 (1H, m, CH), 3.90-3.86 (1H, m, 
CH), 2.52 (1H, br s, OH), 2.44-2.35 (1H, m, CHAHB), 2.16-2.04 (1H, m, CHAHB), 
1.99-1.93 (1H, m, CHCHD), 1.83-1.79 (1H, m, CHCHD), 1.55 (1H, br s, OH), 1.48 
(9H, m, 3xCH3); 
13C NMR δ (90.6 MHz, 323 K, CDCl3) 155.9 (C), 133.3 (2xC), 
133.1 (C), 132.0 (C), 128.6 (CH), 127.2 (CH), 126.4 (CH), 125.5 (CH), 125.2 (CH), 
123.3 (CH), 80.1 (C), 72.3 (CH), 68.1 (CH), 52.8 (CH), 47.2 (CH2), 37.8 (CH), 28.4 
(3xCH3), 25.6 (CH2), 22.8 (CH2); m/z (EI)  369 ([M]
+, 5 %), 313 (26), 312 ([M-
tBu]+, 100), 268 ([M-Boc]+, 12), 223 (27), 180 (29). 
 
Dihydroxy-5a,6,7,8,9,9a-hexahydro-4H-thieno[2,3-c]quinoline-5-carboxylic acid 
tert-butyl ester 206f-208f (∆8,9 , ∆7,8  and ∆6,7 diol mixture) 
General procedure P was followed using phenanthridines 
195f-197f (15 mg, 53 µmol), THF (296 µl), H2O (59 µl), OsO4 
(47 µl, 2.5% w/w in 
tBuOH, 3.7 µmol) and NMO (19 mg, 0.158 
mmol). Flash chromatography (CH2Cl2-CH2Cl2:MeOH, 
100:5) afforded mixture of diols 206f-208f (10 mg, 64%) as a 
yellow oil. 
υmax (CHCl3)/cm
-1 3421 (OH), 2929, 1676 (C=O), 1410, 1365, 1165; m/z (EI) 325 























carboxylic acid tert-butyl ester 206k-208k 
General procedure P was followed using 
phenanthridines 195k-197k (125 mg, 0.38 mmol), 
THF (2.66 ml), H2O (531 µl), OsO4 (332 µl, 2.5% 
w/w 
in tBuOH, 26.6 µmol) and NMO (133 mg, 1.14 mmol). 
Flash chromatography (CH2Cl2:MeOH, 98:2) afforded 
∆
1,2 diol 206k (13 mg, 9%), ∆2,3 diol 207k (31 mg, 
23%), ∆ 3,4 diol 208k (25 mg, 18%), minor diastereomer 209k (3 mg, 2%) and mixed 
diol (48 mg, 35%) giving a total yield (120 mg, 87%).  
 
(1R,2S,4aSR,11bSR)-1,2-Dihydroxy-2,3,4,4a,6,11b-hexahydro-1H-
[1,3]dioxolo[4,5-j]phenanthridine-5-carboxylic acid tert-butyl ester 206k (∆1,2 
isomer) 
Rf [CH2Cl2:MeOH, 9:1] = 0.52; υmax (CHCl3)/cm
-1 3392 
(OH), 1685 (C=O); 1H NMR δ (360 MHz, 323 K, 
CDCl3) 6.83 (1H, s, ArH), 6.61 (1H, s, ArH), 5.94 (2H, 
dd, Ј 3.2, 1.4, OCH2O), 4.66-4.59 (3H, m, 
2xCHOH+CHXHYAr), 4.24 (1H, d, Ј 16.8, CHXHYAr), 
3.75-3.71 (1H, m, CH), 3.20 (1H, br s, CH), 2.41 (1H, br 
s, OH), 2.10-1.83 (3H, m, OH+CH2), 1.70-1.61 (2H, m, 
CH2), 1.52 (9H, s, 3xCH3); 
13C NMR δ (90.6 MHz, 323 K, CDCl3) 154.8 (C), 147.0 
(C), 146.2 (C), 126.8 (C), 126.1 (C), 106.7 (CH), 105.7 (CH), 100.9 (CH2), 79.9 (C), 
71.4 (CH), 67.4 (CH), 47.2 (CH), 43.6 (CH2), 42.8 (CH), 28.9 (3xCH3), 27.3 (CH2), 
24.0 (CH2); m/z (EI) 363 ([M]
























[1,3]dioxolo[4,5-j]phenanthridine-5-carboxylic acid tert-butyl ester 207k (∆2,3 
isomer) 
Rf [CH2Cl2:MeOH, 9:1] = 0.59; υmax (CHCl3)/cm
-1 3391 
(OH), 2931, 1684 (C=O), 1241, 1165; 1H NMR δ (360 
MHz, 323 K, CDCl3) 6.94 (1H, s, ArH), 6.58 (1H, s, 
ArH), 5.93-5.91 (2H, m, OCH2O), 4.72-4.65 (1H, m, 
CH), 4.59 (1H, d, Ј 16.9, CHXHYAr), 3.93 (1H, d, Ј 2.7, 
CH), 3.65-3.61 (1H, m, CH), 3.16 (1H, br s, CH), 2.35-
2.30 (1H, m, CHAHB), 2.26-2.19 (1H, m, CHAHB), 1.90-1.86 (1H, m, CHCHD), 1.56-
1.50 (10H, m, CHCHD+3xCH3); 
13C NMR δ (90.6 MHz, 323 K, CDCl3) 154.7 (C), 
147.0 (C), 146.2 (C), 127.7 (C), 126.3 (C), 106.4 (CH), 105.8 (CH), 100.8 (CH2), 
80.0 (C), 69.4 (CH), 66.7 (CH), 46.3 (CH), 43.6 (CH2), 36.2 (CH), 31.3 (CH2), 29.7 
(CH2), 28.4 (3xCH3); m/z (EI) 363 ([M]
+, 1 %),  306 (12), 263 (18), 262 (100), 218 
(12), 174 (23). 
 
(3R,4S,4aSR,11bSR)-3,4-Dihydroxy-2,3,4,4a,6,11b-hexahydro-1H-
[1,3]dioxolo[4,5-j]phenanthridine-5-carboxylic acid tert-butyl ester 208k (∆3,4 
isomer) 
Rf [CH2Cl2:MeOH, 9:1] = 0.62; υmax (CHCl3)/cm
-1 3391 
(OH), 2924, 1684 (C=O), 1240, 1164; 1H NMR δ (360 
MHz, 323 K, CDCl3) 6.80 (1H, s, ArH), 6.60 (1H, s, 
ArH), 5.93 (2H, dd, Ј 5.0, 1.3, OCH2O), 4.67-4.55 (2H, 
m, CH+CHXHYAr), 4.32 (1H, d, Ј 16.1, CHXHYAr), 3.95 
(1H, d, Ј 2.5, CH), 3.34 (1H, br d, Ј 9.6, CH), 3.17 (1H, 
br s, CH), 2.61 (1H, br s, OH), 2.30-2.20 (1H, m, CHAHB), 2.13-2.05 (1H, m, 
CHAHB), 1.81 (1H, dd, Ј 14.4, 3.0, CHCHD), 1.60-1.45 (11H, m, 
OH+CHCHD+3xCH3); 
13C NMR δ (90.6 MHz, 323 K, CDCl3) 157.2 (C), 150.0 (C), 
146.1 (C), 128.0 (C), 126.4 (C), 106.6 (CH), 105.6 (CH), 100.9 (CH2), 80.8 (C), 69.6 
(2xCH), 53.0 (CH), 44.2 (CH2), 36.7 (CH), 28.4 (3xCH3), 25.4 (CH2), 20.5 (CH2); 























[1,3]dioxolo[4,5-j]phenanthridine-5-carboxylic acid tert-butyl ester 209k (∆2,3 
isomer, minor diastereomer) 
Rf [CH2Cl2:MeOH, 95:5] = 0.37; υmax (CHCl3)/cm
-1 3421 
(OH), 2925, 1684 (C=O), 1236, 1165; 1H NMR δ (360 
MHz, 323 K, CDCl3) 6.99 (1H, s, ArH), 6.57 (1H, s, 
ArH), 5.93 (2H, s, OCH2O), 4.71 (1H, d, Ј 17.1, 
CHXHYAr), 4.38-4.32 (1H, m, CH), 4.27 (1H, d, Ј 16.7, 
CHXHYAr), 3.96 (1H, br s, CH), 3.71 (1H, br s, CH), 
3.07 (1H, br s, CH), 2.76 (1H, dt, Ј 15.5, 3.3, CHAHB), 
2.02-2.00 (1H, m, CHAHB), 1.80-1.72 (2H, m, CH2), 1.51 (9H, s, 3xCH3); 
13C NMR 
δ (90.6 MHz, 323 K, CDCl3) 154.5 (C), 146.7 (C), 146.3 (C), 128.5 (C), 125.7 (C), 
106.9 (CH), 106.3 (CH), 100.9 (CH2), 80.1 (C), 70.5 (CH), 69.0 (CH), 49.7 (CH), 
43.2 (CH2), 33.7 (CH), 30.8 (CH2), 29.4 (CH2), 28.4 (3xCH3); m/z (EI) 364 ([M+H]
+, 
5 %), 363 ([M]+, 2),  306 (16), 262 (100), 218 (16). 
  
Dihydroxy-2,3,4,4a,6,10b-hexahydro-1H-phenanthridine-5-carboxylic acid tert-
butyl ester 206m-207m 
General procedure P was followed using phenanthridines 
96b-98b (200 mg, 0.70 mmol), THF (3.92 ml), H2O (785 
µl), OsO4 (613 µl, 2.5% 
w/w in 
tBuOH, 49.1 µmol) and NMO 
(329 mg, 2.81 mmol). Flash chromatography (CH2Cl2-
CH2Cl2:MeOH, 100:3) afforded mixture of diols 206m-
208m as a colourless oil (156 mg, 70%). HPLC 
(EtOAc:hexane, 3:1) of this mixture afforded ∆1,2 diol 206m (29 mg, 13%), ∆ 2,3 diol 
207m (25 mg, 11%), ∆ 3,4 diol 208m (26 mg, 12%), and mixed diol fractions (44 mg, 






















phenanthridine-5-carboxylic acid tert-butyl ester 206m (∆1,2 isomer) 
Rf [CH2Cl2:MeOH, 9:1] = 0.57; Rt (EtOAc:hexane, 3:1, flow 
rate: 8 ml/min) = 23 min; υmax (CHCl3)/cm
-1 3421 (OH), 1664 
(C=O); 1H NMR δ (360 MHz, 323 K, CDCl3) 7.36-7.34 (1H, 
m, ArH), 7.24-7.18 (2H, m, 2xArH), 7.14-7.12 (1H, m, ArH), 
4.74-4.66 (3H, m, CHOH+CHNBoc+CHXHYAr), 4.35 (1H, d, 
Ј 17.1, CHXHYAr), 3.95 (1H, br s, OH), 3.71 (1H, ddd, Ј 11.4, 
4.7, 2.8, CHOH), 3.40 (1H, br s, CHAr), 1.95-1.85 (1H, m, CHAHB), 1.70-1.60 (2H, 
m, CHAHB+CHCHD), 1.51 (9H, s, 3xCH3), 1.40-1.33 (1H, m, CHCHD); 
13C NMR δ 
(90.6 MHz, 323 K, CDCl3) 154.9 (C), 133.4 (C), 133.1 (C), 126.9 (CH), 126.6 (C), 
126.3 (CH), 125.4 (CH), 79.9 (C), 71.1 (CH), 67.4 (CH), 47.1 (CH), 43.6 (CH2), 42.8 
(CH), 28.4 (3xCH3), 27.4 (CH2), 24.2 (CH2); m/z (EI) 319 ([M]
+, 2 %), 262 ([M-
tBu]+, 100), 218 ([M-Boc]+, 22), 184 (75). This compound was also fully 
characterised by COSY, HSQC and NOESY 2D NMR studies. 
 
(2RS,3SR,4aSR,10bSR)-2,3-Dihydroxy-2,3,4,4a,6,10b-hexahydro-1H-
phenanthridine-5-carboxylic acid tert-butyl ester 207m (∆2,3 isomer) 
Rf [CH2Cl2:MeOH, 9:1] = 0.52; Rt (EtOAc:hexane, 3:1, flow 
rate: 8 ml/min) = 28 min; υmax (CHCl3)/cm
-1 3414 (OH), 
2930, 1671 (C=O), 1406, 1365; 1H NMR δ (360 MHz, 323 
K, CDCl3) 7.47 (1H, d, Ј 7.6, ArH), 7.27-7.20 (2H, m, 
2xArH), 7.12 (1H, d, Ј 6.8, ArH), 4.78-4.72 (1H, m, 
CHNBoc), 4.71 (1H, d, Ј 17.3, CHXHYAr),  4.36 (1H, d, Ј 
17.3, CHXHYAr), 3.92 (1H, m, CHOH), 3.64 (1H, dt, Ј 12.0, 3.9, CHOH), 3.26 (1H, 
br s, CHAr), 2.49 (1H, dt, Ј 13.6, 3.1, CHAHB), 2.25 (1H, ddd, Ј 13.6, 12.0, 4.8, 
CHAHB), 1.94-1.87 (1H, m, CHCHD), 1.54-1.45 (10H, m, CHCHD+3xCH3); 
13C 
NMR δ (90.6 MHz, 323 K, CDCl3) 154.8 (C), 134.5 (C), 133.2 (C), 126.9 (CH), 
126.4 (CH), 126.2 (CH), 125.6 (CH), 80.0 (C), 69.4 (CH), 66.7 (CH), 46.3 (CH), 
43.6 (CH2), 36.3 (CH), 31.5 (CH2), 29.3 (CH2), 28.4 (3xCH3); m/z (EI) 319 ([M]
+, 1 
%), 263 ([M-tBu]+, 27), 262 (80), 218 ([M-Boc]+, 25), 200 (27), 174 (36), 146 (25), 
















phenanthridine-5-carboxylic acid tert-butyl ester 208m (∆3,4 isomer) 
Rf [CH2Cl2:MeOH, 9:1] = 0.58; Rt (EtOAc:hexane, 3:1, flow 
rate: 8 ml/min) = 21 min; υmax (CHCl3)/cm
-1 3394 (OH), 
2978, 2937, 1668 (C=O); 1H NMR δ (360 MHz, 323 K, 
CDCl3) 7.33 (1H, d, Ј 7.5, ArH), 7.27-7.19 (2H, m, 2xArH), 
7.14 (1H, d, Ј 7.1, ArH), 4.80-4.66 (2H, m, 
CHNBoc+CHXHYAr), 4.44 (1H, d, Ј 17.0, CHXHYAr), 3.94 
(1H, dd, Ј 5.9, 2.9, CHOH), 3.31-3.29 (2H, m, CHAr+CHOH), 2.29-2.24 (2H, m, 
CH2), 1.85-1.80 (1H, m, CHAHB), 1.58-1.52 (10H, m, CHAHB+3xCH3); 
13C NMR δ 
(90.6 MHz, 323 K, CDCl3) 156.7 (C), 134.6 (C), 133.3 (C), 126.9 (CH), 126.5 (CH), 
126.2 (CH), 125.3 (CH), 80.8 (C), 69.6 (2xCH), 53.1 (CH), 43.9 (CH2), 36.9 (CH), 
28.4 (3xCH3), 25.4 (CH2), 20.0 (CH2); m/z (EI) 319 ([M]
+, 1 %), 263 ([M-tBu], 3), 
233 (7), 218 ([M-Boc]+, 6). This compound was also fully characterised by COSY, 
HSQC and NOESY 2D NMR studies. 
 
General procedure Q – Hydrochloride salt formation 
To a solution of the appropriate diol(s) 206-208 in CH2Cl2 (2 ml) was added TFA (5 
ml) and the reaction was stirred at r.t. for 2 h. The reaction was diluted with H2O (15 
ml), adjusted to pH 8-9 by the addition of NaOH pellets, and then extracted with 
CH2Cl2 (3 x 15 ml). The combined organics were dried (MgSO4) and concentrated 
under reduced pressure. The resultant oil was taken up in CH2Cl2 (1 ml), cooled to 0 
oC and HCl (excess, 1 M in Et2O) added. The resultant solid was washed with Et2O 











254a (∆1,2, ∆2,3, ∆3,4 isomer mixture) 
General procedure Q was followed using diols 206a-208a 
(16 mg, 48 µmol), CH2Cl2 (2 ml) and TFA (5 ml), then 
CH2Cl2 (1 ml) and HCl (2 ml, 1 M in Et2O) to afford a 
amine hydrochlorides 252a-254a as a yellow oil (9 mg, 
69%). 
m/z (ESI+) 234 ([M+H]+, 100 %), 232 (44); HRMS (ESI+) Found [M+H]+, 




1,2-diol 252b (∆1,2 isomer) 
General procedure Q was followed using diol 206b (10 mg, 
30 µmol), CH2Cl2 (2 ml), and TFA (5 ml), then CH2Cl2 (1 
ml) and HCl (2 ml, 1 M in Et2O) to afford amine 
hydrochloride 252b as a colourless oil (9 mg, 99%). 
1H NMR δ (360 MHz, D2O) 7.09 (1H, dd, Ј 8.6, 5.7, ArH), 
7.03 (1H, dd, Ј 10.2, 2.6, ArH), 6.94 (1H, td, Ј 8.6, 2.7, ArH), 4.28 (1H, d, Ј 16.2, 
CHXHYAr), 4.22 (1H, d, Ј 16.2, CHXHYAr), 3.88 (1H, d, Ј 7.6, CH), 3.78-3.74 (2H, 
m, 2xCH), 3.19 (1H, dd, Ј 8.2, 4.4, CH), 2.01-1.91 (1H, m, CHAHB), 1.81-1.72 (1H, 
m,CHAHB), 1.68-1.60 (2H, m, CH2); 
13C NMR δ (90.6 MHz, D2O) 162.3 (1C, d, Ј 
243.8, C), 135.0 (1C, d, Ј 7.7, C), 129.2 (1C, d, Ј 8.5, CH), 123.7 (C), 116.4 (1C, d, Ј 
23.7, CH), 115.5 (1C, d, Ј 22.1, CH), 70.9 (CH), 68.2 (CH), 52.0 (CH), 43.4 (CH2), 
39.5 (CH), 25.6 (CH2), 21.9 (CH2); m/z (ESI+) 238 ([M+H]
+, 100 %), 236 (86); 




















2,3-diol 253b (∆2,3 isomer) 
General procedure Q was followed using diol 207b (10 
mg, 30 µmol), CH2Cl2 (2 ml), and TFA (5 ml), then 
CH2Cl2 (1 ml) and HCl (2 ml, 1 M in Et2O) to afford 
amine hydrochloride 253b as a colourless oil (7 mg, 86%). 
1H NMR δ (360 MHz, D2O) 7.09-7.05 (1H, m, ArH), 6.98 
(1H, dd, Ј 10.0, 2.1, ArH), 6.91 (1H, td, Ј 8.7, 2.6, ArH), 4.23 (1H, s, CH2Ar), 3.81 
(1H, dd, Ј 9.8, 4.7, CH), 3.77-3.75 (2H, m, 2xCH), 3.27-3.23 (1H, m, CH), 2.10-2.00 
(2H, m, CH2), 1.87-1.80 (1H, m, CH2); 
13C NMR δ (90.6 MHz, D2O) 162.7 (1C, d, Ј 
244.5, C), 137.2 (1C, d, Ј 7.6, C), 129.0 (1C, d, Ј 8.5, CH), 122.8 (C), 115.0 (1C, d, Ј 
22.4, CH), 114.8 (1C, d, Ј 22.9, CH), 67.6 (CH), 66.5 (CH), 51.7 (CH), 43.9 (CH2), 
33.2 (CH2), 31.6 (CH), 29.0 (CH2); m/z (ESI+) 238 ([M+H]
+, 100 %), 211 (12), 179 
(12); HRMS (ESI+) Found [M+H]+, 238.1234. C13H17O2NF requires 238.1238. 
 
(3RS,4SR,4aRS,10bSR)-9-Fluoro-1,2,3,4,4a,5,6,10b-octahydro-phenanthridine-
3,4-diol 254b (∆3,4 isomer)   
General procedure Q was followed using diol 208b (15 
mg, 46 µmol), CH2Cl2 (2 ml), and TFA (5 ml), then 
CH2Cl2 (1 ml) and HCl (2 ml, 1 M in Et2O) to afford 
amine hydrochloride 254b as a yellow oil (9 mg, 74%). 
1H NMR δ (360 MHz, D2O) 7.11-7.05 (2H, m, 2xArH), 6.91 (1H, dd, Ј 8.6, 2.7, 
ArH), 4.23 (1H, d, Ј 16.3, CHXHYAr), 4.17 (1H, d, Ј 16.3, CHXHYAr), 3.84-3.82 
(1H, m6, CH), 3.77 (1H, dd, Ј 9.5, 5.3, CH), 3.59-3.57 (1H, m, CH), 3.32-3.30 (1H, 
m, CH), 2.02-1.92 (2H, m, CH2), 1.64-1.57 (1H, m, CHAHB), 1.39-1.31 (1H, m, 
CHAHB); 
13C NMR δ (90.6 MHz, D2O) 163.1 (1C, d, Ј 245.1, C), 136.3 (C), 129.8 
(1C, d, Ј 8.7, CH), 124.6 (C), 115.1 (1C, d, Ј 22.2, CH), 113.9 (1C, d, Ј 23.3, CH), 
69.5 (CH), 66.7 (CH), 54.6 (CH), 49.5 (CH2), 34.3 (CH), 26.3 (CH2), 21.9 (CH2); 
m/z (ESI+) 238 ([M+H]+, 100 %), 225 (18), 211 (26), 210 (10), 197 (13), 179 (26); 




















phenanthridine-1,2-diol 252c (∆1,2 isomer) 
General procedure Q was followed using diol 206c (21 
mg, 60 µmol), CH2Cl2 (2 ml), and TFA (5 ml), then 
CH2Cl2 (1 ml) and HCl (2 ml, 1 M in Et2O) to afford 
amine hydrochloride 252c as a colourless oil (14 mg, 
82%). 
1H NMR δ (800 MHz, D2O) 7.17 (1H, d, Ј 8.8, ArH), 6.76 (1H, d, Ј 8.8, 2.4, ArH), 
6.64 (1H, d, Ј 1.6, ArH), 4.23 (1H, d, Ј 16.6, CHXHYAr), 4.18 (1H, d, Ј 16.6, 
CHXHYAr), 3.85 (1H, br s, CH), 3.72-3.66 (2H, m, 2xCH), 3.61 (3H, s, CH3), 3.12 
(1H, m, CH), 1.92-1.89 (1H, m, CHAHB), 1.73-1.70 (1H, m, CHAHB), 1.63-1.52 (2H, 
m, CH2); 
13C NMR δ (200.0 MHz, D2O) 158.6 (C), 131.1 (CH), 129.0 (C), 124.9 
(C), 114.7 (CH), 111.9 (CH), 71.1 (CH), 68.1 (CH), 56.0 (CH3), 52.2 (CH), 43.4 
(CH2), 38.7 (CH), 25.5 (CH2), 21.8 (CH2); m/z (ESI+) 250 ([M+H]
+, 100 %), 248 




phenanthridine-2,3-diol 253b (∆2,3 isomer)  
General procedure Q was followed using diol 207b (20 
mg, 57 µmol), CH2Cl2 (2 ml), and TFA (5 ml), then 
CH2Cl2 (1 ml) and HCl (2 ml, 1 M in Et2O) to afford 
amine hydrochloride 253c as a yellow oil (15 mg, 
92%). 
1H NMR δ (360 MHz, D2O) 7.12 (1H, d, Ј 8.7, ArH), 6.79 (1H, dd, Ј 8.5, 2.2, ArH), 
6.62 (1H, br s, ArH), 4.23-4.14 (2H, m, CH2Ar), 3.75-3.64 (3H, m, 3xCH), 3.60 (3H, 
s, OCH3), 3.18-3.13 (1H, m, CH), 2.06-1.94 (2H, m, CH2), 1.85-1.72 (2H, m, CH2); 
13C NMR δ (90.6 MHz, D2O) 158.1 (C), 129.8 (CH), 128.3 (C), 127.3 (C), 115.2 
(CH), 111.5 (CH), 67.6 (CH), 66.4 (CH), 55.7 (CH3), 52.3 (CH), 44.2 (CH2), 32.4 
(CH2), 30.5 (CH), 29.0 (CH2); m/z (ESI+) 250 ([M+H]
+, 100 %), 249 (28), 248 (89); 



















phenanthridine-3,4-diol 254c (∆3,4 isomer) 
General procedure Q was followed using diol 208c (2.1 
mg, 6 µmol), CH2Cl2 (2 ml), and TFA (5 ml), then 
CH2Cl2 (1 ml) and HCl (2 ml, 1 M in Et2O) to afford 
amine hydrochloride 254c as a colourless oil (1.4 mg, 
94%). 
1H NMR δ (800 MHz, D2O) 7.22 (1H, d, Ј 8.0, ArH), 6.82 (1H, dd, Ј 8.8, 3.2, ArH), 
6.67 (1H, d, Ј 2.4, ArH), 4.20 (1H, d, Ј 16.8, CHXHYAr), 4.15 (1H, d, Ј 16.8, 
CHXHYAr), 3.80 (1H, br s, CH), 3.70 (1H, m, CH), 3.64 (3H, s, CH3), 3.60 (1H, m, 
CH), 3.23 (1H, br s, CH), 1.90-1.86 (2H, m, CH2), 1.59-1.56 (1H, m, CHAHB), 1.35-
1.31 (1H, m, CHAHB); 
13C NMR δ (90.6 MHz, D2O) 158.0 (C), 130.9 (CH), 130.0 
(C), 128.6 (C), 114.9 (CH), 111.8 (CH), 70.1 (CH), 69.1 (CH), 55.8 (CH3), 54.7 
(CH), 41.6 (CH2), 33.2 (CH), 26.9 (CH2), 26.0 (CH2); m/z (ESI+) 250 ([M+H]
+, 100 
%), 248 (73), 239 (17), 233 (10), 211 (17), 209 (25), 197 (27), 185 (26); HRMS 
(ESI+) Found [M+H]+, 250.1436. C14H20O3N requires 250.1438. 
 
(1RS,2SR,4aSR,10bSR)-8,9-Dimethoxy-1,2,3,4,4a,5,6,10b-octahydro-
phenanthridine-1,2-diol hydrochloride 252d (∆1,2 isomer) 
General procedure Q was followed using diol 206d (10 
mg, 26 µmol), CH2Cl2 (2 ml), and TFA (5 ml), then 
CH2Cl2 (1 ml) and HCl (2 ml, 1 M in Et2O) to afford 
amine hydrochloride 252d as a yellow oil (9 mg, 88%). 
1H NMR δ (250 MHz, D2O) 6.82 (1H, s, ArH), 6.68 (1H, 
s, ArH), 4.18 (2H, br s, CH2Ar), 3.83-3.80 (1H, m, CH), 3.75-3.68 (2H, m, 2xCH), 
3.66 (3H, s, CH3), 3.64 (3H, s, CH3), 3.09 (1H, q, Ј 4.4, CH), 2.04-1.87 (1H, m, 
CHAHB), 1.79-1.52 (3H, m, CH2+CHAHB); 
13C NMR δ (62.9 MHz, D2O) 148.1 (C), 
147.8 (C), 125.2 (C), 120.0 (C), 112.8 (CH), 109.9 (CH), 71.1 (CH), 68.1 (CH), 56.2 
(2xCH3), 52.2 (CH), 43.2 (CH2), 38.5 (CH), 25.3 (CH2), 21.6 (CH2); m/z (ESI+) 280 
([M+H]+, 61 %), 279 ([M]+, 100); HRMS (ESI+) Found [M+H]+, 280.1542. 



















phenanthridine-2,3-diol hydrochloride 253d (∆2,3 isomer) 
General procedure Q was followed using diols 206d 
and 207d (6.2 mg, 16 µmol), CH2Cl2 (2 ml), and TFA 
(5 ml), then CH2Cl2 (1 ml) and HCl (2 ml, 1 M in Et2O) 
to afford amine hydrochlorides 252d and 253d as a 
yellow oil (3 mg, 60%). Data for ∆2,3 isomer 253d was 
deduced from 1H, 13C and HSQC NMR data for the mixture of 252d and 253d. 
1H NMR δ (500 MHz, D2O) 6.76 (1H, s, ArH), 6.66 (1H, s, ArH), 4.18-4.15 (2H, m, 
CH2Ar), 3.75-3.71 (3H, m, 3xCH), 3.67 (3H, s, OCH3), 3.64 (3H, s, OCH3), 3.18-
3.15 (1H, m, CH), 2.07-2.028 (2H, m, CHAHB+CHCHD), 1.92-1.88 (1H, m, CHAHB), 
1.83-1.78 (1H, m, CHCHD); 
13C NMR δ (125.8 MHz, D2O) 147.9 (C), 147.6 (C), 
125.2 (C), 119.8 (C), 112.7 (CH), 111.1 (CH), 70.9 (CH), 67.5 (CH), 55.9 (2xCH3), 
53.3 (CH), 43.9 (CH2), 33.6 (CH), 30.7 (CH2), 28.9 (CH2); m/z (ESI+) 280 ([M+H]
+, 




phenanthridine-3,4-diol hydrochloride 254d (∆3,4 isomer) 
General procedure Q was followed using diol 208d (10 
mg, 26 µmol), CH2Cl2 (2 ml), and TFA (5 ml), then 
CH2Cl2 (1 ml) and HCl (2 ml, 1 M in Et2O) to afford 
amine hydrochloride 254d as a yellow oil (5 mg, 60%). 
1H NMR δ (360 MHz, D2O) 6.82 (1H, s, ArH), 6.67 (1H, s, ArH), 4.16 (1H, d, Ј 
16.1, CHXHYAr), 4.09 (1H, d, Ј 16.1, CHXHYAr), 3.78 (1H, br s, CH), 3.72-3.65 
(1H, m, CH), 3.65 (3H, s, OCH3), 3.62 (3H, s, OCH3), 3.23 (1H, br s, CH), 2.00-1.89 
(2H, m, CH2), 1.64-1.53 (1H, m, CHAHB), 1.38-1.29 (1H, m, CHAHB); 
13C NMR δ 
(90.6MHz, D2O) 148.6 (C), 147.6 (C), 126.3 (C), 120.7 (C), 110.0 (2xCH), 71.7 
(CH), 69.1 (CH), 56.1 (2xCH3), 54.6 (CH), 41.0 (CH2), 33.4 (CH), 26.0 (CH2), 21.6 
(CH2); m/z (ESI+) 280 ([M+H]
+, 100 %); HRMS (ESI+) Found [M+H]+, 280.1546. 





















1,2-diol hydrochloride 252e (∆1,2 isomer) 
General procedure Q was followed using diol 206e (20 mg, 
54 µmol), CH2Cl2 (2 ml), and TFA (5 ml), then CH2Cl2 (1 
ml) and HCl (2 ml, 1 M in Et2O) to afford amine 
hydrochloride 252e as a colourless oil (11 mg, 67%). 
1H NMR δ (500 MHz, D2O) 8.09 (1H, d, Ј 8.5, ArH), 7.77 
(1H, d, Ј 6.5, ArH), 7.76 (1H, d, Ј 9.0, ArH), 7.48-7.41 (2H, m, 2xArH), 7.19 (1H, d, 
Ј 8.5, ArH), 4.52 (1H, d, Ј 16.5, CHXHYAr), 4.44 (1H, d, Ј 16.5, CHXHYAr), 4.05 
(2H, s, 2xCH), 3.65 (2H, s, 2xCH), 2.22-2.16 (1H, m, CHAHB), 1.92-1.89 (1H, m, 
CHAHB), 1.81 (2H, d, Ј 2.5, CH2); 
13C NMR δ (125.9 MHz, D2O) 135.0 (C), 134.7 
(C), 132.6 (C), 130.8 (CH), 130.7 (CH), 128.7 (2xCH), 127.7 (C), 127.3 (CH), 126.5 
(CH), 74.7 (CH), 71.3 (CH), 56.0 (CH), 46.9 (CH2), 35.7 (CH), 27.8 (CH2), 24.2 
(CH2); m/z (ESI+) 270 ([M+H]
+, 38 %), 261 (13), 260 (15), 239 (36), 217 (15), 192 




2,3-diol hydrochloride 253e (∆2,3 isomer) 
General procedure Q was followed using diol 207e (40 mg, 
66 µmol), CH2Cl2 (2 ml), and TFA (5 ml), then CH2Cl2 (1 
ml) and HCl (2 ml, 1 M in Et2O) to afford amine 
hydrochloride 253e as a colourless oil (20 mg, 61%). 
1H NMR δ (360 MHz, D2O) 7.85 (1H, d, Ј 8.4, ArH), 7.78 
(1H, d, Ј 8.2, ArH), 7.68 (1H, d, Ј 8.6, ArH), 7.51 (1H, t, Ј 7.0, ArH), 7.43 (1H, t, Ј 
7.0, ArH), 7.09 (1H, d, Ј 8.6, ArH), 4.37 (2H, s, CH2Ar), 3.95 (1H, br s, CH), 3.81-
3.76 (2H, m, 2xCH), 3.67 (1H, br s, CH), 2.33-2.17 (2H, m, CH2), 2.94-1.97 (1H, m, 
CHAHB), 1.67-1.52 (1H, m, CHAHB); 
13C NMR δ (62.9 MHz, D2O) 133.9 (C), 131.8 
(C), 130.9 (C), 130.0 (CH), 129.1 (CH), 128.4 (CH), 127.6 (CH), 125.1 (CH), 125.0 
(C), 123.7 (CH), 69.1 (CH), 66.5 (CH), 54.5 (CH), 46.5 (CH2), 34.3 (CH), 30.5 
(CH2), 28.1 (CH2); m/z (ESI+) 270 ([M+H]
+, 100 %), 232 (15), 231 (12), 217 (16), 

















3,4-diol hydrochloride 254e (∆3,4 isomer) 
General procedure Q was followed using diol 208e (23 mg, 
63 µmol), CH2Cl2 (2 ml), and TFA (5 ml), then CH2Cl2 (1 
ml) and HCl (2 ml, 1 M in Et2O) to afford amine 
hydrochloride 254e as a colourless oil (13 mg, 69%). 
1H NMR δ (360 MHz, D2O) 8.05 (1H, d, Ј 7.5, ArH), 7.77-7.73 (2H, m, 2xArH), 
7.46-7.41 (2H, m, 2xArH), 7.16 (1H, d, Ј 8.5, ArH), 4.52 (1H, d, Ј 16.5, CHXHYAr), 
4.39 (1H, d, Ј 16.5, CHXHYAr), 4.04-3.95 (2H, s, 2xCH), 3.64 (1H, d, Ј 11.4, CH), 
3.54 (1H, br s, CH), 2.22-2.13 (1H, m, CHAHB), 1.93-1.89 (1H, m, CHAHB), 1.81-
1.77 (2H, m, CH2); 
13C NMR δ (62.9 MHz, D2O) 133.5 (C), 133.2 (C), 130.9 (C), 
129.3 (CH), 129.2 (CH), 127.3 (2xCH), 125.9 (CH), 125.7 (C), 125.0 (CH), 73.1 
(CH), 69.6 (CH), 54.5 (CH), 45.2 (CH2), 34.0 (CH), 26.2 (CH2), 22.6 (CH2); m/z 
(ESI+) 270 ([M+H]+, 71 %), 248 (12), 245 (14), 234 (15), 217 (21), 203 (16), 172 
(27); HRMS (ESI+) Found [M+H]+, 270.1481. C17H20O2N requires 270.1489. 
 
4,5,5a,6,7,8,9,9a-Octahydro-thieno[2,3-c]quinoline-diol hydrochloride 252f-254f 
(∆8,9 , ∆7,8  and ∆6,7 diol mixture) 
General procedure Q was followed using diol mixture 206f-
208f (9 mg, 31 µmol), CH2Cl2 (2 ml) and TFA (3 ml), then 
CH2Cl2 (1 ml) and HCl (2 ml, 1 M in Et2O) to afford a mixture 
of amine hydrochlorides 252f-254f as a yellow oil (7 mg, 
99%). 
m/z (ESI+) 226 ([M+H]+, 20 %), 225 (11); HRMS (ESI+) Found [M+H]+, 226.0899. 


















j]phenanthridine-1,2-diol hydrochloride 252k (∆1,2 isomer) 
General procedure Q was followed using diol 206k (18 mg, 
50 µmol), CH2Cl2 (2 ml) and TFA (3 ml), then CH2Cl2 (1 
ml) and HCl (2 ml, 1 M in Et2O) to afford amine 
hydrochloride 252k as a yellow solid (9 mg, 61%). 
1H NMR δ (360 MHz, D2O) 6.76 (1H, s, ArH), 6.57 (1H, s, 
ArH), 5.80 (2H, s, OCH2O), 4.21-4.12 (2H, m, CH2Ar), 3.95-3.85 (1H, m, CH), 
3.83-3.75 (2H, m, 2xCH), 3.11-3.05 (1H, m, CH), 2.04-1.59 (6H, m, 2xCH2+2xOH); 
13C NMR δ (90.6 MHz, D2O) 147.9 (C), 147.8 (C), 126.6 (C), 121.3 (C), 110.1 
(CH), 107.3 (CH), 102.5 (CH2), 71.7 (CH), 68.6 (CH), 52.6 (CH), 44.0 (CH2), 39.6 
(CH), 26.0 (CH2), 22.2 (CH2); m/z (ESI+) 264 ([M+H]
+, 4 %), 150 (21), 149 (21); 
HRMS (ESI+) Found [M+H]+, 264.1237. C14H18O4N requires 264.1230. 
 
(2RS,3SR,4aSR,11bSR)-1,2,3,4,4a,5,6,11b-Octahydro-[1,3]dioxolo[4,5-
j]phenanthridine-2,3-diol hydrochloride 253k (∆2,3 isomer) 
General procedure Q was followed using diol 207k (10 
mg, 28 µmol), CH2Cl2 (2 ml) and TFA (3 ml), then 
CH2Cl2 (1 ml) and HCl (2 ml, 1 M in Et2O) to afford 
amine hydrochloride 253k as a yellow solid (7 mg, 81%). 
1H NMR δ (360 MHz, D2O) 6.69 (1H, s, ArH), 6.54 (1H, 
s, ArH), 5.80-5.79 (2H, m, OCH2O), 4.17-4.09 (2H, m, CH2Ar), 3.79-3.72 (3H, m, 
3xCH), 3.14-3.11 (1H, m, CH), 2.09-1.98 (2H, m, CH2), 1.88-1.72 (2H, m, CH2); 
13C 
NMR δ (90.6 MHz, D2O) 148.4 (C), 147.6 (C), 129.2 (C), 120.7 (C), 108.8 (CH), 
107.3 (CH), 102.5 (CH2), 68.3 (CH), 67.1 (CH), 52.9 (CH), 45.1 (CH2), 34.4 (CH2), 
31.9 (CH), 29.8 (CH2); m/z (ESI+) 264 ([M+H]
+, 100 %), 262 (46); HRMS (ESI+) 




















j]phenanthridine-3,4-diol hydrochloride 254k (∆3,4 isomer) 
General procedure Q was followed using diol 208k (5 
mg, 14 µmol), CH2Cl2 (2 ml) and TFA (3 ml), then 
CH2Cl2 (1 ml) and HCl (2 ml, 1 M in Et2O) to afford 
amine hydrochloride 254k as a colourless oil (3 mg, 
73%). 
1H NMR δ (360 MHz, D2O) 6.81 (1H, s, ArH), 6.58 (1H, s, ArH), 5.80 (2H, d, Ј 3.8, 
OCH2O), 4.16 (1H, d, Ј 16.1, CHXHYAr), 4.09 (1H, d, Ј 16.1, CHXHYAr), 3.82-3.80 
(1H, br s, CH), 3.72 (1H, dd, Ј 9.4, 4.5, CH), 3.62-3.59 (1H, m, CH), 3.22-3.21 (1H, 
d, Ј 4.5, CH), 1.93-1.85 (1H, m, CHAHB), 1.63-1.56 (1H, m, CHAHB), 1.39-1.30 (2H, 
m, CH2); 
13C NMR δ (90.6 MHz, D2O) 149.8 (C), 148.4 (C), 129.1 (C), 123.2 (C), 
108.6 (2xCH), 102.1 (CH2), 70.9 (CH), 68.6 (CH), 56.3 (CH), 42.8 (CH2), 35.5 
(CH), 27.7 (2xCH2); m/z (ESI+) 264 ([M+H]
+, 24 %), 225 (29), 211 (29), 179 (61); 
HRMS (ESI+) Found [M+H]+, 264.1234. C14H18O4N requires 264.1230. 
 
(2SR,3RS,4aSR,11bSR)-1,2,3,4,4a,5,6,11b-Octahydro-[1,3]dioxolo[4,5-
j]phenanthridine-2,3-diol 255k (∆2,3 isomer, minor diastereomer) 
General procedure Q was followed using endo-syn diol 
209k (2.3 mg, 6 µmol), CH2Cl2 (2 ml) and TFA (3 ml), 
then CH2Cl2 (1 ml) and HCl (1 ml, 1M in Et2O) to afford 
amine hydrochloride 255k as a colourless oil (1.0 mg, 
60%). 
1H NMR δ (800 MHz, D2O) 6.65 (1H, s, ArH), 6.51 (1H, s, ArH), 5.78 (2H, d, Ј 2.4, 
OCH2O), 4.08 (2H, s, CH2Ar), 3.91 (1H, d, Ј 2.4, CH), 3.72 (1H, ddd, Ј 11.2, 4.0, 
2.4, CH), 3.49 (1H, s, CH), 2.98-2.97 (1H, m, CH), 2.14 (1H, dt, Ј 16.0, 3.2, 
CHAHB), 1.92-1.86 (2H, m, CHAHB+CHCHD), 1.67-1.62 (1H, m, CHCHD); 
13C NMR 
δ (200.0 MHz, D2O) 147.0 (C), 146.4 (C), 129.2 (C), 119.3 (C), 108.0 (CH), 105.9 
(CH), 101.2 (CH2), 69.3 (CH), 67.1 (CH), 51.3 (CH), 45.6 (CH2), 35.4 (CH), 32.0 
(CH2), 31.7 (CH2); m/z (ESI+) 264 ([M+H]
+, 100 %), 209 (13); HRMS (ESI+) 




















252m (∆1,2 isomer) 
General procedure Q was followed using diol 206m (29 mg, 91 
µmol), CH2Cl2 (2 ml) and TFA (3 ml), then CH2Cl2 (1 ml) and 
HCl (1 ml, 1 M in Et2O) to afford amine hydrochloride 252m 
as a colourless oil (20 mg, 86%). 
1H NMR δ (360 MHz, D2O) 7.25-7.22 (1H, m, ArH), 7.17-
7.13 (2H, m, 2xArH), 7.06-7.04 (1H, m, ArH), 4.28 (1H, Ј 16.2, CHXHYAr), 4.21 
(1H, d, Ј 16.2, CHXHYAr), 3.90 (1H, br d, Ј 7.5, CH), 3.75-3.70 (2H, m, 2xCH), 3.17 
(1H, dd, Ј 7.8, 4.4, CH), 1.92-1.85 (1H, m, CHAHB), 1.76-1.70 (1H, m, CHAHB), 
1.63-1.56 (2H, m, CH2); 
13C NMR δ (62.9 MHz, D2O) 131.9 (C), 129.3 (CH), 128.0 
(CH), 127.8 (CH), 127.2 (C), 126.9 (C), 70.5 (CH), 67.7 (CH), 51.6 (CH), 43.0 
(CH2), 38.9 (CH), 25.1 (CH2), 21.4 (CH2); m/z (ESI+) 220 ([M+H]
+, 77 %), 219 
(29); HRMS (ESI+) Found [M+H]+, 220.1331. C13H18O2N requires 220.1332. 
 
(2RS,3SR,4aSR,10bSR)-1,2,3,4,4a,5,6,10b-Octahydro-phenanthridine-2,3-diol 
hydrochloride 253m (∆2,3 isomer) 
General procedure Q was followed using diol 207m (25 mg, 
78 µmol), CH2Cl2 (2 ml) and TFA (3 ml), then CH2Cl2 (1 ml) 
and HCl (1 ml, 1 M in Et2O) to afford amine hydrochloride 
253m as a colourless oil (12 mg, 60%). 
1H NMR δ (360 MHz, D2O) 7.18-7.17 (2H, m, 2xArH), 7.15-
7.10 (1H, m, ArH), 7.02 (1H, d, Ј 7.4, ArH), 4.25-4.17 (2H, m, CH2Ar), 3.78-3.70 
(3H, m, 3xCH), 3.24-3.18 (1H, dt, Ј 10.5, 4.6, CHAr), 2.06-1.97 (2H, m, CH2), 1.85-
1.75 (2H, m, CH2); 
13C NMR δ (150.8 MHz, D2O) 131.1 (CH), 130.8 (C), 130.0 
(CH), 129.4 (C), 129.4 (CH), 129.3 (CH), 70.1 (CH), 68.8 (CH), 54.7 (CH), 46.9 
(CH2), 36.1 (CH2), 33.7 (CH), 31.6 (CH2); m/z (ESI+) 220 ([M+H]
+, 100 %), 219 

















hydrochloride 254m (∆3,4 isomer) 
General procedure Q was followed using diol 208m (26 mg, 
82 µmol), CH2Cl2 (2 ml) and TFA (3 ml), then CH2Cl2 (1 ml) 
and HCl (1 ml, 1 M in Et2O) to afford amine hydrochloride 
254m as a colourless oil 11 mg, 53%. 
1H NMR δ (360 MHz, D2O) 7.29 (1H, d, Ј 6.9, ArH), 7.20 (1H, t, Ј 7.1, ArH), 7.13 
(1H, t, Ј 7.6, ArH), 7.05 (1H, d, Ј 7.5, ArH), 4.24 (1H, d, Ј 16.3, CHXHYAr), 4.18 
(1H, d, Ј 16.3, CHXHYAr), 3.79-3.73 (2H, m, 2xCH), 3.56 (1H, br d, Ј 9.1, CH), 
3.33-3.29 (1H, m, CH), 2.08-1.97 (1H, m, CHAHB), 1.94-1.85 (1H, m, CHAHB), 
1.59-1.53 (1H, m, CHCHD), 1.34-1.26 (1H, m, CHCHD); 
13C NMR δ (62.9 MHz, 
D2O) 133.3 (C), 128.7 (CH), 128.1 (C), 127.4 (CH), 127.0 (CH), 126.8 (CH), 69.0 
(CH), 66.7 (CH), 54.5 (CH), 41.3 (CH2), 33.6 (CH), 25.9 (CH2), 21.5 (CH2); m/z 
(ESI+) 220 ([M+H]+, 100 %), 218 (21); HRMS (ESI+) Found [M+H]+, 220.1331. 













General procedure P was followed using phenanthridines 158-
160 (15 mg, 56 µmol), THF (312 µl), H2O (63 µl), OsO4 (49 
µl, 2.5% w/w in 
tBuOH, 3.9 µmol) and NMO (20 mg, 0.16 
mmol). Flash chromatography (CH2Cl2-CH2Cl2:MeOH, 
100:2) afforded ∆1,2 diol 256 (1 mg, 6%), ∆2,3  diol 257 (1 mg, 
6%), ∆ 3,4 diol 258 (2.4 mg, 14%), and mixed diol (8 mg, 47%) giving a total yield 
(12.4 mg, 73%).  
 
(5aSR,8SR,9RS,9aSR)-5-Methanesulfonyl-4,5,5a,6,7,8,9,9a-octahydro-
thieno[2,3-c]quinoline-8,9-diol 256 (∆1,2 isomer) 
Rf [CH2Cl2:MeOH, 9:1] = 0.09; υmax (CHCl3)/cm
-1 3446 (OH), 
2925, 1319, 1151; 1H NMR δ (250 MHz, CDCl3) 7.27 (1H, d, Ј 
5.3, HetH), 6.95 (1H, d, Ј 5.3, HetH), 4.81 (1H, dd, Ј 16.8, 1.8, 
CHXHYHet), 4.57-4.49 (2H, m, CHOH+NCH), 4.39 (1H, dd, Ј  
17.0, 1.8, CHXHYHet),  3.59-3.50 (1H, m, CH), 3.41 (1H, br s, 
CH), 2.90 (3H, s, CH3), 1.99-1.92 (1H, m, CHAHB), 1.80-1.68 (3H, m, 
CH2+CHAHB); 
13C NMR δ (90.6 MHz, CDCl3) 131.9 (C), 130.5 (C), 124.5 (CH), 
124.4 (CH), 72.0 (CH), 67.6 (CH), 48.6 (CH), 42.1 (CH), 40.7 (CH2), 39.8 (CH3), 
26.6 (CH2), 23.4(CH2); m/z (EI) 303 ([M]
+, 2 %), 281 (5), 267 (8), 228 (41), 149 

























thieno[2,3-c]quinoline-7,8-diol 257 (∆2,3 isomer) 
Rf [CH2Cl2:MeOH, 9:1] = 0.09; υmax (CHCl3)/cm
-1 3396 
(OH), 2927, 1661, 1319, 1151; 1H NMR δ (250 MHz, CDCl3) 
7.25 (1H, d, Ј 5.3, HetH), 7.01 (1H, d, Ј 5.0, HetH), 4.83 (1H, 
dt, Ј 17.0, 0.8, CHXHYHet), 4.43 (1H, dd, Ј  12.3, 4.8, NCH), 
4.34 (1H, dd, Ј  16.8, 3.5, CHXHYHet),  3.98 (1H, s, CHOH), 
3.55-3.46 (1H, m, NCHCH), 3.27 (1H, br s, CHOH), 2.89 (3H, s, CH3), 2.29-2.20 
(2H, m, CH2), 2.04-1.93 (1H, m, CHAHB), 1.87-1.75 (1H, m, CHCHD); 
13C NMR δ 
(90.6 MHz, CDCl3) 134.7 (C), 129.8 (C), 125.0 (CH), 124.1 (CH), 69.2 (CH), 66.8 
(CH), 47.8 (CH), 40.6 (CH2), 39.7 (CH3), 35.4 (CH), 30.5 (CH2), 30.3 (CH2); m/z 
(EI) 303 ([M]+, 5 %), 285 (18), 224 (67), 206 (36), 178 (23), 149 (32), 136 (100); 
HRMS (EI) Found: 303.0593. C12H17O4NS2 requires 303.0594. 
 
(5aRS,6SR,7RS,9aSR)-5-Methanesulfonyl-4,5,5a,6,7,8,9,9a-octahydro-
thieno[2,3-c]quinoline-6,7-diol 258 (∆3,4 isomer) 
Rf [CH2Cl2:MeOH, 9:1] = 0.11; υmax (CHCl3)/cm
-1 3446 
(OH), 2929, 1649, 1315, 1149; 1H NMR δ (360 MHz, CDCl3) 
7.22 (1H, d, Ј 7.6, HetH), 6.90 (1H, d, Ј 7.2, HetH),  4.92 (1H, 
dd, Ј 24.5, 2.2, CHXHYHet), 4.43 (1H, dd, Ј  24.2, 2.9, 
CHXHYHet), 4.33 (1H, dd, Ј  14.8, 7.9, NCH), 4.06 (1H, d, Ј  4.0, CHOH), 3.55 (1H, 
dd, Ј  14.8, 4.3, NCHCH), 3.28 (1H, br s, CHOH), 2.98 (3H, s, CH3), 2.26-2.16 (1H, 
m, CHAHB), 2.09-2.01 (1H, m, CHAHB), 1.83-1.75 (1H, m, CHCHD), 1.40-1.32 (1H, 
m, CHCHD); 
13C NMR δ (90.6 MHz, CDCl3) 135.3 (C), 130.2 (C), 124.7 (CH), 
124.0 (CH), 69.1 (CH), 67.4 (CH2), 55.2 (CH), 40.7 (CH2), 39.6 (CH3), 36.1 (CH), 
25.6 (CH2), 21.7 (CH2); m/z (EI) 303 ([M]
+, 6 %), 285 (20), 228 (22), 224 (100), 206 



























General Procedure R - Zebrafish phenotype screening 
 
The following protocol was used for the preliminary wild-type screening of our 
compound library.172 
1) Chemicals were diluted into the E3 screening medium. Aliquots of 200 µl (or 
multiples thereof) were prepared at concentrations ranging from 100 µM to 1 
µM, all with 0.5% v/v DMSO. When not in use the aliquots were stored in the 
freezer. 
2) Five small breeding tanks were set up in the evening, each containing one 
male zebrafish and one or two females. The tanks were kept in darkness until 
the next morning when the lights were switched on causing the fish to breed. 
3) The embryos were collected, pooled and washed with E3 medium. Dead, 
delayed or unformed embryos were discarded, and the adult fish were 
returned to their main tank. 
4) The embryos were divided into two petri dishes and stored in an incubator at 
28.5 oC until required. 
5) The chemical aliquots were placed in the same incubator to defrost. 
6) Once the embryos had reached the desired age they were distributed in 96-
well plates as appropriate to the screen, with two or three embryos per well. 
7) The surrounding medium was removed from the embryos using a wide-tipped 
Pasteur pipette and then the appropriate 200 µl chemical aliquot was added to 
the well. Four control wells were used per plate, each containing E3 with 
0.5% v/v DMSO. 
8) The plates were incubated at 28.5 oC and examined periodically over the next 
five days using a microscope to assess any phenotypes. Photographs were 
taken where required using a digital camera coupled to a microscope. 
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Ac  acetyl or acetate 
AIBN  azobisisobutyronitrile 
aq  aqueous 
Ar  aryl 
BIOS  biology oriented synthesis 
Bn  benzyl 
Boc  tert-butoxycarbonyl 
Bu  butyl 
CAN  ceric ammonium nitrate 
Cbz  carbobenzyloxy 
CsOH  caesium hydroxide 
COSY  correlation spectroscopy 
Cy  cyclohexyl 
DCC  dicyclohexylcarbodiimide 
dba  dibenzylideneacetone 
DBDMH 1,3-dibromo-5,5-dimethylhydantoin 
DMA  N,N-dimethylacetamide 
DMDO dimethyldioxirane 
DME  1,2-dimethoxyethane 
DMF  N,N-dimethylformamide 
DMAP  dimethylaminopyridine 
DMSO  dimethylsulfoxide 
dr  diastereomeric ratio 
DOS  diversity-oriented synthesis 
dpf  days post fertilisation  
dppa  diphenylphosphorylazide 
EC50 concentration of agonist required to produce 50% of the maximal 
response  
EI  electron impact ionisation 
eq  equivalent 
ESI  electrospray ionisation 
Et  ethyl 
FAB  fast atom bombardment 
FDA  food and drug administration 
FVP  flash vacuum pyrolysis 
h  hour 
HB  Herrmann-Beller 
HMDS  hexamethyldisilazide 
hpf  hours post fertilisation 
HPLC  high performance liquid chromatography 
HRMS  high resolution mass spectrum 
HSQC  heteronuclear single quantum correlation spectroscopy 
IR  infra red 
LDA  lithium diisopropylamide 
mCPBA meta-chloroperoxybenzoic acid 
Abbreviations 
274 
Me  methyl 
µwave  microwave 
mins  minutes 
MP  melting point 
MRSA  methicillin-resistant staphylococcus aureus 
NBS  N-bromosuccinimide 
NMO  N-methylmorpholine N-oxide 
NMR  nuclear magnetic resonance 
3-NOBA 3-nitrobenzylalcohol 
NOESY nuclear Overhauser effect spectroscopy 
P  unspecified protecting group 
PCA  principal component analysis 
PMB  4-methoxylbenzyl 
ppm  parts per million 
PPTS  pyridinium para-toluenesulfonate 
Pr  propyl 
Poc  propargyloxy 
PSSC  protein structure similarity clustering 
py  pyridine 
RCM  ring closing metathesis 
ROM  ring opening metathesis 
ROMP  ring opening metathesis polymerisation 
RRM  ring rearrangement metathesis 
Rf  retention factor 
r.t.  room temperature 
Rt  retention time 
sat  saturated 
SCONP structural classification of natural products 
TBAF  tetrabutylammonium fluoride 
TBAI  tetrabutylammonium iodide 
TFA  trifluoroacetic acid 
THIOG thioglycerol 
TLC  thin layer chromatography 
THF  tetrahydrofuran 
TMS  trimethylsilyl 
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